VCU - Study Finder

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories

630 Study Matches

FearLess in NeuroOncology

Contact(s):

Mary Bridgman - LiveNOW@vcu.edu

Principal Investigator:

System ID: NCT06989086

Show full eligibility criteria

Interventions: BEHAVIORAL: Fearless in Neuro-Oncology

Conditions: Primary Malignant Brain Tumor, Glioblastoma (GBM), Astrocytoma, Oligodendroglioma, Caregiver

Keywords: brain tumor

I'm interested

Share via email

Show 1 location

Study Locations

Hide all locations

Location	Contacts
Virginia Commonwealth University Richmond, Virginia	Ashlee Loughan, PhD - (ashlee.loughan@vcuhealth.org)

A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

Contact(s):

ctrrecruit@vcu.edu

Principal Investigator:

System ID: NCT06765668

Show full eligibility criteria

Inclusion Criteria:

• Participants with PD consistent with the United Kingdom Parkinson's Disease Society Brain Bank Diagnostic Criteria and who are being treated with stable regimens of oral CD-LD.
• Participants with a score of at least 20 units at Screening on the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III total score in the "Off" state.
• Participants with predictable "Off" periods at Screening defined by a score of 1 or 2 (Complexity of Motor Fluctuations) of the MDS-UPDRS Part IV B (Motor Fluctuations).
• By history, for the 4 weeks (28 days) prior to Screening, the participant experiences.
• Daily predictable "wearing-off" episodes with periods of worsening motor symptoms.
• An average of at least 2.5 cumulative hours per day of "Off" time, during the hours the participant awake.
• At Screening, the participant is able to differentiate "On" state from "Off" state as determined by at least 75 percentage (%) concordance with a trained rater (that is, investigator or qualified and certified site staff) in "On/Off" ratings for 8 ratings over a 4-hour training period. The concordance must include at least one "On" and one "Off" rating in this 4-hour training period.
• If the concordance is less than 75%, or if it does not include at least one "On" and one "Off" rating within the first 4-hour training period, a second 4-hour training period should be conducted with the participant before being considered for inclusion in the study.
• If during the second 4-hour training-period a concordance of at least 75% is also not achieved, or if it does not include at least one "On" and one "Off" rating, the participant cannot be included in the study.
• At baseline (Visit 1), review of the 3-day PD diaries confirms the following:
• The participant is able to properly complete the PD diaries with valid entries. Inability to properly complete the diaries is indicated when more than 1 day of a diary is not returned or if more than 1 day of the diary is not valid (that is, more than 2 hours \[4 half-hour periods\] of the 24-hour diary day are missing); and
• The participant has an average of at least 2.5 hours per day of "Off" time, during the hours the participant is awake, over the 3 PD diary days; and
• The participant has at least 1.5 hours of cumulative "Off" time, during the hours the participant is awake, on each of the 3 PD diary days.
• Participant is responsive to CD-LD therapy and currently being treated on a stable regimen of oral CD-LD for at least 4 weeks (greater than equal to \[\>=\] 28 days) prior to baseline (Visit 1) and meets the following criteria: a. Daily Dose Requirements: i. All participants should be taking at least 100 mg of immediate-release (IR) CD-LD or 195 mg of Rytary for the first morning dose. ii. For participants taking IR CD-LD (with or without a bedtime dose of CR CD-LD): * Require a total daily dose of at least 300 mg of LD and a maximum total daily dose of less than equal to \[\<=\]1200 mg LD (from IR CD-LD alone or from IR CD-LD in combination with a single daily bedtime dose of CR CD-LD). * The maximum individual dose allowed is 250 mg of LD. * The minimum individual dose should be at least 100 mg of LD. iii. For participants using a catechol-O-methyltransferase (COMT) inhibitor: * Require a total daily dose of at least 300 mg of LD and a maximum total daily dose of less than \[\<\]1000 mg LD. * The maximum individual dose is 200 mg of LD. iv. For participants using Rytary: * Require a total daily dose of at least 585 mg of LD and a maximum total daily dose of \<2100 mg LD. * The maximum individual dose is 685 mg of LD. b. Dose Frequency Requirement: i. If a participant is using IR/CR CD-LD alone or in combination with a COMT inhibitor, then the dosing frequency must be 3 to 6 times daily. ii. If a participant is using Rytary, then the dosing frequency must be 3 to 4 times daily.
• Participant is able and willing to provide written informed consent prior to the conduct of any study-specific procedures.
• Participant is able and willing to comply with the protocol, including completion of PD diaries, questionnaires, and available for all study visits and telephone calls.
• Participants who have participated in prior CREXONT clinical studies are allowed to be enrolled in this Phase 4 study.

Exclusion Criteria:

• Participant who, in the opinion of the clinical investigator, should not participate in the study based on the CREXONT Prescribing Information.
• Participant had a prior neurosurgical treatment for PD (example, deep brain stimulation \[DBS\] surgery or neurosurgical ablation treatment procedures) or if such procedure is planned or anticipated prior to Visit 4 (Day 42) of the study.
• Participant received the following within 4 weeks (\<=28 days) prior to baseline (Visit 1)
• Any doses of a CR CD-LD apart from a single daily bedtime dose.
• Duopa.
• Nonselective monoamine oxidase inhibitor (MAOI).
• Rescue medication used to treat "off" episodes for example: apomorphine or inhaled LD (Inbrija®).
• Received any investigational drugs within 30 days or 5 times the half-life, whichever is longer, prior to baseline (Visit 1).
• Participant who, in the opinion of the clinical investigator, should not participate in the study (example, based on clinical assessment, participant does not adequately comprehend the terminology needed to complete the PD diary and participant -reported outcomes, or any other reason).
• Employees or family members of the investigator, or study site staff, or Sponsor.

Interventions: DRUG: CREXONT ER

Conditions: Parkinson Disease

I'm interested

Share via email

Show 27 locations

Study Locations

Hide all locations

Location	Contacts
Atrium Health Wake Forest Baptist Adult Neurology - Janeway Tower Winston-Salem, North Carolina	Deepal Shah-Zamora - (dshahzam@wakehealth.edu)
Barrow Neurological Institute Phoenix, Arizona	Nicki Niemann - (MovementResearch@dignityhealth.org)
Central DuPage Hospital - Movement Disorders Center Winfield, Illinois	Martha McGraw - (Martha.McGraw@nm.org)
Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada	Zoltan Mari - (Mariz@ccf.orh)
Icahn School of Medicine at Mount Sinai New York, New York	Joohi Shahed - (joohi.jimenez-shahed@mountsinai.org)
Inova Neurology Fairfax, Virginia	Drew Falconer - (drew.falconer@inova.org)
MedStar Georgetown University Hospital Department of Neurology McLean, Virginia	Fernando Pagan - (LL928@georgetown.edu)
N1 Research LLC Orlando, Florida	Ramon Rodriguez - (rodriguez@neurologyone.com)
NeuroScience Research Center, LLC Canton, Ohio	Ryan Drake - (rsddo@neurocarecenter.com)
Neurology Consultants of Dallas, PA Dallas, Texas	Nirav Pavasia - (npavasia@neurologydallas.com)
Parkinson's Research Centers of America - Long Island Commack, New York	David Kreitzman - (info_LongIsland@parkinsonscenter.org)
Parkinson's Research Centers of America - Orange County Aliso Viejo, California	Mindy Bixby - (Bixby_research@parkinsonscenter.org)
Parkinson's Research Centers of America - Palo Alto Palo Alto, California	Salima Brillman - (info_PaloAlto@parkinsonscenter.org)
Parkinsons Disease and Movement Disorders Center of Boca Raton Boca Raton, Florida	Stuart Isaacson - (info@parkinsonscenter.org)
QUEST Research Institute Farmington Hills, Michigan	Aaron Ellenbogen - (aaron@questri.com)
Texas Movement Disorder Specialists, PLLC Georgetown, Texas	Michael Soileau - (msoileau@txmds.net)
The Movement Disorder Clinic of Oklahoma Tulsa, Oklahoma	Kevin Klos - (kevin.klos@mdcok.com)
The University of Texas Health Science Center at Houston- McGovern Medical School Houston, Texas	Mya Schiess - (Mya.C.Schiess@uth.tmc.edu)
USF Parkinson's Disease and Movement Disorders Center Tampa, Florida	Robert Hauser - (rhauser@usf.edu)
University Hospitals Cleveland Medical Center Cleveland, Ohio	Camilla Kilbane - (Camilla.Kilbane@uhhospitals.org)
University of Arkansas for Medical Sciences Little Rock, Arkansas	Rohit Dhall - (rdhall@uams.edu)
University of Cincinnati Cincinnati, Ohio	Alberto Espay - (espayaj@ucmail.uc.edu)
University of Kansas Medical Center Kansas City, Kansas	Angela Richmond - (arichmond4@kumc.edu)
University of Miami Miami, Florida	Jason Margolesky - (jhmargolesky@med.miami.edu)
Univesity of Miami - Miller School of Medicine Boca Raton, Florida	Henry Moore - (HMoore@med.miami.edu)
VCU Parkinsons Disease and Movement Disorders Center Henrico, Virginia	Leslie Cloud - (Leslie.Cloud@vcuhealth.org)
Visionary Investigators Network Aventura, Florida	Julie Schwartzbard - (DrJ@aventuraneuro.com)

A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis (Kirros)

Contact(s):

Reference Study ID Number: ML44719 https://forpatients.roche.com/ - global-roche-genentech-trials@gene.com

Principal Investigator:

System ID: NCT06096779

Show full eligibility criteria

General

Inclusion Criteria:

* Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology/cytology or clinically by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic participants * Disease that is not amenable to curative surgical and/or locoregional therapies * No prior systemic treatment (including systemic investigational agents) for locally advanced or metastatic and/or unresectable HCC * Measurable disease (at least one untreated target lesion) according to RECIST v1.1 * ECOG Performance Status of 0-2 within 7 days prior to initiation of study treatment * Child-Pugh B7 or B8 cirrhosis at screening and within 7 days prior to study treatment * Adequate hematologic and end-organ function * Life expectancy of at least 12 weeks * Female participants of childbearing potential must be willing to avoid pregnancy and egg donation * Absolute neutrophil count ≥1.0 x 109/L (≥1000/μL) without granulocyte colony-stimulating factor support * Platelet count ≥ 50 × 109/L (50,000/μL) without transfusion * Hemoglobin ≥ 80 g/L (8 g/dL) AST and ALT ≤ 5 × upper limit of normal (ULN) * Serum bilirubin ≤ 3 × ULN * Creatinine clearance ≥ 50 mL/min (calculated using the Cockcroft-Gault formula) * Serum albumin ≥ 20 g/L (2.0 g/dL) without transfusion in the prior 3 months * INR ≤2.3 General

Exclusion Criteria:

* Pregnancy or breastfeeding * Prior treatment with CD137 agonists or immune checkpoint blockade therapies * Treatment with investigational therapy within 28 days prior to initiation of study treatment * Treatment with locoregional therapy to liver within 28 days prior to initiation of study treatment, or non-recovery from side effects of any such procedure * Treatment with systemic immunostimulatory agents * Treatment with systemic immunosuppressive medication * Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment * Inadequately controlled hypertension * Active or history of autoimmune disease or immune deficiency * History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan * Participants who have a known concurrent malignancy that is progressing or requires active treatment, who have not completely recovered from treatment, or who have a significant malignancy history that, in the opinion of the investigator, should preclude participation. * Participants on preventative hormonal therapies (i.e., tamoxifen and other hormonal inhibitors) are not excluded. * Known fibrolamellar HCC, sarcomatoid HCC, other rare HCC variant, or mixed cholangiocarcinoma and HCC * Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases * Prior allogeneic stem cell or solid organ transplantation * Actively listed for liver transplantation * Co-infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) * Untreated or incompletely treated esophageal and/or gastric varices with bleeding or that are at high risk for bleeding * A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment * Grade ≥3 hemorrhage or bleeding event within 6 months prior to initiation of study treatment * Hepatic encephalopathy is allowed if no active symptoms or stable within 3 months of study treatment * History, planned, or recommended placement of transjugular intrahepatic portosystemic shunt (TIPS) is excluded from Cohort A only. TIPS is acceptable in Cohort B. * Diagnostic Paracentesis is allowed. Therapeutic Paracentesis within 3 months is an exclusion criteria * Participants with ascites controlled on diuretics are allowed. * History of spontaneous bacterial peritonitis within last 12 months

Interventions: DRUG: Atezolizumab, DRUG: Bevacizumab

Conditions: Hepatocellular Carcinoma

Keywords: Cirrhosis, liver cancer, liver tumor, Child-Pugh B, hepatocellular carcinoma, atezolizumab, bevacizumab, Immune Checkpoint Inhibitor, Digestive System Neoplasms, Kirros, ML44719, liver disease, Genentech, Immunotherapy, CPB, CPB 7, CPB 8, Tecentriq, Avastin, HCC, Cirrhotic Liver, Fatty Liver

I'm interested

Share via email

Show 61 locations

Study Locations

Hide all locations

Location	Contacts
Barbara Ann Karmanos Cancer Institute Detroit, Michigan
Beth Israel Deaconess Medical Center Boston, Massachusetts
Bon Secours St. Mary's Hospital Richmond, Virginia
California Liver Research Institute Pasadena, California
Cedars Sinai Comprehensive Transplant Center West Hollywood, California
Dayton VA Medical Center - NAVREF - PPDS Dayton, Ohio
Harbor UCLA Medical Center Torrance, California
Hartford Healthcare Cancer Institute at Hartford Hospital Hartford, Connecticut
Henry Ford Health System Detroit, Michigan
Houston Methodist Hospital Houston, Texas
Icahn School of Medicine at Mount Sinai New York, New York
Inova Schar Cancer Institute Fairfax, Virginia
Intermountain Cancer Center St. George, Utah
Intermountain Healthcare Murray, Utah
James J Peters Veterans Administration Medical Center - NAVREF The Bronx, New York
Kaiser Permanente Westside Medical Center Hillsboro, Oregon
Kelsey Research Foundation Houston, Texas
LSU Health Baton Rouge Baton Rouge, Louisiana
Levine Cancer Institute Charlotte, North Carolina
Liver Institute at Methodist Dallas Dallas, Texas
Long Island Heart Associates Mineola, New York
Maryview Hospital, Inc. Newport News, Virginia
Michael E Debakey VA Medical Center - NAVREF - PPDS Houston, Texas
Montefiore Medical Center The Bronx, New York
Moody Outpatient Center ? Parkland Health Dallas, Texas
MorristownMedicalCenter Morristown, New Jersey
NYU Langone Medical Center New York, New York
Nashville General Hospital at Meharry Nashville, Tennessee
Northwestern University Chicago, Illinois
OHSU Knight Cancer Institute Hematology Oncology Portland, Oregon
Orlando Health Inc. Orlando, Florida
Our Lady of the Lake Physician Group Baton Rouge, Louisiana
Pan American Center for Oncology Trials, LLC Rio Piedras,
R.J. Zuckerberg Cancer Hospital/Northwell Health - BRANY - PPDS New Hyde Park, New York
Rocky Mountain Cancer Centers (Williams) - USOR Denver, Colorado
Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey
Rutgers Cancer Institute of New Jersey at University Hospital Newark, New Jersey
Saint Luke?s Hospital of Kansas City Kansas City, Missouri
Stanford Health Care San Jose, California
Texas Oncology (Worth) - USOR Dallas, Texas
Texas Oncology - Denison Cancer Center Denison, Texas
The Duchossois Center for Advanced Medicine Chicago, Illinois
The University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma
The West Clinic (East Campus) Germantown, Tennessee
Thomas Jefferson University Philadelphia, Pennsylvania
Tufts Medical Center Boston, Massachusetts
UC San Diego Moores Cancer Center La Jolla, California
University Hospitals Cleveland Medical Center Cleveland, Ohio
University of Arizona Cancer Center Tucson, Arizona
University of California Davis Medical Center Sacramento, California
University of California Irvine Medical Center Orange, California
University of Illinois Health Outpatient Care Center Chicago, Illinois
University of Kentucky - Markey Cancer Center Lexington, Kentucky
University of Southern California Los Angeles, California
University of Southern California-Keck School of Medicine -1975 Zonal Ave Los Angeles, California
University of Texas Southwestern Medical Center Dallas, Texas
VCU Medical Center North Hospital Richmond, Virginia
Veterans Affairs Ann Arbor Healthcare System Ann Arbor, Michigan
Veterans Affairs Pittsburgh Healthcare System - NAVREF - PPDS Pittsburgh, Pennsylvania
Virginia Mason Medical Center Seattle, Washington
Washington DC VA Medical Center Washington D.C., District of Columbia

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Contact(s):

Takeda Contact - medinfoUS@takeda.com

Principal Investigator:

System ID: NCT05677971

Show full eligibility criteria

Inclusion criteria: * The participant must have a diagnosis of the Z allele homozygotes (PiZZ) genotype AATD. PiZZ diagnosis from source verifiable medical records is permitted. Otherwise, participants must undergo PiZZ confirmatory testing (genotyping for PiS and PiZ alleles) at screening. PiMZ or PiSZ genotypes are not permitted. * The participant, of any sex, is aged 18 to 75 years, inclusive. * The participant's liver biopsy core sample collected should meet the requirements of the protocol. * The participant has evidence of METAVIR stage F2, F3, or F4 liver fibrosis, evaluated by a centrally read baseline liver biopsy during the screening period; or confirmed as meeting all the entry criteria by central reading of a previous biopsy conducted within 6 months before the estimated enrollment date using an adequate liver biopsy and slides as defined in the study laboratory manual. * The participant has a pulmonary status meeting the protocol's requirements. * It must be confirmed that the participant does not have HCC. Participants will be screened for HCC with alpha-fetoprotein (AFP) and abdominal ultrasound. If the participant has any of the following, they will be required to have contrast-enhanced CT or MRI imaging to exclude HCC before randomization. * An adult participant must have a body mass index (BMI) between 18.0 and 39.0 kilograms per meter square (kg\^m2), inclusive. * The participant is a nonsmoker for at least 6 months before screening. Exclusion Criteria * The participant has a history of liver decompensating events (overt hepatic encephalopathy \[West Haven Grade \>=2\] documented by a physician, clinically significant ascites, spontaneous bacterial peritonitis, GI bleeding from varices, hepatopulmonary syndrome, hepatorenal syndrome, portal pulmonary hypertension, or bleeding portal hypertensive gastropathy). * The participant has a history of the presence of medium or large varices or varices with red wale signs based on a previous esophagogastroduodenoscopy (EGD) within 6 months before the estimated enrollment date. For certain participants, an EGD will be required at screening if there is no EGD available within 6 months before the estimated enrollment date. Presence of small varices with no red wale signs on EGD and no history of bleeding will be acceptable for study eligibility. * The participant has evidence of other forms of chronic liver diseases, including viral hepatitis B or C, primary biliary cholangitis, primary sclerosing cholangitis, Wilson disease, alcoholic hepatitis, hemochromatosis, liver cancer, history of biliary diversion, or autoimmune hepatitis. * The participant has alanine transaminase (ALT) or aspartate transaminase (AST) levels \>250 units per liter (U/L). * The participant has a platelet count \<60,000 per cubic millimeter (mm\^3) (\<60 × 10\^9 per liter \[10\^9/L\]). * The participant has albumin \<=2.8 gram per deciliter (g/dL) (28 grams per deciliter \[g/L\]). * The participant has international normalized ratio (INR) \>=1.7. * The participant is expected to have severe and unavoidable high-level exposure to inhaled pulmonary toxins during the study such as may occur with occupational exposure to mineral dusts or metals. * The participant has a history of drug abuse (such as cocaine, phencyclidine) within 1 year before the screening visit or has a positive urine drug screen at screening. * The participant has previously been treated with fazirsiran or any other RNAi for AATD-LD. * The participant has portal vein thrombosis. * The participant has a prior transjugular portosystemic shunt procedure. * The participant has a history of malignancy within the last 5 years, except for adequately treated basal cell carcinoma, squamous cell skin cancer, superficial bladder tumors, or in situ cervical cancer. Participants with other curatively treated malignancies who have no evidence of metastatic disease and a greater than 1-year disease-free interval may be entered after approval by the medical monitor.

Interventions: DRUG: Fazirsiran Injection, OTHER: Placebo

Conditions: Alpha1-Antitrypsin Deficiency

I'm interested

Share via email

Show 82 locations

Study Locations

Hide all locations

Location	Contacts
Amsterdam UMC - VUmc - De Boelelaan Amsterdam,	Site Contact - (j.p.h.drenth@amsterdamumc.nl)
Baylor College of Medicine Medical Center Houston, Texas	Site Contact - (george.cholankeril@bcm.edu)
Bon Secours St. Mary's Hospital Richmond, Virginia	Site Contact - (mitchell_shiffman@bshsi.org)
Boston Medical Center Boston, Massachusetts	Site Contact - (amohanty@bu.edu)
Brigham and Womens Hospital Boston, Massachusetts	Site Contact - (NHASHEMI@BWH.HARVARD.EDU)
CCA Hospital Braga Braga,	Site Contact - (crolanda@med.uminho.pt)
Cardinal Glennon Children's Hospital St Louis, Missouri	Site Contact - (jeffrey.teckman@slucare.ssmhealth.com)
Centre Francois Magendie Pessac,	Site Contact - (maeva.zysman@chu-bordeaux.fr)
Centro Hospitalar do Porto Porto,	Site Contact - (luisazevedomaia@hotmail.com)
Charité - Campus Virchow-Klinikum-Ostring 1 Berlin,	Site Contact - (frank.tacke@charite.de)
Children's Healthcare of Atlanta Atlanta, Georgia
Columbia University Irving Medical Center New York, New York	Site Contact - (mpg2124@cumc.columbia.edu)
Derriford Hospital Plymouth,	Site Contact - (ashwin.dhanda@nhs.net)
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milan, MI	Site Contact - (luca.valenti@policlinico.mi.it)
Fondazione IRCCS Policlinico San Matteo di Pavia Pavia,	Site Contact - (corsico@unipv.it)
GI Research Institute Vancouver, British Columbia	Site Contact - (hinnih@gmail.com)
Gastroenterology & Liver Institute Escondido, California
Hannover Medical School Hanover,	Site Contact - (wedemeyer.heiner@mh-hannover.de)
Henry Ford Medical Center - Columbus Detroit, Michigan	Site Contact - (sgordon3@hfhs.org)
Hopital Beaujon Clichy,	Site Contact - (audrey.payance@aphp.fr)
Hopital PONTCHAILLOU CHU de Rennes Rennes,	Site Contact - (edouard.bardou-jacquet@chu-rennes.fr)
Hopital Paul Brousse Val-de-Marne,	Site Contact - (audrey.coilly@aphp.fr)
Hopital de la Croix Rousse Lyon,	Site Contact - (teresa.antonini@chu-lyon.fr)
Hospital Nélio Mendonça Funchal,	Site Contact - (magnovitorp@gmail.com)
Hospital Purpan Toulouse,	Site Contact - (alric.l@chu-toulouse.fr)
Hospital Sírio-Libanês São Paulo, São Paulo	Site Contact - (gildaporta@gmail.com)
Hospital Universitario Marqués de Valdecilla Santander,	Site Contact - (alvaro.diaz@scsalud.es)
Hospital Universitario Vall d'Hebron - PPDS Barcelona,	Site Contact - (monica.pons@vhir.org)
Hospital Universitario Virgen de la Victoria Málaga,	Site Contact - (andrade@uma.es)
Hospital Universitario Virgen del Rocio - PPDS Seville,	Site Contact - (mromerogomez@us.es)
Hvidovre Hospital Hvidovre,	Site Contact - (elias.badal.rashu@regionh.dk)
ID Clinic Arkadiusz Pisula Mysłowice,	Site Contact - (e.janczewska@poczta.fm)
IRCCS Istituto Clinico Humanitas Rozzano (MI), Lombardy	Site Contact - (alessio.aghemo@humanitasresearch.it)
Indiana University School of Medicine - Indianapolis Indianapolis, Indiana	Site Contact - (rvuppala@iu.edu; mandcruz@iu.edu)
Inselspital Bern Bern,	Site Contact - (studien.hepatologie@insel.ch)
Inspiration Research Limited Toronto, Ontario	Site Contact - (kchapman@inspirationresearch.ca)
Institut klinicke a experimentalni mediciny Prague, Prague	Site Contact - (jan.sperl@ikem.cz)
Karolinska Universitetssjukhuset Huddinge Huddinge,	Site Contact - (staffan.wahlin@ki.se)
King's College Hospital London,	Site Contact - (aftab.ala1@nhs.net)
Klinikum Klagenfurt am Wörthersee Klagenfurt,	Site Contact - (markus@peck.at)
LKH-Universitätsklinikum Graz Graz,	Site Contact - (martin.wagner@medunigraz.at)
Leiden University Medical Center Leiden,	Site Contact - (e.f.a.van_t_wout@lumc.nl)
Mayo Clinic Jacksonville, Florida	Site Contact - (vargas.hugo@mayo.edu)
Mayo Clinic - PPDS Rochester, Minnesota	Site Contact - (malhi.harmeet@mayo.edu)
Medical University of South Carolina Charleston, South Carolina	Site Contact - (strangec@musc.edu)
Medizinische Universitat Innsbruck Innsbruck,	Site Contact - (heinz.zoller@i-med.ac.at; hepa-studyteam@i-med.ac.at)
Medizinische Universität Wien (Medical University of Vienna) Vienna,	Site Contact - (mattias.mandorfer@meduniwien.ac.at)
Morgan Stanley Childrens Hospital of New York Presbyterian (CHONY) - PIN New York, New York
NYU Langone Health New York, New York	Site Contact - (viviana.figueroadiaz@nyulangone.org)
Penn State Health Milton S. Hershey Medical Center Hershey, Pennsylvania	Site Contact - (tcraig@pennstatehealth.psu.edu)
Queen Elizabeth II Health Sciences Center Halifax, Nova Scotia	Site Contact - (julie.zhu@nshealth.ca)
Queen's Medical Centre Nottingham,
Royal Adelaide Hospital Adelaide, South Australia
Royal Free Hospital London,	Site Contact - (aileen.marshall@nhs.net)
Royal Infirmary of Edinburgh Edinburgh,	Site Contact - (michael.williams@nhslothian.scot.nhs.uk)
Schiff Center for Liver Diseases/University of Miami Miami, Florida	Site Contact - (eschiff@med.miami.edu)
St Vincents Hospital Melbourne - PPDS Fitzroy, Victoria	Site Contact - (matthew.conron@svha.org.au)
St. Joseph's Hospital and Medical Center Phoenix, Arizona	Site Contact - (justin.reynolds@dignityhealth.org)
Stanford University Stanford, California	Site Contact - (pkwo@stanford.edu)
Temple University Hospital Philadelphia, Pennsylvania	Site Contact - (yedidya.saiman@tuhs.temple.edu)
Texoma Liver Center Denison, Texas	Site Contact - (h.elgouhari@somacinicaltrials.com)
The Texas Liver Institute San Antonio, Texas	Site Contact - (lawitz@txliver.com)
UCLA Pulmonary and Critical Care Los Angeles, California	Site Contact - (ibarjaktarevic@mednet.ucla.edu)
UZ Antwerpen Edegem,	Site Contact - (sven.francque@uza.be)
UZ Leuven Leuven,	Site Contact - (jef.verbeek@uzleuven.be)
Universidade Estadual Paulista Julio de Mesquita Filho Faculdade de Medicina Campus de Botucatu São Paulo,	Site Contact - (fgromeiro@gmail.com)
Universitetssjukhuset i Linköping Linköping,	Site Contact - (mattias.ekstedt@liu.se)
University Hospitals Cleveland Medical Center Cleveland, Ohio	Site Contact - (seth.sclair@uhhospitals.org)
University of Alabama at Birmingham Birmingham, Alabama	Site Contact - (grayme@uab.edu)
University of Arizona Thomas D. Boyer Liver Institute Tucson, Arizona	Site Contact - (gdblock@deptofmed.arizona.edu)
University of California Benioff Children's Hospital San Francisco, California	Site Contact - (PROSENTH@ucsf.edu)
University of California San Diego, Altman Clinical and Translational Institute La Jolla, California	Site Contact - (roloomba@health.ucsd.edu)
University of Florida Gainesville, Florida	Site Contact - (briana.foerman@medicine.ufl.edu)
University of Iowa Hospitals and Clinics Iowa City, Iowa	Site Contact - (tomohiro-tanaka@uiowa.edu)
University of Maryland Medical Center Baltimore, Maryland	Site Contact - (kshetty@som.umaryland.edu)
University of Michigan Hospital Ann Arbor, Michigan	Site Contact - (rfontana@med.umich.edu)
Universitätsklinikum Schleswig-Holstein - Campus Kiel Kiel,	Site Contact - (rainer.guenther@uksh.de)
Universitätsklinikum Tübingen Tübingen,	Site Contact - (christoph.berg@med.uni-tuebingen.de)
Universitätsklinikum der RWTH Aachen Aachen,	Site Contact - (pstrnad@ukaachen.de)
VCU Medical Center North Hospital Richmond, Virginia	Site Contact - (amon.asgharpour@vcuhealth.org)
Vanderbilt University Medical Center Nashville, Tennessee	Site Contact - (roman.perri@vumc.org)
Washington University School of Medicine in St. Louis St Louis, Missouri	Site Contact - (smeduchenry@wustl.edu)

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

Contact(s):

Chris Korth - clinicaltrials@puretechhealth.com

Principal Investigator:

System ID: NCT05829226

Show full eligibility criteria

Inclusion Criteria:

* Patients ≥ 18 years of age at the time of obtaining informed consent. * Patients with morphologically documented primary or secondary AML by the World Health Organization(WHO) criteria, whose disease is relapsed/refractory to at least one line of prior therapy, with or without an allogeneic stem cell transplant and for whom no standard therapy that may provide clinical benefit is available or for patients who decline available standard of care. * Patients with a documented diagnosis of high-risk myelodysplastic syndrome (MDS), whose disease is relapsed/refractory, post at least one line of treatment based on the revised International Prognostic Scoring System (IPSS-R) and for whom no standard therapy that may provide clinical benefit is available * Patients are able and willing to comply with study procedures as per protocol, including bone marrowbiopsies. * Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. * Patient must meet the following criteria as indicated on the clinical laboratory tests: oWhite blood cell (WBC) count at the time of the first dose of \< 25,000/uL. oAspartate aminotransferase or alanine aminotransferase ≤ 3 × upper limit of normal (ULN; ≤ 5.0× ULN if considered to be due to leukemic involvement). oTotal bilirubin ≤ 2 × ULN (≤ 3 × ULN if considered to be due to leukemic involvement orGilbert's syndrome). oCreatinine clearance of ≥ 60 mL/min.

Exclusion Criteria:

* Patient diagnosed with acute promyelocytic leukemia (APL). * Patient has active malignant tumors other than AML/MDS * Patient has had HSCT and meets any of the following: has undergone HSCT within the 6- month period prior to the first study dose; has ≥ Grade 2 persistent non-hematological toxicity related to the transplant donor lymphocytes infusion. * Patient has active graft versus host disease (GVHD) and patients receiving immunosuppressive treatment for GVHD. * Patient with symptomatic central nervous system (CNS) involvement of leukemia or other CNS diseases related to underlying and secondary effects of malignancy * Patient has had major surgery within 4 weeks prior to the first study dose. * Patient has congestive heart failure New York Heart Association (NYHA) class 3 or 4, or patient with a history of congestive heart failure NYHA class 3 or 4 in the past, unless a screening echocardiogram or multigated acquisition (MUGA) scan performed within 3 months prior to study entry results in a left ventricular ejection fraction (LVEF) that is ≥ 45%. * Patient has any condition which, in the Investigator's opinion, makes the patient unsuitable for study participation.

Interventions: DRUG: LYT-200, DRUG: Venetoclax, DRUG: Azacitidine, DRUG: Decitabine

Conditions: AML, Adult Recurrent, MDS

Keywords: AML Recurrent, AML Relapsed, AML Refractory, Hematological Cancer, Gal-9, Immuno-oncology, MDS, MDS High Risk

I'm interested

Share via email

Show 9 locations

Study Locations

Hide all locations

Location	Contacts
Baptist Health South Florida-Miami Cancer Institute Miami, Florida
Cedars-Sinai Medical Center Los Angeles, California
Karmanos Cancer Institute Detroit, Michigan
Mass. General Hospital-Harvard Boston, Massachusetts
Norton Healthcare-Norton Cancer Institute Louisville, Kentucky
Rhode Island Hospital Providence, Rhode Island
Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey
University of California Irvine Medical Center Orange, California
Virginia Commonwealth University Medical Center Richmond, Virginia

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

Contact(s):

ctrrecruit@vcu.edu

Principal Investigator:

System ID: NCT05382338

Show full eligibility criteria

Inclusion Criteria:

* PRE-ENROLLMENT: Patients must be ≥ 4 years and ≤ 21 years of age at the time of enrollment * PRE-ENROLLMENT: Patient is suspected to have newly-diagnosed medulloblastoma by institutional diagnosis * Please note: Patients with a pending result of CSF cytology tests are eligible for NCI-2014-02057 (APEC14B1-Central Nervous System \[CNS\]) and CNS/Medulloblastoma Pre Enrollment Eligibility Screening * PRE-ENROLLMENT: The patient and/or their parents or legal guardians must have signed informed consent for APEC14B1 Part A - Eligibility Screening and consent for the Molecular Characterization Initiative (MCI) * PRE-ENROLLMENT: The required specimens are projected to be submitted under APEC14B1-CNS as soon as possible, preferably within 5 days of definitive surgery * PRE-ENROLLMENT: All patients must have rapid central pathology review under APEC14B1-CNS prior to study enrollment on ACNS2031 step 1 in order to avoid discordant diagnoses and to verify diagnosis criterion for treatment on ACNS2031. * Note: Patients with a pending result of CSF cytology tests are eligible for the rapid central pathology screening review. Confirmation of CSF negativity is needed for enrollment on the ACNS2031 protocol * PRE-ENROLLMENT: All patients must have rapid central molecular screening review under APEC14B1-CNS prior to study enrollment on ACNS2031 step 1, in order to avoid discordant diagnoses and to verify diagnosis criterion for treatment on ACNS2031 * PRE-ENROLLMENT: All patients who have histopathology confirmed must have rapid central imaging screening review under APEC14B1 prior to study enrollment on ACNS2031 step 1 * Note: Patients must not have metastatic disease on cranial or spinal MRI. Patients with \> 1.5 cm\^2 residual tumor after initial surgical resection may undergo a second surgical resection prior to subsequent therapy to render them eligible for this study. The day of the second resection to remove residual tumor will be regarded as the day of definitive surgery (Day 0) and must be within a month (31 days) of the initial resection * PRE-ENROLLMENT: All patients who have histopathology confirmed must have rapid central audiology review under APEC14B1-CNS prior to study enrollment on ACNS2031 step 1 * Patients must be \>= 4 years and =\< 21 years of age at the time of enrollment * Patients must be newly diagnosed and have eligibility confirmed by rapid central pathology and molecular screening reviews performed on APEC14B1 and via the Molecular Characterization Initiative * Average-risk cohort * Clinico-pathologic criteria: * M0 disease * No diffuse anaplastic histology AND * Molecular criteria: * SHH, p53wt, GLI2 normal, MYCN normal, no chromosome 14q loss * Group 3, MYC normal, no isochromosome 17q * Group 4, no chromosome 11 loss * Low-risk features cohort * Clinico-pathologic criteria: * M0 disease * No diffuse anaplastic histology AND * Molecular criteria: * Group 4, chromosome 11 loss * Patients must have negative lumbar CSF cytology * Note: CSF cytology for staging should be performed no sooner than 14 days post operatively to avoid false positive CSF. Ideally, CSF should be obtained between day 14 and day 21 to allow for final staging status before enrollment onto the study. Patients with positive CSF cytology obtained 0 to 14 days after surgery should have cytology repeated to determine eligibility and final CSF status. Patients with negative CSF cytology from lumbar puncture obtained 0 to 14 days after surgery do not need cytology repeated. Patients with negative CSF cytology from lumbar puncture obtained prior to surgery do not need cytology repeated post-operatively * Patients must have eligibility confirmed by Rapid Central Imaging Review performed on APEC14B1. Patients must have =\< 1.5 cm\^2 cross-sectional area of residual tumor. Whole brain MRI with and without gadolinium and spine MRI with gadolinium must be performed * Patients must weigh \> 10 kg * Patients must be enrolled, and protocol therapy must be projected to begin, no later than 31 days after definitive diagnostic surgery (day 0) * Peripheral absolute neutrophil count (ANC) \>= 1000/uL (within 7 days prior to enrollment) * Platelet count \>= 100,000/uL (transfusion independent) (within 7 days prior to enrollment) * Hemoglobin \>= 8.0 g/dL (may receive red blood cell count \[RBC\] transfusions) (within 7 days prior to enrollment) * A serum creatinine (within 7 days prior to enrollment) based on age/sex as follows: * 4 to \< 6 years (age); 0.8 mg/dL (male) 0.8 mg/dL (female) * 6 to \< 10 years (age); 1 mg/dL (male) 1 mg/dL (female) * 10 to \< 13 years (age); 1.2 mg/dL (male) 1.2 mg/dL (female) * 13 to \< 16 years (age); 1.5 mg/dL (male) 1.4 mg/dL (female) * \>= 16 years (age); 1.7 mg/dL (male) 1.4 mg/dL (female) OR a 24 hour urine Creatinine clearance \>= 70 mL/min/1.73 m\^2 (within 7 days prior to enrollment) OR a glomerular filtration rate (GFR) \>= 70 mL/min/1.73 m\^2 (within 7 days prior to enrollment). GFR must be performed using direct measurement with a nuclear blood sampling method OR direct small molecule clearance method (iothalamate or other molecule per institutional standard) * Note: Estimated GFR (eGFR) from serum creatinine, cystatin C or other estimates are not acceptable for determining eligibility * Total bilirubin =\< 1.5 x upper limit of normal (ULN) for age (within 7 days prior to enrollment) * Serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase \[ALT\]) =\< 135 U/L (within 7 days prior to enrollment) * Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L * Central nervous system function defined as: * Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled * Patients must not be in status epilepticus, a coma or assisted ventilation at the time of study enrollment * Auditory function defined as: * Patients must have normal hearing (defined as International Society of Pediatric Oncology \[SIOP\] grade 0) in at least one ear confirmed by rapid central audiology review performed on APEC14B1 prior to enrollment * All patients and/or their parents or legal guardians must sign a written informed consent * All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

Exclusion Criteria:

* Patients with metastatic disease by either MRI evaluation or lumbar CSF cytology are not eligible. Patients who are unable to undergo a lumbar puncture for assessment of CSF cytology are ineligible * Patients must not have received any prior radiation therapy or chemotherapy (tumor-directed therapy) other than surgical intervention and/or corticosteroids * Patients must not have any known hypersensitivity to STS, sulfates/sulfites, or other thiol agents (e.g., amifostine, n-acetylcysteine, MESNA, and captopril) * Pregnancy and Breastfeeding: * Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential * Lactating females who plan to breastfeed their infants * Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation

Interventions: PROCEDURE: Audiometric Test, PROCEDURE: Auditory Brainstem Response, PROCEDURE: Biospecimen Collection, DRUG: Cisplatin, DRUG: Cyclophosphamide, DRUG: Lomustine, PROCEDURE: Magnetic Resonance Imaging, OTHER: Quality-of-Life Assessment, RADIATION: Radiation Therapy, DRUG: Sodium Thiosulfate, OTHER: Survey Administration, DRUG: Vincristine

Conditions: Childhood Medulloblastoma

I'm interested

Share via email

Show 97 locations

Study Locations

Hide all locations

Location	Contacts
Albany Medical Center Albany, New York
Alfred I duPont Hospital for Children Wilmington, Delaware	Site Public Contact - (Allison.bruce@nemours.org)
Arkansas Children's Hospital Little Rock, Arkansas
Arnold Palmer Hospital for Children Orlando, Florida	Site Public Contact - (Jennifer.spinelli@orlandohealth.com)
BI-LO Charities Children's Cancer Center Greenville, South Carolina	Site Public Contact - (Kim.Williams3@prismahealth.org)
C S Mott Children's Hospital Ann Arbor, Michigan
Cardinal Glennon Children's Medical Center St Louis, Missouri
Carolinas Medical Center/Levine Cancer Institute Charlotte, North Carolina
Centre Hospitalier Universitaire Sainte-Justine Montreal, Quebec	Site Public Contact - (yvan.samson@umontreal.ca)
Centre Hospitalier Universitaire de Sherbrooke-Fleurimont Sherbrooke, Quebec	Site Public Contact - (crcinformation.chus@ssss.gouv.qc.ca)
Children's Healthcare of Atlanta - Arthur M Blank Hospital Atlanta, Georgia	Site Public Contact - (Olivia.Floyd@choa.org)
Children's Hospital Colorado Aurora, Colorado	Site Public Contact - (josh.b.gordon@nsmtp.kp.org)
Children's Hospital Los Angeles Los Angeles, California
Children's Hospital Medical Center Of Akron Akron, Ohio
Children's Hospital New Orleans New Orleans, Louisiana
Children's Hospital and Medical Center of Omaha Omaha, Nebraska
Children's Hospital of Alabama Birmingham, Alabama
Children's Hospital of Michigan Detroit, Michigan	Site Public Contact - (helpdesk@childrensoncologygroup.org)
Children's Hospital of Orange County Orange, California	Site Public Contact - (oncresearch@choc.org)
Children's Hospital of Philadelphia Philadelphia, Pennsylvania	Site Public Contact - (CancerTrials@email.chop.edu)
Children's Hospital of Pittsburgh of UPMC Pittsburgh, Pennsylvania	Site Public Contact - (jean.tersak@chp.edu)
Children's Hospital of San Antonio San Antonio, Texas	Site Public Contact - (bridget.medina@christushealth.org)
Children's Hospital of Wisconsin Milwaukee, Wisconsin	Site Public Contact - (MACCCTO@mcw.edu)
Children's Hospitals and Clinics of Minnesota - Minneapolis Minneapolis, Minnesota	Site Public Contact - (pauline.mitby@childrensmn.org)
Children's Mercy Hospitals and Clinics Kansas City, Missouri	Site Public Contact - (rryan@cmh.edu)
Children's National Medical Center Washington D.C., District of Columbia	Site Public Contact - (OncCRC_OnCall@childrensnational.org)
Cincinnati Children's Hospital Medical Center Cincinnati, Ohio	Site Public Contact - (cancer@cchmc.org)
Connecticut Children's Medical Center Hartford, Connecticut
Corewell Health Children's Royal Oak, Michigan
Dayton Children's Hospital Dayton, Ohio
Dell Children's Medical Center of Central Texas Austin, Texas	Site Public Contact - (TXAUS-DL-SFCHemonc.research@ascension.org)
East Carolina University Greenville, North Carolina	Site Public Contact - (eubankss@ecu.edu)
El Paso Children's Hospital El Paso, Texas	Site Public Contact - (ranjan.bista@ttuhsc.edu)
Geisinger Medical Center Danville, Pennsylvania	Site Public Contact - (HemonCCTrials@geisinger.edu)
Golisano Children's Hospital of Southwest Florida Fort Myers, Florida	Site Public Contact - (molly.arnstrom@leehealth.org)
IWK Health Centre Halifax, Nova Scotia	Site Public Contact - (Research@iwk.nshealth.ca)
Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland	Site Public Contact - (jhcccro@jhmi.edu)
Kaiser Permanente-Oakland Oakland, California	Site Public Contact - (Kpoct@kp.org)
Legacy Emanuel Children's Hospital Portland, Oregon
Loma Linda University Medical Center Loma Linda, California
Marshfield Medical Center-Marshfield Marshfield, Wisconsin
Mary Bridge Children's Hospital and Health Center Tacoma, Washington	Site Public Contact - (research@multicare.org)
Massachusetts General Hospital Cancer Center Boston, Massachusetts
Mayo Clinic in Rochester Rochester, Minnesota
Medical City Dallas Hospital Dallas, Texas
Memorial Regional Hospital/Joe DiMaggio Children's Hospital Hollywood, Florida	Site Public Contact - (OHR@mhs.net)
Miller Children's and Women's Hospital Long Beach Long Beach, California
Montefiore Medical Center - Moses Campus The Bronx, New York	Site Public Contact - (eskwak@montefiore.org)
Mount Sinai Hospital New York, New York	Site Public Contact - (CCTO@mssm.edu)
Nationwide Children's Hospital Columbus, Ohio	Site Public Contact - (Melinda.Triplet@nationwidechildrens.org)
Nemours Children's Clinic - Pensacola Pensacola, Florida	Site Public Contact - (helpdesk@childrensoncologygroup.org)
Nemours Children's Clinic-Jacksonville Jacksonville, Florida	Site Public Contact - (Allison.bruce@nemours.org)
Nemours Children's Hospital Orlando, Florida	Site Public Contact - (Allison.bruce@nemours.org)
New York Medical College Valhalla, New York
Newark Beth Israel Medical Center Newark, New Jersey	Site Public Contact - (Christine.Kosmides@rwjbh.org)
Nicklaus Children's Hospital Miami, Florida
Norton Children's Hospital Louisville, Kentucky	Site Public Contact - (CancerResource@nortonhealthcare.org)
Oregon Health and Science University Portland, Oregon	Site Public Contact - (trials@ohsu.edu)
Phoenix Childrens Hospital Phoenix, Arizona
Prisma Health Richland Hospital Columbia, South Carolina	Site Public Contact - (Kim.Williams3@prismahealth.org)
ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital Toledo, Ohio	Site Public Contact - (PCIOncResearch@promedica.org)
Providence Sacred Heart Medical Center and Children's Hospital Spokane, Washington	Site Public Contact - (HopeBeginsHere@providence.org)
Rady Children's Hospital - San Diego San Diego, California
Rainbow Babies and Childrens Hospital Cleveland, Ohio
Rhode Island Hospital Providence, Rhode Island
Riley Hospital for Children Indianapolis, Indiana
Roswell Park Cancer Institute Buffalo, New York	Site Public Contact - (askroswell@roswellpark.org)
Saint Joseph's Hospital/Children's Hospital-Tampa Tampa, Florida	Site Public Contact - (jennifer.manns@baycare.org)
Saint Joseph's Regional Medical Center Paterson, New Jersey	Site Public Contact - (HallL@sjhmc.org)
Saint Jude Midwest Affiliate Peoria, Illinois
Saint Peter's University Hospital New Brunswick, New Jersey	Site Public Contact - (kcovert@saintpetersuh.com)
Sanford Broadway Medical Center Fargo, North Dakota	Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford USD Medical Center - Sioux Falls Sioux Falls, South Dakota	Site Public Contact - (OncologyClinicalTrialsSF@SanfordHealth.org)
Seattle Children's Hospital Seattle, Washington
Sinai Hospital of Baltimore Baltimore, Maryland
Southern Illinois University School of Medicine Springfield, Illinois
State University of New York Upstate Medical University Syracuse, New York
Stony Brook University Medical Center Stony Brook, New York
The Steven and Alexandra Cohen Children's Medical Center of New York New Hyde Park, New York
UCSF Medical Center-Mission Bay San Francisco, California	Site Public Contact - (cancertrials@ucsf.edu)
UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina	Site Public Contact - (cancerclinicaltrials@med.unc.edu)
USA Health Strada Patient Care Center Mobile, Alabama
UT Southwestern/Simmons Cancer Center-Dallas Dallas, Texas	Site Public Contact - (canceranswerline@UTSouthwestern.edu)
University of Illinois Chicago, Illinois
University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa
University of Mississippi Medical Center Jackson, Mississippi
University of Nebraska Medical Center Omaha, Nebraska	Site Public Contact - (unmcrsa@unmc.edu)
University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma	Site Public Contact - (ou-clinical-trials@ouhsc.edu)
University of Texas Health Science Center at San Antonio San Antonio, Texas	Site Public Contact - (phoresearchoffice@uthscsa.edu)
University of Virginia Cancer Center Charlottesville, Virginia	Site Public Contact - (uvacancertrials@hscmail.mcc.virginia.edu)
University of Wisconsin Carbone Cancer Center - University Hospital Madison, Wisconsin	Site Public Contact - (clinicaltrials@cancer.wisc.edu)
VCU Massey Comprehensive Cancer Center Richmond, Virginia	Site Public Contact - (CTOclinops@vcu.edu)
Valley Children's Hospital Madera, California	Site Public Contact - (Research@valleychildrens.org)
Vanderbilt University/Ingram Cancer Center Nashville, Tennessee
Wake Forest University Health Sciences Winston-Salem, North Carolina
Washington University School of Medicine St Louis, Missouri	Site Public Contact - (info@siteman.wustl.edu)
Yale University New Haven, Connecticut	Site Public Contact - (canceranswers@yale.edu)

A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment (ELFINITY)

Contact(s):

Ipsen Clinical Study Enquiries - clinical.trials@ipsen.com

Principal Investigator:

System ID: NCT06447168

Show full eligibility criteria

Conditions: Primary Biliary Cholangitis

I'm interested

Share via email

Show 50 locations

Study Locations

Hide all locations

Location	Contacts
(G.I.R.I) GI Research Institute Foundation Vancouver,
Aberdeen Royal Infirmary NHS Grampian Grampian Health Board Aberdeen,
Baylor College of Medicine - Advanced Liver Therapies Houston, Texas
Belfast Health and Social Care Trust - Royal Victoria Hospital Belfast,
Beth Israel Deaconess Medical Center, Liver Research Center Boston, Massachusetts
Bon Secours Richmond Community Hospital LLC. d/b/a Bon Secours Liver Institute of Richmond Richmond, Virginia
Bradford Royal Infirmary - Bradford Teaching Hospitals NHS Foundation Bradford,
Cedars-Sinai Medical Center Los Angeles, California
Charité Universitätsmedizin Berlin Berlin,
Clemenceau Medical Center Hospital Dubai,
Cleveland Clinic Foundation Cleveland, Ohio
DRK Kliniken Berlin Mitte Berlin,
Gastro health & Nutrition Seattle, Washington
Gastroenterologsiche Studiengesellschaft Herne Herne,
General Hospital of Athens Laiko Athens,
Hospital of the Merciful Brothers Trier Trier,
Hull Royal Infirmary - Hull University Teaching Hospitals NHS Trust Hull,
Intermountain Medical Center Murray, Utah
Ippokratio General Hospital of Thessaloniki Thessaloniki,
John Radcliffe Hospital - Oxford University Hospitals NHS Foundation Trust Oxford,
King's College Hospital NHS Foundation Trust London,
Klinikum der Johann Wolfgang Goethe-Universitaet Frankfurt,
Liver Center of Texas Dallas, Texas
Medical University Innsbruck Innsbruck,
Medical University of South Carolina (MUSC) Charleston, South Carolina
Mediclinic Airport Road Hospital Dubai,
Medizinische Universitaetsklinik Graz Graz,
Northwell Health Inc, Center for Liver Disease and Transplantation Manhasset, New York
Ospedale Maggiore Della Carita Novara,
Queen Elizabeth Hospital Birmingham - University Hospitals Birmingham NHS Foundation Trust Birmingham,
Queen's Medical Centre - Nottingham University Hospitals NHS Trust Nottingham,
Rashid Hospital Dubai,
Schiff Center for Liver Diseases - University of Miami Miami, Florida
Sheikh Shakhbout Medical City Dubai,
South Denver Gastroenterology,P.C. Englewood, Colorado
Southern California Research Center Coronado, California
Studiengesellschaft BSF Halle,
The Newcastle upon Tyne Hospitals NHS Foundation Trust - Freeman Hospital Newcastle,
The Ottawa Hospital - General Campus Ottawa,
Universita Degli Studi Di Firenze - Azienda Ospedaliero-Universitaria Careggi (AOUC) Florence,
Universitaet des Saarlandes Homburg,
Universitaetsklinikum Leipzig Leipzig,
University General Hospital of Patras Pátrai,
University Hospital of Heraklion Heraklion,
University of Calgary Calgary, Alberta
University of California Davis Medical Center Sacramento, California
Velocity Clinical Research Katy, Texas
Virginia Commonwealth University Medical Center - West Hospital Richmond, Virginia
Virtua Center for Liver Disease - Cherry Hill Cherry Hill, New Jersey
Yale University School of Medicine North Haven, Connecticut

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis (ELFIDENCE)

Contact(s):

Ipsen Clinical Study Enquiries - clinical.trials@ipsen.com

Principal Investigator:

System ID: NCT06016842

Show full eligibility criteria

Inclusion Criteria : * Male or female participants must be ≥18 years of age at the time of signing the informed consent. * Participants with a definite or probable diagnosis of primary biliary cholangitis (PBC) * Participants with cirrhosis at SV1. • Participants must be Child Pugh A or Child Pugh B. * Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Exclusion Criteria : * History or presence of other concomitant liver disease including but not limited to: * i) Primary sclerosing cholangitis (PSC). * ii) Autoimmune hepatitis (AIH) by simplified Diagnostic Criteria of the International Autoimmune Hepatitis Group (IAIHG) ≥6, or if treated for an overlap of PBC with AIH, or if there is clinical suspicion and evidence of overlap AIH features, that cannot be explained alone by insufficient response to UDCA. * iii) Positive hepatitis B surface antigen (HBsAg). Participants with negative HBsAg and positive hepatitis B core antibody (HBcAb) may be eligible if hepatitis B virus deoxyribonucleic acid (HBV DNA) is negative. * iv) Hepatitis C virus (HCV) infection defined by positive anti-HCV antibody and positive HCV ribonucleic acid (RNA) (Note: Participants with positive anti-HCV antibody due to previously treated HCV infection, may be enrolled if a confirmatory HCV RNA is undetectable and sustained viral response has been documented). * v) Alcohol-associated liver disease (ALD). * vi) Nonalcoholic steatohepatitis (NASH). * vii) Other chronic liver diseases, such as alpha-1 antitrypsin deficiency. * History or presence of clinically significant hepatic decompensation, including: * i) History of liver transplantation, current placement on a liver transplant list, current model for end-stage liver disease including (MELD) 3.0 score \>12 due to hepatic impairment. * ii) Evidence of complications of cirrhosis, including hepatic decompensation or evidence of significant portal hypertension complications including presence of uncontrolled ascites; history of variceal bleeding or related interventions (e.g. variceal banding, or transjugular intrahepatic portosystemic shunt placement); presence of hepatic encephalopathy Grade 2 or higher per West-Haven criteria; history or presence of spontaneous bacterial peritonitis. Note: participants with low-risk varices (Grade I) without history of bleeding or other treatment may be eligible to enrol. * iii) Hepatorenal syndrome (HRS) (type I or II ). • vi) Hospitalisation for liver-related complication within 12 weeks prior to SV1. * Known history of human immunodeficiency virus (HIV) infection or having a positive confirmatory test for HIV type 1 or 2. * Medical conditions that may cause non-hepatic increases in ALP (e.g. Paget's disease). * Evidence of any other unstable or untreated clinically significant immunological, endocrine, hematologic, gastrointestinal, neurological, or psychiatric disease as evaluated by the investigator; other clinically significant conditions that are not well controlled. * Non-hepatic medical conditions that may diminish life expectancy to \<2 years, including known cancers. * History of hepatocellular carcinoma. * Alpha-fetoprotein (AFP) \>20 ng/mL with 4-phase liver computerised tomography (CT) or magnetic resonance imaging (MRI) imaging suggesting presence of hepatocellular carcinoma. * Known malignancy or history of malignancy within the last 5 years, with the exception of local, successfully treated basal cell carcinoma or in-situ carcinoma of the uterine cervix. * Administration of the following medications is prohibited during the study, and prior to the study as per the timelines specified below: • i) 3 months prior to screening period: fibrates, seladelpar, glitazones, obeticholic acid, azathioprine, cyclosporine, methotrexate, mycophenolate, pentoxifylline, budesonide and other systemic corticosteroids (parenteral and oral chronic administration only); potentially hepatotoxic drugs (including α-methyl-dopa, sodium valproic acid, isoniazid or nitrofurantoin). * Participants who are currently participating in, plan to participate in, or have participated in an investigational drug study or medical device study containing active substance within 30 days or 5 half-lives, whichever is longer, prior to the screening period. i) If the previous study was for an experimental therapy being studied for potential benefit in PBC, and the potential therapeutic agent was proven to have no beneficial effect in PBC and there are no safety concerns, the participant may enrol after 30 days or 5 half-lives from the last dose of the therapeutic agent, whichever is longer.ii) For therapeutic agents being studied for potential benefit in PBC for which it is still unclear if there may be a potential benefit, participants may enrol after 6 months from the last dose of the therapeutic agent. * Electrocardiogram (ECG) with QT interval corrected by Fridericia's formula (QTcF) \>450 msec in males or QTcF \>470 msec in females for participants without bundle branch block. For participants with bundle branch block or other intraventricular conduction delay, a longer QTcF \>480 msec would be exclusionary. * Total bilirubin (TB) \>5x ULN * Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \>5x ULN at SV1 * Creatinine phosphokinase (CPK) \>2x ULN. * Platelet count \<50,000/μL * International normalised ratio (INR) \>1.8 in the absence of anticoagulant therapy. * Estimated glomerular filtration rate (eGFR) \<45 mL/min/1.73m2 per the Modification of Diet in Renal Disease (MDRD)-6 Study formula at SV1. * Significant renal disease, including nephritic syndrome, chronic kidney disease (CKD) (defined as participants with evidence of significantly impaired kidney function or underlying kidney injury). * For female participants: known current pregnancy, or has a positive serum pregnancy test, or is breastfeeding. * Participants unwilling or unable to be abstinent from alcohol during the study. * History of alcohol abuse, or other substance abuse within 1 year prior to SV1. * Known hypersensitivity to elafibranor or to any of the excipients of the investigational product(s). * Mental instability or incompetence, such that the validity of informed consent or ability to be compliant with the study is uncertain. * Any other condition that, in the opinion of the investigator, would interfere with study participation or completion, or would put the participant at risk, including a potential participant assessed as being at high risk of noncompliance with the study. * Alkaline phosphatase (ALP) ≥10x ULN. * Albumin \<2.8 g/dL due to impaired hepatic function.

Interventions: DRUG: Elafibranor, OTHER: Matched 80 mg placebo

Conditions: Primary Biliary Cholangitis (PBC)

I'm interested

Share via email

Show 160 locations

Study Locations

Hide all locations

Location	Contacts
Agios Savvas Regional Cancer Hospital Athens,
Algemeen Ziekenhuis Delta Roeselare,
American Research Corporation San Antonio, Texas
American Research Corporation at the Texas Liver Institute San Antonio, Texas
Arizona Liver Health Tucson, Arizona
Arkansas Diagnostic Center, PA Little Rock, Arkansas
Artroscan Ostrava,
Assistance Publique - Hopitaux de Paris (AP-HP) - Hopital Universitaire Pitie Salpetriere (Hopital Pitie-Salpetriere) Paris,
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo,
Azienda Ospedaliera di Padova - U.O.C. di Gastroenterologia Padua,
Azienda Ospedaliero Universitaria Federico II di Napoli Naples,
Azienda Ospedaliero Universitaria Modena Modena,
Azienda Ospedaliero Universitaria Pisana Pisa, Tuscany
Baylor Scott & White All Saints Medical Center - Forth Worth Fort Worth, Texas
Bispebjerg Hospital Copenhagen,
Bon Secours St. Mary's Hospital of Richmond, Inc Richmond, Virginia
CHA Bundang Medical Center, CHA University Seongnam-si,
CHU Poitiers Poitiers,
CHU de Nice, Hopital de l'Archet Nice,
Canterbury District Health Board Christchurch,
Cedars-Sinai Medical Center Los Angeles, California
Central Hospital of Northern Pest - Military Hospital Budapest,
Centre Hospitalier Régional Universitaire de Lille - Hôpital Claude Huriez Lille,
Centro Medico Cedid - Centro de Diagnostico Digestivo Viña del Mar,
Centro Medico Colon Córdoba,
Centro de Estudios Clinicos e Investigaciones Medicas (CECIM) Santiago,
Centro de Investigacion Medico Biologica y Terapia Avanzada Jalisco,
Centro de Investigacion y Gastroenterologia SC Mexico City,
Centrul Pentru Studiul Metabolismului Bucharest,
Centrum Medyczne Medyk Sp. z o.o. Sp. K. Rzeszów,
Chung-Ang University Hospital Seoul,
Clinica Universidad Navarra-Sede Madrid Madrid,
Clinique Pasteur Toulouse,
Cluj County Clinical Emergency Hospital Cluj-Napoca,
DIM Centro Medico Buenos Aires,
Diagnostic-Consultative Center Aleksandrovska EOOD Sofia,
Enroll SpA Santiago,
Fondazione I.R.C.C.S. Policlinico San Matteo Pavia,
Footscray Hospital, Western Health Footscray,
Fundacion Respirar (Centro Medico Dra. De Salvo) - Instituto Argentino de Investigaciones Clinicas (IAIC) S.R.L Buenos Aires,
FutureMeds Warszawa Centrum Warsaw,
FutureMeds sp. z o. o Wroclaw,
Galilee Medical Center Nahariya,
Galilee Medical Center, ZIV Medical Center Nahariya,
Gastro health & Nutrition Seattle, Washington
GastroIntestinal Biosciences Los Angeles, California
Gastroenterology Center of the Midsouth Cordova, Tennessee
Gastromedica Srl Iași,
GeneIppokratio General Hospital of Thessaloniki Thessaloniki,
General Hospital of Athens Laiko Athens,
General Oncological Hospital of Kifisia Oi Agioi Anargyroi Athens,
Gent University Hospital Ghent,
Hadassah University Hospital (HUH) - Ein-Kerem Jerusalem,
Hallym University Kangnam Sacred Heart Hospital Seoul,
Hepato-Gastroenterologie HK, s.r.o. Hradec Králové,
Hopital Paul-Brousse - APHP Villejuif,
Hopital Saint Joseph - Marseille Marseille,
Hospices Civils de Lyon (HCL) - Hopital de la Croix-Rousse Lyon,
Hospital Britanico de Buenos Aires Ciudad de Buenos Aires, Buenos Aires
Hospital Clinic i Provincial de Barcelona Barcelona,
Hospital Clinico de la Pontificia Universidad Catolica de Chile Santiago,
Hospital El Cruce Florencio Varela, Buenos Aires,
Hospital Espanol De Mendoza Godoy Cruz, Mendoza Province
Hospital General Universitario Gregorio Maranon (HGUGM) Madrid,
Hospital Universitario Austral Pilar,
Hospital Universitario La Paz Madrid,
Hospital Universitario Miguel Servet Zaragoza,
Hospital Universitario Puerta de Hierro de Majadahonda Majadahonda,
Hospital Universitario Rio Hortega Valladolid,
Hospital Universitario Vall d'Hebron Horta-Guinardó, Barcelona
Hospital Universitario Virgen de la Victoria Málaga,
Hospital Universitario Virgen del Rocio Seville,
Hospital Universitario y Politécnico La Fe Valencia,
Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo Cerqueira César, São Paulo
Hospital de Base - Centro Integrado de Pesquisa ( CIP ) São Paulo,
Hospital de Clinicas de Porto Alegre (HCPA) Porto Alegre,
Hospital de Montecelo Pontevedra,
Houston Methodist Cancer Center Houston, Texas
Huron Gastroenterology Associates - Center for Digestive Care Ypsilanti, Michigan
Impact Research Tx Waco, Texas
Inha University Hospital Incheon,
Inje University Ilsan Paik Hospital Goyang-si, Gyeonggi-do
Institut d Investigacio i Innovacio Parc Tauli, Hospital Universitari Parc Tauli Sabadell,
Institute for Clinical and Experimental Medicine - IKEM Prague,
Instituto D'Or de Pesquisa e Ensino - Hospital Aliança Salvador,
International Center for Research Tampa, Florida
Keimyung University Dongsan Hospital Daegu,
Kenezy County Hospital Debrecen,
Korea University Ansan Hospital Ansan, Gyeonggi-do
Korea University Guro Hospital Seoul,
Krajská nemocnice Liberec Liberec,
Krakowskie Centrum Medyczne Sp.z.o.o - FutureMeds Krakow,
Krakowskie Centrum Medyczne Sp.z.o.o. - FutureMeds Małogoskie,
Kyungpook National University Hospital (KNUH) Junggu,
Liver Associates of Texas Houston, Texas
Liver Center of Texas Dallas, Texas
Louisiana Research Center, LLC Shreveport, Louisiana
Medical Care & Research Yucatán,
Medical University of South Carolina Charleston, South Carolina
Medstar Georgetown Transplant Institute University Hospital (MGUH) Columbia, Washington
Methodist Transplant Physicians Dallas, Texas
Monash University - Monash Health -Monash Medical Centre Melbourne,
NUPEC Cardio Belo Horizonte,
NYU Langone Gastroenterology and Hepatology Associates New York, New York
NZOZ Twoje Zdrowie EL Sp. z o.o. Elblag,
Nepean Clinical School Kingswood,
Niepubliczny Zaklad Opieki Zdrowotnej (NZOZ) - Poliklinika Doktora Bessera Sosnowiec,
Nzoz Centrum BadanKlinicznych Wroclaw,
Ospedale San Gerardo Monza,
Ospedale casa sollievo della sofferenza San Giovanni Rotondo,
Peak Gastroenterology Associates Colorado Springs, Colorado
PlanetMed Sp. z o.o. Wroclaw,
Pusan National University Hospital (PNUH) Busan,
Research Site S.R.O. Pilsen,
Rocky Mountain Gastroenterology Littleton, Colorado
Rush University Medical Center - University Cardiovascular Surgeons Dallas, Texas
Samsung Medical Center Seoul,
Sana S.R.L Bucharest,
Seoul National University Bundang Hospital (SNUBH) Seoul,
Seoul National University Hospital Seoul,
Severance Hospital, Yonsei University Health System Seoul,
Shaare Zedek Medical Center Jerusalem,
South Denver Gastroenterology, P.C. Englewood, Colorado
Southern California Research Center Coronado, California
Southwest Gastroenterology Associates, PC (SWGA) Albuquerque, New Mexico
Spital Clinic Dr I Cantacuzino Bucharest,
St George Hospital Sydney,
Sunshine Coast University Hospital Birtinya, Queensland
Szegedi Tudomanyegyetem AOK, I. sz Belgyogyaszati Klinika Szeged,
Szpital Uniwersytecki w Krakowie Krakow,
Texas Clinical Research Institute Arlington, Texas
The Catholic University of Korea Daejeon St.Mary's Hospital Daejeon,
The Catholic University of Korea, Eunpyeong St. Mary's Hospital Seoul, Eunpyeong-gu
The Catholic University of Korea, Seoul St. Mary's Hospital Seoul,
The Catholic University of Korea, Uijeongbu St. Mary's Hospital Uijeongbu-si,
Tokuda Hospital, Dept. of Internal Medicine Sofia,
Universidad De Los Andes Las Condes,
Universidade Estadual Paulista Julio De Mesquita Filho (UNESP) Hospital das Clinicas Faculdade de Medicina de Botucatu (HCFMB) São Paulo,
Universidade Federal de Goias Goiânia, Goiás
Universitair Ziekenhuis Antwerpen Edegem,
University Health Network (UHN) - Toronto General Hospital (TGH) - Toronto General Research Institute (TGRI) Toronto,
University Hospital City Clinic Cancer Center Sofia,
University Of Miami School Of Medicine, Center For Liver Diseases Miami, Florida
University of Alberta - Faculty of Medicine & Dentistry - The Centre of Excellence for Gastrointestinal Inflammation and Immunity Research (CEGIIR) Edmonton,
University of California Davis Medical Center Sacramento, California
University of California Los Angeles Los Angeles, California
University of Chile Clinical Hospital (Hospital Clinico de la Universidad de Chile) Santiago,
University of Colorado Aurora, Colorado
University of Kansas Medical Center (KUMC) - University of Kansas Liver Center - Hepatology Clinic Kansas City, Kansas
University of Michigan Health System Ann Arbor, Michigan
University of Pittsburgh Pittsburgh, Pennsylvania
University of Texas Southwestern Medical Center at Dallas Dallas, Texas
University of Virginia Medical Center Charlottesville, Virginia
Uniwersyteckie Centrum Kliniczne im. prof. K. Gibinskiego Slaskiego Uniwersytetu Medycznego Katowice,
Velocity Clinical Research at Liver Institute Northwest Seattle, Washington
Virginia Commonwealth University Medical Center - West Hospital Richmond, Virginia
Waikato Hospital Hamilton, Waikato Region
Westmead Hospital Westmead, New South Wales
Ziekenhuis Oost-Limburg Genk,
hospital Italiano de Buenos Aires Ciudad Autonoma Buenos Aires,

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

Contact(s):

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com - Clinical.Trials@bms.com

Principal Investigator:

System ID: NCT06025578

Show full eligibility criteria

Inclusion Criteria * Diagnosis of interstitial lung disease (ILD) with features consistent with progressive ILD within 24 months prior to screening, and ≥ 10% extent of fibrosis on screening high-resolution computed tomography (HRCT). * If on pirfenidone or nintedanib, participants must have been on a stable dose for at least 90 days prior to screening. * If not currently on pirfenidone or nintedanib, participants must not have received either of these medications within 28 days prior to screening. * Mycophenolate mofetil (MMF), mycophenolic acid (MA), azathioprine (AZA), and Tacrolimus are permitted provided that the participant is on a stable dose for at least 90 days prior to screening. If not currently on MMF, MA, AZA, or tacrolimus, participants must not have taken these medications within 28 days prior to screening. * Traditional disease-modifying antirheumatic drug (DMARDs) (eg. Methotrexate, leflunomide, sulfasalazine, or hydroxychloroquine) are permitted provided that the participant is on a stable dose for at least 90 days prior to screening. If not currently on traditional DMARD, participants must not have taken these medications within 28 days prior to screening. * Biologic DMARDs (eg. TNF blockers and IL-1 inhibitors) and Janus kinase inhibitors (JAK inhibitors eg. tofacitinib, upadacitinib) are permitted provided that the participant is on a stable dose for at least 90 days prior to screening. If not currently on Biologic DMARD or JAK inhibitor, participants must not have taken these medications within 28 days prior to screening. * Women who are of childbearing potential must have a highly effective form of contraception and must provide a negative urine/serum pregnancy test. * Men who are sexually active with women of childbearing potential agree to use male barrier contraception. Exclusion Criteria * Idiopathic pulmonary fibrosis with usual interstitial pneumonia (UIP) verification at screening. * History of stroke or transient ischemic attack within 3 months prior to screening. * Participants who exhibit symptoms of heart failure at rest. * Participants who have a current malignancy; a previous malignancy with less than 2 years free of recurrence; and a biopsy that is suspicious for malignancy and the possibility of malignancy cannot be reasonably excluded following additional clinical, laboratory, or other diagnostic evaluations. * Use of systemic corticosteroids equivalent to prednisone \> 15 mg/day is not allowed within 4 weeks prior to screening and during the study. * Other protocol-defined Inclusion/Exclusion criteria apply.

Interventions: DRUG: BMS-986278, DRUG: BMS-986278 Placebo

Conditions: Progressive Pulmonary Fibrosis

Keywords: BMS-986278, LPA1 antagonist, Pulmonary fibrosis, Interstitial lung disease, Rheumatoid Arthritis, Connective Tissue Disorders, Sarcoidosis, Scleroderma, Fibrosis, Antifibrotic therapy

I'm interested

Share via email

Show 536 locations

Study Locations

Hide all locations

Location	Contacts
"Corfu General Hospital ""St. IRINI""" Corfu,
"Ospedale ""Gian Battista Morgagni - Luigi Pierantoni"" di Forli" Forlì,
ACE Hospital & Research Center Pune, Maharashtra
AORN - Ospedali dei Colli Ospedale V. Monaldi Napoli,
Ajou University Hospital Suwon, Gyeonggi-do
All India Institute of Medical Sciences New Delhi, National Capital Territory of Delhi
Alliance Pulmonary Group Guaynabo, PR
Amsterdam UMC - Locatie VUMC - Pulmonale Hypertensie (PH) Kenniscentrum Amsterdam,
AnMed Health Oglesby Center - AnMed Health Pulmonary and Sleep Medicine Anderson, South Carolina
Anhui Medical University - Anhui Chest Hospital Hefei, AH
Anhui Provincial Hospital Hefei City, Anhui Province, Anhui
Asan Medical Center (AMC) Songpa-gu, Seoul
Aso Iizuka Hospital Iizuka-shi,
Assistance Publique Hopitaux de Marseille - Hopital Nord Marseille,
Asst Papa Giovanni XXIII Bergamo, Lombardy
Asthma Bhawan Jaipur, Rajasthan
Athens Medical Center Marousi, Attica
Avanza Medical Research Center Pensacola, Florida
Azienda Ospedaliera San Paolo Milan,
Azienda Ospedaliera Universitaria - Universita di Sassari Sassari,
Azienda Ospedaliero - Universitaria di Modena Policlinico Modena, Emilia-Romagna
Azienda Ospedaliero Universitaria Pisana Pisa, Tuscany
Azienda Ospedaliero Universitaria delle Marche Ancona,
Azienda Ospedaliero-Universitaria Careggi Florence, Tuscany
Baylor College of Medicine Medical Center - Pulmonary, Critical Care, and Sleep Medicine Houston, Texas
Baylor University Medical Center at Dallas Dallas, Texas
Beaumont Hospital, Royal Oak Royal Oak, Michigan
Beijing Chaoyang Hospital, Capital Medical University Beijing, Beijing Municipality
Beijing Friendship Hospital, Capital Medical University Beijing, BJ
Ben-Gurion University of the Negev - Soroka University Medical Center Beersheba, D
Bioreuma Concepción, Bio Bio
Brightshores Health System Owen Sound, Ontario
C.I.C. Joliette Saint-Charles-Borromée, Quebec
C.I.C. Mauricie Inc. Trois-Rivières, Quebec
CEC Centros Estudios Clinicos Santiago, RM
CEMEC - Centro Multidisciplinar de Estudos Clínicos São Bernardo do Campo, São Paulo
CENRESIN - Centro Respiratorio Integral Quillota, Región de Valparaíso
CHRU de Tours - Hôpital Bretonneau Tours,
CHU Dijon - Hôpital François Mitterrand Dijon,
CHU Hopitaux de Bordeaux - Hopital Haut-Leveque Pessac,
CHU UCL Namur - Mont-Godinne Yvoir, Namur
CHU de Brest - Hôpital Cavale Blanche Brest,
CHU de Nantes - Hôpital Nord Laennec Nantes, Pays de la Loire Region
CHU de Nice - Hopital Pasteur Nice,
CICUM San Miguel Guadalajara, Jalisco
Carmel Medical Center Haifa,
Center Hospital of the National Center for Global Health and Medicine Shinjyu-Ku,
Centre Hospitalier Universitaire Grenoble Alpes (CHU Grenoble Alpes) Grenoble, Auvergne-Rhône-Alpes
Centre Hospitalier Universitaire d'Angers Angers,
Centre Hospitalier Universitaire de Liege - Sart Tilman Liège,
Centre Hospitalier de L'Universite de Montreal (CHUM) Montreal, Quebec
Centro Medico Santa Maria Barra Mansa, Rio de Janeiro
Centro Medico de Enfermedades Respiratorias Florida, B
Centro Respiratorio Quilmes Quilmes, Provincia de Buenos Aires, B
Centro Respiratorio de México México, DIF
Centro de Estudos de Pneumologia da Faculdade de Medicina do ABC (CEPFMABC) Santo André, São Paulo
Centro de Investigacion Clinica de Oaxaca (CICLO) Oaxaca City, Oaxaca
Centro de Investigacion Clinica en Mexico (CIMeT) Guadalajara, Jalisco
Centro de Investigacion Curico Curicó, Maule Region
Centro de Investigacion Medica Aguascalientes Aguascalientes, Aguascalientes
Centro de Investigacion Medico Biologica y Terapia Avanzada (CIMBYTA) Guadalajara,
Centro de Investigacion de Enfermedades Respiratorias e Imunologicas (CIERI) Viña del Mar, Región de Valparaíso
Centro de Investigaciones Metabólicas (CINME) Buenos Aires,
Centro de Investigación Clínica Chapultepec S.A. de C.V. Morelia, Michoacán
Centro de Investigación del Maule Talca,
Centrum Medycyny Oddechowej Bialystok, Podlaskie Voivodeship
Chang Gung Medical Foundation - Kaohsiung Branch Kaohsiung City, Kao-Hsiung
Changhua Christian Hospital Changhua County,
Chiba University Hospital Chiba, Chiba,
China Medical University Hospital Taichung,
Christiana Care Pulmonary Associates - Newark Newark, Delaware
Clinica 25 de Mayo Mar del Plata, B
Clinica Cardio Vid Medellín, ANT
Clinica Internacional - Sede San Borja San Borja, Lima region
Clinica La Luz - Lima Lima,
Clinica Providencia San Miguel, LIM
Clinica Ricardo Palma Lima, LIM
Clinica Universidad de Navarra Madrid,
Clinica Universidad de los Andes Santiago, RM
Cliniques Universitaires Saint-Luc Brussels,
Clínica Belén Piura, PIU
Clínica Universidad de Navarra -Madrid Madrid,
Clínica de día Jockey Salud Lima, LIM
Coastal Pulmonary & Critical Care, P.L.C. St. Petersburg, Florida
Connolly Hospital Blanchardstown Dublin,
Consultorios Médicos del Buen Ayre Caba, B
David Geffen School of Medicine at UCLA Los Angeles, California
Diex Recherche - Trois-Rivieres Trois-Rivières, Quebec
Duke University Medical Center Durham, North Carolina
Eastern Health Box Hill, Victoria
Ege Universitesi Tip Fakultesi Hastanesi (Ege University Medical Faculty Hospital) Izmir,
Emory Clinic Atlanta, Georgia
Erasmus MC - Centrum voor Interstitiele Longziekten Rotterdam, South Holland
Escola Paulista de Medicina São Paulo,
Fachkrankenhaus Coswig GmbH Coswig,
Florida Lung, Asthma and Sleep Specialists - Celebration Celebration, Florida
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milan, MI
Fondazione IRCCS Policlinico San Matteo Pavia,
Fondazione IRCCS San Gerardo dei Tintori Monza,
Fondazione Policlinico Universitario Agostino Gemelli Roma,
Fortis Hospital Mohali Mohali, Punjab
Fujita Health University Hospital Toyoake,
Fukuoka University - Chikushi Hospital Chikushino-shi, Fukuoka
Fundacion Enfisema - Instituto Ave Pulmo Mar del Plata, Buenos Aires
Fundacion Respirar Buenos Aires, B
Fundacion Santa Fe de Bogota Bogotá,
Fundación Neumológica Colombiana Bogotá, DC
Gachon University - Gil Medical Center Incheon,
Gallipoli Medical Research Centre - Clinical Trials Unit (CTU) Greenslopes, Queensland
General Hospital of Ningxia Medical University Ningxia, Yinchuan
General Hospital of Thessaloniki - Papageorgiou Thessaloniki,
Gentofte Hospital Hellerup,
Getwell Hospital and Research Institute - Lungs Care Nagpur, Maharashtra
Giromed Institute, SLP Barcelona,
Grant Medical Foundation - Ruby Hall Clinic Pune,
Green City Hospital Bhopal, Madhya Pradesh
Guy's and St Thomas' NHS Foundation Trust - Royal Brompton Hospital London, Greater London
Gyor-Moson-Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz Győr,
HELIOS Klinikum Emil von Behring Berlin, State of Berlin
Hadassah Medical Center (HMC) - Hadassah University Hospital (HUH) - Ein Kerem Jerusalem,
Hamamatsu University Hospital Shizuoka, Hamamatsu,
Hangzhou First People's Hospital Hangzhou,
Health SURA Calle 100 Bogotá, DC
Health SURA Chipichape Santiago de Cali, VAC
Healthy Medical Center Zipaquirá, Cundinamarca
Helios Hanseklinikum Stralsund Stralstund,
Helsinki University Hospital Heart and Lung Center Helsinki, Etelae-Suomen Laeaeni
Henan provincial people's hospital Zhengzhou, HA
Hiroshima Prefectural Hospital Hiroshima, Hirohima-ken
Hokkaido University Hospital Hokkaido, Sapporo,
Hopital Avicenne Bobigny,
Hopitaux Universitaires de Geneve (HUG) Geneva, Canton of Geneva
Hospices Civils de Lyon Bron, Auvergne-Rhône-Alpes
Hospital Alemao Oswaldo Cruz (HAOC) - Centro de Oncologia (Oncology Center) São Paulo,
Hospital CUF Tejo Lisbon,
Hospital Canselor Tuanku Muhriz UKM Cheras,
Hospital Clinic de Barcelona Barcelona,
Hospital Clinico San Carlos Madrid,
Hospital Clinico Universitario Madrid,
Hospital Dia do Pulmão Blumenau, Santa Catarina
Hospital Ernesto Dornelles (HED) Porto Alegre, Rio Grande do Sul
Hospital Madre Teresa Belo Horizonte, Minas Gerais
Hospital Nacional Cayetano Heredia Lima,
Hospital Sao Lucas da PUCRS Porto Alegre,
Hospital Umum Sarawak Kuching,
Hospital Universitari de Bellvitge (IDIBELL) Barcelona,
Hospital Universitario Central de Asturias Oviedo, Principality of Asturias
Hospital Universitario Fundacion Jimenez Diaz Madrid,
Hospital Universitario La Paz Madrid,
Hospital Universitario Marqués de Valdecilla Santander,
Hospital Universitario Puerta De Hierro - Majadahonda Majadahonda, M
Hospital Universitario San Ignacio Bogota, Cundinamarca
Hospital Universitario Vall d'Hebron Horta-Guinardó, Barcelona
Hospital Universitario Virgen de la Victoria Málaga,
Hospital Universitario de La Princesa Madrid, M
Hospital das Clínicas da Universidade Federal de Minas Gerais (UFMG) Belo Horizonte, Minas Gerais
Hospital de Santa Marta Lisbon,
Huadong Hospital Affiliated to Fudan University Shanghai,
Hull and East Yorkshire Hospitals NHS Trust - Castle Hill Hospital Cottingham, Yorkshire and the Humber
Hôpital Bichat - Claude-Bernard Paris, Île-de-France Region
Hôpital Larrey Toulouse,
Ibamedica Santa Fe,
Icahn School of Medicine at Mount Sinai New York, New York
Inje University Busan Paik Hospital BusanjinGu, Busan Gwang'yeogsi
Inje University Haeundae Paik Hospital Busan,
Inje University Ilsan Paik Hospital Goyang-si, Gyeonggi-do
Inselspital - Universitaetsklinik Bern für Pneumologie Bern, Canton of Bern
Inspiration Research Toronto, Ontario
Institut Perubatan Respiratori Kuala Lumpur,
Institute for Respiratory Health Nedlands, Western Australia
Institute of Science Tokyo Hospital Tokyo, Bunkyo-ku,
Instituto De Enfermedades Respiratorias E Investigacion Medica (IERIM) San Juan Bautista, Buenos Aires
Instituto Medico DAMIC Córdoba, Córdoba Province
Instituto Medico INSARES SA Mendoza, M
Instituto Medico de la Fundacion de Estudios Clínicos Rosario, S
Instituto Nacional del Tórax Santiago,
Instituto Neumologico del Oriente Floridablanca, Santander Department
Investigacion Clinica por la Slaud de Cordoba - SALUDCOR Córdoba, Veracruz
Investigaciones en Patologias Respiratorias San Miguel de Tucuman, Tucumán, T
Istanbul Universitesi - Istanbul Tip Fakultesi (ITF) Hastanesi Topkapı,
Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione (ISMETT) Palermo,
Jehangir Clinical Development Center Pune, Maharashtra
Jichi Medical University Hospital Shimotsuke,
Jizankai Medical Foundation Tsuboi Cancer Center Hospital Koriyama-shi, Fukushima
Juntendo University Hospital Bunkyo-ku, Tokyo
K.L.E.S. Dr. Prabhakar Kore Hospital & Medical Research Centre Belagavi, Karnataka
Kameda Medical Center - Kameda Clinic Kamogawa-shi, Chiba
Kanagawa Cardiovascular and Respiratory Center Kanagawa, Yokohama,
Kaohsiung Medical University Chung-Ho Memorial Hospital Kaohsiung City,
Kaplan Medical Center Rehovot, Central District
Keio University Hospital Tokyo, Shinjuku-ku,
Kelowna Respiratory & Allergy Clinic Kelowna, British Columbia
Kepler Universitatsklinikum Linz, Upper Austria
Kindai University Hospital Sayama, Osaka
King George's Medical University Lucknow, Uttar Pradesh
Kitasato University Hospital Sagamihara, Kanagawa
Klinikum der Universitat Munchen Munich, Bavaria
Kobe City Medical Center General Hospital KobeShi, Hyōgo
Krankenhaus Hietzing Vienna,
Krankenhaus der Augustinerinnen- Klinik fuer Pneumologie, Allergologie, Schlaf- und Beatmungsmedizin Cologne, Northwest
Kurume University Hospital Fukuoka,
Kyorin University Hospital Tokyo,
Kyushu University Hospital Fukuoka, Fukuoka,
Layrek Clinical Research Tulsa, Oklahoma
Leeds Teaching Hospitals NHS Trust Leeds, West Yorkshire
Leids Universitair Medisch Centrum Leiden,
Local Institution - 0007 Mexico City,
Local Institution - 0031 Detroit, Michigan
Local Institution - 0033 Towson, Maryland
Local Institution - 0040 Evanston, Illinois
Local Institution - 0045 Louisville, Kentucky
Local Institution - 0053 Burlington, Ontario
Local Institution - 0059 Los Angeles, California
Local Institution - 0066 Massillon, Ohio
Local Institution - 0069 Seoul, Seoul-teukbyeolsi [Seoul]
Local Institution - 0078 Monterrey, Nuevo León
Local Institution - 0079 Tours, Indre-et-Loire
Local Institution - 0090 Bordeaux, Aquitaine
Local Institution - 0093 Salamanca,
Local Institution - 0098 Porto,
Local Institution - 0099 Sherbrooke, Quebec
Local Institution - 0102 Madrid,
Local Institution - 0110 Santiago, Santiago Metropolitan
Local Institution - 0125 Wangen I. Allgaeu, Baden-Wurttemberg
Local Institution - 0131 Busan, Pusan-Kwangyǒkshi
Local Institution - 0142 Münster, Northwest
Local Institution - 0153 Montreal, Quebec
Local Institution - 0166 Ōsaka-sayama, Osaka
Local Institution - 0169 Badalona, B
Local Institution - 0181 Maltepe,
Local Institution - 0197 Valencia, V
Local Institution - 0200 Créteil, Val-de-Marne
Local Institution - 0219 Exeter, South West
Local Institution - 0220 Ocala, Florida
Local Institution - 0224 Gümüşhane, Gümüşhane Province
Local Institution - 0228 Bunkyō City,
Local Institution - 0230 Tokushina-Shi, Tokushima
Local Institution - 0238 Prague,
Local Institution - 0241 Vienna,
Local Institution - 0245 Nagpur, Maharashtra
Local Institution - 0247 Jaipur, Rajasthan
Local Institution - 0251 Milan, MI
Local Institution - 0252 Lille,
Local Institution - 0256 Olomouc, OL
Local Institution - 0259 Krakow, Lesser Poland Voivodeship
Local Institution - 0275 Adelaide, South Australia
Local Institution - 0276 Anjo, Aichi-ken
Local Institution - 0294 Stuttgart, Baden-Wurttemberg
Local Institution - 0299 Heidelberg,VIC, Victoria
Local Institution - 0303 Murdoch, Western Australia
Local Institution - 0304 Salvador, Estado de Bahia
Local Institution - 0331 Chūō, Yamanashi
Local Institution - 0332 Brest, Finistère
Local Institution - 0335 Saint-Cloud, Hauts-de-Seine
Local Institution - 0338 Amsterdam,
Local Institution - 0346 Chicago, Illinois
Local Institution - 0347 Osaka,
Local Institution - 0351 Bristol, BST
Local Institution - 0353 South Shields, STY
Local Institution - 0356 Birtinya, Queensland
Local Institution - 0360 Southport, Queensland
Local Institution - 0365 Frankston, Victoria
Local Institution - 0367 Dunedin, Otago
Local Institution - 0371 Nagoya, Aichi-ken
Local Institution - 0378 Weston, Florida
Local Institution - 0381 London, LND
Local Institution - 0383 Augsburg, Bavaria
Local Institution - 0385 Wels, Upper Austria
Local Institution - 0391 Oslo,
Local Institution - 0392 Sofia,
Local Institution - 0395 Ioannina, Ípeiros
Local Institution - 0397 Chaïdári, Attikí
Local Institution - 0398 Alexandroupoli, Anatolikí Makedonía Kai Thráki
Local Institution - 0407 Ahmedabad, Gujarat
Local Institution - 0411 Mexico City, Mexico City
Local Institution - 0412 A Coruña, A Coruña [La Coruña]
Local Institution - 0416 Riyadh,
Local Institution - 0420 Sarıçam, Adana
Local Institution - 0422 Ankara,
Local Institution - 0423 Kitakyushu-shi, Fukuoka
Local Institution - 0424 Suzhou, Jiangsu
Local Institution - 0427 Singapore, Central Singapore
Local Institution - 0436 Edgewood, Kentucky
Local Institution - 0437 Kansas City, Missouri
Local Institution - 0441 Deagu, Taegu-Kwangyǒkshi
Local Institution - 0445 Riyadh, Riyadh Region
Local Institution - 0456 Seongnam, Kyǒnggi-do
Local Institution - 0457 Nagpur, Maharashtra
Local Institution - 0463 Hermosillo, Sonora
Local Institution - 0464 Pilea Chortiatis, Thessaloniki
Local Institution - 0465 Tacoma, Washington
Local Institution - 0466 Pittsburgh, Pennsylvania
Local Institution - 0467 Darlinghurst, New South Wales
Local Institution - 0468 Santiago,
Local Institution - 0469 Rock Hill, South Carolina
Local Institution - 0470 Santa Cruz de Tenerife,
Local Institution - 0471 Coimbatore, Tamil Nadu
Local Institution - 0473 Graz, Styria
Local Institution - 0476 Engenho Velho da Federação, Salvador
Local Institution - 0478 Sankt Gallen,
Local Institution - 0479 Bangkok,
Local Institution - 0481 Bangkok Noi, Bangkok
Local Institution - 0483 Kajang, Selangor
Local Institution - 0485 Chiang Mai, Chiang Mai
Local Institution - 0487 Solna, Stockholms Län [se-01]
Local Institution - 0488 Madrid,
Local Institution - 0491 Badalona, Barcelona [Barcelona]
Local Institution - 0499 Groningen,
Local Institution - 0503 Cottbus,
Local Institution - 0505 Erlangen, Bavaria
Local Institution - 0512 Bayreuth, Bavaria
Local Institution - 0516 Houston, Texas
Local Institution - 0517 Miami, Florida
Local Institution - 0520 Lodz,
Local Institution - 0526 Tucson, Arizona
Local Institution - 0527 Jaipur, Rajasthan
Local Institution - 0528 Hyderabad, Telangana
Local Institution - 0529 Greenfield Park, Quebec
Local Institution - 0533 Konstanz, Baden-Wurttemberg
Local Institution - 0536 Changsha,
Loyola University Health System Maywood, Illinois
Lungenfachklinik Immenhausen Immenhausen,
M Health Fairview University of Minnesota Medical Center - CSC - Center for Lung Science and Health Minneapolis, Minnesota
MICS Centrum Medyczne Bydgoszcz Bydgoszcz, Kuyavian-Pomeranian Voivodeship
Malcom Randall VA Medical Center Gainesville, Florida
Marengo CIMS Hospital Ahmedabad, Gujarat
Massachusetts General Hospital Boston, Massachusetts
Mater Misericordiae Limited South Brisbane, Queensland
Matsusaka Municipal Hospital Matsusaka-shi, Mie-ken
Max Super Specialty Hospital, Saket - West Block - A Unit of Max Healthcare Institute Limited New Delhi, National Capital Territory of Delhi
McGovern Medical School - UT Physicians - Pulmonary Medicine - Texas Medical Center Location Houston, Texas
MedStar Georgetown University Hospital Washington D.C., District of Columbia
Medical Care & Research S.A. de C.V. Mérida, Yucatán
Medical University of South Carolina- College of Medicine Charleston, South Carolina
Medicos Internistas de Caldas Manizales, CL
Mercy St. Vincent Medical Center Toledo, Ohio
Meris Clinical Research Brandon, Florida
Metroplex Pulmonary and Sleep Center McKinney, Texas
Midland Healthcare & Research Center Lucknow,
Myongji Hospital Goyang-si, Gyeonggi-do
Mérida Investigación Clínica Mérida, Yucatán
NHS Lothian - Royal Infirmary of Edinburgh Edinburgh, EDH
NHS Tayside Dundee, DND
NZOZ Przychodnia Vitamed Bydgoszcz, Kuyavian-Pomeranian Voivodeship
Nagasaki University Hospital Nagasaki, Nagasaki,
Nagoya University Hospital Aichi, Nagoya,
Nanfang Hospital of Southern Medical University Guangzhou, Guangdong
Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School Nanjing, JS
National Hospital Organization - Yamaguchi-Ube Medical Center Ube-shi, Yamaguchi
National Hospital Organization Himeji Medical Center Himeji-Shi, Hyōgo
National Hospital Organization Ibarakihigashi National Hospital Naka-gun, Gunma
National Hospital Organization Kinki-Chuo Chest Medical Center Osaka, Sakai,
National Hospital Organization Kyushu Medical Center Fukuoka, Fukuoka
National Jewish Health Denver, Colorado
National Taiwan University Hospital - The National Center of Excellence for Clinical Trial Taipei,
National Taiwan University Hospital Yun-Lin Branch Yunlin County,
NewportNativeMD, Inc. Newport Beach, California
Nilratan Sircar (NRS) Medical College & Hospital Kolkata, West Bengal
Nippon Medical School Hospital Bunkyo-Ku, Tokyo
Northern Westchester Hospital Mount Kisco, New York
Northwestern Memorial Hospital Chicago, Illinois
Norton Healthcare, Inc. Louisville, Kentucky
OU Health Sciences Center - OU Health Physicians - Cardiology, Pulmonary & Vascular Medicine Clinic Oklahoma City, Oklahoma
Oaxaca Site Management Organization (OSMO) Oaxaca City, Oaxaca
Odense Universitetshospital - Svendborg Sygehus Odense C, Region Syddanmark
Omega Research Consultants LLC DeBary, Florida
OncoCentro - Vina del Mar Viña del Mar,
Oregon Health & Science University - Pulmonary Clinic Portland, Oregon
Osaka Medical and Pharmaceutical University Hospital Takatsuki-Shi,
Ospedale Colonnello D'Avanzo Foggia Foggia,
Ospedale Policlinico di Siena Siena,
Our Lady of Lourdes Hospital - Drogheda Drogheda, LH
Oxford University Hospitals NHS Trust - Churchill Hospital Oxford, Oxfordshire
Papworth Hospital NHS Foundation Trust Cambridge, Cambridgeshire
Peking Union Medical College Hospital Beijing,
Peking University Shenzhen Hospital Shenzhen,
Penn Medicine - Perelman Center for Advanced Medicine Philadelphia, Pennsylvania
Penn State Milton S. Hershey Medical Center Hershey, Pennsylvania
Peterborough City Hospital Peterborough, PTE
Policlínica Piquet Carneiro, Universidade do Estado do Rio de Janeiro Rio de Janeiro, Rio de Janeiro
Pulmonary Specialists of the Palm Beaches Loxahatchee Groves, Florida
Pulmonology Associates - Wynnewood Wynnewood, Pennsylvania
Pulmonology, Sleep, Asthma & Allergy Center of Dublin Dublin, Georgia
Qilu Hospital of Shandong University Jinan, Shandong
Rabin Medical Center - Hasharon Hospital Petah Tikva,
Rambam Health Care Campus - Pulmonology Haifa,
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine - South Branch Shanghai, SH
Renmin Hospital of Wuhan University Wuhan,
Renown Regional Medical Center Reno, Nevada
Respira Salud Clinica Integral Godoy Cruz, M
Rigshospitalet Copenhagen,
Royal Prince Alfred Hospital Camperdown, New South Wales
SALK - Universitatsklinik Fur Pneumologie/ Lungenheilkunde Landeskrankenhaus Salzburg, Salzburger Land
Saiseikai Kumamoto Hospital Kumamoto,
Santa Casa de Misericórdia de Porto Alegre - Hospital Sao Jose Porto Alegre, Rio Grande do Sul
Santiago Clinic Hospital (Hospital Clínico Universitario de Santiago -CHUS) Santiago de Compostela, Galicia
Sapporo Medical University Hospital Sapporo, Hokkaido
Scripps Clinic Torrey Pines La Jolla, California
Semmelweis Egyetem Pulmonologiai Klinika Budapest,
Seoul National University Bundang Hospital Seongnam-si,
Seoul National University Hospital Seoul,
Servicios de Salud IPS Suramericana S.A.S - IPS Sura Industriales Medellín Medellín, ANT
Shamir medical center Be’er Ya‘aqov, M
Shanghai Jiao Tong University - Shanghai Chest Hospital Shanghai, SH
Shanghai Jiaotong University Affiliated Sixth People's Hospital Shanghai,
Shanghai Pulmonary Hospital Shanghai,
Shenyang Chest Hospital Shenyang, Liaoning
Shenzhen People's Hospital Shenzhen,
Shimane University Hospital Izumo-Shi,
Shri Guru Ram Rai (SGRR) Institute of Medical and Health Sciences - Shri Mahant Indiresh Hospital Dehradun, Uttarakhand
Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital Chengdu,
Sir Run Run Shaw Hospital of Zhejiang University School of Medicine Hangzhou, Zhejiang
SoonChunHyang University Bucheon Hospital Bucheon-si, Gyeonggi-do
SoonChunHyang University Seoul Hospital Yongsan-gu, Seoul
South Texas Veterans Health Care System - Audie L. Murphy VA Hospital San Antonio, Texas
Southeastern Research Center Winston-Salem, North Carolina
Spectrum Health Medical Group Pulmonary Grand Rapids, Michigan
St Francis Sleep Allergy & Lung Institute Clearwater, Florida
St. Antonius Ziekenhuis Nieuwegein,
St. John's Medical College Bangalore,
St. Joseph's Healthcare Hamilton Hamilton, Ontario
St. Joseph's Hospital and Medical Center Phoenix, Arizona
St. Paul's Hospital Vancouver, British Columbia
St. Vincent's University Hospital Dublin,
Stamford Health Medical Group - Stamford - 29 Hospital Plaza Suite 605 Stamford, Connecticut
Stanford Hospital and Clinics Stanford, California
Synergy Respiratory & Cardiac Care Sherwood Park, Alberta
TC Saglik Bakanlig -Izmir Dr.Suat Seren Gogus Hastaliklari Ve Cerrahisi Egitim Arastirma Hastanesi Izmir,
Taichung Veterans General Hospital Taichung, China
Taipei Veterans General Hospital Taipei, Beitou District / R.o.c.
Tallaght University Hospital Dublin, Co Dublin
Tampa General Hospital Tampa, Florida
Tel Aviv Sourasky Medical Center Tel Aviv,
Temple University Hospital (TUH) - Temple Lung Center (TLC) Philadelphia, Pennsylvania
Tenri Hospital Tenri,
The Affiliated Hospital of Inner Mongolia Medical University Hohhot,
The Affiliated Hospital of Xuzhou Medical University Xuzhou,
The Calcutta Medical Research Institute (CMRI) Kolkata, West Bengal
The Catholic University of Korea, Bucheon St. Mary's Hospital Bucheonsi Weonmigu,
The First Affiliated Hospital of Guangzhou Medical University Guangzhou,
The First Affiliated Hospital of Nanchang University - Xianghu District Nanchang, JX
The First Affiliated Hospital of Ningbo University Ningbo,
The First Affiliated Hospital of Soochow University Suzhou, Jiangsu
The First Affiliated Hospital of Zhengzhou University Zhengzhou,
The First Affiliated Hospital, Sun Yat-sen University Guangzhou, Guangdong
The First Hospital of China Medical University Shenyang, Liaoning
The First Hospital of Lanzhou University Lanzhou, Gansu
The Jikei University Hospital Minato-ku, Tokyo
The Lung Centre Vancouver, British Columbia
The Lung Research Center Chesterfield, Missouri
The Ohio State University Wexner Medical Center Columbus, Ohio
The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou, Zhejiang
The Second Hospital of Hebei Medical University Shijiazhuang, Hebi
The Second Xiangya Hospital of Central South University Changsha,
The Third Hospital of Hebei Medical University Shijiazhuang,
The University of Alabama at Birmingham Birmingham, Alabama
The University of Chicago Medicine Chicago, Illinois
The University of Vermont Burlington, Vermont
Thomas Jefferson University Hospital - Jane and Leonard Korman Lung Center Philadelphia, Pennsylvania
Thoraxklinik-Heidelberg gGmbH Heidelberg,
Thoraxzentrum Bezirk Unterfranken Münnerstadt, Bavaria
Tianjin Chest Hospital Tianjin, TJ
Tianjin Medical University General Hospital Tianjin,
Toho University - Omori Medical Center Tokyo,
Toho University Ohashi Medical Center Tokyo,
Tokyo Medical University Hospital Shinjuku-Ku, Tokyo
Tokyo Women's Medical University Hospital Tokyo, Shinjuku-ku,
Toranomon Hospital Tokyo, Minato-ku,
Tosei General Hospital Seto,
Turun Yliopistollinen Keskussairaala (TYKS) Turku, Laensi-Suomen Laeaeni
UC Irvine Medical Center Orange, California
UZ Leuven Leuven,
Ulsan University Hospital (UUH) Dong-gu, Ulsan
Uludag Universitesi Tip Fakultesi (Uludag University Faculty of Medicine) Bursa,
Unidad de lnvestigacion CIMA S.C. Chihuahua City,
Unidade Local de Saude Braga Braga,
Unidade Local de Saude de Gaia/Espinho, EPE Vila Nova de Gaia,
Unidade Local de Saude de Loures - Odivelas, E. P. E. Loures,
Unidade Local de Saude de Santa Maria, EPE - Hospital Pulido Valente Lisbon,
Unidade Local de Saude de Santo Antonio, E.P.E. Porto,
Unidade Local de Saude de Sao Joao, EPE - Hospital de Sao Joao Porto,
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei
Unity Hospital Fridley, Minnesota
Universidade Estadual Paulista - Hospital das Clinicas da Faculdade de Medicina de Botucatu (HCFMB) Botucatu, São Paulo
Universitaetsklinikum Essen - Ruhrlandklinik Essen, North Rhine-Westphalia
Universitaetsklinikum Freiburg - Klinik fuer Pneumologie Freiburg I. Breisgau, Baden-Wurttemberg
Universitaetsklinikum Leipzig - Klinik und Poliklinik fuer Pneumologie Leipzig,
University General Hospital Attikon Athens,
University General Hospital of Heraklion Heraklion, Crete,
University Hospital of Ioannina Ioannina, Epirus
University Hospitals Birmingham NHS Foundation Trust - Heartlands Hospital Birmingham, BIR
University Hospitals Birmingham NHS Foundation Trust - New Queen Elizabeth Hospital Birmingham Birmingham,
University Hospitals Cleveland Medical Center Cleveland, Ohio
University of California UC Davis Medical Center Sacramento, California
University of California, San Francisco Medical Center- Pulmonary Practice San Francisco, California
University of Cincinnati College of Medicine Cincinnati, Ohio
University of Colorado Anschutz Medical Campus - Department of Family Medicine Aurora, Colorado
University of Florida (UF) Health Shands Hospital Gainesville, Florida
University of Fukui Hospital Yoshida-gun, Fukui
University of Iowa Hospitals and Clinics Iowa City, Iowa
University of Kansas Medical Center (KUMC) Kansas City, Kansas
University of Maryland - Marlene and Stewart Greenebaum Cancer Center Baltimore, Maryland
University of Michigan Health System - A. Alfred Taubman Health Care Center - Pulmonary Clinic Ann Arbor, Michigan
University of Patras - Rio Regional University Hospital Rio,
University of Southern California (USC) - Keck School of Medicine (KSOM) - Transplant Clinic Los Angeles, California
University of Texas Southwestern Medical Center - Pulmonary Specialty Clinic Dallas, Texas
University of Thessaly- General University Hospital of Larissa Larissa,
University of Utah, University Hospital Salt Lake City, Utah
University of Washington Medical Center Seattle, Washington
Universitätsklinikum Hamburg-Eppendorf (UKE) Hamburg,
Universitätsmedizin der Johannes Gutenberg-Universität Mainz Mainz,
Universitätsspital Basel Basel,
Uniwersytecki Szpital Kliniczny Nr. 1 im. Norberta Barlickiego Lodz,
Uniwersyteckie Centrum Kliniczne Gdansk,
VCU Medical Center Richmond, Virginia
Vanderbilt Lung Institute - One Hundred Oaks Nashville, Tennessee
Velocity Clinical Research Germany GmbH Ahrensburg,
Velocity Clinical Research Inc. Greenville, South Carolina
Vivantes Klinikum Neukolln Berlin,
Vzw Az Groeninge Kortrijk,
WM Clinica Pneumologica Sociedade Simples LTDA Porto Alegre, Rio Grande do Sul
Warminsko-Mazurskie Centrum Chorób Pluc w Olsztynie Olsztyn, Warmian-Masurian Voivodeship
Washington University School of Medicine in St. Louis St Louis, Missouri
West China Hospital, Sichuan University Chengdu, Sichuan
Western Washington Medical Group (WWMG) - Everett - Silver Lake Medical Center Location Everett, Washington
Westmead Hospital Westmead, New South Wales
Wiener Gesundheitsverbund - Klinik Floridsdorf Vienna,
Wonkwang University Hospital Iksansi,
Wuxi People's Hospital Wuxi,
Xi'an International Medical Center Hospital Xi'an,
Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai Shi, Shanghai Sheng
Yale New Haven Hospital New Haven, Connecticut
Yichang Central People's Hospital - Xiling Campus Yichang Shi, HE
Yonsei University Health System, Severance Hospital Seoul,
Zuyderland Medisch Centrum, Sittard-Geleen Heerlen,
hospital Italiano de Buenos Aires Ciudad Autonoma Buenos Aires,

A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF) (OMNY-AF)

Contact(s):

Study Contact - rshar120@its.jnj.com

Principal Investigator:

System ID: NCT06455098

Show full eligibility criteria

Inclusion Criteria:

* Diagnosed with symptomatic paroxysmal AF with:
• At least two symptomatic AF episodes within last six months from enrollment
• At least one electrocardiographically documented AF episode within twelve months prior to enrollment * Failed at least one Class I or Class III antiarrhythmic drug * Willing and capable to provide consent * Able and willing to comply with all pre-, post- and follow-up testing and requirements

Exclusion Criteria:

* Previously diagnosed with persistent AF (greater than \[\>\] 7 days in duration) * AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause. * Previous surgical or catheter ablation for AF * Patients known to require ablation outside the PV ostia and outside the CTI region. * Documented severe dilatation of the left atrium (LAD\>50 mm) antero-posterior diameter on imaging within 6 months prior to enrollment * Documented left atrium (LA) thrombus by imaging within 48 hours of the procedure * Documented severely compromised left ventricular ejection fraction (LVEF \<40%) by imaging within 6 months prior to enrollment * Uncontrolled heart failure or New York Heart Association (NYHA) Class III or IV * History of blood clotting, bleeding abnormalities or contraindication to anticoagulation (heparin, warfarin, or dabigatran) * Documented thromboembolic event (including transient ischemic attack or TIA) within the past 6 months * Previous Percutaneous Coronary Intervention (PCI)/ myocardial infarction \[MI\] within the past 2 months * Coronary Artery Bypass Grafting (CABG) surgery within the past 6 months * Valvular cardiac surgical/percutaneous procedure * Unstable angina within 6 months * Anticipated cardiac transplantation, cardiac surgery, or other major surgery within the next 12 months * Significant pulmonary disease or any other disease or malfunction of the lungs or respiratory system that produces severe chronic symptoms * Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study * Prior diagnosis of pulmonary vein stenosis * Pre-existing hemi diaphragmatic paralysis * Acute illness, active systemic infection, or sepsis * Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch or other abnormality that precludes catheter introduction or manipulation * Severe mitral regurgitation * Presence of an implanted pacemaker or Implantable Cardioverter-Defibrillator (ICD) or other implanted metal cardiac device (other than coronary stents) that may interfere with the PF energy field) * Presence of a condition that precludes vascular access * Current enrollment in an investigational study evaluating another device or drug * Women who are pregnant (as evidenced by pregnancy test if pre-menopausal), lactating, or who are of child-bearing age and plan on becoming pregnant during the course of the clinical investigation * Life expectancy less than 12 months * Presenting contra-indications for the devices used in the study, as indicated in the respective Instructions for Use (IFU)

Interventions: DEVICE: OMNYPULSE™ Catheter with the TRUPULSE Generator

Conditions: Atrial Fibrillation

I'm interested

Share via email

Show 46 locations

Study Locations

Hide all locations

Location	Contacts
Advent Health Orlando Orlando, Florida
Ascension St. Vincent's Jacksonville, Florida
Baptist Health Research Institute Jacksonville, Florida
Beaumont Health Systems Royal Oak, Michigan
Brigham and Women's Hospital Boston, Massachusetts
California Pacific Medical Center- Sutter Health San Francisco, California
Canberra Heart Rhythm Garran,
Cardiovascular Associates of Marin Larkspur, California
Cleveland Clinic Cleveland, Ohio
Emory Saint Joseph's Hospital Atlanta, Georgia
HCA Florida Mercy Hospital Miami, Florida
Hartford Hospital Hartford, Connecticut
Hoag Memorial Hospital Newport Beach, California
Inova Fairfax Medical Campus- Inova Heart and Vascular Institute Falls Church, Virginia
Intermountain Medical Center Murray, Utah
Johns Hopkins Baltimore, Maryland
Lenox Hill Hospital New York, New York
Loma Linda Medical Center Loma Linda, California
Massachusetts General Boston, Massachusetts
Memorial Health University Medical Center Savannah, Georgia
Mills Peninsula Health Services Burlingame, California
Minneapolis Heart Institute Minneapolis, Minnesota
Montefiore Medical Center The Bronx, New York
Morristown Medical Center Morristown, New Jersey
Mount Sinai School of Medicine New York, New York
NCH Healthcare Naples, Florida
New Mexico Heart Institute Albuquerque, New Mexico
New York Presbyterian - Weill Cornell Medical Ctr New York, New York
NorthShore University Medical Center Glenview, Illinois
Northside Hospital Atlanta, Georgia
Phoenix Cardiovascular Research Group Phoenix, Arizona
Piedmont Healthcare Atlanta, Georgia
Providence Saint John s Health Center Santa Monica, California
Royal Adelaide Hospital Adelaide, South Australia
Royal Melbourne Hospital Parkville,
San Diego Cardiac Center San Diego, California
Scripps Clinic/Prebys Cardiovascular Institute La Jolla, California
Sentara Norfolk General Hospital Norfolk, Virginia
St Francis Hospital Roslyn, New York
Texas Cardiac Arrhythmia Research Foundation Austin, Texas
Texas Heart Institute Houston, Texas
University of Colorado Aurora, Colorado
University of Pennsylvania Health System Philadelphia, Pennsylvania
Virginia Commonwealth University Richmond, Virginia
WakeMed Heart & Vascular Raleigh, North Carolina
York Hospital York Village, Maine

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

Contact(s):

ctrrecruit@vcu.edu

Principal Investigator:

System ID: NCT06568172

Show full eligibility criteria

Inclusion Criteria:

* Pathologically (histologically or cytologically) proven diagnosis of invasive cutaneous squamous cell carcinoma (CSCC) or regional lymph node or in-transit metastasis of CSCC * The following CSCC subtypes are eligible according to World Health Organization (WHO) classification if the predominant histology is confirmed CSCC. * Spindle cell squamous cell carcinoma (SCC) * Squamous cell carcinoma with sarcomatoid differentiation * Acantholytic SCC * Clear cell SCC * Lymphoepithelial carcinoma * Note: Keratoacanthoma SCC and Verrucous SCC subtypes are not eligible. * For patients with regional metastasis without a primary tumor at screening: a clinical history of CSCC that drains to the involved regional lymph nodes or in-transit metastases in question is required * For example, a parotid mass shown to be SCC by cytologic analysis of a fine needle aspirate in a patient with a clinical history of CSCC on the ipsilateral scalp would be eligible * For patients with regional metastases without a primary tumor and an ambiguous clinical history: tumor genomic sequencing suggesting a primary tumor of cutaneous origin would be acceptable evidence to establish eligibility * NOTE: Tumor genomic sequencing is not required to determine eligibility, but may be part of the routine evaluation of patients with cancers of unknown primary at some institutions. For example, a parotid mass shown to be SCC by cytologic analysis of fine needle aspirate without a primary tumor and an ambiguous clinical history, but with a tumor genomic sequencing assay demonstrating a high tumor mutation burden (≥ 10 mutations/Mb) and/or a high fraction of ultraviolet (UV) related mutations (\> 50% of mutations \[cytosine (C)/thymine (T)\]C \> T or CC \> TT) and/or the presence of "signature 7" mutations would be eligible (Chang 2021) * Previously untreated or recurrent CSCC * Clinical American Joint Committee on Cancer (AJCC) 8th Edition (eyelid, head and neck sites) or Union for International Cancer Control (UICC) (non-head and neck sites) stage III or IV * Primary tumor site must be in the head and neck cutaneous region, other non-head and neck cutaneous regions, or eyelid cutaneous region * No mucosal squamous cell carcinoma (vermillion lip, nasal, oral, sinonasal, conjunctival, anogenital) * Tumor must be resectable with curative intent. Note: Tumor with bony skull base invasion and/or skull base foramen involvement (T4b) is not eligible. (Patients with T4b eyelid tumors using UICC Staging, and not involving the brain, are eligible.) * At least 1 lesion that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 * No definitive clinical or radiologic evidence of distant metastatic disease (M1), visceral and/or distant nodal disease * Age ≥ 18 * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Not pregnant and not nursing * Negative urine or serum pregnancy test (in persons of childbearing potential) within 14 days prior to registration. Childbearing potential is defined as any person who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal * Absolute neutrophil count (ANC) ≥ 1,000 cells/mm\^3 * Platelets ≥ 75,000 cells/mm\^3 * Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve hemoglobin \[Hgb\] ≥ 8.0 g/dl is acceptable) * Creatinine clearance (CrCL) \> 30mL/min by the Cockcroft-Gault formula * Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (NOTE: For patients with Gilbert's syndrome, total bilirubin ≤ 3 x ULN. Gilbert's syndrome must be documented appropriately as past medical history.) * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) ≤ 3 x institutional ULN * No prior systemic therapy for the study cancer (including patients currently receiving immunotherapy for a separate malignancy) * No prior radiotherapy to the region of the study cancer that would result in cumulative doses of radiation to organs at risk for radiation injury that exceed protocol limitations * No history of myocardial infarction/unstable angina within the last 6 months * New York Heart Association functional classification IIb or better (New York Heart Association \[NYHA\] functional classification III/IV are not eligible) (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association functional classification) * No active infection requiring systemic antibiotics, antiviral, or antifungal treatments * No history of allogeneic stem cell transplantation, or autologous stem cell transplantation * No history of a solid organ transplant (other than corneal transplant) * No active, known, or suspected autoimmune disease * Active or known disease is defined as: * Requiring higher than physiologic steroid levels (\> 10mg prednisone/day or equivalent) or * Requiring disease-modifying agents or * Ongoing or recent (within 5 years prior to registration) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune-related adverse events (irAEs) * NOTES: * Patients meeting the following criteria are not considered immunosuppressed and are eligible to enroll: * Patients who require a brief course of steroids (eg, prophylaxis for imaging assessments due to hypersensitivity to contrast agents) are not excluded * Patients with type I diabetes mellitus, and endocrinopathies (including hypothyroidism due to autoimmune thyroiditis) only requiring hormone replacement, or skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll * Physiologic replacement doses ≤ 10 mg prednisone/day or equivalent allowed, as long as they are not being administered for immunosuppressive intent. Inhaled or topical steroids are permitted * Patients with the following immunosuppressed conditions are eligible to enroll: * Patients with HIV infection on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration are eligible * Patients with chronic lymphocytic leukemia (CLL) with no history of anti-CLL therapy within 6 months prior to registration are eligible * No history of interstitial lung disease (eg, idiopathic pulmonary fibrosis, organizing pneumonia) * No active, noninfectious pneumonitis requiring immune-suppressive therapy * No active tuberculosis * No live vaccines within 28 days prior to registration * No history of allergic reaction to the study agent, compounds of similar chemical or biologic composition to the study agent (or any of its excipients)

Interventions: PROCEDURE: Biospecimen Collection, BIOLOGICAL: Cemiplimab, PROCEDURE: Computed Tomography, RADIATION: Image Guided Radiation Therapy, RADIATION: Intensity-Modulated Radiation Therapy, PROCEDURE: Magnetic Resonance Imaging, PROCEDURE: Positron Emission Tomography, OTHER: Questionnaire Administration, PROCEDURE: Surgical Procedure, PROCEDURE: Surgical Procedure

Conditions: Eyelid Squamous Cell Carcinoma, Recurrent Eyelid Squamous Cell Carcinoma, Recurrent Skin Acantholytic Squamous Cell Carcinoma, Recurrent Skin Clear Cell Squamous Cell Carcinoma, Recurrent Skin Lymphoepithelial Carcinoma, Recurrent Skin Spindle Cell Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Resectable Eyelid Squamous Cell Carcinoma, Resectable Skin Acantholytic Squamous Cell Carcinoma, Resectable Skin Clear Cell Squamous Cell Carcinoma, Resectable Skin Lymphoepithelial Carcinoma, Resectable Skin Spindle Cell Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Skin Acantholytic Squamous Cell Carcinoma, Skin Clear Cell Squamous Cell Carcinoma, Skin Lymphoepithelial Carcinoma, Skin Spindle Cell Squamous Cell Carcinoma, Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8

I'm interested

Share via email

Show 169 locations

Study Locations

Hide all locations

Location	Contacts
Allegheny General Hospital Pittsburgh, Pennsylvania
Alton Memorial Hospital Alton, Illinois
Atrium Health Cabarrus/LCI-Concord Concord, North Carolina
Atrium Health Cleveland/LCI-Cleveland Shelby, North Carolina
Atrium Health Pineville/LCI-Pineville Charlotte, North Carolina
Atrium Health Stanly/LCI-Albemarle Albemarle, North Carolina
Atrium Health Union/LCI-Union Monroe, North Carolina
Atrium Health University City/LCI-University Charlotte, North Carolina
Carolinas Medical Center/Levine Cancer Institute Charlotte, North Carolina
Case Western Reserve University Cleveland, Ohio	Site Public Contact - (CTUReferral@UHhospitals.org)
Cedars Sinai Medical Center Los Angeles, California
Chris O'Brien Lifehouse Camperdown, New South Wales	Site Public Contact - (researchgovernance@lh.org.au)
Christiana Care Health System-Concord Health Center Chadds Ford, Pennsylvania	Site Public Contact - (lbarone@christianacare.org)
City of Hope Antelope Valley Lancaster, California	Site Public Contact - (becomingapatient@coh.org)
City of Hope Comprehensive Cancer Center Duarte, California	Site Public Contact - (becomingapatient@coh.org)
City of Hope South Pasadena South Pasadena, California	Site Public Contact - (becomingapatient@coh.org)
City of Hope Upland Upland, California	Site Public Contact - (becomingapatient@coh.org)
City of Hope at Irvine Lennar Irvine, California
Corewell Health Grand Rapids Hospitals - Butterworth Hospital Grand Rapids, Michigan	Site Public Contact - (crcwm-regulatory@crcwm.org)
Dartmouth Cancer Center - North Saint Johnsbury, Vermont	Site Public Contact - (cancer.research.nurse@hitchcock.org)
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center Lebanon, New Hampshire	Site Public Contact - (cancer.research.nurse@dartmouth.edu)
Drexel Town Square Health Center Oak Creek, Wisconsin
Duke Cancer Center Raleigh Raleigh, North Carolina	Site Public Contact - (NCTNStudyTeam@dm.duke.edu)
Duke University Medical Center Durham, North Carolina
Emory University Hospital Midtown Atlanta, Georgia
Emory University Hospital/Winship Cancer Institute Atlanta, Georgia
First Physicians Group - Silverstein Institute at Floyd Street Sarasota, Florida	Site Public Contact - (researchinstitute@smh.com)
Florida Cancer Specialists - Sarasota Sarasota, Florida	Site Public Contact - (Roster@nrgoncology.org)
Florida Cancer Specialists - Sarasota Downtown Sarasota, Florida
Florida Cancer Specialists - Venice Pinebrook Venice, Florida	Site Public Contact - (ClinicalTrials@FLCancer.com)
Forbes Hospital Monroeville, Pennsylvania
Fox Chase Cancer Center Philadelphia, Pennsylvania
Franciscan Health Indianapolis Indianapolis, Indiana
Froedtert Menomonee Falls Hospital Menomonee Falls, Wisconsin
Froedtert West Bend Hospital/Kraemer Cancer Center West Bend, Wisconsin
Goshen Center for Cancer Care Goshen, Indiana	Site Public Contact - (cccois@goshenhealth.com)
Gundersen Lutheran Medical Center La Crosse, Wisconsin	Site Public Contact - (cancerctr@gundersenhealth.org)
Heartland Oncology and Hematology LLP Council Bluffs, Iowa
Helen F Graham Cancer Center Newark, Delaware	Site Public Contact - (lbarone@christianacare.org)
Henry Ford Hospital Detroit, Michigan	Site Public Contact - (CTOResearch@hfhs.org)
Huntsman Cancer Institute/University of Utah Salt Lake City, Utah	Site Public Contact - (cancerinfo@hci.utah.edu)
IU Health North Hospital Carmel, Indiana	Site Public Contact - (iutrials@iu.edu)
Indiana University/Melvin and Bren Simon Cancer Center Indianapolis, Indiana	Site Public Contact - (iutrials@iu.edu)
Inova Schar Cancer Institute Fairfax, Virginia	Site Public Contact - (Stephanie.VanBebber@inova.org)
Kaiser Permanente-Oakland Oakland, California	Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-South Sacramento Sacramento, California	Site Public Contact - (Kpoct@kp.org)
LSU Health Baton Rouge-North Clinic Baton Rouge, Louisiana	Site Public Contact - (research@ololrmc.com)
Laura and Isaac Perlmutter Cancer Center at NYU Langone New York, New York	Site Public Contact - (CancerTrials@nyulangone.org)
Levine Cancer Institute-Gaston Gastonia, North Carolina
Levine Cancer Institute-Rock Hill Rock Hill, South Carolina
MU Health - University Hospital/Ellis Fischel Cancer Center Columbia, Missouri
Marshfield Medical Center - Weston Weston, Wisconsin	Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-Marshfield Marshfield, Wisconsin	Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Mayo Clinic in Rochester Rochester, Minnesota
Medical College of Wisconsin Milwaukee, Wisconsin
Medical Oncology Hematology Consultants PA Newark, Delaware	Site Public Contact - (lbarone@christianacare.org)
Medical University of South Carolina Charleston, South Carolina	Site Public Contact - (hcc-clinical-trials@musc.edu)
Memorial Hospital East Shiloh, Illinois	Site Public Contact - (dschwab@wustl.edu)
Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey
Memorial Sloan Kettering Bergen Montvale, New Jersey
Memorial Sloan Kettering Cancer Center New York, New York
Memorial Sloan Kettering Commack Commack, New York
Memorial Sloan Kettering Monmouth Middletown, New Jersey
Memorial Sloan Kettering Nassau Uniondale, New York
Memorial Sloan Kettering Westchester Harrison, New York
Methodist Jennie Edmundson Hospital Council Bluffs, Iowa	Site Public Contact - (kathryn.bartz@nmhs.org)
Miami Cancer Institute Miami, Florida
Moffitt Cancer Center Tampa, Florida	Site Public Contact - (ClinicalTrials@moffitt.org)
Moffitt Cancer Center - McKinley Campus Tampa, Florida	Site Public Contact - (ClinicalTrials@moffitt.org)
Moffitt Cancer Center-International Plaza Tampa, Florida	Site Public Contact - (ClinicalTrials@moffitt.org)
Montefiore Medical Center - Moses Campus The Bronx, New York	Site Public Contact - (eskwak@montefiore.org)
Montefiore Medical Center-Einstein Campus The Bronx, New York	Site Public Contact - (eskwak@montefiore.org)
Montefiore Medical Center-Weiler Hospital The Bronx, New York	Site Public Contact - (eskwak@montefiore.org)
NYU Langone Hospital - Long Island Mineola, New York	Site Public Contact - (cancertrials@nyulangone.org)
Nebraska Cancer Specialists/Oncology Hematology West PC - MECC Omaha, Nebraska
Nebraska Medicine-Bellevue Bellevue, Nebraska	Site Public Contact - (unmcrsa@unmc.edu)
Nebraska Medicine-Village Pointe Omaha, Nebraska
Nebraska Methodist Hospital Omaha, Nebraska
Northwestern Medicine Cancer Center Delnor Geneva, Illinois	Site Public Contact - (Donald.Smith3@nm.org)
Northwestern Medicine Cancer Center Kishwaukee DeKalb, Illinois	Site Public Contact - (Donald.Smith3@nm.org)
Northwestern Medicine Cancer Center Warrenville Warrenville, Illinois	Site Public Contact - (Donald.Smith3@nm.org)
Northwestern Medicine Orland Park Orland Park, Illinois	Site Public Contact - (nctnprogram_rhlccc@northwestern.edu)
Northwestern University Chicago, Illinois	Site Public Contact - (cancer@northwestern.edu)
Ohio State University Comprehensive Cancer Center Columbus, Ohio	Site Public Contact - (Jamesline@osumc.edu)
Our Lady of the Lake Physician Group Baton Rouge, Louisiana	Site Public Contact - (research@ololrmc.com)
Penn State Milton S Hershey Medical Center Hershey, Pennsylvania	Site Public Contact - (CTO@hmc.psu.edu)
Peter MacCallum Cancer Centre Melbourne, Victoria
Rock Hill Radiation Therapy Center Rock Hill, South Carolina
Rush MD Anderson Cancer Center Chicago, Illinois	Site Public Contact - (Cancer_Studies@rush.edu)
SUNY Upstate Medical Center-Community Campus Syracuse, New York
Saint Vincent Hospital Erie, Pennsylvania
Sarasota Memorial Health Care Center at University Parkway Sarasota, Florida
Sarasota Memorial Hospital Sarasota, Florida
Sarasota Memorial Hospital-Venice N. Venice, Florida
Siteman Cancer Center at Christian Hospital St Louis, Missouri	Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center at Saint Peters Hospital City of Saint Peters, Missouri	Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center at West County Hospital Creve Coeur, Missouri	Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center-South County St Louis, Missouri	Site Public Contact - (info@siteman.wustl.edu)
Smilow Cancer Hospital Care Center - Guilford Guilford, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center - Waterford Waterford, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center at Greenwich Greenwich, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center-Trumbull Trumbull, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital-Waterbury Care Center Waterbury, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Stanford Cancer Institute Palo Alto Palo Alto, California	Site Public Contact - (ccto-office@stanford.edu)
State University of New York Upstate Medical University Syracuse, New York
The Angeles Clinic and Research Institute - West Los Angeles Office Los Angeles, California	Site Public Contact - (ctsucontact@westat.com)
The James Graham Brown Cancer Center at University of Louisville Louisville, Kentucky
Thomas Jefferson University Hospital Philadelphia, Pennsylvania	Site Public Contact - (ONCTrialNow@jefferson.edu)
Torrance Memorial Physician Network - Cancer Care Torrance, California	Site Public Contact - (courtney.steeneken@tmphysicians.com)
Tower Cancer Research Foundation Beverly Hills, California	Site Public Contact - (towercancerresearch@toweroncology.com)
UC San Diego Health System - Encinitas Encinitas, California
UC San Diego Medical Center - Hillcrest San Diego, California	Site Public Contact - (rhabbaba@health.ucsd.edu)
UC San Diego Moores Cancer Center La Jolla, California	Site Public Contact - (cancercto@ucsd.edu)
UH Seidman Cancer Center at Lake Health Mentor Campus Mentor, Ohio	Site Public Contact - (CTUReferral@UHhospitals.org)
UH Seidman Cancer Center at UH Avon Health Center Avon, Ohio
UHHS-Chagrin Highlands Medical Center Beachwood, Ohio	Site Public Contact - (CTUReferral@UHhospitals.org)
UM Sylvester Comprehensive Cancer Center at Aventura Aventura, Florida
UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables, Florida
UM Sylvester Comprehensive Cancer Center at Deerfield Beach Deerfield Beach, Florida
UM Sylvester Comprehensive Cancer Center at Doral Doral, Florida	Site Public Contact - (kginnity@med.miami.edu)
UM Sylvester Comprehensive Cancer Center at Kendall Miami, Florida
UM Sylvester Comprehensive Cancer Center at Plantation Plantation, Florida
UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina	Site Public Contact - (cancerclinicaltrials@med.unc.edu)
UPMC Hillman Cancer Center Erie Erie, Pennsylvania	Site Public Contact - (haneydl@upmc.edu)
UPMC-Johnstown/John P. Murtha Regional Cancer Center Johnstown, Pennsylvania
USC / Norris Comprehensive Cancer Center Los Angeles, California
UT Southwestern Clinical Center at Richardson/Plano Richardson, Texas	Site Public Contact - (Suzanne.cole@utsouthwestern.edu)
UT Southwestern Simmons Cancer Center - RedBird Dallas, Texas	Site Public Contact - (canceranswerline@utsouthwestern.edu)
UT Southwestern/Simmons Cancer Center-Dallas Dallas, Texas	Site Public Contact - (canceranswerline@UTSouthwestern.edu)
UT Southwestern/Simmons Cancer Center-Fort Worth Fort Worth, Texas	Site Public Contact - (canceranswerline@UTSouthwestern.edu)
University Health Network-Princess Margaret Hospital Toronto, Ontario	Site Public Contact - (clinical.trials@uhn.on.ca)
University Medical Center New Orleans New Orleans, Louisiana	Site Public Contact - (emede1@lsuhsc.edu)
University of Alabama at Birmingham Cancer Center Birmingham, Alabama	Site Public Contact - (charlesbaldwin@uabmc.edu)
University of California Davis Comprehensive Cancer Center Sacramento, California
University of Cincinnati Cancer Center-UC Medical Center Cincinnati, Ohio	Site Public Contact - (cancer@uchealth.com)
University of Cincinnati Cancer Center-West Chester West Chester, Ohio	Site Public Contact - (cancer@uchealth.com)
University of Illinois Chicago, Illinois
University of Kansas Cancer Center Kansas City, Kansas	Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Cancer Center - Lee's Summit Lee's Summit, Missouri	Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Cancer Center - North Kansas City, Missouri	Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Cancer Center-Overland Park Overland Park, Kansas	Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Hospital-Indian Creek Campus Overland Park, Kansas	Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Hospital-Westwood Cancer Center Westwood, Kansas	Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kentucky/Markey Cancer Center Lexington, Kentucky
University of Miami Miller School of Medicine-Sylvester Cancer Center Miami, Florida
University of Michigan - Brighton Center for Specialty Care Brighton, Michigan
University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan	Site Public Contact - (slusserb@med.umich.edu)
University of Nebraska Medical Center Omaha, Nebraska	Site Public Contact - (unmcrsa@unmc.edu)
University of New Mexico Cancer Center Albuquerque, New Mexico	Site Public Contact - (HSC-ClinicalTrialInfo@salud.unm.edu)
University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma	Site Public Contact - (ou-clinical-trials@ouhsc.edu)
University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania
University of Rochester Rochester, New York
University of Texas Health Science Center at San Antonio San Antonio, Texas	Site Public Contact - (phoresearchoffice@uthscsa.edu)
University of Vermont Medical Center Burlington, Vermont	Site Public Contact - (rpo@uvm.edu)
University of Vermont and State Agricultural College Burlington, Vermont	Site Public Contact - (rpo@uvm.edu)
University of Virginia Cancer Center Charlottesville, Virginia	Site Public Contact - (uvacancertrials@hscmail.mcc.virginia.edu)
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center Madison, Wisconsin	Site Public Contact - (clinicaltrials@cancer.wisc.edu)
University of Wisconsin Carbone Cancer Center - University Hospital Madison, Wisconsin	Site Public Contact - (clinicaltrials@cancer.wisc.edu)
UofL Health Medical Center Northeast Louisville, Kentucky	Site Public Contact - (ctoinfo@louisville.edu)
VCU Massey Comprehensive Cancer Center Richmond, Virginia
Vanderbilt University/Ingram Cancer Center Nashville, Tennessee
Wake Forest University Health Sciences Winston-Salem, North Carolina
Washington University School of Medicine St Louis, Missouri	Site Public Contact - (info@siteman.wustl.edu)
West Penn Hospital Pittsburgh, Pennsylvania
Wexford Health and Wellness Pavilion Wexford, Pennsylvania	Site Public Contact - (Dawnmarie.DeFazio@ahn.org)
William S Middleton VA Medical Center Madison, Wisconsin
Wilmot Cancer Institute at Webster Webster, New York	Site Public Contact - (WCICTOresearch@urmc.rochester.edu)
Wollongong Hospital Wollongong, New South Wales
Yale University New Haven, Connecticut	Site Public Contact - (canceranswers@yale.edu)

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

Contact(s):

Clinical Team - clinicaltrials@deciphera.com

Principal Investigator:

System ID: NCT06619561

Show full eligibility criteria

Interventions: DRUG: Vimseltinib

Conditions: Chronic Graft-Versus-Host Disease (cGVHD)

Keywords: Allogeneic hematopoietic stem cell transplant (HSCT), Graft-Versus-Host Disease, GVHD, cGVHD, Graft versus host disease, Immune System Diseases, Organizing Pneumonia, Bronchiolitis Obliterans, Bronchiolitis, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive, Lung Diseases, Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Sclerosis, Fibrosis, Hematopoietic stem cell transplantation, Liver diseases

I'm interested

Share via email

Show 25 locations

Study Locations

Hide all locations

Location	Contacts
AdventHealth Orlando Orlando, Florida
Avera Cancer Institute Sioux Falls, South Dakota
City of Hope National Medical Center Duarte, California
Cleveland Clinic Cleveland, Ohio
Dana-Farber Cancer Institute Boston, Massachusetts
Duke University Hospital Durham, North Carolina
Emory University winship Cancer Institute Atlanta, Georgia
Henry Ford Cancer Institute Detroit, Michigan
Intermountain Health St. George, Utah
Levine Cancer Institute Charlotte, North Carolina
Moffitt Cancer Center Tampa, Florida
Oncology Hematology Care Clinical Trials, LLC Cincinnati, Ohio
Oregon Health and Science University Portland, Oregon
Ronald Regan UCLA Medical Center Los Angeles, California
St. David's South Austin Medical Center Austin, Texas
The Ohio State University Comprehensive Cancer Center Columbus, Ohio
Tristar Bone Marrow Transplant Nashville, Tennessee
UPMC Hillman Cancer Center Pittsburgh, Pennsylvania
University of California Irvine Health Orange, California
University of Illinois Medical Center - Hematology & Oncology Chicago, Illinois
University of Kansas Cancer Center-Westwood Westwood, Kansas
University of Kentucky Markey Cancer Center Lexington, Kentucky
Vanderbilt-Ingram Cancer Center Nashville, Tennessee
Virginia Commonwealth University Richmond, Virginia
Washington University School of Medicine - Siteman Cancer Center St Louis, Missouri

A Trial of Felzartamab in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR) (TRANSCEND)

Contact(s):

US Biogen Clinical Trial Center - clinicaltrials@biogen.com

Principal Investigator:

System ID: NCT06685757

Show full eligibility criteria

Interventions: DRUG: Felzartamab, DRUG: Placebo

Conditions: Antibody-mediated Rejection

Keywords: AMR, Felzartamab, Kidney Transplant

I'm interested

Share via email

Show 52 locations

Study Locations

Hide all locations

Location	Contacts
Auckland City Hospital Auckland,
CHU Grenoble Alpes Hôpital Michallon La Tronche,
CHU Lyon Hôpital Edouard Herriot Bordeaux,
California Pacific Medical Center San Francisco, California
Cedars-Sinai Medical Center Los Angeles, California
Centre Hospitalier Universitaire (CHU) de Toulouse - Hôpital de Rangueil Toulouse,
Charite University Berlin,
Cleveland Clinic Cleveland, Ohio
Cooperman Barnabas Medical Center Livingston, New Jersey
Duke University Durham, North Carolina
Fiona Stanley Hospital Murdoch,
Fundação Oswaldo Ramos - Hospital do Rim (HRIM) Vila Clementino, São Paulo
Hospices Civils de Lyon - Hôpital Édouard Herriot Lyon,
Hospital Clinic de Barcelona Barcelona,
Hospital Del Mar Barcelona,
Hospital Universitario Miguel Servet Zaragoza,
Hospital Universitario Vall d'Hebron Horta-Guinardó, Barcelona
Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo Cerqueira César, São Paulo
Hospital de Base Da Faculdade de Medicina de Sao Jose Do Rio Preto Vila São José, São José Do Rio Preto
Houston Methodist Houston, Texas
Loma Linda San Bernardino, California
Mayo Clinic Jacksonville, Florida
McGill Montreal, Quebec
Medical College of Wisconsin Milwaukee, Wisconsin
Medical University of Vienna Spitalgasse, Vienna
Penn Medicine - Hospital of the University of Pennsylvania Philadelphia, Pennsylvania
Princess Alexandra Hospital Queensland, Queensland
Providence Healthcare Orange, California
The Ohio State University Columbus, Ohio
The University of British Columbia (UBC)/St. Paul's Hospital part of Providence Health Care Vancouver, British Columbia
Tulane University Health Sciences Center New Orleans, Louisiana
UCLA Los Angeles, California
UT Southwestern Medical Center Dallas, Texas
Universitaetsklinikum Carl Gustav Carus Dresden Dresden,
Universitatsklinikum Hamburg-Eppendorf Hamburg,
Universitatsspital Zurich Zurich,
University Hospital Basel Petersgraben, Basel
University of Alberta Edmonton, Alberta
University of California, San Francisco San Francisco, California
University of Chicago Chicago, Illinois
University of Cincinnati Cincinnati, Ohio
University of Colorado Aurora, Colorado
University of Kansas Kansas City, Kansas
University of Michigan Ann Arbor, Michigan
University of Nebraska Omaha, Nebraska
University of Southern California Los Angeles, California
University of Washington Medical Center Seattle, Washington
Vancouver General Hospital Vancouver, British Columbia
Vanderbilt University Nashville, Tennessee
Virginia Commonwealth University Richmond, Virginia
Washington University St Louis, Missouri
Westmead Hospital Westmead, New South Wales

Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+

Contact(s):

Massey IIT Research Operations - masseyepd@vcu.edu

Principal Investigator:

System ID: NCT06846463

Show full eligibility criteria

Inclusion Criteria:

* Patients must have a documented pathologic diagnosis of DLBCL at any stage. * Must have documented MYD88 L265P, CD79B, or NOTCH1 truncation mutation or be CD5+ by IHC. * Age ≥18 years on the day of signing the informed consent form. * Patients must have measurable disease on Positron Emission Tomography-Computed Tomography scan (CT/PET) imaging. * Patient must have received no more than one cycle of R-CHOP prior to enrollment. Length of time between first R-CHOP treatment and planned 2nd R-CHOP treatment should vary by no more than 21 days ± 3 days. * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2. * Adequate bone marrow function as defined by: * Absolute neutrophil count (ANC) ≥1000/mm3, except for patients with bone marrow involvement in which ANC must be ≥500/mm3. * Platelet ≥75,000/mm3, except for patients with bone marrow involvement in which the platelet count must be ≥30,000/mm3. * Hemoglobin ≥7 g/dL, after transfusion if necessary * Adequate organ function defined as: * Creatinine clearance ≥30 mL/min as estimated by the Cockcroft-Gault equation. * Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase, and alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase ≤2.5 × upper limit of normal (ULN). * Serum total bilirubin ≤3 x ULN (except patients with Gilberts syndrome 3g/dl). * Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment. * Women of childbearing potential and men must agree to use one of the following highly effective forms of birth control during the treatment and for 1 month following completion of study treatment for women and for 1 week following completion of study treatment for men. * combined (estrogen and progestogen containing) hormonal contraception: * oral * intravaginal * transdermal * progestogen-only hormonal contraception associated with inhibition of ovulation * oral * injectable * implantable * intrauterine device (IUD) * intrauterine hormone-releasing system (IUS) * bilateral tubal occlusion * vasectomized partner * heterosexual abstinence * Patients must not have any known allergies, hypersensitivity or intolerance to corticosteroids or monoclonal antibodies. * Able to provide written informed consent and can understand and agree to comply with the requirements of the study and the schedule of assessments.

Exclusion Criteria:

* Patients with high grade B-cell lymphoma with myelocytomatosis oncogene (MYC) and BCL-2 and/or BCL6 rearrangements. * Patients with brain metastasis. * Patients with peripheral neuropathy CTCAE grade ≥2. * Any uncontrolled or clinically significant cardiovascular disease including the following: * Myocardial infarction within 6 months before screening. * Unstable angina within 3 months before screening. * New York Heart Association class III or IV congestive heart failure. * History of clinically significant arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes). * Prior malignancy within the past 3 years, except for curatively treated basal or squamous cell skin cancer, non-muscle-invasive bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score 6 prostate cancer. * History of severe bleeding disorder such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring blood transfusion or other medical intervention. * History of stroke or intracranial hemorrhage within 6 months before first dose of study drug. * Severe or debilitating pulmonary disease in the opinion of the treating investigator. * Unable to swallow capsules or disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, bariatric surgery procedures, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction. * Active fungal, bacterial and/or viral infection requiring systemic therapy. * Underlying medical conditions that, in the investigator's opinion, will render the administration of study drug hazardous or obscure the interpretation of toxicity or AEs. * Active infection with HIV, or serologic status reflecting active hepatitis B or C infection as follows: * Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). Patients with presence of HBcAb, but absence of HBsAg, are eligible if hepatitis B virus (HBV) DNA is undetectable (\< 20 IU), and if they are willing to undergo monitoring every 4 weeks for HBV reactivation. * Presence of hepatitis C virus (HCV) antibody. Patients with presence of HCV antibody are eligible if HCV RNA is undetectable. * Major surgery within 4 weeks of the first dose of study drug. * Pregnant or lactating women. * Left ventricular ejection fraction (LVEF) \<55% on screening echocardiogram. * Vaccination or requirement for vaccination with a live vaccine within 28 days prior to the first dose of study drug or at any time during planned study treatment. * Hypersensitivity to zanubrutinib, rituximab, cyclophosphamide, doxorubicin, vincristine, or prednisone. * Requires ongoing treatment with a strong CYP3A inducer (Table 3). * Concurrent participation in another therapeutic clinical trial. * Active and/or ongoing autoimmune anemia and/or autoimmune thrombocytopenia (eg, idiopathic thrombocytopenia purpura). * Requires ongoing treatment with warfarin or warfarin derivatives.

Interventions: DRUG: Zanubrutinib

Conditions: Diffuse Large B-Cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma

I'm interested

Share via email

Show 1 location

Study Locations

Hide all locations

Location	Contacts
Virginia Commonwealth University Richmond, Virginia	Massey Heme Malig Team - (MasseyHemMlg@vcu.edu)

Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure (DRAIN-HF)

Contact(s):

Rubi Reyes-Fuentez - rubi@procyrion.com

Principal Investigator:

System ID: NCT05677100

Show full eligibility criteria

Inclusion Criteria (Randomized Study): * Currently admitted to the hospital with a primary diagnosis of decompensated heart failure, irrespective of ejection fraction (EF); * Patients should be on maximally tolerated diuretic therapy and not diuresing sufficiently before being enrolled in DRAIN-HF. After being up-titrated on diuretics, patients should be followed for at least 24 hours on the higher of: i) furosemide 80 mg IV bid or equivalent or ii) IV furosemide or equivalent IV loop diuretic at a dose 2.5 x total daily home dose of furosemide equivalents in 2 divided doses, as tolerated, patient must have: Urine Output \<1,500mL in a 12-hour period OR a Net Fluid Loss ≤375mL in a 12-hour period. * Persistent signs and/or symptoms of congestion as evidenced by at least 2+ pitting edema, elevated jugular venous pressure \>12 cm water or ascites after treatment with IV diuretics per inclusion criterion 2.; * Age \>21 years and able to provide written informed consent; * Negative pregnancy test if patient is of child-bearing potential. Exclusion Criteria (Randomized Study): * Treatment with high dose IV inotropes within the last 48 hours prior to enrollment. High dose is defined as \>5 µg/kg/min dopamine OR \>5 µg/kg/min dobutamine OR \>0.375 µg/kg/min milrinone; * Active and ongoing hypotension with a systolic blood pressure \<90 mmHg lasting more than 30 minutes or a mean arterial pressure (MAP) \<60 mmHg lasting more than 30 minutes at enrollment; * Treatment with vasopressors (defined as phenylephrine, norepinephrine, epinephrine or, vasopressin) within 48 hours prior to enrollment; * An estimated PASP of \>80 mmHg as measured on echocardiogram or echocardiographic evidence of primarily right heart failure; * Treatment with IV diuretics (does not have to be continuous) for ≥21 days during the current hospitalization (including time spent at an outside hospital); * Acute kidney failure defined as an increase in serum creatinine to ≥4.0mg/dL (≥353.6 µmol/L) at enrollment; * Evidence of contrast induced nephropathy, nephritis or nephrotic syndrome; * Prior kidney transplant, single kidney, partial nephrectomy OR use of dialysis, continuous renal replacement therapy (CRRT) or ultrafiltration in the last 90 days prior to enrollment; * Confirmed decompensated cirrhosis (defined as Child Pugh class B or C) or concern for shock liver (AST \> 1000U/L or total Bilirubin \> 5.0mg/dl) at enrollment; * Presence of an active, uncontrolled infection that would preclude safe placement or removal of the device; * Prior heart transplant or likely heart transplantation before the 30- day follow-up visit; * Current or previous support with a durable LVAD at any time or planned LVAD insertion before the 30-day follow-up visit; * Use of an intra-aortic balloon pump (IABP), extracorporeal membrane oxygenation (ECMO), or percutaneous ventricular assist devices (e.g. Impella or TandemHeart) within the last 30 days; * Known amyloidosis of any type; * Acute myocardial infarction Type 1 within 30 days of enrollment, or planned coronary revascularization in the next 30 days; * Stroke within 30 days of enrollment; * Severe Bleeding Risk (any of the following):
• Previous intracranial bleed unless there is documentation in the medical record (from a physician that is not part of the study) that the patient can safely use anticoagulation for 7 days,
• GI bleeding within 6 months requiring hospitalization and/or transfusion,
• Recent major surgery within 30 days if the surgical wound is judged to be associated with an increased risk of bleeding,
• Procedure with arterial ilio-femoral access \> 6 FR within 30 days,
• Platelet count \<75,000 cells/mm3,
• Uncorrectable bleeding diathesis or coagulopathy (e.g. INR ≥2 not due to anticoagulation therapy) or hypercoaguable state including HIT;
• Inability to tolerate anticoagulation therapy for up to 7 days. * Contraindicated Anatomy :
• Descending aortic anatomy that would prevent safe placement of the device \[\<18 mm or \>31 mm aorta diameter at deployment location (measured between the superior aspect of the T10 vertebra and superior aspect of the L1 vertebra)\],
• Ilio-femoral diameter or peripheral vascular anatomy that would preclude safe placement of a 21F (outer diameter) introducer sheath,
• Femoral artery depth inconsistent with use of closure device,
• Abnormalities or severe vascular disease that would preclude safe access and device delivery (e.g. aneurysm with thrombus, marked tortuosity, significant narrowing or inadequate size of the abdominal aorta, iliac or femoral arteries, or severe calcification),
• Known connective tissue disorder (e.g. Marfan Syndrome) or other aortopathy at risk of vascular injury,
• Any endovascular stent graft in the descending aorta. Any endovascular stent graft in the femoro-iliac vessels that is not well endothelialized and would preclude safe introduction/removal of the Aortix pump as demonstrated by imaging. * Known hypersensitivity or contraindication to study or procedure medications (e.g. anticoagulation therapy) or device materials (e.g. history of severe reaction to nickel or nitinol); * Participation in any other clinical investigation that is likely to confound study results or affect the study; * Poor health such that the patient is unable to undergo the Aortix device placement/retrieval and/or unlikely to be able to survive to the 30-day visit; * Unable or unwilling to undergo screening (imaging, PA Catheter placement), device implant and retrieval procedures or return for 30-day visit. Inclusion Criteria (Advanced Heart Failure Registry): * Currently admitted to the hospital with a primary diagnosis of decompensated HF, irrespective of ejection fraction (EF). * Patient has already been evaluated and indicated to receive an LVAD or heart transplant and will receive the LVAD or be listed for heart transplantation in the next 30 days if their congestion status and renal function improves. * Patient must have been treated with ≥ 80 mg IV furosemide bid or equivalent and have evidence of increasing diuretic dosing requirements over the past 12 months, as tolerated. * Must have evidence of refractoriness to medical management as documented by persistent signs and/or symptoms of congestion as evidenced by at least 2+ pitting edema, elevated jugular venous pressure \>12 cm water, or ascites after treatment with IV diuretics for a minimum of 24 hours. * Serum creatinine ≥ 2.0 mg/dL AND eGFR ≤ 45 ml/min/1.73m2 at time of enrollment * Age ≥ 21 years and able to provide written informed consent. * Negative pregnancy test if patient is of childbearing potential. Exclusion Criteria (Advanced Heart Failure Registry): * Treatment with high dose IV inotropes within 48 hours prior to enrollment. High dose is defined as any one of the following: \>5 µg/kg/min dopamine OR \>5 µg/kg/min dobutamine OR \>0.375 µg/kg/min milrinone. * Active and ongoing hypotension with a systolic blood pressure \<80 mmHg lasting more than 30 minutes or a mean arterial pressure (MAP) \<55 mmHg lasting more than 30 minutes at enrollment. * Treatment with vasopressors (defined as phenylephrine, norepinephrine, epinephrine or, vasopressin) within 48 hours prior to enrollment. * An estimated PASP of \>80 mmHg as measured on echocardiogram or echocardiographic evidence of primarily right heart failure. * Acute kidney failure defined as an increase in serum creatinine to ≥ 4.0mg/dL at enrollment. * Evidence of contrast-induced nephropathy, nephritis, or nephrotic syndrome. * Prior kidney transplant, single kidney, partial nephrectomy OR use of dialysis, continuous renal replacement therapy (CRRT), or ultrafiltration in the last 90 days prior to enrollment. * Confirmed decompensated cirrhosis (defined as Child Pugh class B or C) or concern for shock liver (AST \> 1000U/L or total Bilirubin \> 5.0mg/dl) at enrollment. * Presence of an active, uncontrolled infection that would preclude safe placement or removal of the device. * Current or previous support with a durable LVAD. * INTERMACS Profile 1 at enrollment. * Currently on mechanical ventilatory support. * Use of an intra-aortic balloon pump (IABP) within the last 14 days or use of an extracorporeal membrane oxygenation (ECMO) or percutaneous ventricular assist device (e.g., Impella or TandemHeart) within the last 30 days. * Known amyloidosis of any type. * Acute myocardial infarction Type 1 within 30 days of enrollment or planned coronary revascularization in the next 30 days. * Stroke within 30 days of enrollment. * Severe Bleeding Risk (any of the following): * Previous intracranial bleed unless there is documentation in the medical record (from a physician that is not part of the study) that the patient can safely use anticoagulation for 7 days. * GI bleeding within 6 months requiring hospitalization and/or transfusion. * Recent major surgery within 30 days if the surgical wound is judged to be associated with an increased risk of bleeding. * Procedure with arterial ilio-femoral access \> 6 Fr within 30 days. * Platelet count \<75,000 cells/mm3 . * Uncorrectable bleeding diathesis or coagulopathy (e.g., INR≥ 2 not due to anticoagulation therapy) or hypercoagulable state including HIT. * Inability to tolerate anticoagulation therapy for up to 7 days. * Contraindicated Anatomy : * Descending aortic anatomy that would prevent safe placement of the device \[\<18 mm or \>31 mm aorta diameter at deployment location (measured between the superior aspect of the T10 vertebra and superior aspect of the L1 vertebra)\]. * Ilio-femoral diameter or peripheral vascular anatomy that would preclude safe placement of a 21 Fr (outer diameter) introducer sheath. * Femoral artery depth inconsistent with use of closure device. * Abnormalities or severe vascular disease that would preclude safe access and device delivery (e.g., aneurysm with thrombus; marked tortuosity; significant narrowing or inadequate size of the abdominal aorta, iliac, or femoral arteries; or severe calcification). * Known connective tissue disorder (e.g., Marfan Syndrome) or other aortopathy at risk of vascular injury. * Any endovascular stent graft in the descending aorta. Any endovascular stent graft in the femoro-iliac vessels that is not well endothelialized and would preclude safe introduction/removal of the Aortix pump as demonstrated by imaging. * Known hypersensitivity or contraindication to study or procedure medications (e.g., anticoagulation therapy) or device materials (e.g., history of severe reaction to nickel or nitinol). * Participation in any other clinical investigation that is likely to confound study results or affect the study. * Poor health such that the patient is unable to undergo the Aortix device placement/retrieval and/or unlikely to be able to survive to the 30-day visit. * Unable or unwilling to undergo screening, device implant and retrieval procedures, or return for 30-day visit.

Interventions: DEVICE: Aortix System

Conditions: Heart Failure, Cardiorenal Syndrome, Cardio-Renal Syndrome, ADHF, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure, With Decompensation, Heart Failure, Congestive

Keywords: mechanical circulatory support, percutaneous

I'm interested

Share via email

Show 47 locations

Study Locations

Hide all locations

Location	Contacts
AdventHealth Tampa Tampa, Florida
Advocate Aurora - Good Samaritan Downers Grove, Illinois
Advocate IMMC Chicago, Illinois
Ascension Sacred Heart Pensacola, Florida
Ascension via Christi Kansas Wichita, Kansas
Atrium Health Sanger Heart and Vascular Institute Charlotte, North Carolina	Zaida Roman - (Zaida.Roman@advocatehealth.org)
Banner--University Medical Center Phoenix Phoenix, Arizona
BayCare Medical/St. Joseph's Hospital Tampa, Florida
Baylor Scott & White Plano, Texas
Baylor Scott & White Research Institute Dallas, Texas
Cleveland Clinic Florida Stuart, Florida
Duke University Medical Center Durham, North Carolina
Emory University Hospital Atlanta, Georgia
Hackensack University Medical Center Hackensack, New Jersey
Henry Ford Detroit, Michigan
HonorHealth Medical Center Scottsdale, Arizona
Intermountain Health St. George, Utah
Jefferson Abington Hospital Abington, Pennsylvania
Jersey Shore University Medical Center Neptune City, New Jersey
John Muir Health Concord, California
Mayo Clinic - Arizona Phoenix, Arizona	Alexandra Gaughan, R.N. - (Gaughan.Alexandra@mayo.edu)
Mount Sinai Morningside New York, New York
New York Presbyterian - Brooklyn Methodist Hospital Brooklyn, New York	Jhane Phanor - (jhp4004@nyp.org)
Northwell Health (Lenox Hill) New York, New York
Northwell Health (Staten Island) Staten Island, New York
Novant Health New Hanover Regional Medical Center Wilmington, North Carolina
Nuvance Health Poughkeepsie, New York
Nyph/Cumc New York, New York
Oklahoma Cardiovascular Research Group Oklahoma City, Oklahoma
Oregon Health & Sciences University Portland, Oregon
Penn Presbyterian Medical Center Philadelphia, Pennsylvania
Piedmont Healthcare INC. Augusta, Georgia
San Francisco Veterans Administration San Francisco, California
Semmelweis University Budapest,	Laura Kosa-Hobor - (hobor.laura@semmelweis.hu)
Tallahassee Research Institute Tallahassee, Florida
Texas Heart Institute Houston, Texas
The Ohio State University Columbus, Ohio
Thomas Jefferson University Hospital Philadelphia, Pennsylvania
University of California San Francisco San Francisco, California
University of Chicago Chicago, Illinois
University of Michigan, Cardiovascular Medicine Ann Arbor, Michigan
University of Mississippi Medical Center Jackson, Mississippi
University of South Florida Tampa, Florida
University of Virginia Charlottesville, Virginia
Virginia Commonwealth University Richmond, Virginia
Wellstar Research Institue Marietta, Georgia
Zuckerberg San Francisco General San Francisco, California

ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)

Contact(s):

Clinical Trials Contact Center - ML-004-002@Maplightrx.com

Principal Investigator:

System ID: NCT05081245

Show full eligibility criteria

Interventions: DRUG: ML-004 (IR)/(ER) tablet, DRUG: ML-004 Placebo

Conditions: Autism Spectrum Disorder

Keywords: ASD, Autism, Autism Spectrum Disorder, Social Communication

I'm interested

Share via email

Show 41 locations

Study Locations

Hide all locations

Location	Contacts
AMR-Baber Research Inc Naperville, Illinois
APG Research, LLC Orlando, Florida
Abba Medical Group Miami, Florida
BioBehavioral Research of Austin Austin, Texas
Brain and Mind Centre Camperdown, New South Wales
Cedar Clinical Research Draper, Utah
Center for Autism and the Developing Brain, New York State Psychiatric Institute White Plains, New York
Children's Health Queensland Hospital and Health Service South Brisbane, Queensland
Children's Hospital of Philadelphia Philadelphia, Pennsylvania
Children's National Health System - The Children's Research Institute (CRI) Washington D.C., District of Columbia
Cortica San Rafael, California
Cortica Healthcare Glendale, California
Family Psychiatry of The Woodlands The Woodlands, Texas
Flinders Medical Centre Bedford PK, South Australia
Harmonex Neuroscience Research Dothan, Alabama
Hassman Research Institute Berlin, New Jersey
Holland Bloorview Kids Rehabilitation Hospital Toronto, Ontario
Jersey Shore University Medical Center Neptune City, New Jersey
Lawson Health Research Institute/ London Health Sciences Centre London, Ontario
Lurie Center for Autism Massachusetts General Hospital Lexington, Massachusetts
Massachusetts General Hospital Boston, Massachusetts
Mater Research South Brisbane, Queensland
NRC Research Institute Orange, California
Nathan Kline Institute for Psychiatric Research Orangeburg, New York
Neurobehavioral Medicine Group Bloomfield Hills, Michigan
OCT Research ULC (dba Okanagan Clinical Trials) Kelowna, British Columbia
Ohio State University Nisonger Center Columbus, Ohio
Pacific Clinical Research Management Group Upland, California
Red Oak Psychiatry Associates, PA Houston, Texas
Richmond Behavioral Associates Staten Island, New York
Road Runner Research, Ltd. San Antonio, Texas
Seattle Children's Autism Center Seattle, Washington
Southwest Autism Research & Resource Center, Clinical Research Phoenix, Arizona
Suburban Research Associates Media, Pennsylvania
The Royal Children's Hospital, Murdoch Children's Research Institute Parkville, Victoria
Thompson Autism and Neurodevelopmental Center Orange, California
University of California, San Francisco San Francisco, California
University of Missouri, Thompson Center for Autism & Neurodevelopmental Disorders Columbia, Missouri
University of South Florida Psychiatry and Behavioral Neurosciences Tampa, Florida
Virginia Commonwealth University Richmond, Virginia
Yale Child Study Center New Haven, Connecticut

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

Contact(s):

Upaly Bahadure - upaly@ptxtherapeutics.com

Principal Investigator:

System ID: NCT06854653

Show full eligibility criteria

Inclusion Criteria:

• Adult patient ≥18 years of age at the time of signing the informed consent.
• Patient is capable of giving adequate signed informed consent
• Have a confirmed diagnosis of CTCL with histological confirmation
• Patients must have greater than or equal to Stage Ib disease.
• Has received and failed (or intolerant of) at least 2 prior lines of prior systemic therapy for their disease.
• Has measurable disease defined by at least one of the following, within 28 days prior to start of study treatment: by evaluable by mSWAT or quantifiable by flow cytometry or morphology in blood or measurable by Lugano Criteria.
• On a stable dose of systemic corticosteroid (\< 10 mg prednisone or equivalent) are permitted. Participants on a stable dose of topical corticosteroids are permitted.
• Washout period- must be 2 weeks (4 weeks for monoclonal antibodies) or 5 -half-lives (whichever is longer) since any prior anti-cancer therapy.
• Must be human T-cell lymphotropic virus type 1 (HTLV1) negative.
• Has an ECOG PS of 0 to 2.
• Life expectancy of 3 months or greater
• Has adequate bone marrow function.
• Has adequate hepatic function.
• Has adequate Renal function.
• Has adequate coagulation function.
• Patients with Human Immunodeficiency virus (HIV) must be on established and stable effective anti-retroviral therapy for at least 4 weeks and have an HIV viral load of less than 400 copies/mL.
• Male patients are eligible to participate if they agree to use a highly effective contraception during the treatment period and for at least 3 months after the last dose of study treatment and refrain from donating sperm during this period.
• Female patients are eligible to participate if they are not pregnant, not breastfeeding, and at least one of the following conditions applies: -Not a woman of childbearing potential (WOCBP). * OR * A WOCBP who agrees to use a contraceptive method that is highly effective (with a failure rate of \< 1% per year) or be abstinent from heterosexual intercourse as their preferred method and usual lifestyle, beginning the time of informed consent, during the treatment period and for at least 3 months after the last dose of study treatment.
• A WOCBP must have a negative serum pregnancy within 72 hours of the first dose of study treatment.
• Must be willing and able to adhere to the study as judged by the Investigator.

Exclusion Criteria:

• Patients with known central nervous system involvement.
• Patients who require the use of strong inhibitors or inducers of CYP enzymes or transporters (e.g., CYP3A4, 2D6, 2C19) or (P-gp, BCRP, OATP1B1, OATP1B3, OAT1. OAT3, OCT2, MATE1 and MATE2-K). Patients who are receiving these medications at Screening can be enrolled into the trial if they discontinue them for at least 14 days or 5 half-lives, whichever is longer, before they commence PTX-100. An alternative pharmacological treatment should be instituted by the treating clinician based on clinical judgement.
• Significant cardiovascular disease. A history of, or concurrent interstitial lung disease or severely impaired lung function. 5\. Active viral, bacterial, fungal infection or other serious infection requiring ongoing systemic treatment. Routine antimicrobial prophylaxis is permitted. 6\. Medical history of another malignant tumor within the past 5 years. Exceptions are patients with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ who have undergone curative therapy with no evidence of disease. 7\. On an immunomodulatory drug for concomitant or intercurrent conditions or who have received any of these agents within 4 weeks of baseline. 8\. Patients with active viral (any etiology) hepatitis are excluded. However, patients with serologic evidence of chronic hepatitis B virus (HBV) infection (defined by a positive hepatitis B surface antigen test and a positive anti-hepatitis core antigen antibody test) who have a viral load below the limit quantification (HBV deoxyribose nucleic acid titer \< 1000 cps/mL or 200 IU/mL) and are not currently on viral suppressive therapy may be eligible and should be discussed with the Medical Monitor. Patients with a history of hepatitis C virus infection who have completed curative antiviral treatment and have a viral load below the limit of quantification may be eligible and should be discussed with the Medical Monitor. 9\. A history or current evidence of any condition, laboratory abnormality or other circumstance that might confound the results of the study or interfere with patient participation for the full duration of the study. 10\. Prior allogeneic or autologous hematopoietic transplantation 11. Has a known psychiatric disorder that would interfere with compliance with the requirements of the study. 12\. Is a consumer of illicit or recreational drugs or has a recent history (within the last year) of drug or alcohol abuse or dependence that in the judgment of the Investigator, would interfere with compliance with the requirements of the study.

Interventions: DRUG: PTX-100

Conditions: CTCL

Keywords: Relapsed or refractory Cutaneous T Cell Lymphoma, CTCL, PTX-100, Mycosis Fungoides, Sezary Syndrome, T Cell Lymphoma, Non-Hodgkin Lymphoma, Cutaneous Lymphoma

I'm interested

Share via email

Show 15 locations

Study Locations

Hide all locations

Location	Contacts
CHU de Bordeaux - Hopital Saint André Bordeaux, Bordeaux
City of Hope Comprehensive Cancer Cente Duarte, California
Dana-Farber Cancer Institute Boston, Massachusetts
Epworth Healthcare Richmond, Victoria	Ashna Saini - (Ashna.saini@epworth.org.au)
Hopital Lyon Sud Lyon, Pierre-Benite
Hopital Saint Louis Paris,
IRCCS Azienda Ospedaliero Universitaria di Bologna - Policlinico S. Orsola-Malpighi Bologna, Bologna
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele (HSR) (Istituto Scientifico Universitario San Raffaele) Milan, Milano
Linear Clinical Research Nedlands, Western Australia
Rochester Skin Lymphoma Medical Group. PLLC Rochester, New York	Brian Poligone, MD, PhD - (bpoligone@roclymphoma.com)
Universita degli Studi Di Brescia-Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia Brescia, Brescia
University of California Irvine Irvine, California
Virginia Commonwealth University Massey Comprehensive Cancer Cente Richmond, Virginia
Westmead Hospital Westmead, New South Wales
Yale Cancer Center New Haven, Connecticut

CardiolRx in Recurrent Pericarditis Following IL-1 Blocker Cessation (MAVERIC)

Contact(s):

Andrea B Parker, MSc., PhD - andrea.parker@cardiolrx.com

Principal Investigator:

System ID: NCT06708299

Show full eligibility criteria

Inclusion Criteria:

• Patients 18 years of age or older
• A history of recurrent pericarditis with stable disease and currently being treated with an IL-1 blocker, scheduled to be discontinued. Stable disease is defined as: * treatment with an IL-1 blocker for at least 12 months, * free of pericarditis recurrence for at least 6 months and this recurrence, if present, must have occurred in the setting of an interruption or tapering of an IL-1 blocker; and * treatment with an unchanged dose and regimen of on an IL-1 blocker for at least 3 months prior to randomization.
• Pericarditis pain les or equal than 2 on the 11-point Numerical Rating Scale (NRS) for at least 7 days prior to randomization (Visit 1, Day 1)
• C-Reactive Protein (CRP) \< 1.0 mg/dL during screening within 7 days prior to randomization (Visit 1, Day 1).
• Patients who have had a vasectomy or who are willing to use double barrier contraception methods with partners of childbearing potential during the conduct of the trial and for 2 months after the last dose of trial therapy.
• Patients of childbearing potential willing to use an acceptable method of contraception starting with trial therapy administration and for a minimum of 2 months after trial completion. Otherwise, these patients must be postmenopausal (at least 1 year absence of vaginal bleeding or spotting and confirmed by follicle stimulating hormone \[FSH\] ≥ 40 mIU/mL \[or ≥ 40 IU/L\] if less than 2 years postmenopausal) or be surgically sterile. Acceptable birth control methods that result in a failure rate of less than 1 % include oral, intravaginal or transdermal combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation; oral, injectable or implantable progestogen-only hormonal contraception associated with inhibition of ovulation; intrauterine device (IUD); intrauterine hormone-releasing system (IUS); using double-barrier contraception methods with their partners; bilateral tubal occlusion; vasectomised partner; sexual abstinence.

Exclusion Criteria:

• Pericarditis recurrence(s) during IL-1 blocker treatment without interruption or tapering of the IL-1 blocker
• Diagnosis of pericarditis that is secondary to specific prohibited etiologies, including tuberculosis (TB); neoplastic, purulent, or radiation etiologies; post-thoracic blunt trauma (e.g., motor vehicle accident); systemic autoimmune disease (e.g., systemic lupus erythematosus)
• Primary diagnosis of myocarditis (diagnosis of myopericarditis is accepted)
• Estimated glomerular filtration rate (eGFR) \< 30 mL/min during screening within 7 days prior to randomization (Visit 1, Day 1)
• Elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 5 times the upper limit of normal (ULN) or ALT or AST \> 3x ULN plus bilirubin \> 2x ULN during screening within 7 days prior to randomization (Visit 1, Day 1).
• Sepsis, defined as documented bacteremia during screening within 7 days prior to randomization (Visit 1, Day 1) or other untreated or uncontrolled bacterial infection\*
• Prior history of sustained ventricular arrhythmia(s)
• History of diagnosed long QT syndrome
• QTc interval \> 480 msec (biologically female) or \> 470 msec (biologically male) (please refer to Section 9.2.3 for bundle branch block, bifascicular block and paced rhythm correction) or second or third degree atrioventricular (AV) block in a patient without an implanted functioning pacemaker device during screening within 7 days prior to randomization (Visit 1, Day 1)
• Showing suicidal tendency during the last 12 months, as defined by answering "yes" to question 4 or 5 of the Columbia Suicide Severity Rating Scale (C-SSRS), administered during screening within 7 days prior to randomization (Visit 1, Day 1)
• Participation in a clinical trial in which an investigational drug or device was administered within 30 days of screening or within 5 half-lives of the previous study drug, whichever is longer
• Inability or unwillingness to give informed consent
• Ongoing drug or alcohol abuse in the opinion of the investigator
• On any cannabinoid during the past month or unwilling to stay abstinent from all cannabis products for the duration of the trial
• Pregnant or breastfeeding
• Current diagnosis of active cancer, with the exception of non-melanoma skin cancer
• Any factor, which would make it unlikely that the patient can comply with the trial procedures
• Moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment
• Has received systemic immunomodulatory agents as below prior to randomization:
• Methotrexate (within 2 weeks)
• Azathioprine, mycophenolate mofetil, cyclosporine, tacrolimus, sirolimus, or mercaptopurine (within 24 weeks)
• Canakinumab, TNF inhibitors, IL-6 inhibitors, or janus-activating kinase inhibitors (within 12 weeks)
• Intravenous immune globulin (IVIG) (within 8 weeks)
• Corticosteroids (within 4 weeks)
• Known hypersensitivity to the active substance or any of the excipients of the trial

Interventions: DRUG: CardiolRx

Conditions: Recurrent Pericarditis

Keywords: IL-1 blocker-dependent recurrent pericarditis, pharmaceutically cannabidial

I'm interested

Share via email

Show 26 locations

Study Locations

Hide all locations

Location	Contacts
Cleveland Clinic Cleveland, Ohio	Tom Wang, MD - (Wangt2@ccf.org)
Columbia University - New York Presbyterian New York, New York	Dor Lotan, MD - (dl3491@cumc.columbia.edu)
Columbia University - New York Presbyterian New York, New York
Fatebenefratelli Hospital Milano Milan,	Antonio Brucato, MD - (antonio.brucato@unimi.it)
Hippokration General Hospital Athens,	George Lazaros, MD - (glaz35@hotmail.com)
Houston Methodist Hospital Houston, Texas
Jewish General Hospital Montreal, Quebec	Vartan Mardigyan, MD - (vartan.mardigyan@mail.mcgill.ca)
Johns Hopkins University Baltimore, Maryland
Lenox Hill Hospital New York, New York
Massachusetts General Hospital Boston, Massachusetts	Jonathan Salik, MD - (jsalik@mgh.harvard.edu)
Mayo Clinic Jacksonville, Florida
Mayo Clinic Jacksonville, Florida	Sushil A Luis, MD - (luis.s@mayo.edu)
Mayo Clinic Florida Jacksonville, Florida	Prajwal Reddy, MD - (reddy.prajwal@mayo.edu)
Mayo Clionic Arizona Phoenix, Arizona	Chadi Ayoub, MD - (ayoub.chadi@mayo.edu)
MedStar Health Institute Columbia, Maryland
Minneapolis Heart Institute Minneapolis, Minnesota	David Lin, MD - (David.Lin@allina.com)
NYU Langone Health New York, New York	Michael Garshick, MD - (michael.garshick@nyulangone.org)
Northwestern University Chicago, Illinois	Mohammed Al-Kazaz, MD - (mohamed.alkazaz@nm.org)
UCI Health Orange, California
University Hospital Newark, New Jersey	Alessandro Andreis, MD - (alessandro.andreis@unito.it)
University Hospital Udine Udine,	Valentino Collini, MD - (valentino.collini@asufc.sanita.fvg.it)
University of Padua Padua,	Alida Caforio, MD - (alida.caforio@unipd.it)
University of Utah Hospital Salt Lake City, Utah
University of Vermont Colchester, Vermont	Tracy Hagerty, MD - (tracy.hagerty@uvmhealth.org)
University of Virginia Charlottesville, Virginia	Antonio Abbate, MD - (antonio.abbate@virginia.edu)
Virginia Commonwealth University Richmond, Virginia	Georgia Thomas, MD - (georgia.thomas@vcuhealth.org)

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

Contact(s):

ctrrecruit@vcu.edu

Principal Investigator:

System ID: NCT05053152

Show full eligibility criteria

Inclusion Criteria:

* Pathologically (histologically or cytologically) proven diagnosis of prostate adenocarcinoma at any anatomical location (for example, prostate, metastatic site), including intraductal or ductal carcinoma, at any time before registration * Age \>= 18 years * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 within 180 days prior to registration * Prior curative-intent treatment to the prostate, by either: * External beam and/or brachytherapy to: Prostate alone, prostate and seminal vesicles, prostate and pelvic nodes, or radiation to all three sites * Radical prostatectomy alone, radical prostatectomy plus postoperative radiotherapy to the prostate bed, or radical prostatectomy plus postoperative radiotherapy to the pelvic nodes. * Note: Patients who have received curative intent with radiation prior to prostatectomy are eligible and should be categorized as RT to Intact Prostate since that was the first curative intent * Must meet study entry criteria based on the following diagnostic workup within 120 days prior to registration: * History and physical examination; * Fluciclovine or PSMA PET scan; * PET must be combined with either CT or MRI, but a diagnostic CT or MRI reading/interpretation is not required * 1 - 5 oligometastatic lesions in bone and/or nodal/soft tissue (non-abutting nodes are counted separately) sites on fluciclovine or PSMA PET within 180 days prior to registration and includes at least ONE of the following: * Bone - each metastasis is counted (for example, 2 distinct lesions in the right ilium count as 2 oligometastatic lesions) * Extrapelvic Nodal/ soft tissue - requires at least one extrapelvic inguinal or a nodal/soft tissue lesion superior to the iliac bifurcation (that is, American Joint Committee on Cancer \[AJCC\] M1a version 8) * Note: Although a patient must have bone and/or extrapelvic disease to be eligible, when counting the number of oligometastatic lesions, each lymph node lesion, whether pelvic or extrapelvic, is counted (for example, 2 distinct lymph nodes in the right external iliac basin count as 2 oligometastatic lesions; one extrapelvic and one pelvic node count as 2 oligometastic lesions, etc) * Serum total prostate-specific antigen (PSA) =\< 10.0 ng/mL that also meets ONE of the following PSA recurrence definitions: * If patient has received-radiation therapy to intact prostate, either * PSA \> post-RT nadir PSA + 2 ng/mL obtained within 180 days prior to registration, or * PSA \> 0.2 ng/mL with at least two rises from post-treatment nadir with the most recent PSA within 180 days prior to registration * If patient has received a radical prostatectomy with or without post-op RT, either * Current PSA \> 0.2 ng/mL, with a second confirmatory PSA \> 0.2 ng/mL, with most recent PSA obtained within 180 days prior to registration, or * Two consecutive PSA rises from post-operative nadir, with most recent PSA obtained within 180 days prior to registration * Must have \>= 3 PSA values within the last two years since end of primary treatment or within the last 2 years prior to registration, whichever is less * Note: PSA doubling time must be calculated by entering all PSA values since end of primary treatment or within the last 2 years prior to registration (whichever is less) into the PSA Doubling Time Calculator found at MDCalc.com * Serum total testosterone \>= 100 ng/dL within 180 days prior to registration * Note: Prior androgen deprivation therapy (other than bilateral orchiectomy) is allowed if discontinued prior to registration and serum total testosterone is \>= 100 ng/dL * Total bilirubin: =\< 1.5 x institutional upper limit of normal (ULN) (Note: In subjects with Gilbert's syndrome, if total bilirubin is \> 1.5 x ULN, subject is eligible if direct bilirubin is =\< 1.5 x ULN) (within 180 days prior to registration) * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]): =\< 2.5 x institutional ULN (within 180 days prior to registration) * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated * Note: Known positive test for hepatitis B virus surface antigen (HBV sAg) indicating acute or chronic infection would make the patient ineligible unless the viral load becomes undetectable on suppressive therapy. Patients who are immune to hepatitis B (anti-hepatitis B surface antibody positive) are eligible (e.g. patients immunized against hepatitis B) * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load * Note: Known positive test for hepatitis C virus ribonucleic acid (HCV RNA) indicating acute or chronic infection would make the patient ineligible unless the viral load becomes undetectable on suppressive therapy * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial * The patient must agree to use a highly effective contraception (even men with vasectomies) if he is having sex with a woman of childbearing potential or with a woman who is pregnant while on study drug and for 2 weeks following the last dose of study drug * The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information

Exclusion Criteria:

* Currently on androgen deprivation or anti-androgen therapy * Spinal cord compression, or spinal intramedullary, brain, and/or visceral (for example liver, etc.) metastasis * Note: Spinal metastases (PET-detected) with epidural extension are eligible if there is \> 0.3 cm spatial separation between the gross tumor volume and spinal cord. Lung metastases are eligible * Biopsy-proven prostatic carcinoma with signet-ring, sarcomatoid, or neuroendocrine features (for example, small cell) * Prior metastatic or non-metastatic, invasive malignancy (except non metastatic, non-melanomatous skin cancer) unless continuously disease free for \>= 3 years * Prior chemotherapy for prostate cancer or bilateral orchiectomy * Note: Prior chemotherapy for a different cancer is allowed if continuously disease-free for \>= 3 years * Prior high dose radiotherapy to a lesion (i.e. oligometastatic recurrence by PET) * Note: Lesions included in or near a previously irradiated planning target volume (PTV) are eligible as long as previous delivered dose is estimated to be less than an EQD2 of 50 Gy * Inability to treat all oligometastatic sites with radiotherapy in the judgement of the investigator * Intrapelvic lymph nodes as only site of prostate cancer recurrence * Inability to swallow whole, undivided, unchewed, and uncrushed pills * Known gastrointestinal disorder affecting oral medication absorption * Co-morbidity defined as follows: * Patients with any comorbidities that would prohibit completion of protocol specified therapy * Inflammatory bowel disease in patients in whom abdominopelvic radiotherapy is planned * History of congenital long QT syndrome * Current severe or unstable angina * New York Heart Association functional classification III/IV heart failure (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association functional classification)

Interventions: PROCEDURE: Biospecimen Collection, PROCEDURE: Bone Scan, PROCEDURE: Computed Tomography, OTHER: Fluciclovine F18, PROCEDURE: Magnetic Resonance Imaging, DRUG: Placebo Administration, PROCEDURE: Positron Emission Tomography, PROCEDURE: PSMA PET Scan, DRUG: Relugolix, RADIATION: Stereotactic Body Radiation Therapy

Conditions: Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Ductal Adenocarcinoma, Prostate Intraductal Carcinoma, Stage IVB Prostate Cancer AJCC v8

I'm interested

Share via email

Show 235 locations

Study Locations

Hide all locations

Location	Contacts
AMG Crystal Lake - Oncology Crystal Lake, Illinois	Site Public Contact - (advocateresearch@advocate.com)
AMG Libertyville - Oncology Libertyville, Illinois	Site Public Contact - (advocateresearch@advocatehealth.com)
Adams Cancer Center Gettysburg, Pennsylvania
AdventHealth Altamonte Altamonte Springs, Florida
AdventHealth Celebration Celebration, Florida
AdventHealth Littleton Littleton, Colorado	Site Public Contact - (research.institute@adventhealth.com)
AdventHealth Orlando Orlando, Florida	Site Public Contact - (FH.Cancer.Research@flhosp.org)
AdventHealth Parker Parker, Colorado	Site Public Contact - (research.institute@adventhealth.com)
AdventHealth Porter Denver, Colorado	Site Public Contact - (research.institute@adventhealth.com)
Advocate Christ Medical Center Oak Lawn, Illinois
Advocate Good Samaritan Hospital Downers Grove, Illinois	Site Public Contact - (Barbara.barhamand@advocatehealth.com)
Advocate Good Shepherd Hospital Barrington, Illinois
Advocate Illinois Masonic Medical Center Chicago, Illinois
Advocate Lutheran General Hospital Park Ridge, Illinois
Advocate Sherman Hospital Elgin, Illinois
Advocate South Suburban Hospital Hazel Crest, Illinois
Alta Bates Summit Medical Center-Herrick Campus Berkeley, California	Site Public Contact - (clinicalresearch@sutterhealth.org)
Alton Memorial Hospital Alton, Illinois
Aspirus Cancer Care - James Beck Cancer Center Rhinelander, Wisconsin	Site Public Contact - (Beth.Knetter@aspirus.org)
Aspirus Cancer Care - Stevens Point Stevens Point, Wisconsin	Site Public Contact - (Beth.Knetter@aspirus.org)
Aspirus Cancer Care - Wisconsin Rapids Wisconsin Rapids, Wisconsin
Aspirus Regional Cancer Center Wausau, Wisconsin
Atrium Medical Center-Middletown Regional Hospital Franklin, Ohio	Site Public Contact - (clinical.trials@daytonncorp.org)
Aurora Bay Area Medical Group-Marinette Marinette, Wisconsin	Site Public Contact - (ncorp@aurora.org)
Aurora BayCare Medical Center Green Bay, Wisconsin	Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Grafton Grafton, Wisconsin	Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Milwaukee West Wauwatosa, Wisconsin	Site Public Contact - (ncorp@aurora.org)
Aurora Medical Center in Summit Summit, Wisconsin	Site Public Contact - (ncorp@aurora.org)
Aurora Saint Luke's Medical Center Milwaukee, Wisconsin	Site Public Contact - (ncorp@aurora.org)
Aurora Sinai Medical Center Milwaukee, Wisconsin	Site Public Contact - (ncorp@aurora.org)
Aurora West Allis Medical Center West Allis, Wisconsin	Site Public Contact - (ncorp@aurora.org)
Banner McKee Medical Center Loveland, Colorado
Banner North Colorado Medical Center Greeley, Colorado
Beebe Health Campus Rehoboth Beach, Delaware	Site Public Contact - (research@beebehealthcare.org)
Beebe South Coastal Health Campus Millville, Delaware	Site Public Contact - (research@beebehealthcare.org)
Benefis Sletten Cancer Institute Great Falls, Montana	Site Public Contact - (mccinfo@mtcancer.org)
Bon Secours Cancer Institute at Reynolds Crossing Richmond, Virginia	Site Public Contact - (Anne_caramella@bshsi.org)
Bon Secours Saint Francis Medical Center Midlothian, Virginia	Site Public Contact - (anne_carmellat@bshsi.org)
Bronson Methodist Hospital Kalamazoo, Michigan	Site Public Contact - (crcwm-regulatory@crcwm.org)
Bryn Mawr Hospital Bryn Mawr, Pennsylvania	Site Public Contact - (turzoe@mlhs.org)
CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ) Québec, Quebec	Site Public Contact - (rechclinique@crchuq.ulaval.ca)
CHUM - Centre Hospitalier de l'Universite de Montreal Montreal, Quebec	Site Public Contact - (info.cr.chum@ssss.gouv.qc.ca)
Cancer Care and Hematology-Fort Collins Fort Collins, Colorado	Site Public Contact - (Roster@nrgoncology.org)
Cancer Center at Saint Joseph's Phoenix, Arizona	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Cancer Center of Western Wisconsin New Richmond, Wisconsin	Site Public Contact - (mmcorc@healthpartners.com)
Carle Cancer Center Urbana, Illinois	Site Public Contact - (Research@carle.com)
Carle Physician Group-Mattoon/Charleston Mattoon, Illinois	Site Public Contact - (Research@carle.com)
Carle at The Riverfront Danville, Illinois	Site Public Contact - (Research@Carle.com)
Carlisle Regional Cancer Center Carlisle, Pennsylvania	Site Public Contact - (Roster@nrgoncology.org)
Carolina Regional Cancer Center Myrtle Beach, South Carolina
Case Western Reserve University Cleveland, Ohio
Cedars Sinai Medical Center Los Angeles, California
Central Vermont Medical Center/National Life Cancer Treatment Berlin Corners, Vermont
Chambersburg Hospital Chambersburg, Pennsylvania	Site Public Contact - (Roster@nrgoncology.org)
Chelsea Hospital Chelsea, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Christiana Care Health System-Concord Health Center Chadds Ford, Pennsylvania	Site Public Contact - (lbarone@christianacare.org)
Cleveland Clinic Cancer Center Strongsville Strongsville, Ohio	Site Public Contact - (TaussigResearch@ccf.org)
Cleveland Clinic Cancer Center/Fairview Hospital Cleveland, Ohio	Site Public Contact - (TaussigResearch@ccf.org)
Cleveland Clinic Foundation Cleveland, Ohio	Site Public Contact - (TaussigResearch@ccf.org)
Cleveland Clinic-Weston Weston, Florida	Site Public Contact - (CancerAnswer@ccf.org)
Corewell Health Beaumont Troy Hospital Troy, Michigan
Corewell Health Grand Rapids Hospitals - Butterworth Hospital Grand Rapids, Michigan	Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health William Beaumont University Hospital Royal Oak, Michigan
Covenant Medical Center-Lakeside Lubbock, Texas	Site Public Contact - (jaccresearch@covhs.org)
Crossroads Cancer Center Effingham, Illinois	Site Public Contact - (morganthaler.jodi@mhsil.com)
Dartmouth Cancer Center - North Saint Johnsbury, Vermont	Site Public Contact - (cancer.research.nurse@hitchcock.org)
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center Lebanon, New Hampshire	Site Public Contact - (cancer.research.nurse@dartmouth.edu)
Decatur Memorial Hospital Decatur, Illinois	Site Public Contact - (morganthaler.jodi@mhsil.com)
Divine Providence Hospital Williamsport, Pennsylvania	Site Public Contact - (Roster@nrgoncology.org)
Drexel Town Square Health Center Oak Creek, Wisconsin
East Carolina University Greenville, North Carolina	Site Public Contact - (eubankss@ecu.edu)
East Jefferson General Hospital Metairie, Louisiana	Site Public Contact - (emede1@lsuhsc.edu)
Edwards Comprehensive Cancer Center Huntington, West Virginia	Site Public Contact - (Christina.Cole@chhi.org)
Emory Decatur Hospital Decatur, Georgia	Site Public Contact - (clinicaltrialsoncology@dekalbmedical.org)
Emory Johns Creek Hospital Johns Creek, Georgia	Site Public Contact - (m.lisa.hwang@emory.edu)
Emory Saint Joseph's Hospital Atlanta, Georgia
Emory University Hospital Midtown Atlanta, Georgia
Emory University Hospital/Winship Cancer Institute Atlanta, Georgia
Ephrata Cancer Center Ephrata, Pennsylvania
FHCC at EvergreenHealth Kirkland, Washington
FHCC at Northwest Hospital Seattle, Washington
Fox Chase Cancer Center Philadelphia, Pennsylvania
Fox Chase Cancer Center - East Norriton Hospital Outpatient Center East Norriton, Pennsylvania
Fox Chase Cancer Center Buckingham Furlong, Pennsylvania
Fred Hutchinson Cancer Center Seattle, Washington
Froedtert Menomonee Falls Hospital Menomonee Falls, Wisconsin
Froedtert West Bend Hospital/Kraemer Cancer Center West Bend, Wisconsin
Geisinger Cancer Services-Pottsville Pottsville, Pennsylvania	Site Public Contact - (HemonCCTrials@geisinger.edu)
Geisinger Medical Center Danville, Pennsylvania	Site Public Contact - (HemonCCTrials@geisinger.edu)
Geisinger Medical Oncology-Lewisburg Lewisburg, Pennsylvania	Site Public Contact - (HemonCCTrials@geisinger.edu)
Geisinger Wyoming Valley/Henry Cancer Center Wilkes-Barre, Pennsylvania	Site Public Contact - (HemonCCTrials@geisinger.edu)
GenesisCare USA - Lakewood Ranch Lakewood Rch, Florida
GenesisCare USA - Plantation Plantation, Florida
George Washington University Medical Center Washington D.C., District of Columbia
Goshen Center for Cancer Care Goshen, Indiana	Site Public Contact - (cccois@goshenhealth.com)
Grady Health System Atlanta, Georgia
HSHS Saint Elizabeth's Hospital O'Fallon, Illinois	Site Public Contact - (morganthaler.jodi@mhsil.com)
Helen F Graham Cancer Center Newark, Delaware	Site Public Contact - (lbarone@christianacare.org)
Highland Hospital Rochester, New York
Hillcrest Hospital Cancer Center Mayfield Heights, Ohio	Site Public Contact - (TaussigResearch@ccf.org)
IRMC Cancer Center Indiana, Pennsylvania	Site Public Contact - (haneydl@upmc.edu)
Iowa Methodist Medical Center Des Moines, Iowa
Jupiter Medical Center Jupiter, Florida
LSU Healthcare Network / Metairie Multi-Specialty Clinic Metairie, Louisiana
Langlade Hospital and Cancer Center Antigo, Wisconsin	Site Public Contact - (Juli.Alford@aspirus.org)
Lankenau Medical Center Wynnewood, Pennsylvania	Site Public Contact - (turzoe@mlhs.org)
Los Angeles General Medical Center Los Angeles, California
Marshfield Medical Center - Minocqua Minocqua, Wisconsin	Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center - Weston Weston, Wisconsin	Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-EC Cancer Center Eau Claire, Wisconsin	Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-Marshfield Marshfield, Wisconsin	Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-Rice Lake Rice Lake, Wisconsin	Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-River Region at Stevens Point Stevens Point, Wisconsin	Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Mary Bird Perkins Cancer Center Baton Rouge, Louisiana	Site Public Contact - (clinicalresearch@marybird.com)
Mary Bird Perkins Cancer Center - Gonzales Gonzales, Louisiana	Site Public Contact - (clinicalresearch@marybird.com)
Mary Bird Perkins Cancer Center - Metairie Metairie, Louisiana
Mary Greeley Medical Center Ames, Iowa
McFarland Clinic - Ames Ames, Iowa	Site Public Contact - (ksoder@mcfarlandclinic.com)
Medical Center of the Rockies Loveland, Colorado
Medical College of Wisconsin Milwaukee, Wisconsin
Medical Oncology Hematology Consultants PA Newark, Delaware	Site Public Contact - (lbarone@christianacare.org)
Memorial Hospital East Shiloh, Illinois	Site Public Contact - (dschwab@wustl.edu)
Memorial Hospital North Colorado Springs, Colorado
Memorial Medical Center Modesto, California	Site Public Contact - (clinicalresearch@sutterhealth.org)
Methodist Medical Center of Illinois Peoria, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
MetroHealth Medical Center Cleveland, Ohio	Site Public Contact - (ababal@metrohealth.org)
Miami Valley Hospital Dayton, Ohio	Site Public Contact - (clinical.trials@daytonncorp.org)
Miami Valley Hospital North Dayton, Ohio	Site Public Contact - (clinical.trials@daytonncorp.org)
Miami Valley Hospital South Centerville, Ohio	Site Public Contact - (clinical.trials@daytonncorp.org)
Michigan Healthcare Professionals Clarkston Clarkston, Michigan	Site Public Contact - (rudi.ross@profoundresearch.io)
Michigan Healthcare Professionals Farmington Farmington Hills, Michigan	Site Public Contact - (rudi.ross@profoundresearch.io)
Michigan Healthcare Professionals Macomb Macomb, Michigan	Site Public Contact - (rudi.ross@profoundresearch.io)
Michigan Healthcare Professionals Madison Heights Madison Heights, Michigan	Site Public Contact - (rudi.ross@profoundresearch.io)
Michigan Healthcare Professionals Troy Troy, Michigan	Site Public Contact - (rudi.ross@profoundresearch.io)
Moffitt Cancer Center Tampa, Florida	Site Public Contact - (ClinicalTrials@moffitt.org)
Moffitt Cancer Center - McKinley Campus Tampa, Florida	Site Public Contact - (ClinicalTrials@moffitt.org)
Moffitt Cancer Center-International Plaza Tampa, Florida	Site Public Contact - (ClinicalTrials@moffitt.org)
Munson Medical Center Traverse City, Michigan	Site Public Contact - (crcwm-regulatory@crcwm.org)
OSF Saint Francis Medical Center Peoria, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
Ohio State University Comprehensive Cancer Center Columbus, Ohio	Site Public Contact - (Jamesline@osumc.edu)
Oregon Health and Science University Portland, Oregon	Site Public Contact - (trials@ohsu.edu)
Paoli Memorial Hospital Paoli, Pennsylvania	Site Public Contact - (turzoe@mlhs.org)
Parkview Regional Medical Center Fort Wayne, Indiana
Penn State Milton S Hershey Medical Center Hershey, Pennsylvania	Site Public Contact - (CTO@hmc.psu.edu)
Phelps Health Delbert Day Cancer Institute Rolla, Missouri	Site Public Contact - (research@phelpshealth.org)
Piedmont Fayette Hospital Fayetteville, Georgia
Piedmont Hospital Atlanta, Georgia
Poudre Valley Hospital Fort Collins, Colorado
Premier Blood and Cancer Center Dayton, Ohio
ProHealth D N Greenwald Center Mukwonago, Wisconsin	Site Public Contact - (research.institute@phci.org)
ProHealth Oconomowoc Memorial Hospital Oconomowoc, Wisconsin
ProMedica Flower Hospital Sylvania, Ohio	Site Public Contact - (PCIOncResearch@promedica.org)
Ralph H Johnson VA Medical Center Charleston, South Carolina	Site Public Contact - (ashley.salvo@va.gov)
Regions Hospital Saint Paul, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Riddle Memorial Hospital Media, Pennsylvania	Site Public Contact - (turzoe@mlhs.org)
Rocky Mountain Cancer Centers-Boulder Boulder, Colorado	Site Public Contact - (info@westernstatesncorp.org)
Roswell Park Cancer Institute Buffalo, New York	Site Public Contact - (askroswell@roswellpark.org)
Saint Francis Medical Center Cape Girardeau, Missouri	Site Public Contact - (sfmc@sfmc.net)
Sanford Broadway Medical Center Fargo, North Dakota	Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford Cancer Center Oncology Clinic Sioux Falls, South Dakota	Site Public Contact - (OncologyClinicTrialsSF@sanfordhealth.org)
Sanford Roger Maris Cancer Center Fargo, North Dakota	Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford USD Medical Center - Sioux Falls Sioux Falls, South Dakota	Site Public Contact - (OncologyClinicalTrialsSF@SanfordHealth.org)
Sechler Family Cancer Center Lebanon, Pennsylvania	Site Public Contact - (doxenberg@wellspan.org)
Shaw Cancer Center Edwards, Colorado
Siteman Cancer Center at Christian Hospital St Louis, Missouri	Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center at Saint Peters Hospital City of Saint Peters, Missouri	Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center at West County Hospital Creve Coeur, Missouri	Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center-South County St Louis, Missouri	Site Public Contact - (info@siteman.wustl.edu)
Springfield Memorial Hospital Springfield, Illinois	Site Public Contact - (pallante.beth@mhsil.com)
Sutter Medical Center Sacramento Sacramento, California	Site Public Contact - (clinicalresearch@sutterhealth.org)
Sutter Pacific Medical Foundation Santa Rosa, California	Site Public Contact - (clinicalresearch@sutterhealth.org)
Sutter Solano Medical Center/Cancer Center Vallejo, California	Site Public Contact - (clinicalresearch@sutterhealth.org)
The James Graham Brown Cancer Center at University of Louisville Louisville, Kentucky
The Valley Hospital - Luckow Pavilion Paramus, New Jersey
Tower Cancer Research Foundation Beverly Hills, California	Site Public Contact - (towercancerresearch@toweroncology.com)
Trinity Health Grand Rapids Hospital Grand Rapids, Michigan	Site Public Contact - (crcwm-regulatory@crcwm.org)
Trinity Health IHA Medical Group Hematology Oncology - Brighton Brighton, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology - Canton Canton, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital Chelsea, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus Ypsilanti, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Medical Center - Brighton Brighton, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Medical Center - Canton Canton, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Saint Joseph Mercy Hospital Ann Arbor Ann Arbor, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Saint Joseph Mercy Oakland Hospital Pontiac, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Saint Mary Mercy Livonia Hospital Livonia, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California
UCHealth Greeley Hospital Greeley, Colorado	Site Public Contact - (Roster@nrgoncology.org)
UCHealth Highlands Ranch Hospital Highlands Ranch, Colorado
UCHealth Memorial Hospital Central Colorado Springs, Colorado
UCHealth University of Colorado Hospital Aurora, Colorado
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California	Site Public Contact - (ucstudy@uci.edu)
UH Seidman Cancer Center at Lake Health Mentor Campus Mentor, Ohio
UH Seidman Cancer Center at UH Avon Health Center Avon, Ohio
UHHS-Chagrin Highlands Medical Center Beachwood, Ohio
UI Health Care Mission Cancer and Blood - Des Moines Clinic Des Moines, Iowa
UPMC Altoona Altoona, Pennsylvania	Site Public Contact - (Roster@nrgoncology.org)
UPMC Cancer Center at UPMC Horizon Farrell, Pennsylvania	Site Public Contact - (Roster@nrgoncology.org)
UPMC Cancer Center at UPMC Northwest Seneca, Pennsylvania
UPMC Hillman Cancer Center Erie Erie, Pennsylvania	Site Public Contact - (haneydl@upmc.edu)
UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion Mechanicsburg, Pennsylvania	Site Public Contact - (haneydl@upmc.edu)
UPMC Hillman Cancer Center in Coraopolis Moon Township, Pennsylvania	Site Public Contact - (haneydl@upmc.edu)
UPMC Memorial York, Pennsylvania
UPMC Pinnacle Cancer Center/Community Osteopathic Campus Harrisburg, Pennsylvania	Site Public Contact - (klitchfield@PINNACLEHEALTH.org)
UPMC Washington Hospital Radiation Oncology Washington, Pennsylvania	Site Public Contact - (cancer@washingtonhospital.org)
UPMC-Heritage Valley Health System Beaver Beaver, Pennsylvania	Site Public Contact - (haneydl@upmc.edu)
UPMC-Magee Womens Hospital Pittsburgh, Pennsylvania
UPMC-Passavant Hospital Pittsburgh, Pennsylvania
UPMC-Saint Margaret Pittsburgh, Pennsylvania
UPMC-Shadyside Hospital Pittsburgh, Pennsylvania
USC / Norris Comprehensive Cancer Center Los Angeles, California
UW Cancer Center at ProHealth Care Waukesha, Wisconsin	Site Public Contact - (Chanda.miller@phci.org)
University Health Network-Princess Margaret Hospital Toronto, Ontario	Site Public Contact - (clinical.trials@uhn.on.ca)
University Hospitals Parma Medical Center Parma, Ohio
University Hospitals Portage Medical Center Ravenna, Ohio
University Medical Center New Orleans New Orleans, Louisiana	Site Public Contact - (emede1@lsuhsc.edu)
University of Michigan Health - Sparrow Lansing Lansing, Michigan	Site Public Contact - (harsha.trivedi@umhsparrow.org)
University of Michigan Health - West Wyoming, Michigan	Site Public Contact - (crcwm-regulatory@crcwm.org)
University of New Mexico Cancer Center Albuquerque, New Mexico
University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma	Site Public Contact - (ou-clinical-trials@ouhsc.edu)
University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania
University of Rochester Rochester, New York
University of Vermont Medical Center Burlington, Vermont	Site Public Contact - (rpo@uvm.edu)
University of Washington Medical Center - Montlake Seattle, Washington
UofL Health Medical Center Northeast Louisville, Kentucky	Site Public Contact - (ctoinfo@louisville.edu)
Upper Valley Medical Center Troy, Ohio	Site Public Contact - (clinical.trials@daytonncorp.org)
VCU Community Memorial Health Center South Hill, Virginia	Site Public Contact - (nemer.elmouallem@vcuhealth.org)
VCU Massey Cancer Center at Stony Point Richmond, Virginia	Site Public Contact - (ctoclinops@vcu.edu)
VCU Massey Comprehensive Cancer Center Richmond, Virginia	Site Public Contact - (CTOclinops@vcu.edu)
Vince Lombardi Cancer Clinic - Oshkosh Oshkosh, Wisconsin	Site Public Contact - (ncorp@aurora.org)
Vince Lombardi Cancer Clinic-Sheboygan Sheboygan, Wisconsin	Site Public Contact - (ncorp@aurora.org)
Washington University School of Medicine St Louis, Missouri	Site Public Contact - (info@siteman.wustl.edu)
WellSpan Health-York Cancer Center York, Pennsylvania
WellStar Cobb Hospital Austell, Georgia	Site Public Contact - (research@wellstar.org)
Wellstar Kennestone Hospital Marietta, Georgia	Site Public Contact - (research@wellstar.org)
Wilmot Cancer Institute at Webster Webster, New York	Site Public Contact - (WCICTOresearch@urmc.rochester.edu)

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation (HERMES)

Contact(s):

Novo Nordisk - clinicaltrials@novonordisk.com

Principal Investigator:

System ID: NCT05636176

Show full eligibility criteria

Inclusion Criteria:

* Serum high-sensitivity C-reactive protein (hs-CRP) greater than equal to 2 milligrams per liter (mg/L) at screening (visit 1) Disease specific - cardiovascular * At least one of the following:
• N-terminal-pro-brain natriuretic peptide (NT-proBNP) greater than equal to 300 picograms per milliliter (pg/mL) at screening (Visit 1) for patients without ongoing atrial fibrillation/flutter. If ongoing atrial fibrillation/flutter at screening (visit 1), NTproBNP must be greater than equal to 600 pg/mL. Note that the screening electrocardiogram (ECG) must be obtained the same day as sampling for NT-proBNP.
• Hospitalisation or urgent/unplanned visit with a primary diagnosis of decompensated heart failure which required intravenous loop diuretic treatment, within the last 9 months prior to screening (visit 1) in combination with NT-proBNP greater than equal to 200 pg/mL at screening (Visit 1) for patients without ongoing atrial fibrillation/flutter. If ongoing atrial fibrillation/flutter at screening (visit 1), NT-proBNP must be greater than equal to 600 pg/mL. * Diagnosis of heart failure (New York Heart Association \[classification\] \[NYHA\] Class II-IV). * Left ventricular ejection fraction (LVEF) greater than 40 percentage (%) documented by echocardiography within 12 months prior to or at screening (visit 1). The LVEF must be documented in medical records and the most recent measurement must be used to determine eligibility with no interim event signalling potential deterioration in ejection fraction (e.g., myocardial infarction \[MI\] or heart failure \[HF\] hospitalisation). * Structural heart disease and/or functional heart disease documented by echocardiography within 12 months prior to or at screening (visit 1) showing at least one of the following: * Left atrial (LA) volume index greater than 34 milliliter per meter square (mL/m\^2). * LA diameter greater than equal to 3.8 centimeter (cm). * LA length greater than equal to 5.0 cm. * LA area greater than equal to 20 cm square. * LA volume greater than equal to 55 milliters (mL). * Intraventricular septal thickness greater than equal to 1.1 cm. * Posterior wall thickness greater than equal to 1.1 cm. * Left ventricular (LV) mass index greater than equal to 115 grams per meter square (g⁄m\^2 ) in men or greater than equal to 95 g⁄m\^2 in women. * E/e' (mean septal and lateral) greater than equal to 10. * e' (mean septal and lateral) less than 9 centimeter per second (cm/s). * No heart failure hospitalisations or urgent heart failure visits between screening (visit 1) and randomisation (visit 2).

Exclusion Criteria:

Medical conditions - cardiovascular * Myocardial infarction, stroke, unstable angina pectoris, transient ischaemic attack, or heart failure hospitalisation, within 30 days prior to screening (visit 1). * Systolic blood pressure greater than equal to 180 millimeters of mercury (mmHg) at screening (visit 1). If the systolic blood pressure is 160-179 mmHg, the patient should be receiving greater than equal to 3 antihypertensive drugs. (Note: Potential participants may be retested for this criterion within the visit window and without rescreening, at the discretion of the investigator). * Heart rate above 110 or below 40 beats per minute as evaluated on the electrocardiogram (ECG) performed at screening (visit 1) (Note: Potential participants may be retested for this criterion within the visit window and without rescreening, at the discretion of the investigator). * Planned coronary, carotid or peripheral artery revascularisation known during the screening period (visit 1). (Note: Planned coronary angiogram is not exclusionary). * Planned cardiac device or atrial flutter/atrial fibrillation ablation procedure known during the screening period (visit 1). * Major cardiac surgical, non-cardiac surgical, or major endoscopic procedure (thoracoscopic or laparoscopic) within the past 60 days prior to randomisation (visit 2) or any major surgical procedure planned at the time of randomisation (visit 2). * Heart failure due to infiltrative cardiomyopathy (e.g., sarcoid, amyloid), arrhythmogenic right ventricular cardiomyopathy, Takutsubo cardiomyopathy, genetic hypertrophic cardiomyopathy or obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac tamponade, uncorrected more than moderate primary valve disease. * Primary pulmonary hypertension, chronic pulmonary embolism, severe pulmonary disease including COPD. * Any other condition judged by the investigator that could account for heart failure symptoms and signs (e.g., anaemia, hypothyroidism). Medical conditions - infections/immunosuppression \- Clinical evidence of, or suspicion of, active infection at the discretion of the investigator.

Interventions: DRUG: Ziltivekimab, DRUG: Placebo

Conditions: Heart Failure

I'm interested

Share via email

Show 1075 locations

Study Locations

Hide all locations

Location	Contacts
"AHEPA" University General Hospital of Thessaloniki Thessaloniki,
"AHEPA" University General Hospital of Thessaloniki Thessaloniki,
"AHEPA" University General Hospital of Thessaloniki Thessaloniki,
"Carol Davila" Military Emergency Hospital Bucharest,
"Carol Davila" Military Emergency Hospital Bucharest,
"Hygeia" General Hospital of Athens Athens,
"Hygeia" General Hospital of Athens Athens,
"MHAT - UniHospital" OOD Panagyurishte,
"MHAT - UniHospital" OOD Panagyurishte,
"Medical center Medconsult Pleven" OOD Pleven,
"Medical center Zara-Med" EOOD Stara Zagora,
"Sotiria" Thoracic Diseases Hospital of Athens Athens,
"UMHAT Plovdiv" AD Plovdiv,
'G. Gennimatas' General Hospital of Athens Athens,
'Ippokrateio' General Hospital of Thessaloniki Thessaloniki,
'MHAT Sveta Karidad' EAD Plovdiv,
'Medical Center Hipokrena' EOOD Sevlievo,
4 Wojskowy Szpital Kliniczny Z Poliklinika Samodzielny Publiczny Zaklad Opieki Zdrowotnej We Wroclawiu Wroclaw, Lower Silesian Voivodeship
A.O.U. Ferrara, Sant'Anna Cona (Ferrara), Fe
A.O.U. Ferrara, Sant'Anna Cona (Ferrara), Fe
AIG Hospitals,Hyderabad Hyderabad, Telangana
AIG Hospitals,Hyderabad Hyderabad, Telangana
AORN "San Pio"- Benevento Benevento, Bn
AORN "San Pio"- Benevento - UOC Cardiologia Interventistica ed UTIC Benevento, Bn
AORN "Sant'Anna e San Sebastiano" Caserta, Ce
AORN "Sant'Anna e San Sebastiano" Caserta, Ce
AOU Maggiore della Carità di Novara - Dipartimento Toraco-Cardio-Vascolare - SCDU Cardiologia Novara,
AOUI Verona Verona,
AOUI Verona Verona,
ASL Al Di Alessandria - Ospedale Santo Spirito - Casale Monferrato - Cardiologia Casale Monferrato, Al
ASST Fatebenefratelli Ospedale Luigi Sacco Medicina Interna Milan,
ASST Fatebenefratelli Ospedale Luigi Sacco Medicina Interna Milan,
AZ Groeninge - Kortrijk - Cardiology Kortrijk,
AZORG Aalst - Moorselbaan Aalst,
Aakash Healthcare Super Speciality Hospital New Delhi,
Aarhus Universitetshospital, Hjertesygdomme Aarhus N,
Aarhus Universitetshospital, Skejby Hjertesygdomme Aarhus N,
Aberdeen Royal Infirmary Aberdeen,
Adoria Riga,
Advanced Cardiovascular, LLC Alexander City, Alabama
Advanced Heart Care LLC Bridgewater, New Jersey
Advocate Good Samaritan Downers Grove, Illinois
Afyonkarahisar Health Sciences University Afyonkarahisar,
Afyonkarahisar Sağlık Bilimleri Üniversitesi Sağlık Uygulama Ve Araştırma Merkezi- Kardiyoloji Afyonkarahisar,
Akdeniz University Medical Faculty Antalya,
Akdeniz University Medical Faculty Antalya,
Akershus universitetssykehus HF Lørenskog,
Al-Zoebi Wermsdorf,
Albert Schweitzer Ziekenhuis locatie Dordwijk Dordrecht,
Alexandra General Hospital, Therapeutic Clinic Athens,
Alexandra General Hospital, Therapeutic Clinic Athens,
Aligarh Muslim University Aligarh,
All India Institute of Medical Sciences (AIIMS) New Delhi, National Capital Territory of Delhi
All India Institute of Medical Sciences (AIIMS) New Delhi, National Capital Territory of Delhi
All India Institute of Medical Sciences (AIIMS), Jodhpur Jodhpur, Rajasthan
Allegheny Health Network Pittsburgh, Pennsylvania
Alta Clinical Research Edmonton, Alberta
Amavita Research Services, LLC North Miami Beach, Florida
American Heart of Poland S.A. Zgierz,
American Heart of Poland S.A. Zgierz,
American Heart of Poland S.A. Zgierz,
American Heart of Poland S.A. Zgierz,
American Heart of Poland S.A. Zgierz,
American Heart of Poland S.A. Zgierz,
American Heart of Poland S.A. Zgierz,
American Heart of Poland S.A. Zgierz,
American Heart of Poland S.A. Zgierz,
Amkardia s.r.o. Brno,
Amrita Institute of Medical Sciences Kochi, Kerala
Ankara Sehir Hastanesi Cardiology Ankara,
Ankara Sehir Hastanesi Cardiology Ankara,
Apex Research Foundation, LLC Jackson, Tennessee
Aphp-Hopital La Pitie Salpetriere-1 Paris,
Aphp-Hopital Lariboisiere-1 Paris,
Arina Trial Research Kft. Orosháza, Bekes County
Arneja Heart & Multispeciality Hospital Nagpur, Maharashtra
Asahikawa-Kosei General Hospital_Cardiology Hokkaido,
Asan Medical Center Seoul,
Ascension Saint Agnes Heart Ca Baltimore, Maryland
Asha Clinical Rsch-Munster, LLC Hammond, Indiana
Associação Lar São Francisco de Assis na Providência de Deus - Bragança Paulista Bragança Paulista, São Paulo
Asst Papa Giovanni XXIII Bergamo, Lombardy
Audie L. Murphy VA Hospital San Antonio, Texas
Aultman Hospital Canton, Ohio
Aurora St. Luke's Medi Ctr Milwaukee, Wisconsin
Austin Heart Austin, Texas
Azienda Ospedaliera Dei Colli - Monaldi - Centro ricerche cardiologiche Napoli,
Azienda Ospedaliera San Gerardo Monza,
Azienda Ospedaliera Universitaria Senese Siena, Si
Azienda Ospedaliera di Perugia;Ospedale S. Maria della Misericordia Perugia, Pg
Azienda Ospedaliera di Rilievo Nazionale AORN Dei Colli, "V.Monaldi", Napoli,
Azienda Ospedaliero-Universitaria Renato Dulbecco Catanzaro, Cz
Azienda Sanitaria Locale Roma 1 - Ospedale San Filippo Neri - Cardiologia Clinica Roma, Rm
Azienda Sanitaria Ospedaliera Ordine Mauriziano SC Cardiologia Torino, To
Azienda Sanitaria Ospedaliera Ordine Mauriziano SC Cardiologia Torino, To
Azienda Sanitaria Univ Giuliano Isontina Trieste,
Azienda Sanitaria Univ Giuliano Isontina Trieste,
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII Bergamo, Lombardy
B J Goverment Medical College and Sassoon General Hospital Pune, Maharashtra
BENIMED, s.r.o. Piešťany,
Balticmed Świnoujście Sp. z o. o. Świnoujście,
Banner University Medical Ctr Phoenix, Arizona
Banner University Medical Ctr Phoenix, Arizona
Banphaeo General Hospital Samutsakhon,
Baptist Health Hardin Elizabethtown, Kentucky
Baptist Health Louisville Louisville, Kentucky
Baptist Health Research Institute Jacksonville, Florida
Baptist Health South Florida Miami, Florida
Barnabas Health Livingston, New Jersey
Barwon Health (The Geelong Hospital) Geelong, Victoria
Basildon University Hospital Basildon, Essex
Basildon University Hospital Basildon, Essex
Beijing Anzhen Hospital, Capital Medical University Beijing, Beijing Municipality
Bella Praxis S.R.L. Paşcani,
Betegápoló Irgalmasrend, Budai Irgalmasrendi Kórház Budapest,
Biopharma Clinical Research Services, LLC Los Angeles, California
Biopharma Informatic_Houston Houston, Texas
Bispebjerg og Frederiksberg Hospital Frederiksberg,
Borsod-Abaúj-Zemplén Vármegyei Központi Kórház És Egyetemi Oktatókórház Miskolc,
Bridgeport Hospital Bridgeport, Connecticut
Bucheon Sejong Hospital Bucheon-si, Gyeonggi-do
Buddhachinaraj Hospital_Cardiology Phitsanulok,
Békés Vármegyei Központi Kórház Gyula,
Békés Vármegyei Központi Kórház Gyula,
CARDIO D&R, s.r.o. Košice,
CCIH-Consultoria em Controle de Infecção Hospitalar Ltda Belo Horizonte, Minas Gerais
CEDIR - Centro de diagnóstico y rehabilitación Santa Fe Santa Fe,
CEMEDIC CABA,
CEMEDIC CABA,
CHEAR Center LLC The Bronx, New York
CHR de la Citadelle Liège,
CHU de Montréal Montreal, Quebec
CIMS- Care Institute of Medical Sciences Ahmedabad, Gujarat
CINCAME Tijuana, Estado de Baja California
CIP Centro Integrado de Pesquisas do Hospital de Base São José do Rio Preto, São Paulo
CISSSL Hôsp Pierre-Le Gardeur Terrebonne, Quebec
CIUSSS de l'E CHUS_Sherbrooke Sherbrooke, Quebec
CMI Dr. Cristian Podoleanu Târgu Mureş, Targu Mures
CMU - Hematology and Oncology Chiang Mai,
CPS Research Waterloo, Ontario
Cabinet Medical de Cardiologie Dr. Calin Pop Baia Mare,
Cambridge Cardiac Care Centre Cambridge, Ontario
Cambridge Medical Trials Alexandria, Louisiana
Capital Area Research LLC Camp Hill, Pennsylvania
Capital Cardiology Associates_Albany Albany, New York
Capitol Cardiology Assoc_Lanham Lanham, Maryland
Card Specialists of Willowbrook Houston, Texas
Cardiac Clinical Research Unit, University of Cape Town Cape Town, Western Cape
Cardio Partners Clin Res Inst Wellington, Florida
Cardio-Vajira Bangkok,
Cardio-Vajira Bangkok,
CardioVasc HR Inc Saint-Jean-sur-Richelieu, Quebec
Cardiolg Assoc Rsch LLC_Tupelo Tupelo, Mississippi
Cardiolink Clin Trials S.C. Monterrey, Nuevo León
Cardiolink Clin Trials S.C. Monterrey, Nuevo León
Cardiologicum Dresden und Pirna - MVZ "Am Felsenkeller" (Dresden) Dresden,
Cardiology & Medicine Clinic Little Rock, Arkansas
Cardiology Associates of Fairfield County Stamford, Connecticut
Cardiology Research_Bloemfontein Bloemfontein, Free State
Cardiology and Rehabilitation Clinic Klaipėda,
Cardiomed SRL Craiova,
Cardiovascular Rsrch of NW_IN Munster, Indiana
CardiovidCentro Cardiovascular Colombiano ClinicaSantaMaria Medellín,
Care Clinic Sp. z o. o. Katowice,
Care Clinic Sp. z o. o. Katowice,
Carient Heart and Vascular Manassas, Virginia
Carteret Medical Group Morehead City, North Carolina
Centre Hospitalier Intercommunal Toulon La Seine-Sur-Mer - Hopital Sainte Musse Toulon,
Centre Hospitalier Universitaire Grenoble Alpes-Site Nord Michallon-1 Grenoble,
Centre Hospitalier Universitaire de Montpellier-Hopital Arnaud de Villeneuve Montpellier,
Centre Hospitalier Universitaire de Poitiers Poitiers,
Centre Hospitalier Universitaire de Poitiers Poitiers,
Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil-1 Toulouse,
Centre Hospitalier de Pau - Hopital Francois Mitterrand Pau,
Centricity Research Oshawa Oshawa, Ontario
Centro Hospitalar Lisboa Norte Lisbon,
Centro de Atención e Investigación Médica S.A.S. (CAIMED SAS) Chía, Cundinamarca
Centro de Diag. e Pesquisa da Osteoporose do Espírito Santo Vitória, Espírito Santo
Centro de Estudios Clinicos de Querétaro S.C. Querétaro,
Centro de Imagen y Tecnologia en Intervención Cardiovascular México, La Magdalena Contreras
Centro de Investigaciones Clinica Baigorria Santa Fé, Santa Fe Province
Centro de Investigaciones Clinica Baigorria Santa Fé, Santa Fe Province
Centro de Investigaciones Clinicas del Litoral Santa Fe,
Centro de Investigaciones Medicas Mar del Plata Mar del Plata,
Centro de Investigaciones Médicas Clínica de Fracturas y Or Mar del Plata,
Centro de Investigaciones Médicas Clínica de Fracturas y Or Mar del Plata,
Centro de Investigación Biomédica y Farmacéutica S.C. Mexico City,
Centro de Investigación y Control Metabólico S. C. San Nicolás de los Garza, Nuevo León
Centro de atención e investigación cardiovascular del Potosí San Luis Potosí City,
Centro para el Desarrollo de la Medicina y la Asistencia Culiacán, Sinaloa
Centrul Medical Emerald Bucharest,
Centrul Medical de Diagnostic si Tratament Ambulatoriu Neomed Brasov,
Cerrahpaşa Kardiyoloji Enstitüsü Istanbul,
Chang Gung Medical Foundation - Linkou Branch Taoyuan District,
Chang Gung Memorial Hospital - Kaohsiung Branch Kaohsiung City,
Changi General Hospital Singapore,
Changsha Central Hospital Changsha, Hunan
Changzhou No.2 People's Hospital, Yanghu Branch Changzhou, Jiangsu
Charite Universitätsmedizin Berlin KöR Berlin,
Charité - Campus Virchow-Klinikum - Kardiologie, Angiologie und Intensivmedizin (CRU) Berlin,
Chiang Rai Prachanukroh Hospital Chiang Rai,
Chicago Medical Research LLC Hazel Crest, Illinois
China-Japan Friendship Hospital Beijing,
China-Japan Friendship Hospital Beijing,
China-Japan Union Hospital of Jilin University-Cardiology Changchun, Jilin
Chinese Academy of Medical Sciences Fuwai Hospital Beijing, Beijing Municipality
Chongqing University Three Gorges Hospital Chongqing,
Chongqing University Three Gorges Hospital Chongqing,
Chonnam National University Hospital Gwangju,
Chru de Nancy - Hopital Brabois Vandœuvre-lès-Nancy,
Chulabhorn Hospital Lak Si,
Chulabhorn hospital_Cardiovascular Bangkok,
Chungbuk National University Hospital Chungju,
Chungnam National University Hospital Daejeon,
Chutoen General Medical Center_Cardiology Shizuoka,
Clinica Imbanaco SAS Santiago de Cali, Valle del Cauca Department
Clinica de la Costa Barranquilla, Atlántico
Clinical Advancement Ctr, PLLC San Antonio, Texas
Clinical Best Solutions Sp. z o.o., Sp. k Lublin,
Clinical Centre of Serbia, Emergency Centre, Department of Cardiology Belgrade,
Clinical Centre of Serbia, Emergency Centre, Department of Cardiology Belgrade,
Clinical Hospital Center Bezanijska Kosa Belgrade,
Clinical Hospital Centre Osijek Osijek,
Clinical Hospital Centre Zemun Belgrade,
Clinical Projects Research Worcester, Western Cape
Clinical Projects Research Worcester, Western Cape
Clinical Research Institute of South Africa KwaDukuza, KwaZulu-Natal
Clinical Research Institute of South Africa KwaDukuza, KwaZulu-Natal
Clinical Research Solutions Inc. Waterloo, Ontario
Clinical Trials Service s.r.o. Uherské Hradiště,
Clinical Trials Service s.r.o. Uherské Hradiště,
Clinical centre of Serbia, Clinic for cardiology Belgrade,
Clinitrials Perth, Western Australia
Clínica Nuevas Tecnologías en Diabetes y Endocrinología Seville,
Colosseumklinikken Medisinske Senter AS Oslo,
Complejo Hospitalario Universitario A Coruna A Coruña,
Concord Repatriation General Hospital - Cardiology Concord, New South Wales
Concord Repatriation General Hospital - Cardiology Department Concord, New South Wales
Corazón IPS S.A.S Barranquilla,
Cork University Hospital Cork,
Coromed SMO Kft. Pécs,
Craigavon Area Hospital_Cardiovascular Research Unit Craigavon,
Ctr de méd métab de Lanaudière Terrebonne, Quebec
Ctr for Cardiovascular Innovation Vancouver, British Columbia
DCC 1 - Lom EOOD Lom,
DCC Aleksandrovska EOOD Sofia,
DCC Ascendent OOD Sofia,
DIM Clinica Privada Ramos Mejía,
DRC Kft. Balatonfüred,
Dallas Heart and Vascular Duncanville, Texas
David Turbay, MD, PLLC El Paso, Texas
Davius Clinicmed Srl Bucharest,
Dawson Clinical Research Guelph, Ontario
Dayanand Medical College & Hospital Ludhiana, Punjab
Deep Hospital Ludhiana, Punjab
Detroit Med Center-Wayne State Detroit, Michigan
Deventer Ziekenhuis Deventer,
Diabetes Heart Research Centre Toronto, Ontario
Diagnostic Consulting Center 1- Lom EOOD Lom,
Diex Recherche Trois-Rivieres Trois-Rivières, Quebec
Diseño y Planeacion en Investigacion Medica S.C. Guadalajara, Jalisco
Dokuz Eylul University School of Medicine, Cardiology Izmir,
Donna Medplus S.R.L. Bucharest,
Donna Medplus S.R.L. Bucharest,
Dr B L Kapur Memorial Hospital New Delhi,
Dr Corbett Cape Town, Western Cape
Dr Garda Cardiology Practice Johannesburg, Gauteng
Dr Hendrik Snyman's Practice Mossel Bay, Western Cape
Dr Mpe's Practice Pretoria, Gauteng
Dr. Abdulah Nakas General Hospital Sarajevo,
Dr. Abdulah Nakas General Hospital Sarajevo,
Dr. Lakatos Ferenc Kardiológus ,Belgyógyász Magán szakrendelés Békéscsaba, Bekes County
Dr. Siyami Ersek Gogus Kalp ve Damar Cerrahisi EAH Istanbul,
Duke University Durham, North Carolina
Duke University/Southeastern Lumberton, North Carolina
Duke University/Southeastern Lumberton, North Carolina
E Coast Inst for Rsrch LLC_Jacksonville Jacksonville, Florida
EMED Centrum Usług Medycznych Ewa Smialek Rzeszów,
EPIC Hospital Ahmedabad, Gujarat
EURÉKA-CENTER Orvosi és Szolgáltató Betéti Társaság Baja,
East Rand Physicians Benoni, Gauteng
East Tallinn Central Hospital Tallinn,
Eastern Shore Rsrch Inst, LLC Fairhope, Alabama
Echipa Medical.33 S.R.L Timișoara,
Ecocard Srl Bucharest,
Ecocard Srl Bucharest,
Ege University School of Medicine, Cardiology Department Izmir,
Elite Research Center Flint, Michigan
Emergency Institute For Cardiovascular Diseases And Transplant Târgu Mureş,
Emergency Internal Medicine Clinic Belgrade,
Emergency Internal Medicine Clinic Belgrade,
Emory University School of Medicine_Atlanta Atlanta, Georgia
Endeavor Health Clinical Operations-NCH Arlington Heights, Illinois
Epworth Healthcare Richmond, Victoria
Erasmus MC Rotterdam,
Erciyes University Cardiology Kayseri,
Eskisehir Osmangazi University-Cardio Eskişehir,
Eukarya Pharmasite S.C. Monterrey, Nuevo León
Eurolatino Medical Research Center Uberlândia, Minas Gerais
Excellentis Clinical Trial Consultants George, Eastern Cape
FN Hradec Kralove Hradec Králové,
FN Hradec Kralove Hradec Králové,
Facharztzentrum Dresden Betriebsgesellschaft mbH Dresden,
Fairview Health Services Maplewood, Minnesota
Fakultna Nemocnica Trnava Trnava,
Fakultni nemocnice Plzen - Lochotin Plzen - Lochotín,
Fakultní poliklinika VFN ambulance Srdecniho selhani Prague,
Fakultní poliklinika VFN ambulance Srdecniho selhani Prague,
Fließer-Görzer [Ordination] Saint Stefan,
Fließer-Görzer [Ordination] Saint Stefan,
Flinders Medical Centre Bedford PK, South Australia
Fondazione CNR-Regione Toscana Gabriele Monasterio Pisa, Pi
Fondazione IRCCS Policlinico San Matteo Pavia,
Fondazione IRCCS Policlinico San Matteo Pavia,
Fondazione Salvatore Maugeri I.R.C.C.S. - Bari Bari,
Fondazione Toscana Gabriele Monasterio - Dipartimento Cardiotoracico - UOC Cardiologia e Medicina Cardiovascolare Pisa, Pi
Fortis Escorts Heart Institute, New Delhi New Delhi, National Capital Territory of Delhi
Fortis Hospital, Mohali Mohali, Punjab
Franciscan Network-IN Heart PHY Indianapolis, Indiana
Franciscan Network-IN Heart PHY Indianapolis, Indiana
Frankston Hospital Frankston, Victoria
Fukuoka University Hospital_Cardiology Fukuoka-shi, Fukuoka,
Fundacion Favaloro CABA, Buenos Aires, Argentina
Fundacion Favaloro CABA, Buenos Aires, Argentina
Fundacion Favaloro CABA, Buenos Aires, Argentina
Fundacion Respirar Buenos Aires, B
Fundacion Santa Fe de Bogota Bogotá,
Fundacion del Caribe para la Investigacion Biomedica-BIOS Barranquilla,
Fundacion del Caribe para la Investigacion Biomedica-BIOS Barranquilla,
Fundación Hospital Universidad del Norte Soledad, Barranquilla
Fundación Hospital Universidad del Norte Soledad, Barranquilla
Fundación para la Investigación del Hospital Clínico de Valencia (INCLIVA) Valencia,
G B Pant Institute of Postgraduate Medical Education and Research New Delhi, National Capital Territory of Delhi
G.A. Research Associates Ltd. Moncton, New Brunswick
GA Arrhythmia Cons & Rsch Inst Macon, Georgia
GK Neiroklinika Riga,
GNRC Hospital Guwahati, Assam
Gachon University Gil Medical Center Incheon,
Geisinger Medical Center Danville, Pennsylvania
General Hospital "Euromedik 2" Belgrade,
General Hospital Of Mytilene Vostanio Mytilene,
General Hospital of Athens "Elpis" Ampelokipoi/Athens,
General Hospital of Chalkida Chalcis,
General Hospital of Chios "Skilitsio" Chios,
General Hospital of Kalamata Kalamata,
General Hospital of Ningxia Medical University Ningxia, Yinchuan
General Hospital of Thessaloniki 'G. Gennimatas Thessaloniki,
General Oncological Hospital of Kifissia Agioi Anargyroi Kifissia,
General University Hospital of Patras Rio, Patras
General University Hospital of Patras Rio, Patras
General hospital Celje - cardiology Celje,
Genl Hospital of Athens Ippokrateio,A' Cardiology Univ dpt Athens,
Gesundheitscentrum Mainz (Regner / Schmitt) Mainz,
Glasgow Clinical Research Facility Glasgow,
Gornoslaskie Centrum Medyczne Im Prof. Leszka Gieca Sląskiego Uniwersytetu Medycznego W Katowicach Katowice, Silesian Voivodeship
Gosford Hospital Gosford,
Gottsegen György Országos Kardiológiai Intézet Budapest,
Government Medical College and Super Speciality Hospital, Nagpur Nagpur, Maharashtra
Government Medical College, Kozhikode Kozhikode, Kerala
Guardian Research Org LLC Winter Park, Florida
Guru Nanak CARE Hospitals Hyderabad, Telangana
Guru Nanak CARE Hospitals Hyderabad, Telangana
Gyncentrum Sp. z o. o. Katowice,
Gyncentrum Sp. z o. o. Katowice,
HUS, Sydän- ja keuhkokeskus, kardiologian tutkimusyksikkö HUS,
Hacettepe University Medical Faculty_Ankara Ankara,
Hadassah Ein Karam MC - Cardio Department Jerusalem,
Haga Ziekenhuis The Hague,
Hainan General Hospital Haikou,
Hainan General Hospital Haikou,
Hallym University Sacred Heart Hospital Anyang,
Hamanomachi Hospital_Cardiovascular medicine Fukuoka,
Hamilton Hlth Sc. - General Site Hamilton, Ontario
Harlem Cardiology_Madison ave New York, New York
Haukeland Universitetssykehus Bergen,
Hawthorne Health Diamondhead, Mississippi
Hawthorne Health NC Concord, North Carolina
Health Sciences North Rsrch Inst Greater Sudbury, Ontario
Health Step Finland Oy Kuopio,
Healthy Heart Cardiology Grand Rapids, Michigan
Heart Center Rsrch_Hunstville Huntsville, Alabama
Heart Clinic of Hammond Hammond, Louisiana
Heart Grp_ Lancaster Gen Hlth Lancaster, Pennsylvania
Heart House_Elmer Elmer, New Jersey
Heart MD_Allen TX Allen, Texas
Heart of Australia Chelmer, Queensland
HeartWest Cardiology - Hoppers Crossing Hoppers Crossing, Victoria
Hebei General Hospital Shijiazhuang, Hebei
Henry Ford Hlth System_Detroit Detroit, Michigan
Herlev og Gentofte Hospital Hellerup, Capital Region
Herz-Kreislauf-Zentrum Klinikum Hersfeld-Rotenburg GmbH Rotenburg A.d. Fulda,
Hightech Medical Services S.R.L. Bucharest,
Hillel Yafe MC - Cardiology Department Hadera,
Hippokration Hospital Athens,
Hospital Angeles de Xalapa Xalapa, Veracruz
Hospital Angeles de Xalapa Xalapa, Veracruz
Hospital Canselor Tuanku Muhriz UKM Cheras,
Hospital Cardiologica Aguascalientes Aguascalientes, Aguascalientes
Hospital Cardiologica Aguascalientes Aguascalientes, Aguascalientes
Hospital Clinic i Provincial Barcelona,
Hospital Clinico San Carlos Madrid,
Hospital Cuf Descobertas S.A. Lisbon,
Hospital Da Luz S.A. Lisbon,
Hospital Del Mar Barcelona,
Hospital General de Medellin Medellín, Antioquia
Hospital General de Medellin Medellín, Antioquia
Hospital General de Valencia Valencia,
Hospital Germans Trias I Pujol Badalona,
Hospital Italiano Buenos Aires,
Hospital Kuala Lumpur Kuala Lumpur,
Hospital Mãe de Deus - Porto Alegre Porto Alegre/RS,
Hospital Ramon Y Cajal Madrid,
Hospital Serdang Kajang, Selangor
Hospital Serdang Kajang, Selangor
Hospital Sultanah Aminah Johor Bahru, Johor
Hospital Sultanah Aminah Johor Bahru, Johor
Hospital Sultanah Bahiyah Alor Setar, Kedah,
Hospital São Lucas Copacabana Rio de Janeiro,
Hospital Tengku Ampuan Afzan Kuantan, Pahang
Hospital Univ. de Gran Canaria Doctor Negrín Las Palmas de Gran Canaria,
Hospital Universitario La Luz Madrid,
Hospital Universitario La Paz Madrid,
Hospital Universitario Puerta de Hierro Majadahonda Majadahonda,
Hospital Universitario Puerta de Hierro Majadahonda Majadahonda,
Hospital Universitario de Gran Canaria Doctor Negrín Las Palmas de Gran Canaria,
Hospital Universiti Kebangsaan Malaysia Kuala Lumpur,
Hospital Universiti Sains Malaysia Kubang Kerian, Kelantan
Hospital Vithas Sevilla Seville,
Hospital da Luz Lisbon,
Hospital da Luz Setúbal Setúbal,
Hospital de Bellvitge L'Hospitalet de Llobregat,
Hospital de Cascais Alcabideche,
Hospital de Clínicas da Universidade Federal de Goiânia Goiânia/GO,
Hospital de Clínicas de Porto Alegre Porto AlegreRS,
Hospital of Lithuanian University of Health Sciences Kauno Klinikos Kaunas,
Houston Methodist Hospital Houston, Texas
Houston Methodist Hospital Houston, Texas
Huai'an First People's Hospital, Nanjing Medical University Huai'an, Jiangsu
Huashan Hospital Fudan University Shanghai,
Hyogo Prefectural HarimaHimeji General Medical Center_Cardiology Himeji-shi, Hyogo,
ICM - Instituto do Coração de Marília Marília,
IPGME&R and SSKM Hospital Kolkata, West Bengal
IPS Centro Cientifico Asistencial Jose Luis Accini SAS Barranquilla, Atlántico
IPS médicos Internistas de Caldas S.A.S. Manizales, Caldas Department
IRCCS Ospedale Policlinico San Martino Genova, Metropolitan City of Genoa
Iatriko Athinon (Athens Medical Canter) Pylea, Thessaloniki,
Iatriko Athinon (Athens Medical Canter) Pylea, Thessaloniki,
Iatros International Bloemfontein,
Imed 19- privat Vienna,
Imed 19- privat Vienna,
Ind. Prak. Lek. w dziedz. Kardiologii lek. med. K. Cymerman Gdynia, Pomeranian Voivodeship
Inha University Hospital Incheon,
Inspira Health Mullica Hill, New Jersey
Institut de Cardiologie de Montreal Montreal, Quebec
Institute for Cardiovascular Diseases ''Dedinje'' Belgrade,
Institute for Cardiovascular Diseases of Vojvodina - Sremska Kamenica Kamenitz,
Instituto D'Or de Pesquisa e Ensino Rio de Janeiro,
Instituto Nacional de Cardiologia Ignacio Chavez Mexico City,
Instituto de Cardiología de Corrientes Corrientes,
Instituto de Investigaciones Clinicas San Nicolas San Nicolás,
Instituto de Investigaciones Clínicas Mar del Plata,
Instituto de Moléstias Cardiovasculares de Tatuí Ltda Tatuí, São Paulo
Instituto de Pesquisa Clinica de Campinas Campinas, São Paulo
Institutul De Urgenta Pentru Boli Cardiovasculare Prof. Dr. C. C. Iliescu Bucharest,
Institutul de Boli Cardiovasculare "Prof. Dr. George I.M. Georgescu" Iași,
Institutul de Boli Cardiovasculare Timisoara Timișoara,
Instytut Centrum Zdrowia Matki Polki Lodz,
Integral Pesquisa e Ensino Votuporanga,
Integrative Research Assoc Inc Fort Lauderdale, Florida
Intercard Spolka z ograniczona odpowiedzialnoscia Pińczów,
Interna SK s.r.o. Svidník, Presov
Internacionalni medicinski centar PRIORA Čepin,
Internal Medicine Clin Trials Monterrey, Nuevo León
Intradia s.r.o. Nitra,
InvivoCure Van Nuys, California
InvivoCure -2 Denver, Colorado
InvivoCure -2 Denver, Colorado
Ishikawa Prefectural Central Hospital_Cardiology Ishikawa,
Iwate Prefectural Central Hospital Morioka,
Iwate Prefectural Central Hospital_Cardiology Morioka-shi, Iwate,
JA Shizuoka Kohseiren Enshu Hospital_ cardiology Hamamatsu-shi, Shizuoka,
JCHO Kyushu Hospital_Cardiology Kitakyushu-shi, Fukuoka,
JCHO Tokuyama Community Health Center_Department of Cardiology Yamaguchi,
JIPMER Puducherry,
JSC "Saules seimos medicinos centras" Kaunas,
JSC Inlita Santaros Vilnius,
Jacksonville Ctr for Clin Res Jacksonville, Florida
Jahn Ferenc Del-Pesti Korhaz es Rendelointezet Budapest,
James River Cardiology Richmond, Virginia
Jantar Sp. z o.o. Ostrów Wielkopolski,
Japan Community Health care Organization Kyushu Hospital_Cardiology Kitakyushu-shi, Fukuoka,
Jehangir Clinical Development Centre Pune, Maharashtra
Jilin Province People's Hospital-Cardiology Changchun, Jilin
Jmf Clínica Do Coração Ltda Aracaju,
Johese Clinical Research Centurion, Gauteng
John Radcliffe Hospital Oxford,
John Radcliffe Hospital Oxford,
Johns Hopkins University_Baltimore Baltimore, Maryland
Josha Research Bloemfontein, Free State
Juntendo University Hospital_Cardiology Tokyo,
Justus-Liebig-Universität Gießen - Kardiologie Giessen,
K&R Research Llc Marion, Ohio
KARDIO-SANUS, spol. s r.o. Bratislava,
KARDIOLOGIE - LIBEREC s.r.o. Liberec,
KARDIOLOGIE - LIBEREC s.r.o. Liberec,
KB Dubrava, Zavod za bolesti srca i krvnih zila Zagreb, City of Zagreb
KBC Rijeka, Zavod za kardiomiopatije Rijeka,
KBC Split Split,
KEM Hospital Pune, Maharashtra
KKR Tohoku Kosai Hospital_Cardiology Miyagi,
KLE's Dr. Prabhakar Kore Hospital & Medical Research Centre Karnataka,
Kagawa Prefectural Central Hospital, Cardiovascular Medicine Takamatsu-shi, Kagawa,
Kagoshima City Hospital_Cardiovascular Medicine Kagoshima,
Kanagawa Prefectural Hospital Organization Kanagawa Cardiovascular and Respiratory Center_Cardiology Kanagawa,
Kanagawa Prefectural Hospital Organization Kanagawa Cardiovascular and Respiratory Center_Cardiology Kanagawa,
Kaohsiung Medical University Chung-Ho Memorial Hospital Kaohsiung City,
Kaplan MC - Heart Failure Unit Rehovot,
Kardio Brynów Sp. z o. o. Katowice,
Kardio Life Włocławek, Kuyavian-Pomeranian Voivodeship
Kardiologická a interní ambulance Prague,
Kardiologie Hassloch Haßloch,
Kardiologie MUDr. Libor Nechvátal s.r.o. Brno,
Kardiologie Trutnov Ferkl Trutnov,
Kardiologie Vinohrady s.r.o. Prague,
Kardiologisch-Angiologische Praxis Herzzentrum Bremen Bremen,
Kardiologisch-Angiologische Praxis Herzzentrum Bremen Bremen,
Kardiologische Gemeinschaftspraxis Papenburg Papenburg,
Kardiologisk Odense & Svendborg Svendborg,
Kardiopraxis Schirmer Kaiserslautern,
Kath. Klinikum Bochum gGmbH - St. Josef-Hospital Kardiologie Bochum,
Kath. St. Paulus GmbH - St Johannes Hospital Dortmund - Kardiologie Dortmund,
Kaunas Hospital of the Lithuanian University of Health Sciences Kaunas,
Kawartha Cardiology Clinical Trials Peterborough, Ontario
Keimyung University Dongsan Hospital Daegu,
Keio University Hospital_Cardiology Tokyo,
Khoo Teck Puat Hospital Singapore,
King Chulalongkorn Memorial Hospital Thailand,
King Chulalongkorn Memorial Hospital Thailand,
King George's Medical University (KGMU) Lucknow, Uttar Pradesh
King George's Medical University (KGMU) Lucknow, Uttar Pradesh
Kishiwada Tokushukai Hospital_Cardiology Kishiwada-shi, Osaka,
Klaipeda University Hospital Klaipėda,
Klaipeda University Hospital Klaipėda,
Klinik Favoriten Vienna,
Klinik Favoriten Vienna,
Klinik Ottakring Vienna,
Klinikiniai sprendimai, Kaunas Kaunas,
Kocaeli Universitesi Tip Fakultesi Hastanesi Kocaeli,
Konstantopouleio G.H. of Athens, "Agia Olga" Athens,
Korczowski Bartosz Gabinet Lekarski Rzeszów,
Korea University Anam Hospital Seoul,
Korea University Guro Hospital Seoul,
Krankenhaus St. Josef Braunau Braunau am Inn,
Krankenhaus St. Josef Braunau Braunau am Inn,
Kuang Tien General Hospital Taichung,
KwaPhila Health Solutions Durban, KwwaZulu Natal
Kyoto University Hospital Kyoto, Kyoto,
Kyushu University Hospital_Cardiovascular Medicine Fukuoka,
Kyushu University Hospital_Cardiovascular Medicine Fukuoka,
LMU Klinikum München Klinik und Poliklinik 1 München,
Lakshmi Hospital Palakkad, Kerala
Lalitha Super Specialities Hospital Guntur, Andhra Pradesh
Lalitha Super Specialities Hospital Guntur, Andhra Pradesh
Laurelton Heart Specialist PC Rosedale, New York
Lausmed Kft. Baja, Bács-Kiskun county
Lenasia Clinical Trial Centre Lenasia, Gauteng
Lishui People's Hospital Lishui, Zhejiang
Lishui People's Hospital-Cardiology Lishui, Zhejiang
Lisie Hospital Kochi, Kerala
Logan Health Research Kalispell, Montana
Lotus Med SRL Bucharest,
Louisiana Heart Center Bogalusa, Louisiana
Lundquist Inst-Biomed Innovtn Torrance, California
Léda Platán Magánklinika Zalaegerszeg, Zala County
MD Medical Research Oxon Hill, Maryland
MDHAT "Dr. Stephen Cherkezov" AD Veliko Tarnovo,
MED-CENTRUM, s.r.o. Martin,
MEDIVASA, s.r.o., Kardiologicka ambulancia 1, 2 Žilina,
MHAT "Knyaginya Klementina" -Sofia EAD Sofia,
MHAT Heart and Brain Pleven,
MHAT Heart and Brain EAD Burgas,
MHAT Sveta Sofia EOOD Sofia,
MS Ramaiah Bengaluru,
MS Ramaiah Bengaluru,
MVZ CCB Frankfurt Und Main-Taunus GbR Frankfurt,
Maastricht Universitair Medisch Centrum Maastricht,
Maharaj Nakorn Chiang Mai Hospital Chiang Mai,
Maharat Nakhon Ratchasima Hospital Nakhon Ratchasima,
Manchester Royal Infirmary_Manchester_0 Manchester,
Manipal Hospital, Old Airport Road, Bengaluru Bangalore, Karnataka
Manshadi Heart Institute Stockton, California
Marian David, MD, PC Kew Gardens, New York
Mat Cord Biomedica S.R.L. Buzău,
Mater Miscericordiae Hospital Dublin,
Mater Private Network - Dublin Dublin,
Mater Private Network Cork Mahon, Cork,
Mautalen Salud e investigación CABA, Buenos Aires
Medanta - The Medicity Multi-Speciality Hospital, Gurugram Gurugram, Haryana
MediNess Sp. z o.o. Krakow, Lesser Poland Voivodeship
MediNess Sp. z o.o. Krakow, Lesser Poland Voivodeship
Medical Centre - Avitsena EOOD Kardzhali,
Medical Centre Cardiomed 2020 EOOD Sliven,
Medical Centre Hera - Kyustendil EOOD Kyustendil,
Medical Centre Intermedica OOD Sofia,
Medical Centre Nevromedics EOOD Veliko Tarnovo,
Medical Network Sp. z o. o. Warsaw,
Medical Network Sp. z o. o. Warsaw,
Medical center ISUL - Tsaritsa Yoanna EOOD Sofia,
Medical center Leskovac Leskovac,
Medical center Uzice Užice,
Medical centre "Zdrave 1" OOD Kozloduy,
Medical centre Health Care OOD Sandanski,
Medication Mgmnt, LLC_Grnsboro Greensboro, North Carolina
Medisch Spectrum Twente Enschede,
Medizinische Universität Graz Graz,
Medizinische Universität Graz Graz,
Medizinische Universität Wien Vienna,
Medizinische Universität Wien Vienna,
Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training Research Hospital_Istanbul Istanbul,
Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training Research Hospital_Istanbul Istanbul,
Memorial Region Hosp_Hollywood Hollywood, Florida
Mersin University Cardiology Mersin,
Methodist Medical Center of Illinois Peoria, Illinois
Mianyang Central Hospital-Cardiology Mianyang, Sichuan
Midwest Cardiovascu Rsrch Foundation Elkhart, Indiana
Midwest Cardiovascular Institute Naperville, Illinois
Midwest Heart & Vasc Spec Overland Park, Kansas
Midwest Heart & Vasc Spec Overland Park, Kansas
Mie Prefectural General Medical Center_Cardiology Mie,
Minneapolis VA Health Care Sys Minneapolis, Minnesota
Mitoyo General Hospital_Cardiovascular medicine Kagawa,
Monument Health Clinical Rsrch Rapid City, South Dakota
Morehouse School of Medicine Atlanta, Georgia
Mount Sinai Hosp at NYC New York, New York
Mount Sinai Hosp at NYC New York, New York
NCH Research Institute Naples, Florida
NJ Heart Linden, New Jersey
NJ Heart Linden, New Jersey
NSC Research, Inc Johns Creek, Georgia
NUPEC Cardio Belo Horizonte,
NY Presbyt Hosp-W Cornell Med New York, New York
NZOZ Centrum Medyczne SERAFIN-MED Halina Serafin Żarów,
Nagasaki Harbor Medical Center_Cardiovascular medicine Nagasaki,
Narayana Institute of Cardiac Sciences Bengaluru, Karnataka
Narodny ustav srdcovych a cievnych chorob, a.s. Bratislava,
Narodny ustav srdcovych a cievnych chorob, a.s. Bratislava,
National Cerebral and Cardiovascular Center Hospital_Department of Heart Failure Osaka,
National Heart Centre Singapore Singapore,
National Heart Institute Cal Beverly Hills, California
National Hospital Organization Iwakuni Clinical Center_Cardiovascular Medicine Yamaguchi,
National Hospital Organization Mito Medical Center_Cardiovascular medicine Ibaraki,
National Hospital Organization Osaka National Hospital_Cardiovascular Division Osaka,
National Hospital Organization Sendai Medical Center_Cardiovascular medicine Miyagi,
National Multiprofile Transport Hospital "Tsar Boris III" Sofia,
National University Hospital Singapore Singapore,
Nature Coast Clin Rsrch_Crystal River Crystal River, Florida
Nemocnica S Poliklinikou Brezno N.O. Brezno, Banská Bystrica Region
Nemocnice Slany Kardiologie Slaný,
Nemocnice Slany Kardiologie Slaný,
Nemocnicna a.s. Malacky,
Neurocord Medical SRL Craiova,
Neurocord Medical SRL Craiova,
New Generation of Medical Research Hialeah, Florida
New Generation of Medical Research Hialeah, Florida
Nightingale Research Adelaide, South Australia
Nirmal Hospital Pvt. Ltd. Surat, Gujarat
North America Research Institute San Dimas, California
North Estonia Medical Centre Foundation Tallinn,
North Shore Heart Centre North Vancouver, British Columbia
North Shore Heart Centre North Vancouver, British Columbia
North Tyneside General Hospital North Shields,
North York Diagn & Cardiac Ctr North York, Ontario
Northern Jiangsu People's Hospital Yangzhou,
Northern Jiangsu People's Hospital Yangzhou,
Nova Scotia Health Halifax, Nova Scotia
OLVG Oost Amsterdam,
OSF HealthCare_Cardiovasc Inst Rockford, Illinois
Ocala Cardiovascular Research Ocala, Florida
Ogaki Municipal Hospital_Cardiology Gifu,
Okayama City General Medical Center Okayama City Hospital_Cardiovascular Medicine Okayama,
Okayama Medical Center_Cardiology Okayama,
Okayama University Hospital_Cardiovascular Medicine Okayama-shi, Okayama,
Okayama University Hospital_Cardiovascular Medicine Okayama-shi, Okayama,
Opca bolnica Karlovac Karlovac,
Opca bolnica Karlovac Karlovac,
Ormond Beach Clinical Research Ormond Beach, Florida
Osaka University Hospital_Cardiovascular medicine Osaka,
Oslo universitetssykehus HF - Ullevål Oslo,
Osmania General Hospital Hyderabad, Telangana
Osmania General Hospital Hyderabad, Telangana
Ospedale Ca' Foncello Treviso, Veneto
Ospedale Misericordia Grosseto Grosseto,
Ospedale Santo Spirito Casale Monferrato, Al
Ospedali riuniti di Foggia Foggia,
P. Stradins Clinical University Hospital Riga,
PHI City General Hospital 8th September Skopje,
PHI University Clinic for Cardiology Skopje,
PHI University Clinic for Cardiology Skopje,
PROCAPE Recife/PE,
PTE ÁOK I. sz. Belgyógyászati Klinika Pécs, Baranya
PTE ÁOK I. sz. Belgyógyászati Klinika Pécs, Baranya
PUCCAMP - Hospital e Maternidade Celso Pierro Campinas, São Paulo
PUCPR - Pontificia Universidade Catolica do Parana Curitiba, Paraná
Palm Research Center Inc. Las Vegas, Nevada
Panek Med Centrum Leczenia Chorob Naczyn Bialystok, Podlaskie Voivodeship
Partnrs Adv Cardio Eval (PACE) Newmarket, Ontario
Peking University Third Hospital-Cardiology Beijing, Beijing Municipality
Penn State Health-Berks Cardiology Wyomissing, Pennsylvania
Penn State Hershey Medical Center Hershey, Pennsylvania
Penn State Hlth Holy Spirit Med Ctr Camp Hill, Pennsylvania
Pentucket Medical Associates Haverhill, Massachusetts
Periphery University Hospital of Heraklion Heraklion, Crete
PharmaTex Research, LLC Amarillo, Texas
Pioneer Clinical Studies-Coral Gables Coral Gables, Florida
Policska nemocnice Polička,
Poliklinika Aritmija Zagreb, City of Zagreb
Poliklinika Magnolija d.o.o. Zagreb,
Poliklinika Medikol_Cakovec_Cardiology Čakovec,
Poliklinika Solmed Zagreb, City of Zagreb
Polimedica Centrum Badań, Profilaktyki i Leczenia Sp. z o. o. Warsaw,
Polimedica Centrum Badań, Profilaktyki i Leczenia Sp. z o. o. Warsaw,
Poličská nemocnice s.r.o. Polička,
Poradnia Aka-Med Centrum Sp. z o.o. Ruda Śląska, Silesian Voivodeship
Post Graduate Institute of Medical Education & Research_Chandigarh Chandigarh, Punjab
Presidio Ospedaliero di Rivoli Rivoli, To
Prisma Health-Midlands Columbia, South Carolina
Private Healthcare Institution - Acibadem Sistina Hospital Skopje Skopje,
Pro Familia Altera Sp. z o.o. Katowice, Silesian Voivodeship
Professor Skride Heart Clinic Riga,
Promotora Medica Las Americas S.A. Medellín,
Providence Med Research Ctr Spokane, Washington
Purushotham & Akther Kotha MD, inc. La Mesa, California
Pusan National University Hospital Seogu, Busan Gwang'yeogsi
Pusan National University Yangsan Hospital Yangsan, Gyeongsangnam-do
RYEXO Clinical Research Pretoria, Gauteng
RYEXO Clinical Research Pretoria, Gauteng
Rabin MC Beilinson - Heart Failure Unit Petah Tikva,
Radboudumc Nijmegen, Gelderland
Rakuwakai Marutamachi Hospital_Cardiology Kyoto,
Rama Research LLC Marion, Ohio
Ramathibodi Hospital-Cardiovascular metabolic Center Bangkok,
Rambam MC - Heart Failure Unit Haifa,
Ramesh Hospitals Vijayawada, Andhra Pradesh
Raslouw Private Hospital Pretoria, Gauteng
Reid Physician Associates Richmond, Indiana
Renmin Hospital of Wuhan University-Cardiology Wuhan, Hubei
Republican Siauliai Hospital Consulting Outpatient Clinic Šiauliai,
Rhythm Heart Institute Vadodara, Gujarat
Riga 1st Hospital Riga,
Riga East Clinical University Hospital - Clinic "Gailezers" Riga,
Rikshospitalet - Kardiologisk forskning Oslo,
Roanoke Heart Institute Roanoke, Virginia
Robley Rex VA Medical Center Louisville, Kentucky
Rocky Mountain Regional VAMC Aurora, Colorado
Rodrigo Botero S.A.S Medellín, Antioquia
Royal Adelaide Hospital Cardiovascular Clinical Trials Adelaide, South Australia
Royal Bournemouth Hospital Bournemouth, Dorset
Royal Bournemouth Hospital Bournemouth, Dorset
Royal Brisbane and Women's Hospital Herston, Queensland
Royal Columbian Hospital New Westminster, British Columbia
Royal Devon University Healthcare NHS Foundation Trust Exeter,
Royal Devon University Healthcare NHS Foundation Trust Exeter,
Royal Hobart Hospital Saint Hobart, Tasmania
Royal University Hospital Saskatoon, Saskatchewan
S Denver Cardiology Associates Littleton, Colorado
S.C. Centrul Medical Unirea S.R.L. Brasov,
S.P. Medical College and A.G. Hospitals Bikaner, Rajasthan
S.P. Medical College and A.G. Hospitals Bikaner, Rajasthan
SC Cardiomed SRL Iași,
SC Consultmed SRL Iași,
SC Diamed Obesity SRL Galati,
SCANMED Spółka Akcyjna Kutno,
SMH Cardiology Clinical Trials Inc. Surrey, British Columbia
SMS Medical College & Attached Hospitals Jaipur, Rajasthan
SMS Medical College & Attached Hospitals Jaipur, Rajasthan
Saga-ken Medical Centre Koseikan_Cardiology Saga,
Sahyadri Clinical Research And Development Center Pune, Maharashtra
Saint Michael's Med Ctr NJ Newark, New Jersey
Saint Michael's Med Ctr NJ Newark, New Jersey
Saiseikai Imabari Hospital Imabari-shi, Ehime,
Saiseikai Imabari Hospital_Cardiology Imabari-shi, Ehime,
Saiseikai Suita Hospital_Cardiovascular Medicine Osaka,
Saiseikai Yokohamashi Nanbu Hospital_Cardiology Yokohama-shi, Kanagawa,
Samodzielny Publiczny Specjalistyczny Szpital Zachodni Im.Sw.Jana Pawla II Grodzisk Mazowiecki,
Samodzielny Publiczny Szpital Kliniczny Im. Prof. W. Orłowskiego Centrum Medycznego Kształcenia Podyplomowego Warsaw, Masovian Voivodeship
Samodzielny Publiczny Zaklad Opieki Zdrowotnej Ministerstwa Spraw Wewnetrznych i Administracji w Rzeszowie Rzeszów, Podkarpackie Voivodeship
Samsung Medical Center Seoul,
San Diego Cardiac Center San Diego, California
Sanford Health_Sioux Falls Sioux Falls, South Dakota
Sanford Health_Sioux Falls Sioux Falls, South Dakota
Santa Sp. z o.o. Lodz,
Saratoga Clinical Research Saratoga Springs, New York
Sarawak Heart Centre Kota Samarahan, Sarawak
Sardar Vallabhbhai Patel Institute of Medical Sciences and Research Ahmedabad, Gujarat
Sardar Vallabhbhai Patel Institute of Medical Sciences and Research Ahmedabad, Gujarat
Saul Vizel Pro. Med. Corp Cambridge, Ontario
Sc Sal Med Srl Piteşti,
Scripps Memorial Hospital La Jolla La Jolla, California
Seinäjoen keskussairaala Seinäjoki,
Selma Medical Associates Winchester, Virginia
Selma Medical Associates Winchester, Virginia
Selye János Kórház Komárom, Komárom-Esztergom
Semmelweis Egyetem Városmajori Szív- és Érgyógyászat Budapest,
Sengkang General Hospital Singapore,
Sengupta Hospital and Research Institute Nagpur, Maharashtra
Sengupta Hospital and Research Institute Nagpur, Maharashtra
Sentara Health Research Center Norfolk, Virginia
Seoul National University Bundang Hospital Seongnam-si,
Seoul National University Hospital Seoul,
Seth GS medical college and KEM Hospital Mumbai, Maharashtra
Severance Hospital, Yonsei University Health System Seoul,
Shaanxi Provincial People's Hospital-Cardiology Xi'an, Shaanxi
Shamir MC - Cardio and Pedi Beer Yaakov,
Shanghai Xuhui Central Hospital Shanghai,
Shanghai Xuhui Central Hospital Shanghai,
Sheba MC - Cardiology Clinical Research Unit Tel Litwinsky,
Shenzhen People's Hospital Shenzhen,
Sherman Clinical Research Sherman, Texas
Shop#1 Health Emporium Midrand, Gauteng
Showa University Fujigaoka Hospital_Cardiology Yokohama, Kanagawa
Shri B. D. Mehta Mahavir Heart Institute Surat, Gujarat
Shri B. D. Mehta Mahavir Heart Institute Surat, Gujarat
Shri Krishna Hrudayalaya & Critical Care Centre Nagpur, Maharashtra
Shri Krishna Hrudayalaya & Critical Care Centre Nagpur, Maharashtra
Shri Mahant Indiresh Hospital Dehradun, Uttarakhand
Siddhartha Medical College & Government General Hospital Vijaywada, Andhra Pradesh
Siping Central People's Hospital Siping, Jilin
Sir Ganga Ram Hospital-Cardiology New Delhi,
Siriraj Hospital Bangkok,
Sjællands Universitetshospital_Roskilde Roskilde,
Slaskie Centrum Chorob Serca w Zabrzu Zabrze, Silesian Voivodeship
Sociedade Hospitalar Angelina Caron, Brazil Campina Grande do Sul, Paraná
Somogy Megyei Kaposi Mor Oktato Korhaz Kaposvár, Somogy County
Songklanagarind Hospital Songkhla,
Songklanagarind Hospital Songkhla,
Sourasky MC - Cardio Vascular Research Center Tel Aviv,
South Oklahoma Heart Research, LLC Oklahoma City, Oklahoma
Southmead Hospital Bristol,
Southmead Hospital Bristol,
Specijalna bolnica Krapinske Toplice - Kardiologija Krapinske Toplice, Krapinsko Zagorska County
Specijalna bolnica Medico Rijeka,
Specjalistyczna Praktyka Lekarska L. Bryniarski Krakow,
Spedali Civili Brescia Brescia, Bs
Spital Judetean De Urgenta Satu Mare Satu Mare,
Spitalul Clinic Judetean De Urgenta Bihor Oradea,
Spitalul Clinic Judetean De Urgenta Sfantul Apostol Andrei Constanta Constanța,
Spitalul Clinic Judetean De Urgenta Sfantul Apostol Andrei Constanta Constanța,
Spitalul Clinic Judetean De Urgenta Targu Mures Târgu Mureş,
Spitalul Clinic Judetean de Urgenta Brasov Brasov,
Spitalul Clinic Municipal de Urgenta Timisoara Timișoara,
Spitalul Clinic de Urgenta "Sf. Ioan" Bucuresti Bucharest,
Spitalul Judetean de Urgenta Braila Brăila,
Spitalul Universitar de Urgenta Bucuresti Bucharest,
Spitalul Universitar de Urgență Elias Bucharest,
Sri Jayadeva Institute of Cardiovascular Sciences & Research Bengaluru, Karnataka
Sri Jayadeva Institute of Cardiovascular Sciences & Research Bengaluru, Karnataka
Srinagarind Hospital Khon Kaen,
St George's Hospital Tooting, London
St George's Hospital Tooting, London
St James's CRF Dublin,
St James's CRF Dublin,
St Johns Ctr Clin Rsch-St. Aug Saint Augustine, Florida
St Louis Heart & Vascular, P.C. St Louis, Missouri
St Pauls Hospital Vancouver, British Columbia
St. Boniface Hospital Winnipeg, Manitoba
St. Joseph's Hospital Tampa, Florida
St. Luke's Idaho Cardiology Associates Meridian, Idaho
St. Michael's Hospital_Toronto Toronto, Ontario
St. Richards Hospital Chichester, West Sussex
St. Richards Hospital_Cardiology Chichester, West Sussex
Stanford Univ School of Med Palo Alto, California
Stavanger Universitetssykehus, Helse Stavanger HF Stavanger,
Stony Brook University Hospital Stony Brook, New York
StudyCor Jyväskylä,
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University Guangzhou,
Sun Yat-sen Memorial Hospital, Sun Yat-sen Universtiy Guangzhou, Guangdong
Sunpasitthiprasong Hospital Ubon Ratchathani,
Swedish Medical Center_Seattle Seattle, Washington
Swedish Medical Center_Seattle Seattle, Washington
Sydney Cardiometabolic Centre Liverpool, New South Wales
Synexus Helderberg Clinical Research Centre Somerset West, Western Cape
Synexus Helderberg Clinical Research Centre Somerset West, Western Cape
Synexus Watermeyer Clinical Research Centre Pretoria, Gauteng
Szegedi Tudomanyegyetem Szeged,
Szegedi Tudományegyetem II. sz Belgyógyászati és Kardiológia Szeged, Csongrád-Csanád
Szpital Miejski w Gliwicach Sp. z o.o. Gliwice,
Szpital Św. Anny w Miechowie Miechów,
Szpitale Powiatowe Sp. z o.o. Łask,
TYKS Sydänkeskus Turku,
Tagore Medical Center Balatonfüred,
Taichung Veterans General Hospital Taichung, China
Taipei Medical University Hospital Taipei,
Taipei Veterans General Hospital Taipei, Beitou District / R.o.c.
Taipei Veterans General Hospital Taipei, Beitou District / R.o.c.
Tan Tock Seng Hospital Singapore,
Tartu University Hospital Tartu,
Tays Sydänsairaala Tampere,
Tennova HC Turkey Creek MC Knoxville, Tennessee
Texas Heart Inst Medical Ctr Houston, Texas
Texas Institute of Cardiology PA McKinney, Texas
Thammasat Hospital Pathum Thani,
Thammasat University Hospital Klong Luang, Pathumthani, Changwat Pathum Thani
The Affiliated Hospital of Jiangsu University Zhenjiang, Jiangsu
The Affiliated Hospital of Jining Medical University-Cardiology Jining, Shandong
The Affiliated Hospital of Xuzhou Medical University-Cardiology Xuzhou, Jiangsu
The Affiliated Hospital of Xuzhou Medical University-Cardiology Xuzhou, Jiangsu
The Canberra Hospital_Garran Garran, Australian Capital Territory
The Catholic University of Korea, Seoul St. Mary's Hospital Seoul,
The First Affiliated Hospital of Chongqing Medical University-Cardiology Chongqing, Chongqing Municipality
The First Affiliated Hospital of Harbin Medical University-Cardiovascular Harbin, Heilongjiang
The First Affiliated Hospital of Jinan University Guangzhou, Guangdong
The First Affiliated Hospital of Soochow University Suzhou, Jiangsu
The First Affiliated Hospital of Soochow University Suzhou, Jiangsu
The First Affiliated Hospital of WMU-Cardiology Wenzhou, Zhejiang
The First Affiliated Hospital of Xi'an Jiaotong University-Cardiovascular Xi'an, Shaanxi
The First Affiliated Hospital of Zhejiang University School of Medicine Hangzhou, Zhejiang
The First Hospital of Anhui University of Science & Technology (Huainan First People's Hospital)-Cardiology Huainan, Anhui
The First Hospital of Hebei Medical University-Cardiovascular Shijiazhuang, Hebei
The First People's Hospital of Changzhou Changzhou,
The Heartbeat Trust Dublin,
The Jackson Clinic, PA Jackson, Tennessee
The Madras Medical Mission Chennai, Tamil Nadu
The People's Hospital of Guangxi Zhuang Autonomous Region Nanning, Guangxi
The People's Hospital of Liaoning Province-Cardiology Shenyang, Liaoning
The Queen's Medical Center Honolulu, Hawaii
The Research Group of Lexington LLC Lexington, Kentucky
The Royal Oldham Hospital_Cardiology Outpatients Dept. Oldham,
The Second Affiliated Hospital Of Chongqing Medical University Chongqing, Chongqing Municipality
The Second Affiliated Hospital of Nanchang University-Cardiology Nanchang, Jiangxi
The Second Affiliated Hospital of Nanjing Medical university Nanjing,
The Second Affiliated Hospital of Shantou University Medical College-Cardiovascular Shantou, Guangdong
The Second Hospital & Clinical Medical School, Lanzhou University-Internal Medicine & Cardiovascular Lanzhou, Gansu
The Third Xiangya Hospital of Central South University Changsha, Hunan
The Univ. of Tokyo Hp., Dept. of Cardiovascular Medicine Bunkyo-ku, Tokyo,
The University of Osaka Hospital_Cardiovascular medicine Osaka,
The Valley Hosptial Ridgewood, New Jersey
The Valley Hosptial Ridgewood, New Jersey
Thomas Jefferson University_Philadelphia Philadelphia, Pennsylvania
Tianjin Chest Hospital Tianjin, TJ
Tianjin Union Medical Center Tianjin, Tianjin Municipality
Tiervlei Trial Centre Cape Town, Western Cape
Tohoku Medical and Pharmaceutical University Hospital_Division of Cardiology Miyagi,
Tokai University Hospital_Cardiology Kanagawa,
Tokyo Shinagawa Hospital_Cardiovascular Medicine Tokyo,
Tokyo-Eki Center-building Clinic_Internal Medicine Tokyo,
Tongji Hospital of Tongji University-Cardiology Shanghai, Shanghai Municipality
Tottori University Hospital_Cardiovascular Medicine Tottori,
Townsville University Hospital Douglas,
Toyama University Hospital_Internal Medicine 2 Toyama,
Trakya University Edirne,
Tread Research (Pty)Ltd Cape Town, Western Cape
Treant zorggroep Emmen,
Trinity Health Michigan Heart Ypsilanti, Michigan
Tzaneio General Hospital of Piraeus Piraeus,
U.G.H of Athens "Attikon" Chaidari, Athens,
UCI Health Orange, California
UKC Ljubljana, Cardiology department Ljubljana,
UKC Maribor - cardiology Maribor,
UKC Maribor - cardiology Maribor,
UMC Groningen Groningen,
UMHAT "Dr. Georgi Stranski" Pleven Pleven,
UMHAT Sveti Georgi EAD, Plovdiv, Clinic of Cardiology Plovdiv,
UNC Cardiology Outpatient Ctr Chapel Hill, North Carolina
UNC Rex Healthcare Raleigh, North Carolina
UT Physicians - Houston Medical Center Houston, Texas
UTD SW Medical Center-Dallas Dallas, Texas
UZ Brussel Brussels,
UZA - UZ Antwerpen - Cardiology Department Edegem,
Uni-Med. Göttingen - Kardiologie, Pneumologie Göttingen,
UniCardia & UniMedica & UniEstetica Krakow,
Unidad de Estudios Clínicos de la Fundación Cardiovascular de Colombia Bucaramanga-piedecuesta, Valle Del Menzuli - Santander, Santander Department
Unidade Local De Saude Da Guarda E.P.E. - Hospital Sousa Martins Guarda,
Unidade Local De Saude Da Regiao De Leiria E.P.E.- Hospital de Santo André Leiria,
Unidade Local De Saude De Lisboa Ocidental E.P.E. - Hospital São Francisco Xavier Lisbon,
Unidade Local De Saude De Santa Maria E.P.E. Lisbon,
Unidade Local De Saude de Tâmega e Sousa E.P.E. Guilhufe - Penafiel,
Unidade Local Saúde Baixo Mondego, E.P.E. - Hospital Distrital Figueira Da Foz E.P.E. Figueira da Foz Municipality,
Unidade Local de Saúde Entre Douro e Vouga E.P.E. - Hospital São Sebastião Santa Maria da Feira,
Unidade Local de Saúde da Arrábida, E.P.E. Setúbal,
Unidade Local de Saúde de Santo António, E.P.E Porto,
Unidade de Local de Saúde de Braga Braga,
Unidade de Pesquisa Clínica do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo Ribeirão Preto, São Paulo
Uniklinik Aachen - Med. Klinik I Aachen,
Uniklinik Jena - Kardiologie Jena,
Uniklinik Klinikum Bielefeld - Kardiologie und Internist. Intensivmedizin Bielefeld,
Uniklinik TU Dresden - Herzzentrum Dresden GmbH Dresden,
Uniklinikum Salzburg Kardiologie Salzburg,
Univ Gen Hospital Larisa, Cardiology Medicine Clinic Larissa/Thessaly, Greece
Univ. of Nebraska Medical Center_Omaha Omaha, Nebraska
Universidade Federal de São Paulo - UNIFESP São Paulo/SP,
Universitatsklinikum Würzburg - Zentrum für Herzinsuffizienz Würzburg,
Universiti Teknologi MARA, Sungai Buloh Campus Sungai Buloh, Selangor
University Clinical Centre Kragujevac Kragujevac,
University Clinical Centre Nis, Clinic for Cardiology Niš,
University Clinical Centre Sarajevo Sarajevo,
University Clinical Centre of the Republic Srpska Banja Luka,
University Hospital Aintree Liverpool,
University Hospital Centre Zagreb Zagreb, City of Zagreb
University Hospital Centre Zagreb Zagreb, City of Zagreb
University Hospital Hairmyres - Cardiology East Kilbride, South Lanarkshire
University Hospital Monklands - Cardiology Research Airdrie, Lanarkshire
University Hospital Sveti Duh Zagreb,
University Malaya Medical Centre Kuala Lumpur,
University Medical Center Hamburg-Eppendorf Hamburg, City state of Hamburg
University Medical Center New Orleans New Orleans, Louisiana
University at Buffalo_Erie County Med Ctr Buffalo, New York
University of Calgary_Calgary Calgary, Alberta
University of Iowa Hospitals and Clinics Iowa City, Iowa
University of Louisville Louisville, Kentucky
University of Michigan Medicine Ann Arbor, Michigan
University of North Tees Hospital Stockton-on-Tees,
University of North Tees Hospital Stockton-on-Tees,
University of Vermont Medical Center Burlington, Vermont
University of Virginia Charlottesville, Virginia
Universitätsklinikum Frankfurt aM - Kardiologie Frankfurt am Main,
Universitätsklinikum Freiburg - Medical Center Freiburg im Breisgau,
Universitätsklinikum Hamburg-Eppendorf - University Medical Center Hamburg-Eppendorf Hamburg,
Universitätsklinikum Leipzig - Klinik und Poliklinik für Kardiologie Leipzig,
Universitätsklinikum des Saarlandes - Innere Med. III Homburg,
Uniwersytecki Szpital Kliniczny im. J.Mikulicza-Radeckiego Wroclaw, Lower Silesian Voivodeship
Uniwersytecki Szpital Kliniczny nr 2 Uniwersytetu Medycznego w Łodzi Lodz,
Uniwersytecki Szpital Kliniczny w Bialymstoku K. Kardio Bialystok, Podlaskie Voivodeship
Uwajima City Hospital_ Cardiology Uwajima-shi, Ehime
VA Greater Los Angeles Hlthcare System Los Angeles, California
VA Loma Linda Hlthcr Sys Loma Linda, California
VA Medical Center_Salem Salem, Virginia
VMMC & Safdarjung Hospital New Dehli, New Delhi
Vajira Hospital - Cardio Bangkok,
Valley Clinical Trials Covina, California
Valley Clinical Trials, Inc. Northridge, California
Valley Health Link Winchester, Virginia
Velocity - Clinical Research Germany GmbH Berlin,
Venizeleio Pananeio Heraklion,
Veritas Hospital_Cardiology Hyōgo,
Viacar Recherche Clinique Inc. Longueuil, Quebec
Victoria Heart Institute Foundation Victoria, British Columbia
Vilnius University Hospital Santaros Klinikos Vilnius,
Virginia Commonwealth University Richmond, Virginia
Virginia Heart Falls Church, Virginia
Virginia Mason Medical Center Seattle, Washington
Vita Longa Sp. z o. o. Katowice,
Vita Longa Sp. z o. o. Katowice,
Vseobecna kardiologicka ambulance Tábor,
Vseobecna kardiologicka ambulance Tábor,
Všeobecná kardiologická ambulance s.r.o. Tábor,
WVU Heart & Vascular Institute Morgantown, West Virginia
William S Middleton Mem VA Hosp Madison, Wisconsin
Winchester Dist Memorial Hosp Winchester, Ontario
Winter Haven Hospital Winter Haven, Florida
Witham Health Services Lebanon, Indiana
Wits Bara Clinical Trial Site Johannesburg, Gauteng
Wits Clinical Research Johannesburg, Gauteng
Wojewodzki Szpital Im. Sw.Ojca Pio W Przemyslu Przemyśl,
Wojewodzki Szpital Zespolony Im.L.Rydygiera W Toruniu Torun, Kuyavian-Pomeranian Voivodeship
Wojewódzki Specjalistyczny Szpital im.Wl. Bieganskiego, Lodz,
Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy Warsaw,
Women's College Hospital Toronto,
Wonju Severance Christian Hospital Gangwon-do,
Wuhan Asia Heart Hospital-Department of Cardiovascular Wuhan, Hubei
Wycombe General Hospital High Wycombe,
Yao Tokushukai General Hospital_Cardiovascular division Osaka,
Yokohama Minami Kyousai Hospital_Cardiology Kanagawa,
York Clinical Research LLC Norfolk, Virginia
Zane Lucane GP Practice Grobiņa, South Kurzeme Municipality
Zdrowie S.C. Agnieszka I Donald Drożdż Wroclaw, Lower Silesian Voivodeship
Zemgales diabetes centre Jelgava,
Zentrum fuer klinische Studien Suedbrandenburg GmbH Elsterwerda,
Zhejiang Provincial People's Hospital Hangzhou,
Zhongda Hospital Southeast University Nanjin,
Ziekenhuis Oost-Limburg AV - Cardiology Genk,
Zupanijska bolnica Cakovec Čakovec,
Zuyderland ziekenhuis Heerlen,
i9 Pesquisas Clínicas Campinas, São Paulo
zero PRAXEN Mannheim-Schwetzingerstadt Mannheim,
Észak-Pesti Centrumkórház Honvédkórház Budapest,

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

Contact(s):

ctrrecruit@vcu.edu

Principal Investigator:

System ID: NCT06465316

Show full eligibility criteria

Inclusion Criteria:

* Patients must have histologically or cytologically confirmed multiple myeloma (MM), as defined in the International Myeloma Working Group (IMWG) criteria * If patients have undergone autologous stem cell transplant (SCT), day 0 of SCT must be \> 100 days to be eligible for the study * Patients must have had disease progression after ≥ 4 prior lines of anti-myeloma treatments including one proteasome inhibitor (e.g., bortezomib, carfilzomib, ixazomib), one immunomodulatory imide drug (ImiD) (e.g., thalidomide, lenalidomide, pomalidomide \[POM\]), and one anti-CD38 monoclonal antibody (e.g., daratumumab, isatuximab) * Patients must have measurable disease, defined as: * Serum M-protein ≥ 0.5 g/dL (≥ 5 g/L) * Urine M-protein ≥ 200 mg/24 h * Serum free light chain (FLC) assay: "involved" FLC level ≥ 10 mg/dL (≥ 100 mg/L) and an abnormal serum free light chain ratio (\< 0.26 or \> 1.65) * Note: Patients with non-secretory disease will be allowed to participate * Age ≥ 18 years * Because no dosing or adverse event data are currently available on the use of iberdomide in combination with teclistamab in patients \< 18 years of age, children are excluded from this study * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60) * Hemoglobin ≥ 7.0 g/dL (≤ 28 days prior to registration) (Without growth factor support, blood transfusion, or platelet stimulating agents for the past 7 days, excluding erythropoietin) * Absolute neutrophil count ≥ 1,000/mcL (≤ 28 days prior to registration) (Without growth factor support, blood transfusion, or platelet stimulating agents for the past 7 days, excluding erythropoietin) * Platelets ≥ 50,000/mcL (≤ 28 days prior to registration) (Without growth factor support, blood transfusion, or platelet stimulating agents for the past 7 days, excluding erythropoietin) * Total bilirubin ≤ 2 x institutional upper limit of normal (ULN) (≤ 28 days prior to registration) * Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase \[SGPT\]) ≤ 3 x institutional ULN (≤ 28 days prior to registration) * Estimated glomerular filtration rate (eGFR) \> 30 mL/min (≤ 28 days prior to registration) * Spot urine (albumin/creatine ratio) ≤ 500mg/g (56 mg/mmol) OR urine dipstick negative/trace (if \> 1+ only eligible if confirmed ≤ 500 mg/g (56 mg/mmol) by albumin/creatinine ratio (spot urine from first void) (≤ 28 days prior to registration) * Note: Laboratory results obtained during screening should be used to determine eligibility criteria. In situations where laboratory results are outside the permitted range, the investigator may re-test the subject and the subsequent within range screening result may be used to confirm eligibility * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load * Patients with treated brain metastases are eligible if follow-up brain imaging done a minimum of 28 days after completion of central nervous system (CNS)-directed therapy shows no evidence of progression * Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class II or better * Based on the mechanism of action, teclistamab may cause fetal harm when administered to a pregnant woman. Females of child-bearing potential (FCBP): should use effective contraception during treatment with teclistamab and for 5 months after the last dose. FCBP should not breast feed during treatment with teclistamab and for 5 months after the last dose. Should a FCBP become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. The effects of iberdomide on the developing human fetus are unknown. However, IMiDs are known to be teratogenic. FCBP must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10-14 days prior to starting iberdomide, and again within 24 hours. FCBP must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control-one highly effective method and one additional effective method-at the same time, at least 28 days before starting iberdomide, while taking iberdomide, and for 28 days following discontinuation from the study. Examples of highly effective methods are intrauterine device, hormonal contraceptives, tubal ligation, or partner's vasectomy. Examples of barrier method are male condom, diaphragm, or cervical cap. FCBP must also agree to ongoing pregnancy testing. Men must practice complete abstinence or agree to use a condom during sexual contact with FCBP while participating in the study, during dose interruptions, and for at least 28 days following discontinuation from the study, even if he has undergone a successful vasectomy. All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risk of fetal exposure * Men must agree to abstain from donating and semen or sperm while taking iberdomide, during dose interruptions, and for at least 28 days after the last dose of iberdomide. FCBP must agree not to donate eggs (ova, oocytes) for the purpose of reproduction during this period * All patients must agree to abstain from donating blood products while taking iberdomide and for at least 28 days after the last dose of iberdomide * Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study subjects * Willingness to adhere to the study visit schedule and other protocol requirements and provide mandatory blood and bone marrow specimens for correlative research * Willingness to return to the enrolling institution for follow-up

Exclusion Criteria:

* Patients who have active plasma cell leukemia, active amyloid light chain (AL) (primary) amyloidosis, active polyneurophathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes (POEMS) syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma proliferative disorder, myeloma protein, and skin changes), and Waldenstrom macroglobulinemia are ineligible * If a patient develops recurrent/refractory (R/R) disease while receiving the most recent line of therapy, there is no need for a washout period * Patients who have had prior anti-BCMA directed bispecific antibody (BsAb) therapy exposure (prior treatment with anti-BCMA directed antibody drug conjugate, anti-BCMA-directed chimeric antigen receptor (CAR) T cell therapy, and prior non-BCMA-targeting BsAb are permitted) * Patients who have had prior treatment with a cereblon E3 ligase modulator, including mezigdomide, iberdomide, and CFT7455 (all currently in clinical development) * Patients who received plasmapheresis ≤ 7 days prior to registration * Patients who received a prior allogeneic stem cell transplant. Autologous SCT is allowed * Patients who received a live or live-attenuated vaccine ≤ 30 days prior to registration. Patients are allowed to receive a COVID-19 vaccine at any timepoint during protocol treatment * Systemic active infection requiring treatment * Any unresolved toxicity ≥ grade 2 from previous treatment except for alopecia or peripheral neuropathy up to grade 2 * Patients who have had any major surgery ≤ 4 weeks prior to registration * Patients with uncontrolled intercurrent illness or any other significant condition(s) that would make this protocol unreasonably hazardous * Patients with evidence of active mucosal or internal bleeding * Current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. Stable chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) or hepatobiliary involvement of malignancy is acceptable if participant otherwise meets entry criteria * Patients with known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to drugs chemically related to teclistamab or iberdomide, or any of the components of the study treatment * Patients who are taking any anticancer therapy other than hormonal therapy (for prostrate or breast cancer) and palliative radiotherapy (defined as radiation to ≤ 3 sites of active multiple myeloma) * Patients who require immunosuppressive medications including, but not limited to, systemic corticosteroids at doses exceeding 10 mg/day of prednisone or equivalent. Use of immunosuppressive medications for the management of iberdomide-related adverse events (AEs) or in subjects with contrast allergies is acceptable. In addition, use of inhaled, topical, intranasal corticosteroids or local steroid injection (e.g., intra-articular injection) is permitted. Temporary use of corticosteroids for concurrent illnesses (e.g., food allergies, computed tomography \[CT\] scan contrast hypersensitivity, pneumonia, etc.) are acceptable * Patients who require medications that are strong inhibitors or inducers of CYP3A4/5 * Patients who are receiving any other investigational agents * Patients with uncontrolled intercurrent illness or any other significant condition(s) that would make participation in this protocol unreasonably hazardous * Pregnant women are excluded from this study because iberdomide is a thalidomide analog and thalidomide is a known human teratogen. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with iberdomide, breastfeeding should be discontinued if the mother is treated with iberdomide. These potential risks may also apply to other agents used in this study * Patients who are unable or unwilling to undergo protocol required thromboembolism prophylaxis are excluded

Interventions: PROCEDURE: Biospecimen Collection, PROCEDURE: Bone Marrow Aspiration, PROCEDURE: Bone Marrow Biopsy, PROCEDURE: Computed Tomography, DRUG: Iberdomide, PROCEDURE: Magnetic Resonance Imaging, PROCEDURE: Positron Emission Tomography, DRUG: Teclistamab

Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma

I'm interested

Share via email

Show 10 locations

Study Locations

Hide all locations

Location	Contacts
Mayo Clinic Hospital in Arizona Phoenix, Arizona
Mayo Clinic in Florida Jacksonville, Florida
Mayo Clinic in Rochester Rochester, Minnesota
Moffitt Cancer Center Tampa, Florida	Site Public Contact - (ClinicalTrials@moffitt.org)
Ohio State University Comprehensive Cancer Center Columbus, Ohio	Site Public Contact - (Jamesline@osumc.edu)
Smilow Cancer Hospital Care Center - Guilford Guilford, Connecticut	Site Public Contact - (canceranswers@yale.edu)
University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma	Site Public Contact - (ou-clinical-trials@ouhsc.edu)
VCU Massey Comprehensive Cancer Center Richmond, Virginia	Site Public Contact - (CTOclinops@vcu.edu)
Yale University New Haven, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Yale-New Haven Hospital North Haven Medical Center North Haven, Connecticut	Site Public Contact - (canceranswers@yale.edu)

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression (IMAGINATION)

Contact(s):

WA43966 https://forpatients.roche.com/ - global-roche-genentech-trials@gene.com

Principal Investigator:

System ID: NCT05797610

Show full eligibility criteria

Inclusion Criteria:

* Primary IgAN, as evidenced by a kidney biopsy performed within 10 years prior to or during screening, without known secondary cause * Treatment with maximum tolerated doses of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) for at least 90 days immediately prior to screening, and without an intent to modify the dose during the study, except for interruptions due to illness (not greater than 7 consecutive days), unless the potential participant is intolerant to these medications * Urine Protein-to-Creatinine Ratio (UPCR) ≥ 1 gram per gram (g/g) or urine protein excretion ≥ 1 gram per day (g/day) (with UPCR ≥ 0.8 g/g), all measured from a 24-hour urine collection during screening * eGFR ≥ 20 mL/min/1.73 m\^2, as calculated by the 2021 CKD-EPI creatinine equation (Inker et al. 2021a) * Vaccination against Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae according to national vaccination recommendations * Female participants of childbearing potential must use adequate contraception

Exclusion Criteria:

* Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 12 weeks after the final dose of sefaxersen * Histopathologic or other evidence of another autoimmune glomerular disease * Presence of ≥ 50% crescents on kidney biopsy, sustained doubling of serum creatinine within 3 months prior to screening, or rapidly progressive glomerulonephritis in the opinion of the investigator * History of kidney transplantation * Glycated Hemoglobin (HbA1c) ≥ 6.5% or a clinical diagnosis of diabetes mellitus of any type * Systolic blood pressure \>140 mmHg or diastolic blood pressure \>90 mmHg from the average of two measurements performed at least 1 minute apart during screening * Initiation of sodium-glucose cotransporter-2 (SGLT2) inhibitors within 16 weeks prior to screening or during screening * Initiation of endothelin receptor antagonists within 90 days prior to screening or during screening * Initiation of mineralocorticoid receptor antagonists or non-dihydropyridine calcium channel blockers within 90 days prior to screening or during screening * Use of herbal therapies within 90 days prior to or during screening * Treatment with investigational therapy within 28 days prior to screening or 5.5 drug-elimination half-lives of that investigational product prior to screening * Treatment with an investigational therapy planned during the treatment period * Previous treatment with sefaxersen * Treatment with oral or intravenous (IV) corticosteroids with a dose equivalent to ≥ 7.5 milligrams per day (mg/day) of prednisone for 7 days or equivalent to ≥ 5 mg/day of prednisone for 14 days within 90 days prior to screening * Treatment with corticosteroids with systemic effects during screening * Treatment with a systemic calcineurin inhibitor within 2 months prior to screening or during screening * Treatment with anti-CD20 therapy within 9 months of screening or during screening * Treatment with other systemic immunosuppressive agents within 6 months of randomization including, but not limited to, complement inhibitors, alkylating agents (e.g., cyclophosphamide or chlorambucil), azathioprine, or mycophenolate * Planned major procedure or major surgery during screening or the study * Substance abuse within 12 months prior to screening or during screening * Any serious medical condition or abnormality in clinical laboratory tests that precludes an individual's safe participation in and completion of the study * History of malignancy within \< 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death * Usage of Glucagon-like Peptide-1 (GLP-1)-based therapy (i.e., GLP-1 mono-agonists, GLP-1/GIP dual agonists, etc.) within 90 days prior to screening or during screening, or intent to initiate during the study period

Interventions: DRUG: Sefaxersen (RO7434656), DRUG: Placebo

Conditions: Primary IgA Nephropathy

I'm interested

Share via email

Show 193 locations

Study Locations

Hide all locations

Location	Contacts
Academic Medical Research Institute - Los Angeles Los Angeles, California
Addenbrookes Hospital Cambridge,
Affiliated Hospital of Jiangsu University Zhenjiang,
Ajou University Hospital Suwon, Gyeonggi-do
Azienda Ospedaliera Universitaria Federico II Napoli, Campania
Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari Bari,
Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi-Via Massarenti Bologna, Emilia-Romagna
Beijing Friendship Hospital, Capital Medical University - PPDS Beijing, Beijing Municipality
C.H. Regional Reina Sofia - PPDS Córdoba,
CHA Bundang Medical Center, CHA University Seongnam-si,
CHU Boulogne sur Mer Boulogne-sur-Mer,
Cangzhou Central Hospital Cangzhou Shi, Hebei
Cape Breton Regional Hospital Sydney, Nova Scotia
Care Institute Idaho Kidney Institute Idaho Falls, Idaho
Care Institute Idaho Kidney Institute Idaho Falls, Idaho
Central Florida Kidney Specialists Orlando, Florida
Centre Hospitalier Annonay,
Centre Hospitalier Universitaire de Quebec Québec,
Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada Ciudad Autonoma Buenos Aires,
Centro de Investigacion Clinica Chapultepec S. A. de C. V. Morelia, Michoacán
Centro de Pesquisa Clinica da Fundação Pró Rim Joinville, Santa Catarina
Chang Gung Medical Foundation Kaohsiung City,
Chang Gung Memorial Hospital, Linkou Taoyuan District,
Changhua Christian Hospital Changhua County,
Changi General Hospital Singapore,
Changzhou First People's Hospital Changzhou,
China Medical University Hospital Taichung,
Christus Latam Hub Center Of Excellence & Innovation Monterrey, Nuevo León
Chungbuk National University Hospital Chungju,
Churchill Hospital Oxford,
Clinica San Cosme Fracc Lomas Del Campestre, Aguascalientes
Consultorios Medicos Dr. Doreski Ciudad Autonoma Buenos Aires,
Cowry Medical Group LLC Acworth, Georgia
Faculdade de Medicina da Universidade de Sao Paulo São Paulo, São Paulo
Fakultni nemocnice Hradec Kralove Hradec Králové, Hradec Králové
Far Eastern Memorial Hospital New Taipei City,
Fondazione Policlinico Universitario A Gemelli Rome, Lazio
Freire Pesquisa Clinica Belo Horizonte, Minas Gerais
Fujita Health University Hospital Toyoake,
Gangdong Kyung Hee University Hospital Seoul,
General Hospital of Ningxia Medical University Ningxia, Yinchuan
Global Medical Research - M3 WR Dallas, Texas
Guangdong Provincial People's Hospital Guangzhou,
Guys and St Thomas Hospital London,
Hallym University Sacred Heart Hospital Anyang,
Hirosaki University Hospital Aomori, Hirosaki,
Hiroshima University Hospital Hiroshima,
Hokkaido University Hospital Hokkaido, Sapporo,
Hope Clinic & Research Center Hialeah, Florida
Hopital Bichat - Claude Bernard AP-HP Paris,
Hopital Henri Mondor Créteil,
Hopital Tenon Paris,
Hospital Ampang Ampang,
Hospital Do Rim E Hipertensao Fundacao Oswaldo Ramos São Paulo, São Paulo
Hospital Kuala Lumpur Kuala Lumpur,
Hospital Ribera Polusa Lugo,
Hospital Seri Manjung Seri Manjong, Pahang
Hospital Sibu Sibu, Sarawak
Hospital Tengku Ampuan Afzan Kuantan, Pahang
Hospital Universitari Arnau de Vilanova Lleida,
Hospital Universitario 12 de Octubre Madrid,
Hospital Universitario La Paz - PPDS Madrid,
Hospital Universitario Vall d'Hebron - PPDS Barcelona,
Hospital Universitario Virgen del Rocio - PPDS Seville,
Hospital de Clinicas de Porto Alegre HCPA PPDS Porto Alegre, Rio Grande do Sul
Hyogo Prefectural Nishinomiya Hospital Nishinomiya,
Hôpital de Rangueil Toulouse,
IRCCS Pavia - Istituti Clinici Scientifici Maugeri Spa ? Società Benefit Pavia, Lombardy
Instituto D?Or Pesquisa e Ensino - Hospital Gloria D?Or Rio de Janeiro,
Instituto Medico de la Fundacion Estudios Clinicos Rosario,
Instituto Mexicano de Trasplantes Cuernavaca, Morelos
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran Mexico City, DIF
Ippokratio General Hospital of Thessaloniki Thessaloniki,
Iwate Medical University Hospital Shiwa-gun, Iwate
Japanese Red Cross Fukuoka Hospital Fukuoka,
Jichi Medical University Hospital Shimotsuke,
Juntendo University Hospital Bunkyo-ku, Tokyo
Juntendo University Nerima Hospital, department of renal and hypertension Tokyo,
Juntendo University Urayasu Hospital Chiba,
Kanazawa Medical University Hospital Ishikawa,
Kidney Disease Medical Group Inc-1505 Wilson Ter Glendale, California
Kidney and Hypertension Center Victorville, California
Kings College Hospital London,
Klinikum Koln-Merheim Cologne,
Konkuk University Medical Center Seoul,
Kumamoto University Hospital Kumamoto,
Kyoto City Hospital Nakagyo-ku,
L&C Professional Medical Research Institute West Miami, Florida
LCC Medical Research - Miami - ClinEdge - PPDS Miami, Florida
Leicester General Hospital Leicester,
Liverpool Hospital Liverpool,
London Health Sciences Centre · Victoria Hospital London, Ontario
Mackay Memorial Hospital-Taipei branch Zhongshan Dist.,
Massachussets General Hospital Boston, Massachusetts
Matsuyama Red Cross Hospital Matsuyama, Ehime
Medizinische Hochschule hannover Hanover,
Milwaukee Nephrologists, Sc Wauwatosa, Wisconsin
Miri Hospital Miri,
Montreal General Hospital Montreal, Quebec
NYU Langone Nephrology Associates - Mineola Mineola, New York
Nara Medical University Hospital Kashihara,
Nara Prefecture General Medical Center Nara,
National Hospital Organization Okayama Medical Center Okayama,
National University Hospital Singapore,
Nepean Hospital Kingswood, New South Wales
Nephrologisches Zentrum Villingen-Schwenningen Villingen-Schwenningen,
Nephrology Associates of Northern Illinois Hinsdale, Illinois
Nephrology Associates of Northern Virginia Inc Fairfax, Virginia
Ningbo No.2 Hospital Ningbo,
North America Research Institute-San Dimas San Dimas, California
North Carolina Nephrology, PA Raleigh, North Carolina
Ohio State University Wexner Medical Center - Outpatient Care East Columbus, Ohio
Okayama University Hospital Okayama,
Osaka University Hospital Suita,
Ospedale Policlinico San Martino Genoa, Liguria
Ospedale San Giovanni Bosco Turin, Piedmont
Peking University First Hospital Beijing,
Peking University People's Hospital Beijing,
Pioneer Research Solutions Houston, Texas
Princess Alexandra Hospital Queensland, Queensland
Prolato Clinical Research Center Houston, Texas
Queen Mary Hospital Hong Kong,
R & H Clinical Research Katy, Texas
Renmin Hospital of Wuhan University Wuhan,
Revival Research Corporation - Sherman - ClinEdge - PPDS Sherman, Texas
Royal Adelaide Hospital Adelaide, South Australia
Royal Melbourne Hospital Parkville,
Ruijin Hospital Shanghai Jiaotong University School of Medicine Shanghai, Shanghai Municipality
SCM Clinic - Prywatny Szpital Specjalistyczny Krakow,
SMG-SNU Boramae Medical Center Seoul,
SPZOZ Centralny Szpital Klin Lodz,
Saitama Medical University Hospital Saitama,
Salford Royal Hospital Salford,
Samsung Medical Center Seoul,
Sanatorio Allende Córdoba,
Sanatorio Mayo Privado Córdoba,
Santa Casa de Misericordia de Belo Horizonte - PPDS Belo Horizonte, Minas Gerais
Seoul National University Bundang Hospital Seongnam-si,
Seoul National University Hospital Seoul,
Shenzhen People's Hospital Shenzhen,
Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital Chengdu, Sichuan
Sierra Nevada Nephrology Consultants Reno, Nevada
Singapore General Hospital Singapore,
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University Hangzhou,
Soon Chun Hyang University Hospital Bucheon Bucheon-si,
Southern California Medical Research Center La Palma, California
St George Hospital Sydney,
Sunnybrook Health Sciences Centre Toronto, Ontario
Sunrise Medical Management LLC Surprise, Arizona
Sunshine Hospital St Albans, Victoria
Szpital Kliniczny Dzieciatka Jezus Warsaw,
Szpital Kliniczny im. H.Swiecickiego UM w Poznaniu Późna,
Taichung Veterans General Hospital Taichung, China
Taiping Hospital Taiping, Perak
Tan Tock Seng Hospital Singapore,
Texas Kidney Institute - Dallas Dallas, Texas
The First Affiliated Hospital of NanChang University Nanchang, Jiangxi
The First Affiliated Hospital of Xian Jiao Tong University Xi'an,
The First Hospital of Hebei Medical University Shijiazhuang, Hebei
The Jikei University Hospital Minato-ku, Tokyo
The Second Affiliated Hospital of Nanchang University Nanchang, Jiangxi
The Second Affiliated Hospital of Nanjing Medical university Nanjing,
The Second Affiliated Hospital of Soochow University Suzhou,
The University of Hong Kong - Shenzhen Hospital Shenzhen,
Tohoku University Hospital Miyagi, Sendai,
Tokushima University Hospital Tokushima, Tokushima,
Tokyo Medical University Ibaraki Medical Center Inashiki-Gun,
Tokyo Women's Medical University Hospital Tokyo, Shinjuku-ku,
Tucson Neuroscience Research - M3 WR Tucson, Arizona
UAB Nephrology Research Clinic Birmingham, Alabama
University General Hospital of Heraklion Heraklion, Crete,
University General Hospital of Patras Pátrai,
University Malaya Medical Centre Kuala Lumpur,
University of California, Los Angeles (UCLA) - Hematology/Oncology Santa Monica Los Angeles, California
University of Iowa Iowa City, Iowa
University of Mississippi Medical Center Jackson, Mississippi
University of Tsukuba Hospital Ibaraki, Tsukuba,
University of Yamanashi Hospital Chūō,
University of the Ryukyus Hospital Okinawa,
Universitätsklinikum der RWTH Aachen Aachen,
Universitätsmedizin der Johannes Gutenberg-Universität Mainz Mainz,
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu Wroc?aw,
Uniwersytecki Szpital Kliniczny w Opolu Opole,
Utah Kidney Research Institute Salt Lake City, Utah
Vancouver General Hospital Vancouver, British Columbia
Venizeleio General Hospital of Heraklion Heraklion,
Virginia Commonwealth University Richmond, Virginia
Vseobecna Fakultni Nemocnice v Praze Prague,
West China Hospital, Sichuan University Chengdu, Sichuan
Wuxi People's Hospital Wuxi,
Xinhua Hospital Affiliated To Shanghai Jiaotong University School of Medicine Shanghai,
Yamaguchi University Hospital Yamaguchi, Ube,
Zhejiang Provincial People?s Hospital Hangzhou,

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Contact(s):

ctrrecruit@vcu.edu

Principal Investigator:

System ID: NCT06169215

Show full eligibility criteria

Inclusion Criteria:

* Presence of newly diagnosed (dx) multiple myeloma (MM) as defined by standard International Myeloma working group (IMWG). * Presence of high risk cytogenetics using fluorescent in situ hybridization (FISH) \[del(17p), t(4;14), t(14;16), t(14;20), chromosome 1 abnormalities, MYC translocation, tetrasomies, complex karyotype, high lactate dehydrogenase (LDH), or extramedullary MM. * Patients are allowed to have received one cycle of bortezomib-based doublet or triplet therapy. For instance, if a newly diagnosed patient with MM is in need of urgent therapy, they may be enrolled after having received one cycle of bortezomib, cyclophosphamide, dexamethasone. * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%). * Absolute neutrophil count ≥ 1,000/mcL (\> 500 if bone marrow \[BM\] clonal plasma cell involvement greater than 50%). * Platelets ≥ 100,000/mcL (\> 50,000 if BM clonal plasma cell involvement greater than 50%). * Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (with the exception of patients with Gilbert's syndrome who have a high baseline bilirubin). * Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase \[SGPT\]) ≤ 3 × institutional ULN. * Glomerular filtration rate (GFR) ≥ 30 mL/min. * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load. * Patients with treated brain involvement are eligible if follow-up brain imaging performed within 10 days after central nervous system (CNS)-directed therapy shows no. * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better. * The effects of selinexor (KPT-330) on the developing human fetus are unknown. For this reason and because selective nuclear export inhibitors as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men with partners of women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men (with partners of women of childbearing potential) treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of study treatment administration. Adequate contraception should continue for 7 months for females and for 4 months for males after completion of the study treatment. * Female of childbearing potential (FCBP) must have a negative pregnancy test during screening. They must either commit to continue abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 4 weeks before therapy, while taking lenalidomide, during dose interruptions, and for 7 months after study treatment. If menstrual cycles are irregular, the pregnancy testing should occur every 2 weeks. Pregnancy testing and counseling should be performed if a patient misses her period or if there is any abnormality in her menstrual bleeding. Lenalidomide treatment must be discontinued during this evaluation. * Men who are sexually active with FCBP must agree to use a latex or synthetic condom while taking lenalidomide, during dose interruptions and for up to 4 weeks after discontinuing lenalidomide, even if they have undergone a successful vasectomy. Male patients taking lenalidomide must abstain from donating blood, semen, or sperm during study participation and for at least 4 weeks after discontinuation from lenalidomide. * Patients who are randomized to receive lenalidomide need to register into the mandatory Risk Evaluation and Mitigation Strategies (REMS) program and be willing and able to comply with the requirements of REMS. * Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.

Exclusion Criteria:

* Patients who are in urgent need for MM therapy (such as in the setting of acute kidney injury, or high disease burden concerning for impending organ failure) may begin study treatment immediately after receiving one cycle of bortezomib combination (e.g. bortezomib-dexamethasone or cyclophosphamide-bortezomib-dexamethasone) or one course of pulse dose dexamethasone 20-40mg once daily for four days. No washout period is required. * Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \> grade 1) with the exception of alopecia. * Patients who are receiving any other investigational agents. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to selinexor (KPT-330) or other agents used in study. * Concomitant medications: Supportive care therapies such as bone directed therapies (zoledronic acid, denosumab), intravenous immunoglobulin therapy (IVIG) and anti-viral agents are allowed and recommended as per standard of care (SOC). Strong CYP3A4 inhibitors and strong CYP3A4 inducers are prohibited, due to their respective increase or decrease in bortezomib exposure. If strong CYP3A4 inhibitors cannot be avoided, then patients will be monitored for signs of bortezomib toxicity and a dose reduction of bortezomib will be considered. * Patients with uncontrolled intercurrent illness or any other significant condition(s) that would make participation in this protocol unreasonably hazardous. * Pregnant women are excluded because this study involves an investigational drug that may cause genotoxic, teratogenic, and mutagenic effects on the developing fetus and newborn and drugs that have known genotoxic, teratogenic, or abortifacient effect. * Because there is potential risk for adverse events in nursing infants secondary to treatment of the mother with the drugs used in this study, breastfeeding is not allowed during treatment for all drugs and for 2 months after last dose of bortezomib and 1 week after the last dose of selinexor.

Interventions: PROCEDURE: Biospecimen Collection, PROCEDURE: Bone Marrow Aspiration, PROCEDURE: Bone Marrow Biopsy, DRUG: Bortezomib, PROCEDURE: Computed Tomography, DRUG: Daratumumab and Recombinant Human Hyaluronidase, DRUG: Dexamethasone, DRUG: Lenalidomide, PROCEDURE: Magnetic Resonance Imaging, PROCEDURE: Positron Emission Tomography, DRUG: Selinexor

Conditions: Multiple Myeloma

I'm interested

Share via email

Show 27 locations

Study Locations

Hide all locations

Location	Contacts
Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland	Site Public Contact - (jhcccro@jhmi.edu)
Laura and Isaac Perlmutter Cancer Center at NYU Langone New York, New York	Site Public Contact - (CancerTrials@nyulangone.org)
NYP/Weill Cornell Medical Center New York, New York
NYU Langone Hospital - Brooklyn Brooklyn, New York	Site Public Contact - (david.wallach@nyulangone.org)
NYU Langone Hospital - Long Island Mineola, New York	Site Public Contact - (cancertrials@nyulangone.org)
Ohio State University Comprehensive Cancer Center Columbus, Ohio	Site Public Contact - (Jamesline@osumc.edu)
Smilow Cancer Center/Yale-New Haven Hospital New Haven, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center - Guilford Guilford, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center - Waterford Waterford, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center - Westerly Westerly, Rhode Island	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center at Glastonbury Glastonbury, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center at Greenwich Greenwich, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center at Long Ridge Stamford, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center at Saint Francis Hartford, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center-Fairfield Fairfield, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center-Trumbull Trumbull, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital-Derby Care Center Derby, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital-Torrington Care Center Torrington, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital-Waterbury Care Center Waterbury, Connecticut	Site Public Contact - (canceranswers@yale.edu)
UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California	Site Public Contact - (ucstudy@uci.edu)
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California	Site Public Contact - (ucstudy@uci.edu)
UCI Health Laguna Hills Laguna Hills, California	Site Public Contact - (ucstudy@uci.edu)
University of California Davis Comprehensive Cancer Center Sacramento, California
VCU Massey Comprehensive Cancer Center Richmond, Virginia	Site Public Contact - (CTOclinops@vcu.edu)
Vanderbilt University/Ingram Cancer Center Nashville, Tennessee
Yale University New Haven, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Yale-New Haven Hospital North Haven Medical Center North Haven, Connecticut	Site Public Contact - (canceranswers@yale.edu)

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer (Krascendo 1)

Contact(s):

Reference Study ID Number: BO45217 https://forpatients.roche.com/ - global-roche-genentech-trials@gene.com

Principal Investigator:

System ID: NCT06497556

Show full eligibility criteria

Inclusion Criteria:

* Unequivocal histologically or cytologically confirmed diagnosis of metastatic or locally advanced NSCLC not amenable to treatment with surgical resection or combined chemoradiation * Disease progression during or after treatment with at least one prior systemic therapy but no more than three lines of prior systemic therapy in the advanced or metastatic setting * Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 * Documentation of the presence of a KRAS G12C mutation * Availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen in a paraffin block (preferred) or 10-15 (15 preferred) unstained, freshly cut, serial slides with an associated pathology report * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Life expectancy of \>= 12 weeks

Exclusion Criteria:

* Known hypersensitivity to any of the components of divarasib, or sotorasib or adagrasib * Malabsorption syndrome or other condition that would interfere with enteral absorption * Known concomitant second oncogenic driver * Mixed small-cell lung cancer or large cell neuroendocrine histology * Known and untreated, or active central nervous system (CNS) metastases * Leptomeningeal disease or carcinomatous meningitis * Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures biweekly or more frequently * Any infection that, in the opinion of the investigator, could impact patient safety, or treatment with therapeutic oral or IV antibiotics within 14 days prior to Day 1 of Cycle 1 * Prior treatment with any KRAS G12C inhibitor or pan-KRAS/RAS inhibitor * More than 30 Gy of radiotherapy to the lung within 6 months of randomization * Uncontrolled tumor-related pain * Unresolved toxicities from prior anticancer therapy * History of malignancy within 5 years prior to screening, with the exception of the cancer under investigation in this study and malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate \>90%), such as adequately treated carcinoma in situ of the cervix, nonmelanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer

Interventions: DRUG: Divarasib, DRUG: Sotorasib, DRUG: Adagrasib

Conditions: Non-small Cell Lung Cancer, KRAS G12C Lung Cancer

Keywords: Advanced Non-Small Cell Lung Cancer, KRAS G12 Lung Cancer, Advanced Lung Cancer, Metastatic lung cancer, Divarasib, KRAS G12C Inhibitor, KRAS G12C Positive, KRAS Mutation, KRAS G12C Mutation, Lung Cancer Mutation

I'm interested

Share via email

Show 253 locations

Study Locations

Hide all locations

Location	Contacts
A.O. Universitaria Di Parma Parma, Emilia-Romagna
A.O.U. Maggiore della Carità Novara, Piedmont
AO Ospedali Riuniti Villa Sofia-Cervello-Presidio Ospedaliero Cervello Palermo, Sicily
ARKE Estudios Clínicos S.A. de C.V. Mexico City,
AUSL della Romagna Ravenna, Emilia-Romagna
AZ Delta (Campus Rumbeke) Roeselare,
AZ.Osp S. Orsola ? Malpighi-Reparto di Oncologia Medica Bologna, Emilia-Romagna
AZORG Campus Aalst-Moorselbaan Aalst,
Aarhus Universitetshospital Aarhus,
Addenbrooke's Hospital Cambridge,
Ag. Loukas Hospital Thessaloniki,
Allegheny Cancer Center Pittsburgh, Pennsylvania
Amphia Ziekenhuis Breda,
Asklepios Fachkliniken GmbH Gauting,
Asst Papa Giovanni XXIII Bergamo, Lombardy
Avera Cancer Institute Sioux Falls, South Dakota
Az. Osp. Pugliese Ciaccio Catanzaro, Calabria
Azienda Ospedaliero Universitaria Pisana Pisa, Tuscany
Azienda Ospedaliero-Universitaria Careggi Florence, Tuscany
Azienda Sanitaria Universitaria Friuli Centrale ? PO Universitario Santa Maria della Misericordia Udine, Friuli Venezia Giulia
Banner Health MD Anderson AZ Phoenix, Arizona
Banner Health MD Anderson AZ Phoenix, Arizona
Baptist Clinical Research Institute Memphis, Tennessee
Baptist Health Lexington Lexington, Kentucky
Bay Pines Foundation Inc Bay Pines, Florida
Beatson West of Scotland Cancer Centre Glasgow,
Beth Israel Deaconess Medical Center Boston, Massachusetts
Blackpool Victoria Hospital Blackpool,
CH de Saint Quentin Saint-Quentin,
CHRU Brest Brest,
CHRU Lille Lille,
CHU Angers Angers,
CHU Bordeaux Pessac,
CHU Montpellier Montpellier,
CHU UCL Mont-Godinne Mont-godinne,
CHU de Liège (Sart Tilman) Liège,
CHUC - Unidade de Pneumologia Oncológica Coimbra,
Cancer Specialists of North Florida Jacksonville, Florida
Cancer and Hematology Centers of Western Michigan Grand Rapids, Michigan
Castle Hill Hospital Cottingham,
Centre Antoine Lacassagne Centre Régional de Lutte Contre Le Cancer Nice,
Centre Leon Berard Lyon,
Centro Clinico Champalimaud Lisbon,
Centro Hospitalar do Porto ? Hospital de Santo António Porto,
Centro Oncológico Korben Ciudad Autonoma Buenos Aires,
Centro de Infusion E Investigacion Oncologia de Saltillo Sc Saltillo, Coahuila
Chang Gung Medical Foundation - Linkou Taoyuan District,
Charité Universitätsmedizin Berlin, Med Klinik Infekto und Pneumo Berlin,
Chonnam National University Hwasun Hospital Hwasun-gun,
Chru de Strasbourg Strasbourg,
Chu Toulouse Bron,
Chung Shan Medical University Hospital Taichung,
Chungbuk National University Hospital Chungju,
Clinica Onconeo Campo Grande, Mato Grosso do Sul
Cliniques Universitaires St-Luc Brussels,
Clínica Adventista Belgrano Ciudad Autonoma Buenos Aires,
Clínica Integral Internacional de Oncología S de RL de CV Puebla City, Puebla
Columbia University Medical Center New York, New York
Community Clinical Trials Orange, California
Curie Oncology (Farrer) Singapore,
Dana Farber Cancer Institute Boston, Massachusetts
Dana Farber/Harvard Cancer Center (Foxborough) Foxborough, Massachusetts
Dana-Farber Cancer Institute Boston, Massachusetts
Dolno?L?Skie Centrum Onkologii, Pulmonologii I Hematologii Wroc?aw,
East Carolina University Greenville, North Carolina
Errikos Dynan Hospital Athens,
Evangelische Lungenklinik Berlin Berlin,
Firsthealth of The Carolinas Pinehurst, North Carolina
Florida Cancer Specialists West Palm Beach, Florida
Florida Cancer Specialists West Palm Beach, Florida
Florida Cancer Specialists. St. Petersburg, Florida
Fox Chase Cancer Center Philadelphia, Pennsylvania
Gachon University Gil Medical Center Incheon,
GenesisCare North Shore St Leonards, New South Wales
Gibbs Cancer Center & Research Institute Spartanburg, South Carolina
Guy's Hospital - Cancer Centre London,
Gävle Sjukhus Gävle,
Helios Klinikum Emil von Behring GmbH Berlin,
Helsinki University Central Hospital Helsinki,
Henry Ford Health System;Clinical Trials Office Detroit, Michigan
Herlev Hospital Herlev,
Hia Sainte Anne Toulon,
Hokkaido University Hospital Hokkaido, Sapporo,
Hong Kong Integrated Oncology Centre Hong Kong,
Hopital Louis Pradel Bron,
Hopital Tenon Paris,
Hospital Alemão Oswaldo Cruz São Paulo, São Paulo
Hospital Brasilia Lago Sul, Federal District
Hospital Britanico Buenos Aires,
Hospital Civil De Guadalajara Fray Antonio Alcalde Guadalajara, Jalisco
Hospital De La Santa Creu I Sant Pau Barcelona,
Hospital General Universitario Gregorio Marañon Madrid,
Hospital Mãe de Deus Porto Alegre, Rio Grande do Sul
Hospital Nossa Senhora da Conceicao Porto Alegre, Rio Grande do Sul
Hospital Nuestra Senora de Valme Seville, Sevilla
Hospital Regional Universitario de Malaga Málaga,
Hospital Sao Rafael - HSR Salvador, Estado de Bahia
Hospital Sírio-Libanês São Paulo, São Paulo
Hospital Universitario La Fe Valencia,
Hospital Universitario La Paz Madrid,
Hospital Universitario Miguel Servet Zaragoza,
Hospital Vall Hebron Barcelona,
Hospital de Base de Sao Jose do Rio Preto São José do Rio Preto, São Paulo
Hospital de Braga Braga,
Hospital de Cancer de Barretos Barretos, São Paulo
Hsin-Chu Branch of National Taiwan University Hospital Hsinchu,
IPO do Porto Porto,
IRCCS Istituto Clinico Humanitas Rozzano (MI), Lombardy
IRCCS Istituto Oncologico Veneto (IOV) Padua, Veneto
IRCCS Istituto Regina Elena (IFO) Rome, Lazio
IU Health Ball Memorial Hospital Muncie, Indiana
Institut Catala d Oncologia Hospitalet L'Hospitalet de Llobregat, Barcelona
Institut für Lungenforschung Wien Vienna,
Instytut "Centrum Zdrowia Matki Polki" ?ód?,
Instytut Gruzlicy i Chorob Pluc Warsaw,
Irccs Ist. Tumori Giovanni Paolo Ii Bari, Apulia
Isala Zwolle,
JPS Health Network Fort Worth, Texas
Jeroen Bosch Ziekenhuis 's-Hertogenbosch,
Jessa Zkh (Campus Virga Jesse) Hasselt,
Jewish General Hospital Montreal, Quebec
KEM/Evang. Kliniken Essen Mitte gGmbH Essen,
Kaohsiung Medical University Chung-Ho Memorial Hospital Kaohsiung City,
Keimyung University Dongsan Medical Center Daegu,
Kindai University Hospital Sayama, Osaka
Kinghorn Cancer Centre Darlinghurst, New South Wales
Klinik Penzing Vienna,
Klinikum Bogenhausen München,
Klinikum Braunschweig Braunschweig,
Klinikum Esslingen Esslingen am Neckar,
Klinikum Koeln-Merheim Cologne,
Klinikum Würzburg Mitte gGmbH Würzburg,
Korea University Anam Hospital Seoul,
Korea University Guro Hospital Seoul,
Krakowski Szpital Specjalistyczny im sw. Jana Paw?a II Krakow,
Krankenhaus Martha-Maria Halle-Doelau gGmbH Halle,
Krankenhaus Nord - Klinik Floridsdorf Vienna,
Kujawsko-Pomorskie Centrum Pulmonologii Bydgoszcz,
Kuopio Uni Hospital Kuopio,
Kyungpook National University Chilgok Hospital Daegu,
Kyushu University Hospital Fukuoka, Fukuoka,
Liverpool Hospital Liverpool,
Los Angeles Cancer Network Los Angeles, California
LungenClinic Grosshansdorf GmbH Großhansdorf,
Lungenfachklinik Immenhausen Immenhausen,
Lungenklinik Hemer Hemer,
Lyell McEwin Hospital Elizabeth Vale, South Australia
MD Anderson Cancer Center Houston, Texas
Medisch Centrum Haaglanden, locatie Antoniushove Leidschendam,
Metropolitan Hospital Fourth Oncology Clinic Faliro,
Minnesota Oncology Edina Edina, Minnesota
Mission Cancer + Blood - IMMC Des Moines, Iowa
Mount Sinai Medical Center Miami Beach, Florida
Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad Warsaw,
National Cancer Center Hospital ChuoKu, Tokyo
National Cancer Centre Singapore,
National Taiwan University Hospital Taipei,
Nebraska Methodist Estabrook Cancer Center Omaha, Nebraska
New England Cancer Specialists Westbrook, Maine
New York Cancer & Blood Specialists The Bronx, New York
New York Cancer & Blood Specialists - New Hyde Park New Hyde Park, New York
New York Cancer and Blood Specialists-Central Park Hematology & Oncology New York, New York
Niigata Cancer Center Hospital Niigata,
North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists Shirley, New York
Norton Cancer Institute- Poplar Louisville, Kentucky
Nottingham City Hospital Nottingham,
Ohio State University Comprehensive Cancer Center Columbus, Ohio
Okayama University Hospital Okayama,
Oncoclínicas Rio de Janeiro S.A. Rio de Janeiro,
Oncology Associates of Oregon, P.C Eugene, Oregon
Oregon Health & Science University Portland, Oregon
Ospedale Civile SS Annunziata Sassari, Sardinia
Ospedale Policlinico San Martino Genoa, Liguria
PanAmerican Clinical Research, Querétaro Queréaro, Querétaro
Peter MacCallum Cancer Centre Melbourne, Victoria
Pius Hospital Oldenburg Oldenburg,
Prince of Wales Hosp Shatin,
Princess Margaret Cancer Center Toronto, Ontario
Pusan National University Hospital Seogu, Busan Gwang'yeogsi
Pusan National University Yangsan Hospital Yangsan, Gyeongsangnam-do
Queen Mary Hospital Hong Kong,
Radomskie Centrum Onkologii Radom,
Regionshospitalet Gødstrup Herning,
Renown Regional Medical Center Hospital Reno, Nevada
Royal Marsden Hospital (Sutton) Sutton,
Royal Marsden Hospital - London London,
Rush University Medical Center Chicago, Illinois
SCRI Mark H. Zangmeister Center Columbus, Ohio
SLK Kliniken Heilbronn GmbH, Standort Fachklinik Löwenstein Löwenstein,
Samsung Medical Center Seoul,
Sanatorio Parque S.A. Rosario,
Santa Casa de Misericordia de Porto Alegre Porto Alegre, Rio Grande do Sul
Sendai Kousei Hospital Miyagi,
Seoul National University Bundang Hospital Seongnam-si,
Seoul National University Hospital Seoul,
Shikoku Cancer Center Ehime,
Shizuoka Cancer Center Shizuoka,
Siriraj Hospital - Chulabhorn Bone Marrow Transplant Centre Bangkok,
Songklanagarind Hospital Songkhla,
Srinagarind Hospital Khon Kaen,
St James University Hospital Leeds,
St. Vincent's Hospital Gyeonggi-do,
Summit Cancer Care PC Savannah, Georgia
Sunshine Coast University Hospital Birtinya, Queensland
Taipei Veterans General Hospital Taipei, Beitou District / R.o.c.
Taylor Cancer Research Center Maumee, Ohio
Tennessee Oncology Nashville, Tennessee
Tennessee Oncology, PLLC - Chattanooga Chattanooga, Tennessee
Texas Oncology - Northeast Texas Longview, Texas
The Cancer Institute Hospital of JFCR Tokyo,
The Christie NHS Foundation Trust Manchester,
Theageneio Hospital Thessaloniki,
Thoraxklinik Heidelberg gGmbH Heidelberg,
Torbay Hospital Torquay,
Tuen Mun Hospital Hong Kong,
Turku Uni Central Hospital Turku,
UC Health Oncology Research Colorado Springs, Colorado
UCLA Hematology / Oncology Clinic Los Angeles, California
UZ Antwerpen Edegem,
UZ Brussel Brussels,
Uniklinik Schleswig-Holstein Kiel,
Universitatsklinikum Essen Essen,
Universitatsklinikum Regensburg Regensburg,
Universitatsklinikum Schleswig-Holstein Lübeck,
University Cancer & Blood Center, LLC Athens, Georgia
University Hospital of Larissa Larissa,
University Hospitals of North Midlands NHS Trust-Royal Stoke University Hospital Stoke-on-Trent,
University of Arkansas for Medical Sciences Little Rock, Arkansas
University of California, San Francisco San Francisco, California
University of Chicago Medical Center Chicago, Illinois
University of Miami Miami, Florida
University of Michigan Ann Arbor, Michigan
University of North Carolina at Chapel Hill Chapel Hill, North Carolina
Universität Des Saarlandes Homburg,
Universität Mannheim Mannheim,
Universitätsklinikum Münster, Medizinische Klinik A, Translationale Onkologie Münster,
Uniwersytecki Szpital Kliniczny nr 4 w Lublinie Lublin,
Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii Gdansk,
Uoa Sotiria Hospital Athens,
VA Shreveport Healthcare System Shreveport, Louisiana
VITAZ Sint-Niklaas,
Vajira Hospital Bangkok,
Velindre NHS Trust - Velindre Cancer Centre Cardiff,
Virginia Commonwealth University - Massey Cancer Center Richmond, Virginia
Wakayama Medical University Hospital Wakayama,
Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie Olsztyn,
Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu Poznan,
William Osler Health Centre - Brampton Civic Hospital Brampton, Ontario
Yale Cancer Center New Haven, Connecticut
ZAS Sint Augustinus Wilrijk Wilrijk,
Ziekenhuis Rijnstate Arnhem,
Ziekenhuis St. Jansdal Harderwijk,
Zuckerberg San Francisco General Hospital San Francisco, California

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Contact(s):

Sharon Palmer - spalmer@swog.org

Principal Investigator:

System ID: NCT05561387

Show full eligibility criteria

Inclusion Criteria:

* Participants must have documented multiple myeloma satisfying standard International Myeloma Working Group (IMWG) diagnostic criteria within 28 days prior to registration * Participants must have measurable disease within 28 days prior to registration as defined by any of the following: * Immunoglobulin (Ig) G myeloma (serum monoclonal paraprotein \[M-protein\] level \>= 0.5 gram/deciliter \[g/dL\] or urine M-protein level \>= 200 milligram\[mg\]/24 hours\[hrs\]); OR * IgA, IgM, IgD, or IgE multiple myeloma (serum M-protein level \>= 0.2 g/dL or urine M-protein level \>= 200 mg/24 hrs); OR * Light chain multiple myeloma (serum immunoglobulin free light chain \>= 10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio) * All disease must be assessed and documented on the baseline/pre-registration tumor assessment form * Participants must have a calculated myeloma frailty index (Myeloma Frailty Score Calculator; http://www.myelomafrailtyscorecalculator.net/) categorized as frail or intermediate fit (regardless of age) within 28 days prior to registration * For Participants Meeting "Frail" Status: * Participants with any degree of kidney dysfunction are allowed; however, participants on dialysis are not eligible * For Participants Meeting "Frail" Status: * Hemoglobin \>= 7 g/dL (must be performed within 28 days prior to registration) * Note: growth factor and transfusion utilization are allowed if cytopenias are considered secondary to bone marrow involvement from MM) * For Participants Meeting "Frail" Status: * Platelets \>= 50 x 10\^9/L (must be performed within 28 days prior to registration) * Note: growth factor and transfusion utilization are allowed if cytopenias are considered secondary to bone marrow involvement from MM) * For Participants Meeting "Frail" Status: * Absolute neutrophil count (ANC) \>= 0.75 x10\^9/L (must be performed within 28 days prior to registration) * Note: growth factor and transfusion utilization are allowed if cytopenias are considered secondary to bone marrow involvement from MM) * For Participants Meeting "Intermediate Fit" Status, one or more of the following criteria must be present: * Kidney dysfunction showing calculated creatinine clearance (CrCl) \<30 ml/min. * Actual lab serum creatinine value with a minimum of 0.7 mg/dL. * Participants must have bone marrow function assessed and meet the below criteria ranges: * Hemoglobin between 7-8 g/dL, OR * Platelets between 50-75 x10\^9/L, OR * ANC between 0.75-1 x10\^9/L * Note: growth factor and transfusion utilization are allowed as long as cytopenias are considered secondary to bone marrow involvement from MM) * Revised International Staging System (R-ISS) stage III disease * Note: All labs must be performed within 28 days prior to registration * Participants must have a complete medical history and physical exam within 28 days prior to registration * Participants must have whole body imaging within 60 days prior to registration. The recommended method of imaging is a positron emission tomography/computed tomography (PET/CT); a low-dose whole body CT scan or whole-body magnetic resonance imaging (MRI) or skeletal survey should be done only if a PET/CT scan cannot be done or is non-feasible. This must be documented in the comments section of the Onstudy form. * Total bilirubin =\< 2 times institutional upper limit of normal (ULN) unless history of Gilbert's disease. Participants with history of Gilbert's disease must have total bilirubin =\< 5 x institutional ULN (within 28 days prior to registration) * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 3 × institutional ULN (within 28 days prior to registration) * Participants must have adequate cardiac function, as assessed by the treating physician within 14 days prior to registration. Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification and must not be assessed as class 3 or 4 * Participants with known diabetes must show evidence of controlled disease within 14 days prior to registration. Uncontrolled diabetes is defined as: A glycosylated hemoglobin (Hg)A1C \> 7 * Participants with known human immunodeficiency virus (HIV)-infection must be receiving anti-retroviral therapy and have an undetectable viral load test on the most recent test result obtained, within 6 months prior to registration * All participants with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load on suppressive therapy within 28 days prior to registration * Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, participant must have an undetectable HCV viral load within 28 days prior to registration * Participants must have an Eastern Cooperative Oncology Group (ECOG)/Zubrod performance status score of 0-2 (Note: Participants with ECOG/Zubrod performance score \[PS\] 3, especially where the deterioration of PS is considered secondary to the MM diagnosis, will be allowed) * Participants must be offered the opportunity to participate in specimen banking. With participant consent, specimens must be collected and submitted via the Southwest Oncology Group (SWOG) specimen tracking system * Participants who are able to complete the patient-reported outcomes measures in English or Spanish must agree to participate in the PRO portion of the study * Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines. For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations

Exclusion Criteria:

* Participants must not have received any prior systemic therapy for multiple myeloma with the exception of any one or more of the following: * An emergency use of a short course of corticosteroids (equivalent of dexamethasone 160 mg) any time before registration, or * Up to one complete cycle of a non-daratumumab and hyaluronidase-fihj containing anti-myeloma regimen (1 cycle = 21 or 28 days depending on the regimen being used), or * Localized palliative radiation therapy for multiple myeloma, as long as the radiation therapy is completed at least 3 days prior to starting the systemic treatment as per the study protocol. * Participants must not have evidence of grade 4 peripheral neuropathy prior to study registration * Participants must not have uncontrolled blood pressure within 14 days prior to registration. Uncontrolled blood pressure: systolic blood pressure (SBP) \> 140 mmHg or diastolic blood pressure (DBP) \> 90 mmHg. Participants are permitted to be receiving multiple anti-hypertensive medications (unless otherwise indicated in the study). All blood pressure measurements within the 14 days prior to registration must be SBP =\< 140 and DBP =\< 90. A participant with a single blood pressure elevation who upon rechecking has a normal blood pressure will remain eligible at the discretion of the registering investigator. * Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the investigational regimen. * Participants must not be pregnant or nursing. Individuals who are of reproductive potential must have agreed to use an effective contraceptive method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 24 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen.

Interventions: DRUG: Bortezomib, DRUG: Daratumumab and Hyaluronidase-fihj, DRUG: Dexamethasone, DRUG: Lenalidomide, OTHER: Quality-of-Life Assessment, OTHER: Questionnaire Administration

Conditions: Plasma Cell Myeloma

I'm interested

Share via email

Show 397 locations

Study Locations

Hide all locations

Location	Contacts
21st Century Oncology-Pontiac Pontiac, Michigan	Site Public Contact - (Emily.Crofts@trinity-health.org)
Abbott-Northwestern Hospital Minneapolis, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Academic Hematology Oncology Specialists Grosse Pointe Woods, Michigan	Site Public Contact - (karen.forman@ascension.org)
Advanced Breast Care Center PLLC Warren, Michigan	Site Public Contact - (karen.forman@ascension.org)
Alaska Breast Care and Surgery LLC Anchorage, Alaska	Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org)
Alaska Oncology and Hematology LLC Anchorage, Alaska	Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org)
Alaska Women's Cancer Care Anchorage, Alaska	Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org)
Alegent Health Bergan Mercy Medical Center Omaha, Nebraska	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Alegent Health Immanuel Medical Center Omaha, Nebraska	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Alegent Health Lakeside Hospital Omaha, Nebraska	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Alegent Health Mercy Hospital Council Bluffs, Iowa
Anchorage Associates in Radiation Medicine Anchorage, Alaska	Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org)
Anchorage Oncology Centre Anchorage, Alaska	Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org)
Anchorage Radiation Therapy Center Anchorage, Alaska	Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org)
Armes Family Cancer Center Findlay, Ohio	Site Public Contact - (clinical.trials@daytonncorp.org)
Ascension Borgess Cancer Center Kalamazoo, Michigan	Site Public Contact - (crcwm-regulatory@crcwm.org)
Ascension Saint John Hospital Detroit, Michigan	Site Public Contact - (karen.forman@ascension.org)
Ascension Saint Joseph Hospital Tawas City, Michigan	Site Public Contact - (lori.srebinski@ascension.org)
Ascension Saint Mary's Hospital Rhinelander, Wisconsin	Site Public Contact - (lori.srebinski@ascension.org)
Ascension Saint Mary's Hospital Rhinelander, Wisconsin	Site Public Contact - (Beth.Knetter@aspirus.org)
Ascension Saint Michael's Hospital Stevens Point, Wisconsin	Site Public Contact - (Beth.Knetter@aspirus.org)
Aspirus Cancer Care - Wisconsin Rapids Wisconsin Rapids, Wisconsin
Aspirus Medford Hospital Medford, Wisconsin	Site Public Contact - (Beth.Knetter@aspirus.org)
Aspirus Regional Cancer Center Wausau, Wisconsin
Avera Cancer Institute Sioux Falls, South Dakota	Site Public Contact - (OncRegulatory@avera.org)
Avera Cancer Institute at Yankton Yankton, South Dakota	Site Public Contact - (OncRegulatory@avera.org)
Avera Cancer Institute-Aberdeen Aberdeen, South Dakota	Site Public Contact - (oncregulatory@avera.org)
BJC Outpatient Center at Sunset Hills Sunset Hills, Missouri
Bay Area Hospital Coos Bay, Oregon	Site Public Contact - (cherie.cox@bayareahospital.org)
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center Houston, Texas	Site Public Contact - (burton@bcm.edu)
Ben Taub General Hospital Houston, Texas
Bethesda North Hospital Cincinnati, Ohio	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Bhadresh Nayak MD PC-Sterling Heights Sterling Heights, Michigan	Site Public Contact - (karen.forman@ascension.org)
Blanchard Valley Hospital Findlay, Ohio	Site Public Contact - (clinical.trials@daytonncorp.org)
Borgess Medical Center Kalamazoo, Michigan	Site Public Contact - (crcwm-regulatory@crcwm.org)
Bronson Battle Creek Battle Creek, Michigan	Site Public Contact - (crcwm-regulatory@crcwm.org)
Bronson Methodist Hospital Kalamazoo, Michigan	Site Public Contact - (crcwm-regulatory@crcwm.org)
CARTI Cancer center Little Rock, Arkansas	Site Public Contact - (Research@CARTI.com)
CHI Health Good Samaritan Kearney, Nebraska	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Cambridge Medical Center Cambridge, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Cancer Care Center of O'Fallon O'Fallon, Illinois	Site Public Contact - (morganthaler.jodi@mhsil.com)
Cancer Care Specialists of Illinois - Decatur Decatur, Illinois	Site Public Contact - (morganthaler.jodi@mhsil.com)
Cancer Center at Saint Joseph's Phoenix, Arizona	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Cancer Center of Western Wisconsin New Richmond, Wisconsin	Site Public Contact - (mmcorc@healthpartners.com)
Cancer and Hematology Centers of Western Michigan - Norton Shores Norton Shores, Michigan	Site Public Contact - (connie.szczepanek@crcwm.org)
Capital Region Southwest Campus Jefferson City, Missouri	Site Public Contact - (amy.franken@health.missouri.edu)
Carle Cancer Center Urbana, Illinois	Site Public Contact - (Research@carle.com)
Carle Physician Group-Effingham Effingham, Illinois	Site Public Contact - (Research@carle.com)
Carle Physician Group-Mattoon/Charleston Mattoon, Illinois	Site Public Contact - (Research@carle.com)
Carle at The Riverfront Danville, Illinois	Site Public Contact - (Research@Carle.com)
Caro Cancer Center Caro, Michigan	Site Public Contact - (lori.srebinski@ascension.org)
Central Care Cancer Center - Bolivar Bolivar, Missouri	Site Public Contact - (aroland@kccop.org)
Central Care Cancer Center - Garden City Garden City, Kansas	Site Public Contact - (aroland@kccop.org)
Central Care Cancer Center - Great Bend Great Bend, Kansas	Site Public Contact - (aroland@kccop.org)
Centralia Oncology Clinic Centralia, Illinois	Site Public Contact - (morganthaler.jodi@mhsil.com)
Clackamas Radiation Oncology Center Clackamas, Oregon	Site Public Contact - (CanRsrchStudies@providence.org)
Commonwealth Cancer Center-Corbin Corbin, Kentucky	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Community Medical Center Missoula, Montana	Site Public Contact - (HemonCCTrials@geisinger.edu)
Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center Saint Joseph, Michigan	Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health Lakeland Hospitals - Niles Hospital Niles, Michigan
Corewell Health Reed City Hospital Reed City, Michigan	Site Public Contact - (crcwm-regulatory@crcwm.org)
Cox Cancer Center Branson Branson, Missouri
CoxHealth South Hospital Springfield, Missouri
Creighton University Medical Center Omaha, Nebraska	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Crossroads Cancer Center Effingham, Illinois	Site Public Contact - (morganthaler.jodi@mhsil.com)
Dayton Physician LLC-Miami Valley Hospital North Dayton, Ohio	Site Public Contact - (clinical.trials@daytonncorp.org)
Dayton Physicians LLC - Troy Troy, Ohio	Site Public Contact - (clinical.trials@daytonncorp.org)
Dayton Physicians LLC-Atrium Franklin, Ohio	Site Public Contact - (clinical.trials@daytonncorp.org)
Dayton Physicians LLC-Miami Valley South Centerville, Ohio	Site Public Contact - (clinical.trials@daytonncorp.org)
Dayton Physicians LLC-Wayne Greenville, Ohio	Site Public Contact - (clinical.trials@daytonncorp.org)
Decatur Memorial Hospital Decatur, Illinois	Site Public Contact - (morganthaler.jodi@mhsil.com)
Delbert Day Cancer Institute at PCRMC Rolla, Missouri	Site Public Contact - (research@phelpshealth.org)
Duluth Clinic Ashland Ashland, Wisconsin	Site Public Contact - (CancerTrials@EssentiaHealth.org)
Edward Hines Jr VA Hospital Hines, Illinois
Essentia Health - Baxter Clinic Baxter, Minnesota
Essentia Health - Deer River Clinic Deer River, Minnesota	Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health - Ely Clinic Ely, Minnesota
Essentia Health - Fosston Fosston, Minnesota	Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health - International Falls Clinic International Falls, Minnesota
Essentia Health - Jamestown Clinic Jamestown, North Dakota	Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health - Moose Lake Clinic Moose Lake, Minnesota
Essentia Health - Park Rapids Park Rapids, Minnesota	Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Cancer Center Duluth, Minnesota	Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Cancer Center-South University Clinic Fargo, North Dakota	Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Hibbing Clinic Hibbing, Minnesota
Essentia Health Saint Joseph's Medical Center Brainerd, Minnesota	Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Saint Mary's - Detroit Lakes Clinic Detroit Lakes, Minnesota	Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Saint Mary's Hospital - Superior Superior, Wisconsin
Essentia Health Saint Mary's Medical Center Duluth, Minnesota	Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Sandstone Sandstone, Minnesota	Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Virginia Clinic Virginia, Minnesota	Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health-Hayward Clinic Hayward, Wisconsin	Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health-Spooner Clinic Spooner, Wisconsin	Site Public Contact - (CancerTrials@EssentiaHealth.org)
Exeter Hospital Exeter, New Hampshire
Fairview Clinics and Surgery Center Maple Grove Maple Grove, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Fairview Lakes Medical Center Wyoming, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Fairview Northland Medical Center Princeton, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Fairview Southdale Hospital Edina, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Flaget Memorial Hospital Bardstown, Kentucky	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Freeman Health System Joplin, Missouri	Site Public Contact - (LJCrockett@freemanhealth.com)
Fremont - Rideout Cancer Center Marysville, California
Geisinger Medical Center Danville, Pennsylvania	Site Public Contact - (HemonCCTrials@geisinger.edu)
Geisinger Medical Oncology-Lewisburg Lewisburg, Pennsylvania	Site Public Contact - (HemonCCTrials@geisinger.edu)
Geisinger Wyoming Valley/Henry Cancer Center Wilkes-Barre, Pennsylvania	Site Public Contact - (HemonCCTrials@geisinger.edu)
Gene Upshaw Memorial Tahoe Forest Cancer Center Truckee, California
Genesee Cancer and Blood Disease Treatment Center Flint, Michigan	Site Public Contact - (wstrong@ghci.org)
Genesee Hematology Oncology PC Flint, Michigan	Site Public Contact - (wstrong@ghci.org)
Genesys Hurley Cancer Institute Flint, Michigan	Site Public Contact - (wstrong@ghci.org)
Good Samaritan Hospital - Cincinnati Cincinnati, Ohio	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Good Samaritan Regional Health Center Mount Vernon, Illinois
Great Lakes Cancer Management Specialists-Doctors Park East China, Michigan	Site Public Contact - (karen.forman@ascension.org)
Great Lakes Cancer Management Specialists-Macomb Medical Campus Macomb, Michigan	Site Public Contact - (karen.forman@ascension.org)
Great Lakes Cancer Management Specialists-Macomb Professional Building Warren, Michigan	Site Public Contact - (karen.forman@ascension.org)
Great Lakes Cancer Management Specialists-Van Elslander Cancer Center Grosse Pointe Woods, Michigan	Site Public Contact - (karen.forman@ascension.org)
Greater Baltimore Medical Center Baltimore, Maryland
Greater Dayton Cancer Center Kettering, Ohio	Site Public Contact - (clinical.trials@daytonncorp.org)
Greater Regional Medical Center Creston, Iowa	Site Public Contact - (cancerresearch@mercydesmoines.org)
Gundersen Lutheran Medical Center La Crosse, Wisconsin	Site Public Contact - (cancerctr@gundersenhealth.org)
HSHS Saint Elizabeth's Hospital O'Fallon, Illinois	Site Public Contact - (morganthaler.jodi@mhsil.com)
Harrison Medical Center Bremerton, Washington	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Health Partners Inc Minneapolis, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Heartland Regional Medical Center Saint Joseph, Missouri	Site Public Contact - (linda.schumacher@mymlc.com)
Helen DeVos Children's Hospital at Spectrum Health Grand Rapids, Michigan	Site Public Contact - (crcwm-regulatory@crcwm.org)
Hematology Oncology Consultants-Clarkston Clarkston, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Hennepin County Medical Center Minneapolis, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Holy Cross Hospital Fort Lauderdale, Florida	Site Public Contact - (eileen.georgi@holy-cross.com)
Hope Cancer Center Pontiac, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Hurley Medical Center Flint, Michigan	Site Public Contact - (wstrong@ghci.org)
Huron Gastroenterology PC Ypsilanti, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
IU Health North Hospital Carmel, Indiana	Site Public Contact - (iutrials@iu.edu)
Illinois CancerCare - Washington Washington, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Bloomington Bloomington, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Canton Canton, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Carthage Carthage, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Dixon Dixon, Illinois
Illinois CancerCare-Eureka Eureka, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Galesburg Galesburg, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Kewanee Clinic Kewanee, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Macomb Macomb, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Ottawa Clinic Ottawa, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Pekin Pekin, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Peoria Peoria, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Peru Peru, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Princeton Princeton, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
Indiana University/Melvin and Bren Simon Cancer Center Indianapolis, Indiana	Site Public Contact - (iutrials@iu.edu)
Indu and Raj Soin Medical Center Beavercreek, Ohio	Site Public Contact - (clinical.trials@daytonncorp.org)
John L McClellan Memorial Veterans Hospital Little Rock, Arkansas
Jupiter Medical Center Jupiter, Florida
Kadlec Clinic Hematology and Oncology Kennewick, Washington	Site Public Contact - (research@kadlecmed.org)
Katmai Oncology Group Anchorage, Alaska	Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org)
Kettering Medical Center Kettering, Ohio	Site Public Contact - (clinical.trials@daytonncorp.org)
Lake Regional Hospital Osage Beach, Missouri	Site Public Contact - (clinicaltrials@lakeregional.com)
Lakeland Medical Center Saint Joseph Saint Joseph, Michigan	Site Public Contact - (crcwm-regulatory@crcwm.org)
Lakeview Hospital Stillwater, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Langlade Hospital and Cancer Center Antigo, Wisconsin	Site Public Contact - (Juli.Alford@aspirus.org)
Lehigh Valley Hospital - Muhlenberg Bethlehem, Pennsylvania	Site Public Contact - (Morgan_M.Horton@lvhn.org)
Lehigh Valley Hospital-Cedar Crest Allentown, Pennsylvania	Site Public Contact - (Morgan_M.Horton@lvhn.org)
Lehigh Valley Hospital-Hazleton Hazleton, Pennsylvania	Site Public Contact - (Morgan_M.Horton@lvhn.org)
Littleton Adventist Hospital Littleton, Colorado
Longmont United Hospital Longmont, Colorado	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Lovelace Medical Center-Saint Joseph Square Albuquerque, New Mexico	Site Public Contact - (AYost@nmcca.org)
Loyola Center for Health at Burr Ridge Burr Ridge, Illinois
Loyola Medicine Homer Glen Homer Glen, Illinois
Loyola University Medical Center Maywood, Illinois
M D Anderson Cancer Center Houston, Texas	Site Public Contact - (askmdanderson@mdanderson.org)
MD Anderson League City League City, Texas	Site Public Contact - (askmdanderson@mdanderson.org)
MD Anderson West Houston Houston, Texas	Site Public Contact - (askmdanderson@mdanderson.org)
MD Anderson in Sugar Land Sugar Land, Texas	Site Public Contact - (askmdanderson@mdanderson.org)
MD Anderson in The Woodlands Conroe, Texas	Site Public Contact - (askmdanderson@mdanderson.org)
Macomb Hematology Oncology PC Warren, Michigan	Site Public Contact - (karen.forman@ascension.org)
Marjorie Weinberg Cancer Center at Loyola-Gottlieb Melrose Park, Illinois
Marshall Cancer Center Cameron Park, California	Site Public Contact - (cancerservices@marshallmedical.org)
Marshfield Clinic - Ladysmith Center Ladysmith, Wisconsin	Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Clinic - Wisconsin Rapids Center Wisconsin Rapids, Wisconsin	Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Clinic-Chippewa Center Chippewa Falls, Wisconsin	Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Clinic-Minocqua Center Minocqua, Wisconsin	Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Clinic-Wausau Center Wausau, Wisconsin	Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center - Neillsville Neillsville, Wisconsin	Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center - Weston Weston, Wisconsin	Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-EC Cancer Center Eau Claire, Wisconsin	Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-Marshfield Marshfield, Wisconsin	Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-Rice Lake Rice Lake, Wisconsin	Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-River Region at Stevens Point Stevens Point, Wisconsin	Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Mayo Clinic in Florida Jacksonville, Florida
Mayo Clinic in Rochester Rochester, Minnesota
Medical Oncology and Hematology Associates-West Des Moines Clive, Iowa
Memorial Hospital of Carbondale Carbondale, Illinois	Site Public Contact - (clinical.research@sih.net)
Memorial Medical Center Modesto, California	Site Public Contact - (pallante.beth@mhsil.com)
Mercy Cancer Center - Carmichael Carmichael, California	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Mercy Cancer Center - Elk Grove Elk Grove, California	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Mercy Cancer Center - Rocklin Rocklin, California	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Mercy Cancer Center - Sacramento Sacramento, California	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Mercy Cancer Center-West Lakes Clive, Iowa	Site Public Contact - (cancerresearch@mercydesmoines.org)
Mercy Clinic-Rolla-Cancer and Hematology Rolla, Missouri
Mercy Hospital Coon Rapids, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Mercy Hospital Fort Smith Fort Smith, Arkansas
Mercy Hospital Joplin Joplin, Missouri	Site Public Contact - (esmeralda.carrillo@mercy.net)
Mercy Hospital Oklahoma City Oklahoma City, Oklahoma
Mercy Hospital Saint Louis St Louis, Missouri
Mercy Hospital South St Louis, Missouri	Site Public Contact - (Danielle.Werle@mercy.net)
Mercy Hospital Springfield Springfield, Missouri
Mercy Hospital Washington Washington, Missouri
Mercy Medical Center Springfield, Massachusetts	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Mercy Medical Center - Des Moines Des Moines, Iowa	Site Public Contact - (cancerresearch@mercydesmoines.org)
Mercy Medical Center-West Lakes West Des Moines, Iowa	Site Public Contact - (cancerresearch@mercydesmoines.org)
Mercy San Juan Medical Center Carmichael, California	Site Public Contact - (OncologyResearch@DignityHealth.org)
Mercy UC Davis Cancer Center Merced, California	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Methodist Medical Center of Illinois Peoria, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
Michael E DeBakey VA Medical Center Houston, Texas
Michigan Breast Specialists-Warren Warren, Michigan	Site Public Contact - (karen.forman@ascension.org)
Midlands Community Hospital Papillion, Nebraska
Miller-Dwan Hospital Duluth, Minnesota	Site Public Contact - (CancerTrials@EssentiaHealth.org)
Minnesota Oncology - Burnsville Burnsville, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Minnesota Oncology Hematology PA-Maplewood Maplewood, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Minnesota Oncology Hematology PA-Woodbury Woodbury, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Mission Cancer and Blood - Ankeny Ankeny, Iowa
Mission Cancer and Blood - Laurel Des Moines, Iowa
Mission Hope Medical Oncology - Arroyo Grande Arroyo Grande, California	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Mission Hope Medical Oncology - Santa Maria Santa Maria, California	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Missouri Baptist Medical Center St Louis, Missouri
Missouri Baptist Sullivan Hospital Sullivan, Missouri
Monticello Cancer Center Monticello, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Munson Medical Center Traverse City, Michigan	Site Public Contact - (crcwm-regulatory@crcwm.org)
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center New York, New York	Site Public Contact - (cancerclinicaltrials@cumc.columbia.edu)
New Ulm Medical Center New Ulm, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Newland Medical Associates-Clarkston Clarkston, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Newland Medical Associates-Pontiac Pontiac, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
North Memorial Medical Health Center Robbinsdale, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Northwest Cancer Center - Hobart Hobart, Indiana
Northwest Cancer Center - Main Campus Crown Point, Indiana
Northwest Cancer Center - Valparaiso Valparaiso, Indiana	Site Public Contact - (CancerResearch@COMHS.org)
Northwest Oncology LLC Dyer, Indiana
Northwest Wisconsin Cancer Center Ashland, Wisconsin	Site Public Contact - (CancerTrials@EssentiaHealth.org)
Oncology Hematology Associates of Saginaw Valley PC Saginaw, Michigan	Site Public Contact - (lori.srebinski@ascension.org)
Oncology Hematology Care Inc-Kenwood Cincinnati, Ohio	Site Public Contact - (clinical.trials@daytonncorp.org)
Orion Cancer Care Findlay, Ohio	Site Public Contact - (clinical.trials@daytonncorp.org)
Pacific Central Coast Health Center-San Luis Obispo San Luis Obispo, California	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Park Nicollet Clinic - Saint Louis Park Saint Louis Park, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Parker Adventist Hospital Parker, Colorado
Parkland Health Center - Farmington Farmington, Missouri
PeaceHealth Saint John Medical Center Longview, Washington	Site Public Contact - (kmakin-bond@peacehealth.org)
PeaceHealth Saint Joseph Medical Center Bellingham, Washington
PeaceHealth Southwest Medical Center Vancouver, Washington	Site Public Contact - (kmakin-bond@peacehealth.org)
PeaceHealth United General Medical Center Sedro-Woolley, Washington	Site Public Contact - (lkey@peacehealth.org)
Penrose-Saint Francis Healthcare Colorado Springs, Colorado	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Physicians' Clinic of Iowa PC Cedar Rapids, Iowa
Pocono Medical Center East Stroudsburg, Pennsylvania	Site Public Contact - (Morgan_M.Horton@lvhn.org)
Porter Adventist Hospital Denver, Colorado
Presbyterian Kaseman Hospital Albuquerque, New Mexico	Site Public Contact - (WBurman@phs.org)
Presbyterian Rust Medical Center/Jorgensen Cancer Center Rio Rancho, New Mexico	Site Public Contact - (WBurman@phs.org)
Prisma Health Cancer Institute - Butternut Greenville, South Carolina
Prisma Health Cancer Institute - Easley Easley, South Carolina	Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Eastside Greenville, South Carolina
Prisma Health Cancer Institute - Faris Greenville, South Carolina
Prisma Health Cancer Institute - Greer Greer, South Carolina
Prisma Health Cancer Institute - Seneca Seneca, South Carolina
Prisma Health Cancer Institute - Spartanburg Boiling Springs, South Carolina
Providence Alaska Medical Center Anchorage, Alaska	Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org)
Providence Cancer Institute Clackamas Clinic Clackamas, Oregon	Site Public Contact - (CanRsrchStudies@providence.org)
Providence Medical Foundation - Santa Rosa Santa Rosa, California
Providence Newberg Medical Center Newberg, Oregon	Site Public Contact - (CanRsrchStudies@providence.org)
Providence Portland Medical Center Portland, Oregon	Site Public Contact - (CanRsrchStudies@providence.org)
Providence Queen of The Valley Napa, California
Providence Regional Cancer Partnership Everett, Washington	Site Public Contact - (marilyn.birchman@providence.org)
Providence Regional Cancer System-Aberdeen Aberdeen, Washington	Site Public Contact - (deidre.dillon@providence.org)
Providence Regional Cancer System-Centralia Centralia, Washington	Site Public Contact - (deidre.dillon@providence.org)
Providence Regional Cancer System-Lacey Lacey, Washington	Site Public Contact - (deidre.dillon@providence.org)
Providence Regional Cancer System-Shelton Shelton, Washington	Site Public Contact - (deidre.dillon@providence.org)
Providence Regional Cancer System-Yelm Yelm, Washington	Site Public Contact - (deidre.dillon@providence.org)
Providence Saint Joseph Medical Center/Disney Family Cancer Center Burbank, California	Site Public Contact - (Najee.Boucher@providence.org)
Providence Saint Mary Regional Cancer Center Walla Walla, Washington	Site Public Contact - (Cheryl.Dodd@providence.org)
Providence Saint Vincent Medical Center Portland, Oregon	Site Public Contact - (CanRsrchStudies@providence.org)
Providence Santa Rosa Memorial Hospital Santa Rosa, California
Providence Willamette Falls Medical Center Oregon City, Oregon	Site Public Contact - (CanRsrchStudies@providence.org)
Regions Hospital Saint Paul, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Reid Health Richmond, Indiana	Site Public Contact - (clinical.trials@daytonncorp.org)
Research Medical Center Kansas City, Missouri	Site Public Contact - (aroland@kccop.org)
Rice Memorial Hospital Willmar, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Ridgeview Medical Center Waconia, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Riverwood Healthcare Center Aitkin, Minnesota	Site Public Contact - (CancerTrials@EssentiaHealth.org)
Rocky Mountain Cancer Centers-Penrose Colorado Springs, Colorado	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Rocky Mountain Regional VA Medical Center Aurora, Colorado
Rogue Valley Medical Center Medford, Oregon	Site Public Contact - (research@asante.org)
Rush - Copley Medical Center Aurora, Illinois	Site Public Contact - (Cancer.Research@rushcopley.com)
Rush-Copley Healthcare Center Yorkville, Illinois	Site Public Contact - (Cancer.Research@rushcopley.com)
SIH Cancer Institute Carterville, Illinois	Site Public Contact - (clinical.research@sih.net)
Saint Anthony Hospital Lakewood, Colorado	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Anthony's Health Alton, Illinois
Saint Catherine Hospital Garden City, Kansas	Site Public Contact - (protocols@swog.org)
Saint Charles Health System Bend, Oregon	Site Public Contact - (nosall@stcharleshealthcare.org)
Saint Charles Health System-Redmond Redmond, Oregon
Saint Elizabeth Boardman Hospital Boardman, Ohio	Site Public Contact - (clinical.trials@daytonncorp.org)
Saint Elizabeth Regional Medical Center Lincoln, Nebraska
Saint Elizabeth Youngstown Hospital Youngstown, Ohio	Site Public Contact - (clinical.trials@daytonncorp.org)
Saint Francis Cancer Center Greenville, South Carolina	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Francis Medical Center Cape Girardeau, Missouri	Site Public Contact - (sfmc@sfmc.net)
Saint Francis Regional Medical Center Shakopee, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Saint John Macomb-Oakland Hospital Warren, Michigan	Site Public Contact - (karen.forman@ascension.org)
Saint John's Hospital - Healtheast Maplewood, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Saint Joseph Hospital Lexington, Kentucky	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Joseph Hospital East Lexington, Kentucky	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Joseph London London, Kentucky	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Joseph Medical Center Tacoma, Washington	Site Public Contact - (andersonj@illinoiscancercare.com)
Saint Joseph Mercy Brighton Brighton, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Saint Joseph Mercy Canton Canton, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Saint Joseph Mercy Chelsea Chelsea, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Saint Joseph Mercy Hospital Ann Arbor, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Saint Joseph Mercy Oakland Pontiac, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Saint Joseph Mount Sterling Mount Sterling, Kentucky	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Joseph Radiation Oncology Resource Center Lexington, Kentucky	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Joseph Warren Hospital Warren, Ohio	Site Public Contact - (clinical.trials@daytonncorp.org)
Saint Louis Cancer and Breast Institute-Ballwin Ballwin, Missouri
Saint Louis Cancer and Breast Institute-South City St Louis, Missouri
Saint Luke's Cancer Institute - Boise Boise, Idaho	Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Fruitland Fruitland, Idaho	Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Meridian Meridian, Idaho	Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Nampa Nampa, Idaho	Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Twin Falls Twin Falls, Idaho	Site Public Contact - (eslinget@slhs.org)
Saint Mary Corwin Medical Center Pueblo, Colorado	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Mary Medical Center Hobart, Indiana	Site Public Contact - (CancerResearch@COMHS.org)
Saint Mary's Hospital Centralia, Illinois	Site Public Contact - (protocols@swog.org)
Saint Mary's Oncology/Hematology Associates of Marlette Marlette, Michigan	Site Public Contact - (lori.srebinski@ascension.org)
Saint Mary's Oncology/Hematology Associates of West Branch West Branch, Michigan	Site Public Contact - (lori.srebinski@ascension.org)
Saint Patrick Hospital - Community Hospital Missoula, Montana	Site Public Contact - (amy.hanneman@providence.org)
Sainte Genevieve County Memorial Hospital Sainte Genevieve, Missouri
Sanford Bismarck Medical Center Bismarck, North Dakota	Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford Broadway Medical Center Fargo, North Dakota	Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford Cancer Center Oncology Clinic Sioux Falls, South Dakota	Site Public Contact - (OncologyClinicTrialsSF@sanfordhealth.org)
Sanford Cancer Center Worthington Worthington, Minnesota
Sanford Joe Lueken Cancer Center Bemidji, Minnesota	Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford Medical Center Fargo Fargo, North Dakota
Sanford Roger Maris Cancer Center Fargo, North Dakota	Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford South University Medical Center Fargo, North Dakota
Sanford Thief River Falls Medical Center Thief River Falls, Minnesota
Sanford USD Medical Center - Sioux Falls Sioux Falls, South Dakota	Site Public Contact - (OncologyClinicalTrialsSF@SanfordHealth.org)
Smilow Cancer Center/Yale-New Haven Hospital New Haven, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center - Guilford Guilford, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center - Waterford Waterford, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center - Westerly Westerly, Rhode Island	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center at Glastonbury Glastonbury, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center at Greenwich Greenwich, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center at Long Ridge Stamford, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center at Saint Francis Hartford, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center-Fairfield Fairfield, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center-Trumbull Trumbull, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital-Derby Care Center Derby, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital-Torrington Care Center Torrington, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital-Waterbury Care Center Waterbury, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Southeast Cancer Center Cape Girardeau, Missouri
Southern Illinois University School of Medicine Springfield, Illinois
Southpointe-Sanford Medical Center Fargo Fargo, North Dakota
Southwest Oncology PC Durango, Colorado	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Sovah Health Martinsville Martinsville, Virginia	Site Public Contact - (sharon.hubbard@lpnt.net)
Spectrum Health at Butterworth Campus Grand Rapids, Michigan	Site Public Contact - (crcwm-regulatory@crcwm.org)
Springfield Clinic Springfield, Illinois
Swedish Cancer Institute-Edmonds Edmonds, Washington	Site Public Contact - (PCRC-NCORP@Swedish.org)
Swedish Cancer Institute-Issaquah Issaquah, Washington	Site Public Contact - (PCRC-NCORP@Swedish.org)
Swedish Medical Center-Ballard Campus Seattle, Washington	Site Public Contact - (PCRC-NCORP@Swedish.org)
Swedish Medical Center-Cherry Hill Seattle, Washington	Site Public Contact - (PCRC-NCORP@Swedish.org)
Swedish Medical Center-First Hill Seattle, Washington	Site Public Contact - (PCRC-NCORP@Swedish.org)
The Carle Foundation Hospital Urbana, Illinois	Site Public Contact - (Research@carle.com)
The Community Hospital Munster, Indiana
ThedaCare Regional Cancer Center Appleton, Wisconsin	Site Public Contact - (ResearchDept@thedacare.org)
TriHealth Cancer Institute-Anderson Cincinnati, Ohio	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
TriHealth Cancer Institute-Westside Cincinnati, Ohio	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Trinity Health Grand Rapids Hospital Grand Rapids, Michigan	Site Public Contact - (crcwm-regulatory@crcwm.org)
Trinity Health IHA Medical Group Hematology Oncology - Brighton Brighton, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology - Canton Canton, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital Chelsea, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus Ypsilanti, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Muskegon Hospital Muskegon, Michigan	Site Public Contact - (crcwm-regulatory@crcwm.org)
Trinity Health Saint Mary Mercy Livonia Hospital Livonia, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
United Hospital Saint Paul, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Unity Hospital Fridley, Minnesota
University of Arkansas for Medical Sciences Little Rock, Arkansas
University of California Davis Comprehensive Cancer Center Sacramento, California
University of Iowa Healthcare Cancer Services Quad Cities Bettendorf, Iowa	Site Public Contact - (kedaprile@rccqc.com)
University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa
University of Michigan Health - Sparrow Lansing Lansing, Michigan	Site Public Contact - (harsha.trivedi@umhsparrow.org)
University of Michigan Health - West Wyoming, Michigan	Site Public Contact - (crcwm-regulatory@crcwm.org)
University of New Mexico Cancer Center Albuquerque, New Mexico	Site Public Contact - (HSC-ClinicalTrialInfo@salud.unm.edu)
University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma	Site Public Contact - (ou-clinical-trials@ouhsc.edu)
University of Rochester Rochester, New York
University of Texas Health Science Center at San Antonio San Antonio, Texas	Site Public Contact - (phoresearchoffice@uthscsa.edu)
VCU Community Memorial Health Center South Hill, Virginia	Site Public Contact - (nemer.elmouallem@vcuhealth.org)
VCU Massey Cancer Center at Stony Point Richmond, Virginia	Site Public Contact - (ctoclinops@vcu.edu)
Valley Radiation Oncology Peru, Illinois
Virginia Cancer Institute Richmond, Virginia	Site Public Contact - (smoore@vacancer.com)
Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia	Site Public Contact - (CTOclinops@vcu.edu)
Wayne Hospital Greenville, Ohio	Site Public Contact - (clinical.trials@daytonncorp.org)
West Michigan Cancer Center Kalamazoo, Michigan	Site Public Contact - (crcwm-regulatory@crcwm.org)
West Virginia University Charleston Division Charleston, West Virginia
Western Illinois Cancer Treatment Center Galesburg, Illinois
Women's Diagnostic Center - Munster Munster, Indiana	Site Public Contact - (mnicholson@comhs.org)
Woodland Memorial Hospital Woodland, California	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Yale University New Haven, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Yale-New Haven Hospital North Haven Medical Center North Haven, Connecticut	Site Public Contact - (canceranswers@yale.edu)

A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation (ATHENA)

Contact(s):

Novo Nordisk - clinicaltrials@novonordisk.com

Principal Investigator:

System ID: NCT06200207

Show full eligibility criteria

Inclusion Criteria:

* Serum high-sensitivity C-reactive protein (hs-CRP) greater than or equal to 2 milligrams per liter (mg/L) at screening (visit 1) * Disease specific - cardiovascular: * N-terminal-pro-brain natriuretic peptide (NT-proBNP) greater than or equal to 225 picograms per milliliter (pg/mL) (375 pg/mL for participants with atrial fibrillation/flutter) at screening * Diagnosis of heart failure (New York heart association (NYHA) Class II-III) * Left ventricular ejection fraction (LVEF) greater than 40 percent documented by echocardiography within 12 months prior to or at screening (visit 1). The LVEF must be documented in medical records and the most recent measurement must be used to determine eligibility with no interim event signalling potential deterioration in ejection fraction (example myocardial infarction (MI) or heart failure (HF) hospitalisation) * Structural heart disease and/or functional heart disease documented by echocardiography within 12 months prior to or at screening (visit 1) showing at least one of the following:
• Left atrial (LA) volume index greater than 34 milliliter per square meter (mL/m\^2)
• LA diameter greater than or equal to 3.8 centimeter (cm)
• LA length greater than or equal to 5.0 cm
• LA area greater than or equal to 20 square centimeter (cm\^2)
• LA volume greater than or equal to 55 milliliter (mL)
• Intraventricular septal thickness greater than or equal to 1.1 cm
• Posterior wall thickness greater than or equal to 1.1 cm
• LV mass index greater than or equal to 115 gram per square meter (g/m\^2) in men or greater than or equal to 95 g/m\^2 in women h) E/e' (mean septal and lateral) greater than or equal to 10 i) e' (mean septal and lateral) less than 9 centimeter per second (cm/s) * No heart failure hospitalisations or urgent heart failure visits between screening and randomisation * Able to perform the 6-minute walk test (6MWT) at screening with a minimum distance of 100 metres * Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score lesser than 80 at screening

Exclusion Criteria:

* Medical conditions - cardiovascular: * Myocardial infarction, stroke, unstable angina pectoris, transient ischaemic attack, or heart failure hospitalisation within 30 days prior to screening (visit 1) * Systolic blood pressure greater than or equal to 180 millimeters of mercury (mmHg) at screening (visit 1). If the systolic blood pressure is 160-179 mmHg, the patient should be receiving greater than or equal to 3 antihypertensive drugs * Heart rate above 110 or below 40 beats per minute as evaluated on the Electrocardiogram (ECG) performed at screening (visit 1) * Planned coronary, carotid or peripheral artery revascularisation known during the screening period (visit 1) * Planned cardiac device or atrial flutter/atrial fibrillation ablation procedure known during the screening period (visit 1) * Major cardiac surgical, non-cardiac surgical, or major endoscopic procedure (thoracoscopic or laparoscopic) within the past 60 days prior to randomisation (visit 2) or any major surgical procedure planned at the time of randomisation (visit 2) * Heart failure due to infiltrative cardiomyopathy (e.g., sarcoid, amyloid), arrhythmogenic right ventricular cardiomyopathy, Takutsubo cardiomyopathy, genetic hypertrophic cardiomyopathy or obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac tamponade, uncorrected more than moderate primary valve disease * Primary pulmonary hypertension, chronic pulmonary embolism, severe pulmonary disease including chronic obstructive pulmonary disease (COPD) * Any other condition judged by the investigator that could account for heart failure symptoms and signs (e.g., anaemia, hypothyroidism) * Medical conditions - infections/immunosuppression: * Clinical evidence of, or suspicion of, active infection at the discretion of the investigator

Interventions: DRUG: Ziltivekimab, DRUG: Placebo

Conditions: Heart Failure, Systemic Inflammation

I'm interested

Share via email

Show 236 locations

Study Locations

Hide all locations

Location	Contacts
"AHEPA" University General Hospital of Thessaloniki Thessaloniki,
"Hygeia" General Hospital of Athens Athens,
"Laiko" General Hospital of Athens Athens,
"Medical Center Hera" EOOD - Sofia Sofia,
"UMHAT "Sveta Anna" Sofia" AD, Clinic of Cardiology Sofia,
"UMHATEM N.I. Pirogov" EAD Sofia,
'G. Gennimatas' General Hospital of Athens Athens,
'G. Gennimatas' General Hospital of Athens Athens,
'Ippokrateio' General Hospital of Thessaloniki Thessaloniki,
10 Wojskowy Szpital Kliniczny z Polikliniką - Samodzielny Publiczny Zakład Opieki Zdrowotnej w Bydgoszczy Bydgoszcz,
4 Wojskowy Szpital Kliniczny Z Poliklinika Samodzielny Publiczny Zaklad Opieki Zdrowotnej We Wroclawiu Wroclaw, Lower Silesian Voivodeship
AMS Cardiology Horsham, Pennsylvania
Advanced Cardiovascular, LLC Alexander City, Alabama
Advara Heartcare Mulgrave, Victoria
Afyonkarahisar Health Sciences University Afyonkarahisar,
Afyonkarahisar Sağlık Bilimleri Üniversitesi Sağlık Uygulama Ve Araştırma Merkezi- Kardiyoloji Afyonkarahisar,
Alexandra General Hospital, Therapeutic Clinic Athens,
All India Institute of Medical Sciences (AIIMS) New Delhi, National Capital Territory of Delhi
All India Institute of Medical Sciences (AIIMS), Bhubaneswar Bhubaneswar, Odisha
All India Institute of Medical Sciences (AIIMS), Nagpur Nagpur, Maharashtra
American Heart of Poland S.A. Zgierz,
American Heart of Poland S.A. Zgierz,
Ankara Sehir Hastanesi Cardiology Ankara,
Ankara Sehir Hastanesi Cardiology Ankara,
B M Birla Heart Research Centre Kolkata, West Bengal
Ballarat Base Hospital Ballarat, Victoria
Ballarat Base Hospital Ballarat, Victoria
Basaksehir Cam ve Sakura Sehir Hastanesi Istanbul,
Bursa Şehir Hastanesi- Kardiyoloji Bursa,
CHLO, EPE - Hospital São Francisco Xavier Lisbon,
CHTâmega e Sousa - Hospital Padre Américo Guilhufe - Penafiel,
CHU de Quebec-Uni Laval-Hotel Québec,
CIPREC Pueyrredon Buenos Aires,
CPS Research Waterloo, Ontario
CPS Research Waterloo, Ontario
Cambridge Cardiac Care Centre Cambridge, Ontario
Cardio and Vascular Assoc-CAVA Bloomfield Hills, Michigan
Cardiology & Medicine Clinic Little Rock, Arkansas
Cardiología Palermo City of Buenos Aires, Buenos Aires
Cardiomedicum Sp. z o.o. Krakow, Lesser Poland Voivodeship
Cardiomedicum Sp. z o.o. Krakow, Lesser Poland Voivodeship
Centre Hospitalier Intercommunal Toulon La Seine-Sur-Mer - Hopital Sainte Musse Toulon,
Centre Hospitalier Regional Universitaire de Tours-Hopital Trousseau Chambray-lès-Tours,
Centre Hospitalier Universitaire de Poitiers Poitiers,
Centre Hospitalier Universitaire de Rennes - Hopital Pontchaillou Rennes,
Centre Hospitalier Universitaire de Rouen-Hopital Charles Nicolle Rouen,
Centro Cardiovascular Salta Salta,
Centro Hospitalar Lisboa Norte Lisbon,
Centro Hospitalar de Setubal Setúbal,
Centro Medico Dra. Laura Maffei e Investigacion Clínica Apli Buenos Aires,
Centro Médico CIMEL Lanús Este, Buenos Aires
Centro de Investigación y Prevención Cardiovascular La Serena,
Centrum Medyczne Intercor Sp. z o.o. Bydgoszcz, Kuyavian-Pomeranian Voivodeship
Chicago Medical Research LLC Hazel Crest, Illinois
Chopda Medicare and Research Centre Pvt. Ltd. Nashik, Maharashtra
Chopda Medicare and Research Centre Pvt. Ltd. Nashik, Maharashtra
Chru de Nancy - Hopital Brabois Vandœuvre-lès-Nancy,
Clearwater Cardiovascular Consultants Largo, Florida
Clearwater Cardiovascular Consultants Largo, Florida
Clinical Advancement Ctr, PLLC San Antonio, Texas
Clinical Advancement Ctr, PLLC San Antonio, Texas
Clinical Research Solutions Inc. Waterloo, Ontario
Clínica Nuevas Tecnologías en Diabetes y Endocrinología Seville,
Complejo Hospitalario Universitario de Santiago Santiago de Compostela,
Consultorio Integral de Atención al Diabético Morón,
Corcare Cardiovascular Research Scarborough Village, Ontario
David Turbay, MD, PLLC El Paso, Texas
Diabetes Heart Research Centre Toronto, Ontario
Diabetes Heart Research Centre Toronto, Ontario
Dr. Ram Manohar Lohia Institute of Medical Sciences Lucknow, Uttar Pradesh
Eastern Shore Rsrch Inst, LLC Fairhope, Alabama
Erciyes University Cardiology Kayseri,
Erciyes University Cardiology Kayseri,
Eskisehir Osmangazi University Sağlık Uygulama ve Arastirma Eskişehir, Odunpazari
Evangelismos Hospital Athens,
Fiona Stanley Hospital Cardiology Murdoch, Western Australia
Formed 2 Sp. z o.o. Oświęcim, Lesser Poland Voivodeship
Fundación para la Investigación del Hospital Clínico de Valencia (INCLIVA) Valencia,
Futuremeds Birmingham,
G B Pant Institute of Postgraduate Medical Education and Research New Delhi, National Capital Territory of Delhi
G B Pant Institute of Postgraduate Medical Education and Research New Delhi, National Capital Territory of Delhi
GA Arrhythmia Cons & Rsch Inst Macon, Georgia
Ganesh Shankar Vidyarthe Memorial (GSVM) Medical College Kanpur, Uttar Pradesh
Ganesh Shankar Vidyarthe Memorial (GSVM) Medical College Kanpur, Uttar Pradesh
Gen Hospital of Thessaloniki G.Papanikolaou,Cardiology Dpt Thessaloniki,
General Hospital of Chalkida Chalcis,
General Hospital of Chios "Skilitsio" Chios,
Gesundheitscentrum Mainz (Regner / Schmitt) Mainz,
Guru Nanak CARE Hospitals Hyderabad, Telangana
Hospital Gregorio Maranon Madrid,
Hospital Raja Perempuan Zainab II Kelantan,
Hospital Raja Perempuan Zainab II Kelantan,
Hospital Raja Permaisuri Bainun Ipoh Ipoh, Perak
Hospital Ramon Y Cajal Madrid,
Hospital Serdang Kajang, Selangor
Hospital Sultanah Aminah Johor Bahru, Johor
Hospital Sultanah Aminah Johor Bahru, Johor
Hospital Sultanah Bahiyah Alor Setar, Kedah,
Hospital Tengku Ampuan Afzan Kuantan, Pahang
Hospital Universitario Puerta de Hierro Majadahonda Majadahonda,
Hospital Universitario de Salamanca Salamanca,
Hospital Universitario de Salamanca Salamanca,
Hospital Virgen del Camino - Sanlúcar de Barrameda Sanlúcar de Barrameda,
Hospital Vithas Sevilla Seville,
Hospital da Luz Lisbon,
Illawarra Heart Health Centre Wollongong, New South Wales
Ind. Prak. Lek. w dziedz. Kardiologii lek. med. K. Cymerman Gdynia, Pomeranian Voivodeship
Innera s.r.o. Benešov,
Institut de Cardiologie de Montreal Montreal, Quebec
Instituto de Investigaciones Clinicas Quilmes SRL Buenos Aires,
Investigaciones Clínicas Tucumán San Miguel de Tucumán, Tucumán.,
Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) Puducherry, Tamil Nadu
Jawaharlal Nehru Medical College and Hospital Aligarh, Uttar Pradesh
Jawaharlal Nehru Medical College and Hospital Aligarh, Uttar Pradesh
John Hunter Hospital New Lambton Heights, New South Wales
John Hunter Hospital - Cardiovascular Department New Lambton Heights, New South Wales
KLE's Dr. Prabhakar Kore Hospital & Medical Research Centre Karnataka,
KLE's Dr. Prabhakar Kore Hospital & Medical Research Centre Karnataka,
Kansas City VA Medical Center Kansas City, Missouri
Kansas City VA Medical Center Kansas City, Missouri
Kardio Life Włocławek, Kuyavian-Pomeranian Voivodeship
Kardio Life Włocławek, Kuyavian-Pomeranian Voivodeship
Kardiologicka ambulance Brno s.r.o. Brno,
Kardiologie Trutnov Ferkl Trutnov,
Kardiologisch-Angiologische Praxis Herzzentrum Bremen Bremen,
Kardiopraxis Schirmer Kaiserslautern,
Kasturba Medical College and Hospital, Manipal Udupi, Karnataka
Kasturba Medical College and Hospital, Manipal Udupi, Karnataka
Kath. Hospitalvereinigung Thüringen gGmbH - KKH St. Johann Nepomuk - Innere Med. II Erfurt,
King George Hospital Visakhapatnam, Andhra Pradesh
Kocaeli Universitesi Tip Fakultesi Hastanesi Kocaeli,
Konstantopouleio G.H. of Athens, "Agia Olga" Athens,
Linden sp. z o.o. sp. k. Krakow, Lesser Poland Voivodeship
Long Island Cardiovascular Consultants PC Lake Success, New York
MD Medical Research Oxon Hill, Maryland
MEDICON a.s. Prague,
MHAT "Puls" AD Cardiology Department Blagoevgrad,
MHAT Haskovo AD Haskovo,
MHAT Heart and Brain Pleven,
MVZ CCB Frankfurt Und Main-Taunus GbR Frankfurt,
MVZ im Altstadt-Carree Fulda GmbH - Zentrum für klinische Studien Fulda,
Malla Reddy Narayana Multispeciality Hospital Hyderabad, Telangana
Manipal Hospital, Mysuru Mysuru, Karnataka
Maryland Cardiovascular Specialists - Baltimore Baltimore, Maryland
Medical Center Synexus Sofia Sofia,
Medical center ISUL - Tsaritsa Yoanna EOOD Sofia,
Metropolitan General Hospital Healthcare Facilities Operation And Management Single Member S.A. Athens,
Millennium Cardiology Farmington Hills, Michigan
Montreal General Hospital Montreal, Quebec
Mount Sinai Hosp at NYC New York, New York
Naval Hospital of Athens Athens,
Naval Hospital of Athens Athens,
Nemocnice AGEL Třinec-Podlesí a.s. Třinec,
Ninewells Hospital Dundee,
Northwell Health Phys Cardio Riverhead, New York
Northwest Heart Center Tomball, Texas
Ocala Cardiovascular Research Ocala, Florida
Ordinace pro choroby srdce Chomutov,
Ormond Beach Clinical Research Ormond Beach, Florida
Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji Warsaw,
Peterborough City Hospital Peterborough, PTE
PharmaTex Research Amarillo, Texas
PharmaTex Research Amarillo, Texas
Polyclinique Vauban Valenciennes,
Pratia S.A. Jelenia Góra, Lower Silesian Voivodeship
Private Practice Leadership LLC. Katy, Texas
Prywatna Praktyka Lekarska Anna Chudoba Żyrardów, Masovian Voivodeship
Raigmore Hospital Inverness,
Rajiv Gandhi Super Speciality Hospital New Delhi, National Capital Territory of Delhi
Renown Regional Medical Center Reno, Nevada
Rhythm Heart Institute Vadodara, Gujarat
S.P. Medical College & Associated Group of Hospitals Bikaner, Rajasthan
Samodzielny Publiczny Zaklad Opieki Zdrowotnej W Pulawach Puławy, Lublin Voivodeship
Sanatorio Esperanza Esperanza, Santa Fe,
Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow, Uttar Pradesh
Saul Vizel Pro. Med. Corp Cambridge, Ontario
Sengupta Hospital and Research Institute Nagpur, Maharashtra
Sentara Health Research Center Norfolk, Virginia
Sherman Clinical Research Sherman, Texas
Siddhartha Medical College & Government General Hospital Vijaywada, Andhra Pradesh
Sir Ganga Ram Hospital New Delhi, National Capital Territory of Delhi
Sismanogleio General Hospital Marousi,
South California Heart Spc Pasadena, California
Sri Jayadeva Institute of Cardiovascular Sciences & Research Bengaluru, Karnataka
Sri Jayadeva Institute of Cardiovascular Sciences & Research Bengaluru, Karnataka
St John's Medical College Hospital Bengaluru, Karnataka
St John's Medical College Hospital Bengaluru, Karnataka
St Johns Ctr Clin Rsch-St. Aug Saint Augustine, Florida
St. Richards Hospital_Cardiology Chichester, West Sussex
Svitavska nemocnice Kardiologie Svitavy,
Szpitale Pomorskie Sp. z o.o. Gdynia, Pomeranian Voivodeship
Szpitale Pomorskie Sp. z o.o. Gdynia, Pomeranian Voivodeship
T.C. Saglık Bakanlıgı Adana Sehir Egitim ve Arastirma Hastan Adana,
T.C. Saglık Bakanlıgı Adana Sehir Egitim ve Arastirma Hastan Adana,
The Canberra Hospital_Garran Garran, Australian Capital Territory
The Cardiologists Pty Ltd Epping, Victoria
The Cardiologists Pty Ltd Epping, Victoria
The Prince Charles Hospital Chermside, Queensland
The Prince Charles Hospital Chermside, Queensland
Trakya University Edirne,
Trakya University Edirne,
Trialmed Sp. z o. o. Piotrkow Trybunalski,
Trialmed Sp. z o. o. Piotrkow Trybunalski,
U.G.H of Athens "Attikon" Chaidari, Athens,
U.G.H of Athens "Attikon" Chaidari, Athens,
UCI Health Orange, California
UMHAT Sveti Georgi EAD, Plovdiv, Clinic of Cardiology Plovdiv,
Uniklinik TU Dresden - Herzzentrum Dresden GmbH Dresden,
Univ Gen Hospital Larisa, Cardiology Medicine Clinic Larissa/Thessaly, Greece
University Malaya Medical Centre Kuala Lumpur,
University Malaya Medical Centre Kuala Lumpur,
University of Calgary_Calgary Calgary, Alberta
University of North Carolina at Chapel Hill Chapel Hill, North Carolina
University of Pennsylvania Hospital Philadelphia, Pennsylvania
University of Texas Southwestern Medical Center Dallas, Texas
Universitätsklinikum Freiburg - Medical Center Freiburg im Breisgau,
Universitätsklinikum des Saarlandes - Innere Med. III Homburg,
Uniwersytecki Szpital Kliniczny W Poznaniu Poznan,
Uniwersytecki Szpital Kliniczny W Poznaniu Poznan,
Uniwersytecki Szpital Kliniczny nr 2 Uniwersytetu Medycznego w Łodzi Lodz,
Uniwersytecki Szpital Kliniczny w Bialymstoku Bialystok,
Uniwersytecki Szpital Kliniczny w Bialymstoku Bialystok,
UofL Health Care Outpatient Louisville, Kentucky
Valley Clinical Trials, Inc. Northridge, California
Valley Clinical Trials, Inc. Northridge, California
Vardhaman Mahavir Medical College & Safdarjung Hospital New Delhi, National Capital Territory of Delhi
Velocity Clin Rsrch - Savannah Savannah, Georgia
Vijan Hospital & Research Centre Nashik, Maharashtra
Vijan Hospital & Research Centre Nashik, Maharashtra
Villoo Poonawalla Memorial Hospital Pune, Maharashtra
Virginia Commonwealth University Richmond, Virginia
Vojenská nemocnice Brno p.o. Brno,
Washington University St Louis, Missouri
Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika Lodz, Łódź Voivodeship
Zanamed Medical Clinic Sp. z o.o. Lublin,
Zentrum fuer klinische Studien Suedbrandenburg GmbH Elsterwerda,

Global Prospective, Observational Cohort of Adult Patients With Primary Sclerosing Cholangitis (WIND-PSC Study) (WIND-PSC)

Contact(s):

Stephen Rossi, PharmD - stephen@pscpartners.org

Principal Investigator:

System ID: NCT06297993

Show full eligibility criteria

Inclusion Criteria:

• Adult patients between 18 and 75 years of age (inclusive) who can comprehend instructions, follow the study procedures and are willing to sign an Informed Consent Form (ICF).
• Confirmed clinical diagnosis of large duct PSC.

Exclusion Criteria:

• Clinically significant acute or chronic liver disease of an etiology other than PSC (including but not limited to metabolic-dysfunction associated steatohepatitis (MASH), PBC, HCV, HBV, or alcoholic hepatitis, Wilson's disease, alpha-1 antitryp-sin deficiency, acute or chronic drug-induced liver injury) * Patients with PSC and elements of AIH overlap are allowed to enroll * Patients with metabolic dysfunction associated steatotic liver disease (MASLD) or benign steatosis are allowed to enroll
• Small-Duct PSC.
• Clinically diagnosed secondary or IgG4-related sclerosing cholangitis.
• Clinically diagnosed infections (including acute cholangitis) and receiving treatment within the past 7 days; patients on chronic suppressive antibiotics for acute cholangitis will be allowed to enroll
• Hospitalization in the past 7 days
• UDCA dose \>28 mg/kg
• Evidence of current or historical decompensated cirrhosis based on the following clinical events: * Ascites \> Grade 2 and requiring treatment * Esophageal or gastric variceal bleeding requiring hospitalization * Hepatic encephalopathy (as defined by a West Haven score ≥ 2) * Spontaneous bacterial peritonitis defined as ascites absolute neutrophil count \>250/mm3 in the absence of an intra-abdominal source of infection * AKI-HRS according to AASLD Guidelines (Flamm 2021) * Portal hypertension based on a platelet count \< 150 × 109/L and LSM \> 15 kPa with clinical, laboratory, imaging and/or other relevant parameters
• Prior liver transplantation
• MELD 3.0 Score \>15. For subjects on anticoagulation medication, baseline INR determination for MELD score calculation should take this use into account.
• History, evidence, or high suspicion of hepatobiliary malignancies or active colon cancer based on imaging, screening laboratory values, and/or clinical symptoms. Patients with a history of colon cancer who have undergone a colectomy and have no current evidence of colon cancer will be allowed to enroll in the study.
• Participants with current clinical or laboratory evidence of any severe, progressive, or uncontrolled disease, related or unrelated to PSC and which, in the opinion of the investigator, has an expected survival of less than 52 weeks.
• Participants who are impaired, incapacitated, or incapable of completing study-related assessments or giving informed consent.
• Prisoners or participants who are involuntarily incarcerated.
• Participants who are currently participating in an investigational PSC therapy clinical study or who have participated in such a study within the past 12 weeks
• Absence of data in medical records to assess inclusion and exclusion criteria.

Conditions: PSC

I'm interested

Share via email

Show 13 locations

Study Locations

Hide all locations

Location	Contacts
Auckland University Auckland,	Yuliya Evdokimova - (yuliya@adhb.govt.nz)
California Pacific Medical Center San Francisco, California	Stefanie Roberts, BS - (stefanie.roberts@sutterhealth.org)
Indiana University Indianapolis, Indiana	Rebecca Gerstorff - (rebgerst@iu.edu)
Massachusetts General Hospital Boston, Massachusetts	Shruti Patel - (spatel172@mgb.org)
Mayo Clinic Jacksonville, Florida	Paige Powrie - (Powrie.Paige@mayo.edu)
Schiff Center for Liver Diseases / University of Miami Miami, Florida	Cynthia Levy, MD - (clevy@med.miami.edu)
UC Davis Sacramento, California	Richard Dean - (rjdean@ucdavis.edu)
University Health Network Toronto, Ontario	Madeline Cameron, HBsc, CRC - (madeline.cameron@uhn.ca)
University Medical Center Hamburg-Eppendorf Hamburg, City state of Hamburg	Jan-Philipp Weltzsch, MD - (j.weltzsch@uke.de)
University of Alberta Edmonton, Alberta	Rebecca Miller - (rebecca.gildr@ualberta.ca)
University of California, San Francisco San Francisco, California	Fawzy Barry - (fawzy.barry@ucsf.edu)
Virginia Commonwealth University Richmond, Virginia	Caitlin Hurst, BS - (caitlin.hurst@vcuhealth.org)
Yale University New Haven, Connecticut	Suzie Christopher - (suzie.christopher@yale.edu)

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)

Contact(s):

Director Regulatory Affairs - langerj@nrgoncology.org

Principal Investigator:

System ID: NCT05879926

Show full eligibility criteria

Inclusion Criteria:

* A patient cannot be considered eligible for this study unless ALL of the following conditions are met. * The patient or a legally authorized representative must provide study-specific informed consent prior to pre-entry and, for patients treated in the U.S., authorization permitting release of personal health information. * Female patients must be greater than or equal to 18 years of age. * Patients must be premenopausal (evidence of functioning ovaries) at the time of pre-entry. For study purposes, premenopausal is defined as: * Age 50 years or under with spontaneous menses within 12 months; or * Age greater than 50-60 years with spontaneous menses within 12 months plus follicle-stimulating hormone (FSH) and estradiol levels in the premenopausal range; or * Patients with amenorrhea due to IUD or prior uterine ablation must have FSH and estradiol levels in the premenopausal range; or * Patients with prior hysterectomy must have FSH and estradiol levels in the premenopausal range. * The patient must have an ECOG performance status of less than or equal to 2 (or Karnofsky greater than or equal to 60%). * Patients may have ipsilateral or contralateral synchronous breast cancer if the highest stage tumor meets entry criteria, and the other sites of disease would not require chemotherapy or HER2-directed therapy. * Patients may have multicentric or multifocal breast cancer if the highest stage tumor meets entry criteria, and the other sites of disease would not require chemotherapy or HER2-directed therapy. * Patient may have undergone a total mastectomy, skin-sparing mastectomy, nipple-sparing mastectomy, or a lumpectomy. * For patients who undergo a lumpectomy, the margins of the resected specimen or re-excision must be histologically free of invasive tumor and DCIS (ductal carcinoma in situ) with no ink on tumor as determined by the local pathologist. If pathologic examination demonstrates tumor at the line of resection, additional excisions may be performed to obtain clear margins. Positive posterior margin is allowed if surgeon deems no further resection possible. (Patients with margins positive for LCIS (lobular carcinoma in situ) are eligible without additional resection.) * For patients who undergo mastectomy, the margins must be free of residual gross tumor. (Patients with microscopic positive margins are eligible if post-mastectomy RT (radiation therapy) of the chest wall will be administered.) * Patient must have undergone axillary staging with sentinel node biopsy (SNB), targeted axillary dissection (TAD), or axillary lymph node dissection (ALND). * The following staging criteria must be met postoperatively according to AJCC 8th edition criteria: * By pathologic evaluation, primary tumor must be pT1-3. (If N0, must be T1c or higher.) * By pathologic evaluation, ipsilateral nodes must be pN0 or pN1 (pN1mi, pN1a, pN1b, pN1c). * Patients with positive isolated tumor cells (ITCs) in axillary nodes will be considered N0 for eligibility purposes. * Patients with micrometastatic nodal involvement (0.2-2 mm) will be considered N1. * Oncotype DX RS (recurrence score) requirements\*: * If node-negative: * Oncotype DX RS must be RS 21-25, or * Oncotype DX RS must be 16-20 and disease must be high clinical risk, defined as: low histologic grade with primary tumor size greater than 3 cm, intermediate histologic grade with primary tumor size greater than 2 cm, or high histologic grade with primary tumor size greater than 1 cm. * If 1-3 nodes involved: * Oncotype DX RS must be less than 26. \* Patients with a "Low Risk" or "MP1" MammaPrint (a genomic test that analyzes the activity of certain genes in early-stage breast cancer) result must have eligibility assessed with an Oncotype DX RS at pre-entry (see Section 3.1). Blocks or unstained slides must be sent to the Genomic Health centralized laboratory for testing at no cost to these patients. If MammaPrint High Risk or MP2, these patients are not eligible. * The tumor must be ER and/or PgR-positive (progesterone receptor) by current ASCO/CAP guidelines based on local testing results. Patients with greater than or equal to 1% ER and/or PgR staining by IHC will be classified as positive. * The tumor must be HER2-negative by current ASCO/CAP (American Society of Clinical Oncology/College of American Pathologists) guidelines based on local testing results. * The interval between the last surgery for breast cancer (including re-excision of margins) and pre-entry must be no more than 16 weeks. * Short course of endocrine therapy of less than 6 weeks duration before pre-entry is acceptable either as neoadjuvant or adjuvant therapy. An Oncotype DX RS must be performed on core biopsy specimen obtained prior to initiation of neoadjuvant endocrine therapy if received. * Patients with a prior or concurrent non-breast malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. This would include prior cancers treated with curative intent. * HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. * Radiation therapy should be used according to standard guidelines; the intended radiation therapy should be declared prior to pre-entry.

Exclusion Criteria:

* • Definitive clinical or radiologic evidence of metastatic disease. * pT4 (pathological state) tumors, including inflammatory breast cancer. * History of ipsilateral or contralateral invasive breast cancer. (Patients with synchronous and/or previous DCIS or LCIS are eligible.) * If prior ipsilateral DCIS was treated with lumpectomy and XRT (ionizing radiation therapy), a mastectomy must have been performed for the current cancer. * Life expectancy of less than 10 years due to co-morbid conditions in the opinion of the investigator. Known results from most recent lab studies obtained as part of routine care prior to study entry showing ANY of the following values: * ANC (absolute neutrophil count) less than 1200/mm3; * Platelet count less than 100,000/mm3; * Hemoglobin less than 10 g/dL; * Total bilirubin greater than ULN (upper limit of normal) for the lab or greater than 1.5 x ULN for patients who have a bilirubin elevation due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin; * AST(aspartate aminotransferase)(SGOT)/ALT (alanine transminase)(SGPT): greater than 3 × institutional ULN; * Renal function of GFR (glomular filtration rate) less than 30 mL/min/1.73m2. * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better. * Non-epithelial breast malignancies such as sarcoma or lymphoma. * Any treatment with radiation therapy, chemotherapy, or biotherapy administered for the currently diagnosed breast cancer prior to pre-entry. (Patients with prior ET of more than 6 weeks duration for treatment of this cancer are not eligible.) Prior tamoxifen given for breast cancer prevention is allowed. Prior AI or GnRH for fertility preservation is allowed. * Hormonally based contraceptive measures must be discontinued prior to pre-entry (including progestin/progesterone IUDs). * Patients with evidence of chronic hepatitis B virus (HBV) infection are ineligible unless the HBV viral load is undetectable on suppressive therapy. Patients with a history of hepatitis C virus (HCV) infection are ineligible unless they have been treated and cured or have an undetectable HCV viral load if still on active therapy. * Pregnancy or lactation at the time of pre-entry. (Note: Pregnancy testing according to institutional standards for women of childbearing potential must be performed within 2 weeks prior to pre-entry.) * Other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements or interfere with interpretation of study results.

Interventions: DRUG: Ovarian Function Suppression + Aromatase Inhibitor, DRUG: Adjuvant Chemotherapy + Ovarian Function Suppression

Conditions: Breast Cancer

I'm interested

Share via email

Show 1175 locations

Study Locations

Hide all locations

Location	Contacts
AMG Crystal Lake - Oncology Crystal Lake, Illinois	Site Public Contact - (advocateresearch@advocate.com)
AMG Libertyville - Oncology Libertyville, Illinois	Site Public Contact - (advocateresearch@advocatehealth.com)
Abbott-Northwestern Hospital Minneapolis, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Adams Cancer Center Gettysburg, Pennsylvania
Addison Gilbert Hospital Gloucester, Massachusetts
Advanced Breast Care Center PLLC Warren, Michigan
AdventHealth Altamonte Altamonte Springs, Florida
AdventHealth Littleton Littleton, Colorado
AdventHealth Orlando Orlando, Florida	Site Public Contact - (FH.Cancer.Research@flhosp.org)
AdventHealth Parker Parker, Colorado
AdventHealth Porter Denver, Colorado
Advocate Christ Medical Center Oak Lawn, Illinois
Advocate Good Samaritan Hospital Downers Grove, Illinois	Site Public Contact - (Barbara.barhamand@advocatehealth.com)
Advocate Good Shepherd Hospital Barrington, Illinois
Advocate High Tech Medical Park Palos Heights, Illinois	Site Public Contact - (ncorp@aah.org)
Advocate Illinois Masonic Medical Center Chicago, Illinois
Advocate Lutheran General Hospital Park Ridge, Illinois
Advocate Outpatient Center - Aurora Aurora, Illinois	Site Public Contact - (ncorp@aah.org)
Advocate Outpatient Center - Oak Lawn Oak Lawn, Illinois	Site Public Contact - (ncorp@aah.org)
Advocate Sherman Hospital Elgin, Illinois
Advocate South Suburban Hospital Hazel Crest, Illinois
Alaska Breast Care and Surgery LLC Anchorage, Alaska	Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org)
Alaska Oncology and Hematology LLC Anchorage, Alaska	Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org)
Alaska Women's Cancer Care Anchorage, Alaska	Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org)
Alegent Health Bergan Mercy Medical Center Omaha, Nebraska	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Alegent Health Immanuel Medical Center Omaha, Nebraska	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Alegent Health Lakeside Hospital Omaha, Nebraska	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Alegent Health Mercy Hospital Council Bluffs, Iowa
Allegheny General Hospital Pittsburgh, Pennsylvania
Allegiance Health Jackson, Michigan	Site Public Contact - (CTOResearch@hfhs.org)
Alliance for Childhood Diseases/Cure 4 the Kids Foundation Las Vegas, Nevada	Site Public Contact - (research@sncrf.org)
Alta Bates Summit Medical Center-Herrick Campus Berkeley, California	Site Public Contact - (clinicalresearch@sutterhealth.org)
Anchorage Associates in Radiation Medicine Anchorage, Alaska	Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org)
Anchorage Oncology Centre Anchorage, Alaska
Anchorage Radiation Therapy Center Anchorage, Alaska
Ann M Wierman MD LTD Las Vegas, Nevada	Site Public Contact - (research@sncrf.org)
Annie Penn Memorial Hospital Reidsville, North Carolina	Site Public Contact - (stacey.phelps@conehealth.com)
Armes Family Cancer Center Findlay, Ohio
Aspirus Cancer Care - James Beck Cancer Center Rhinelander, Wisconsin	Site Public Contact - (Beth.Knetter@aspirus.org)
Aspirus Cancer Care - Stevens Point Stevens Point, Wisconsin	Site Public Contact - (Beth.Knetter@aspirus.org)
Aspirus Cancer Care - Wisconsin Rapids Wisconsin Rapids, Wisconsin
Aspirus Medford Hospital Medford, Wisconsin	Site Public Contact - (Beth.Knetter@aspirus.org)
Aspirus Regional Cancer Center Wausau, Wisconsin
Asplundh Cancer Pavilion Willow Grove, Pennsylvania	Site Public Contact - (ONCTrialNow@jefferson.edu)
Atrium Health Cabarrus/LCI-Concord Concord, North Carolina
Atrium Health Cleveland/LCI-Cleveland Shelby, North Carolina
Atrium Health Lincoln/LCI-Lincolnton Lincolnton, North Carolina
Atrium Health Pineville/LCI-Pineville Charlotte, North Carolina
Atrium Health Stanly/LCI-Albemarle Albemarle, North Carolina
Atrium Health Union/LCI-Union Monroe, North Carolina
Atrium Health University City/LCI-University Charlotte, North Carolina
Atrium Medical Center-Middletown Regional Hospital Franklin, Ohio	Site Public Contact - (clinical.trials@daytonncorp.org)
Augusta Health Center for Cancer and Blood Disorders Fishersville, Virginia
Augusta Oncology Associates PC-D'Antignac Augusta, Georgia
Augusta Oncology Associates PC-Wheeler Augusta, Georgia
Aultman Alliance Community Hospital Alliance, Ohio
Aultman Health Foundation Canton, Ohio	Site Public Contact - (ClinicalReserachDept@aultman.com)
Aurora Bay Area Medical Group-Marinette Marinette, Wisconsin	Site Public Contact - (ncorp@aurora.org)
Aurora BayCare Medical Center Green Bay, Wisconsin	Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Grafton Grafton, Wisconsin	Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Kenosha South Kenosha, Wisconsin	Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Milwaukee Milwaukee, Wisconsin	Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Milwaukee West Wauwatosa, Wisconsin	Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Racine Racine, Wisconsin	Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Southern Lakes VLCC Burlington, Wisconsin	Site Public Contact - (ncorp@aurora.org)
Aurora Health Care Germantown Health Center Germantown, Wisconsin	Site Public Contact - (ncorp@aurora.org)
Aurora Medical Center in Summit Summit, Wisconsin	Site Public Contact - (ncorp@aurora.org)
Aurora Saint Luke's Medical Center Milwaukee, Wisconsin	Site Public Contact - (ncorp@aurora.org)
Aurora Saint Luke's South Shore Cudahy, Wisconsin	Site Public Contact - (ncorp@aurora.org)
Aurora Sinai Medical Center Milwaukee, Wisconsin	Site Public Contact - (ncorp@aurora.org)
Aurora West Allis Medical Center West Allis, Wisconsin	Site Public Contact - (ncorp@aurora.org)
Avera Cancer Institute Sioux Falls, South Dakota	Site Public Contact - (OncRegulatory@avera.org)
Avera Cancer Institute - Mitchell Mitchell, South Dakota	Site Public Contact - (OncRegulatory@avera.org)
Avera Cancer Institute at Pierre Pierre, South Dakota	Site Public Contact - (OncRegulatory@avera.org)
Avera Cancer Institute at Yankton Yankton, South Dakota	Site Public Contact - (OncRegulatory@avera.org)
Avera Cancer Institute-Aberdeen Aberdeen, South Dakota	Site Public Contact - (oncregulatory@avera.org)
BJC Outpatient Center at Sunset Hills Sunset Hills, Missouri
Baptist Cancer Center-Grenada Grenada, Mississippi	Site Public Contact - (BCCclintrials@bmhcc.org)
Baptist Health Corbin Corbin, Kentucky
Baptist Health Floyd New Albany, Indiana	Site Public Contact - (Roster@nrgoncology.org)
Baptist Health Hamburg Lexington, Kentucky
Baptist Health Hardin Elizabethtown, Kentucky
Baptist Health Lexington Lexington, Kentucky
Baptist Health Louisville Louisville, Kentucky	Site Public Contact - (Cbcresearch@bhsi.com)
Baptist Health Paducah Paducah, Kentucky
Baptist MD Anderson Cancer Center Jacksonville, Florida
Baptist Memorial Hospital and Cancer Center-Collierville Collierville, Tennessee	Site Public Contact - (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Desoto Southhaven, Mississippi	Site Public Contact - (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Golden Triangle Columbus, Mississippi	Site Public Contact - (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Memphis Memphis, Tennessee	Site Public Contact - (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Oxford Oxford, Mississippi	Site Public Contact - (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Union County New Albany, Mississippi	Site Public Contact - (BCCclintrials@bmhcc.org)
Bay Area Hospital Coos Bay, Oregon	Site Public Contact - (cherie.cox@bayareahospital.org)
Bayhealth Hospital Kent Campus Dover, Delaware	Site Public Contact - (clinical_trials@bayhealth.org)
Bayhealth Hospital Sussex Campus Milford, Delaware	Site Public Contact - (clinical_trials@bayhealth.org)
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center Houston, Texas	Site Public Contact - (burton@bcm.edu)
Baystate Medical Center Springfield, Massachusetts	Site Public Contact - (tamara.wrenn@baystatehealth.org)
Beacon Kalamazoo Kalamazoo, Michigan
Beacon Kalamazoo Cancer Center Kalamazoo, Michigan
Beebe Health Campus Rehoboth Beach, Delaware	Site Public Contact - (research@beebehealthcare.org)
Beebe Medical Center Lewes, Delaware	Site Public Contact - (research@beebehealthcare.org)
Beebe South Coastal Health Campus Millville, Delaware	Site Public Contact - (research@beebehealthcare.org)
Bellin Memorial Hospital Green Bay, Wisconsin
Ben Taub General Hospital Houston, Texas
Benefis Sletten Cancer Institute Great Falls, Montana	Site Public Contact - (mccinfo@mtcancer.org)
Beth Israel Deaconess Medical Center Boston, Massachusetts
Beth Israel Deaconess Medical Center/Winchester Center for Cancer Care Winchester, Massachusetts
Bethesda North Hospital Cincinnati, Ohio	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Beverly Hospital Beverly, Massachusetts
Beverly Hospital Cancer Center at Anna Jaques Newburyport, Massachusetts
Bhadresh Nayak MD PC-Sterling Heights Sterling Heights, Michigan
Billings Clinic Cancer Center Billings, Montana	Site Public Contact - (research@billingsclinic.org)
Billings Clinic-Cody Cody, Wyoming	Site Public Contact - (research@billingsclinic.org)
Blanchard Valley Hospital Findlay, Ohio
Bon Secours Cancer Institute at Reynolds Crossing Richmond, Virginia	Site Public Contact - (Anne_caramella@bshsi.org)
Bon Secours Memorial Regional Medical Center Mechanicsville, Virginia	Site Public Contact - (anne_carmellat@bshsi.org)
Bon Secours Richmond Community Hospital Richmond, Virginia	Site Public Contact - (anne_carmellat@bshsi.org)
Bon Secours Saint Francis Medical Center Midlothian, Virginia	Site Public Contact - (anne_carmellat@bshsi.org)
Bon Secours Saint Mary's Hospital Richmond, Virginia	Site Public Contact - (anne_carmellat@bshsi.org)
Bon Secours Westchester Emergency Center Midlothian, Virginia	Site Public Contact - (anne_carmellat@bshsi.org)
Bozeman Health Deaconess Hospital Bozeman, Montana	Site Public Contact - (mccinfo@mtcancer.org)
Bronson Battle Creek Battle Creek, Michigan	Site Public Contact - (crcwm-regulatory@crcwm.org)
Bronson Methodist Hospital Kalamazoo, Michigan	Site Public Contact - (crcwm-regulatory@crcwm.org)
Bryn Mawr Hospital Bryn Mawr, Pennsylvania	Site Public Contact - (turzoe@mlhs.org)
CARTI Cancer center Little Rock, Arkansas	Site Public Contact - (Research@CARTI.com)
CHI Health Good Samaritan Kearney, Nebraska	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
CHI Health Saint Francis Grand Island, Nebraska	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
CHRISTUS Highland Medical Center Shreveport, Louisiana	Site Public Contact - (Nancy.hassan@christushealth.org)
CHU de Quebec-Hopital du Saint-Sacrement (HSS) Québec, Quebec	Site Public Contact - (jbegin@uresp.ulaval.ca)
CHUM - Centre Hospitalier de l'Universite de Montreal Montreal, Quebec	Site Public Contact - (info.cr.chum@ssss.gouv.qc.ca)
California Pacific Medical Center-Pacific Campus San Francisco, California	Site Public Contact - (clinicalresearch@sutterhealth.org)
Camden Clark Medical Center Parkersburg, West Virginia	Site Public Contact - (cancertrialsinfo@hsc.wvu.edu)
Cancer Care Associates PC Royal Oak, Michigan
Cancer Care Associates of York York, Pennsylvania
Cancer Care Center of O'Fallon O'Fallon, Illinois	Site Public Contact - (morganthaler.jodi@mhsil.com)
Cancer Care Northwest - Spokane South Spokane, Washington	Site Public Contact - (research@ccnw.net)
Cancer Care Northwest-North Spokane Spokane, Washington	Site Public Contact - (research@ccnw.net)
Cancer Care Northwest-Valley Spokane, Washington	Site Public Contact - (research@ccnw.net)
Cancer Care Specialists of Illinois - Decatur Decatur, Illinois	Site Public Contact - (morganthaler.jodi@mhsil.com)
Cancer Center at Saint Joseph's Phoenix, Arizona	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Cancer Center of Western Wisconsin New Richmond, Wisconsin	Site Public Contact - (mmcorc@healthpartners.com)
Cancer Center-Metro Medical Center Bayamon Bayamón,
Cancer Centers of Southwest Oklahoma Research Lawton, Oklahoma
Cancer Hematology Centers - Flint Flint, Michigan	Site Public Contact - (wstrong@ghci.org)
Cancer and Blood Specialists-Henderson Henderson, Nevada	Site Public Contact - (research@sncrf.org)
Cancer and Hematology Centers of Western Michigan - Norton Shores Norton Shores, Michigan	Site Public Contact - (connie.szczepanek@crcwm.org)
Capital Health Medical Center-Hopewell Pennington, New Jersey	Site Public Contact - (clinicaltrials@capitalhealth.org)
Carle BroMenn Medical Center Normal, Illinois	Site Public Contact - (Research@Carle.com)
Carle Cancer Center Urbana, Illinois	Site Public Contact - (Research@carle.com)
Carle Cancer Institute Normal Normal, Illinois	Site Public Contact - (Research@Carle.com)
Carle Physician Group-Effingham Effingham, Illinois	Site Public Contact - (Research@carle.com)
Carle Physician Group-Mattoon/Charleston Mattoon, Illinois	Site Public Contact - (Research@carle.com)
Carle at The Riverfront Danville, Illinois	Site Public Contact - (Research@Carle.com)
Caro Cancer Center Caro, Michigan
Carolinas Medical Center/Levine Cancer Institute Charlotte, North Carolina
Carson Tahoe Regional Medical Center Carson City, Nevada	Site Public Contact - (research@sncrf.org)
Castle Medical Center Kailua, Hawaii
Cedars Sinai Medical Center Los Angeles, California
Cedars-Sinai Cancer - Tarzana Tarzana, California
Centra Alan B Pearson Regional Cancer Center Lynchburg, Virginia	Site Public Contact - (Kevin.Patel@centrahealth.com)
Central Care Cancer Center - Bolivar Bolivar, Missouri	Site Public Contact - (aroland@kccop.org)
Central Care Cancer Center - Garden City Garden City, Kansas	Site Public Contact - (aroland@kccop.org)
Central Care Cancer Center - Great Bend Great Bend, Kansas	Site Public Contact - (aroland@kccop.org)
Central Vermont Medical Center/National Life Cancer Treatment Berlin Corners, Vermont
Centralia Oncology Clinic Centralia, Illinois	Site Public Contact - (morganthaler.jodi@mhsil.com)
Centre Hospitalier Universitaire de Sherbrooke-Fleurimont Sherbrooke, Quebec	Site Public Contact - (crcinformation.chus@ssss.gouv.qc.ca)
Centro Comprensivo de Cancer de UPR San Juan,	Site Public Contact - (Roster@nrgoncology.org)
Chambersburg Hospital Chambersburg, Pennsylvania	Site Public Contact - (Roster@nrgoncology.org)
Chelsea Hospital Chelsea, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Christiana Care - Union Hospital Elkton, Maryland	Site Public Contact - (frank.crum@christianacare.org)
Christiana Care Health System-Christiana Hospital Newark, Delaware	Site Public Contact - (lbarone@christianacare.org)
Christiana Care Health System-Concord Health Center Chadds Ford, Pennsylvania	Site Public Contact - (lbarone@christianacare.org)
Christiana Care Health System-Wilmington Hospital Wilmington, Delaware	Site Public Contact - (lbarone@christianacare.org)
City of Hope Comprehensive Cancer Center Duarte, California
City of Hope Newport Beach Newport Beach, California
City of Hope South Bay Torrance, California
City of Hope South Pasadena South Pasadena, California
City of Hope Upland Upland, California
City of Hope at Irvine Lennar Irvine, California
Clackamas Radiation Oncology Center Clackamas, Oregon	Site Public Contact - (CanRsrchStudies@providence.org)
Cleveland Clinic Akron General Akron, Ohio	Site Public Contact - (CancerAnswer@ccf.org)
Cleveland Clinic Cancer Center Independence Independence, Ohio	Site Public Contact - (TaussigResearch@ccf.org)
Cleveland Clinic Cancer Center Mansfield Mansfield, Ohio	Site Public Contact - (TaussigResearch@ccf.org)
Cleveland Clinic Cancer Center Strongsville Strongsville, Ohio	Site Public Contact - (TaussigResearch@ccf.org)
Cleveland Clinic Cancer Center/Fairview Hospital Cleveland, Ohio	Site Public Contact - (TaussigResearch@ccf.org)
Cleveland Clinic Foundation Cleveland, Ohio	Site Public Contact - (TaussigResearch@ccf.org)
Cleveland Clinic Wooster Family Health and Surgery Center Wooster, Ohio	Site Public Contact - (TaussigResearch@ccf.org)
Cleveland Clinic-Weston Weston, Florida	Site Public Contact - (CancerAnswer@ccf.org)
Coborn Cancer Center at Saint Cloud Hospital Saint Cloud, Minnesota	Site Public Contact - (coborncancercenter@centracare.com)
Columbus Oncology and Hematology Associates Dublin, Ohio	Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Columbus Oncology and Hematology Associates Inc Columbus, Ohio	Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
CommonSpirit Cancer Center Mercy Durango, Colorado	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Commonwealth Cancer Center-Corbin Corbin, Kentucky	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Community Hospital of Anaconda Anaconda, Montana	Site Public Contact - (mccinfo@mtcancer.org)
Community Medical Center Missoula, Montana	Site Public Contact - (mccinfo@mtcancer.org)
Community Medical Center Missoula, Montana	Site Public Contact - (Lennette.Gonzales@rwjbh.org)
Community Medical Center Missoula, Montana	Site Public Contact - (HemonCCTrials@geisinger.edu)
Comprehensive Cancer Centers of Nevada Las Vegas, Nevada	Site Public Contact - (research@sncrf.org)
Comprehensive Cancer Centers of Nevada - Central Valley Las Vegas, Nevada	Site Public Contact - (research@sncrf.org)
Comprehensive Cancer Centers of Nevada - Henderson Henderson, Nevada	Site Public Contact - (research@sncrf.org)
Comprehensive Cancer Centers of Nevada - Northwest Las Vegas, Nevada	Site Public Contact - (research@sncrf.org)
Comprehensive Cancer Centers of Nevada - Town Center Las Vegas, Nevada	Site Public Contact - (research@sncrf.org)
Comprehensive Cancer Centers of Nevada-Horizon Ridge Henderson, Nevada	Site Public Contact - (research@sncrf.org)
Comprehensive Cancer Centers of Nevada-Southeast Henderson Henderson, Nevada	Site Public Contact - (research@sncrf.org)
Comprehensive Cancer Centers of Nevada-Summerlin Las Vegas, Nevada	Site Public Contact - (research@sncrf.org)
Comprehensive Medical Center PLLC Royal Oak, Michigan
Condell Memorial Hospital Libertyville, Illinois	Site Public Contact - (advocateresearch@advocatehealth.com)
Cone Health Cancer Center Greensboro, North Carolina	Site Public Contact - (stacey.phelps@conehealth.com)
Cone Health Cancer Center at Alamance Regional Burlington, North Carolina	Site Public Contact - (stacey.phelps@conehealth.com)
Cone Health Cancer Center at Asheboro Asheboro, North Carolina
Cone Health Cancer Center at Drawbridge Parkway Greensboro, North Carolina	Site Public Contact - (stacey.phelps@conehealth.com)
Cone Health MedCenter Asheboro Asheboro, North Carolina	Site Public Contact - (stacey.phelps@conehealth.com)
Cooper Hospital University Medical Center Camden, New Jersey
Corewell Health Beaumont Troy Hospital Troy, Michigan
Corewell Health Dearborn Hospital Dearborn, Michigan
Corewell Health Farmington Hills Hospital Farmington Hills, Michigan
Corewell Health Grand Rapids Hospitals - Butterworth Hospital Grand Rapids, Michigan	Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital Grand Rapids, Michigan	Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center Saint Joseph, Michigan	Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health Lakeland Hospitals - Niles Hospital Niles, Michigan
Corewell Health Lakeland Hospitals - Saint Joseph Hospital Saint Joseph, Michigan	Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health Reed City Hospital Reed City, Michigan	Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health William Beaumont University Hospital Royal Oak, Michigan
Cox Cancer Center Branson Branson, Missouri
CoxHealth South Hospital Springfield, Missouri
Creighton University Medical Center Omaha, Nebraska	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Crossroads Cancer Center Effingham, Illinois	Site Public Contact - (morganthaler.jodi@mhsil.com)
Dana-Farber Cancer Institute Boston, Massachusetts
Dana-Farber/Brigham and Women's Cancer Center at South Shore South Weymouth, Massachusetts
Danbury Hospital Danbury, Connecticut
Dartmouth Cancer Center - North Saint Johnsbury, Vermont	Site Public Contact - (cancer.research.nurse@hitchcock.org)
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center Lebanon, New Hampshire	Site Public Contact - (cancer.research.nurse@dartmouth.edu)
Dayton Physician LLC - Englewood Dayton, Ohio
Dayton Physicians LLC - Troy Troy, Ohio
Dayton Physicians LLC-Atrium Franklin, Ohio
Dayton Physicians LLC-Miami Valley South Centerville, Ohio
Dayton Physicians LLC-Wayne Greenville, Ohio
Decatur Memorial Hospital Decatur, Illinois	Site Public Contact - (morganthaler.jodi@mhsil.com)
Delaware Clinical and Laboratory Physicians PA Newark, Delaware
Delaware Health Center-Grady Cancer Center Delaware, Ohio	Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Dickstein Cancer Treatment Center White Plains, New York	Site Public Contact - (mcortese@wphospital.org)
Dillon Health Center/Shaw Cancer Center Dillon, Colorado
Divine Providence Hospital Williamsport, Pennsylvania	Site Public Contact - (Roster@nrgoncology.org)
Doctors Cancer Center Manatí,
Doctors Hospital Columbus, Ohio	Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Drexel Town Square Health Center Oak Creek, Wisconsin
Dublin Methodist Hospital Dublin, Ohio	Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Duke Cancer Center Cary Cary, North Carolina	Site Public Contact - (NCTNStudyTeam@dm.duke.edu)
Duke University Medical Center Durham, North Carolina
Duke Women's Cancer Care Raleigh Raleigh, North Carolina
Duluth Clinic Ashland Ashland, Wisconsin	Site Public Contact - (CancerTrials@EssentiaHealth.org)
East Carolina University Greenville, North Carolina	Site Public Contact - (eubankss@ecu.edu)
Eden Hospital Medical Center Castro Valley, California	Site Public Contact - (clinicalresearch@sutterhealth.org)
Edward Hospital/Cancer Center Naperville, Illinois
Edward Hospital/Cancer Center?Plainfield Plainfield, Illinois	Site Public Contact - (Cancerresearch@edward.org)
Eisenhower Medical Center Rancho Mirage, California
Elmhurst Memorial Hospital Elmhurst, Illinois	Site Public Contact - (Jrohde@emhc.org)
Emory Decatur Hospital Decatur, Georgia	Site Public Contact - (clinicaltrialsoncology@dekalbmedical.org)
Emory Johns Creek Hospital Johns Creek, Georgia	Site Public Contact - (m.lisa.hwang@emory.edu)
Emory Saint Joseph's Hospital Atlanta, Georgia
Emory University Hospital Midtown Atlanta, Georgia
Emory University Hospital/Winship Cancer Institute Atlanta, Georgia
Englewood Hospital and Medical Center Englewood, New Jersey
Enloe Medical Center Chico, California
Ephrata Cancer Center Ephrata, Pennsylvania
Essentia Health - Baxter Clinic Baxter, Minnesota
Essentia Health - Deer River Clinic Deer River, Minnesota	Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health - Ely Clinic Ely, Minnesota
Essentia Health - Fosston Fosston, Minnesota	Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health - International Falls Clinic International Falls, Minnesota
Essentia Health - Jamestown Clinic Jamestown, North Dakota	Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health - Moose Lake Clinic Moose Lake, Minnesota
Essentia Health - Park Rapids Park Rapids, Minnesota	Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health - Saint Joseph's Crosslake Clinic Crosslake, Minnesota
Essentia Health - Saint Joseph's Pequot Lakes Clinic Pequot Lakes, Minnesota
Essentia Health - Saint Joseph's Pine River Clinic Pine River, Minnesota
Essentia Health - Saint Joseph's Staples Clinic Staples, Minnesota
Essentia Health Cancer Center Duluth, Minnesota	Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Cancer Center-South University Clinic Fargo, North Dakota	Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Hibbing Clinic Hibbing, Minnesota
Essentia Health Saint Joseph's Medical Center Brainerd, Minnesota	Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Saint Mary's - Detroit Lakes Clinic Detroit Lakes, Minnesota	Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Saint Mary's Hospital - Superior Superior, Wisconsin
Essentia Health Saint Mary's Medical Center Duluth, Minnesota	Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Sandstone Sandstone, Minnesota	Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Virginia Clinic Virginia, Minnesota	Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health-Hayward Clinic Hayward, Wisconsin	Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health-Spooner Clinic Spooner, Wisconsin	Site Public Contact - (CancerTrials@EssentiaHealth.org)
FHCC Overlake Bellevue, Washington
FHCC at EvergreenHealth Kirkland, Washington
FHCC at Northwest Hospital Seattle, Washington
FMH James M Stockman Cancer Institute Frederick, Maryland
Fairview Clinics and Surgery Center Maple Grove Maple Grove, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Fairview Lakes Medical Center Wyoming, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Fairview Northland Medical Center Princeton, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Fairview Southdale Hospital Edina, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Farmington Health Center Farmington, Utah	Site Public Contact - (cancerinfo@hci.utah.edu)
First Physicians Group - Silverstein Institute at Floyd Street Sarasota, Florida
First Physicians Group - Urology Robotic and Minimally Invasive Surgery Sarasota, Florida
First Physicians Group-Sarasota Sarasota, Florida
FirstHealth of the Carolinas-Moore Regional Hospital Pinehurst, North Carolina	Site Public Contact - (jcwilliams@firsthealth.org)
Flaget Memorial Hospital Bardstown, Kentucky	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Florida Cancer Specialists - Bradenton Cancer Center Bradenton, Florida
Florida Cancer Specialists - Sarasota Sarasota, Florida
Florida Cancer Specialists - Sarasota Downtown Sarasota, Florida
Florida Cancer Specialists - Venice Island Venice, Florida
Florida Cancer Specialists - Venice Pinebrook Venice, Florida
Forbes Hospital Monroeville, Pennsylvania
Fox Chase Cancer Center Philadelphia, Pennsylvania
Franciscan Health Indianapolis Indianapolis, Indiana
Franciscan Health Mooresville Mooresville, Indiana
Franciscan Health Munster Munster, Indiana
Fred Hutchinson Cancer Center Seattle, Washington
Fred and Pamela Buffett Cancer Center - Kearney Kearney, Nebraska	Site Public Contact - (unmcrsa@unmc.edu)
Frederick Memorial Hospital Frederick, Maryland
Freeman Health System Joplin, Missouri	Site Public Contact - (LJCrockett@freemanhealth.com)
Freeman Physician Group of Pittsburg Pittsburg, Kansas	Site Public Contact - (BNMathew@freemanhealth.com)
Fremont - Rideout Cancer Center Marysville, California
Fresno Cancer Center Fresno, California	Site Public Contact - (Kpoct@kp.org)
Froedtert Menomonee Falls Hospital Menomonee Falls, Wisconsin
Froedtert West Bend Hospital/Kraemer Cancer Center West Bend, Wisconsin
Geisinger Cancer Center Dickson City Dickson City, Pennsylvania	Site Public Contact - (hemoncctrials@geisinger.edu)
Geisinger Cancer Services-Pottsville Pottsville, Pennsylvania	Site Public Contact - (HemonCCTrials@geisinger.edu)
Geisinger Medical Center Danville, Pennsylvania	Site Public Contact - (HemonCCTrials@geisinger.edu)
Geisinger Medical Oncology-Lewisburg Lewisburg, Pennsylvania	Site Public Contact - (HemonCCTrials@geisinger.edu)
Geisinger Wyoming Valley/Henry Cancer Center Wilkes-Barre, Pennsylvania	Site Public Contact - (HemonCCTrials@geisinger.edu)
Gene Upshaw Memorial Tahoe Forest Cancer Center Truckee, California
Genesee Hematology Oncology PC Flint, Michigan	Site Public Contact - (wstrong@ghci.org)
Genesys Hurley Cancer Institute Flint, Michigan	Site Public Contact - (wstrong@ghci.org)
George Washington University Medical Center Washington D.C., District of Columbia
Gibbs Cancer Center-Gaffney Gaffney, South Carolina	Site Public Contact - (kmertz-rivera@gibbscc.org)
Gibbs Cancer Center-Pelham Greer, South Carolina	Site Public Contact - (kmertz-rivera@gibbscc.org)
Glens Falls Hospital Glens Falls, New York
Good Samaritan Hospital - Cincinnati Cincinnati, Ohio	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Good Samaritan University Hospital West Islip, New York
Goshen Center for Cancer Care Goshen, Indiana	Site Public Contact - (cccois@goshenhealth.com)
Grady Health System Atlanta, Georgia
Grady Memorial Hospital Delaware, Ohio	Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Grant Medical Center Columbus, Ohio	Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Great Falls Clinic Great Falls, Montana	Site Public Contact - (mccinfo@mtcancer.org)
Greater Baltimore Medical Center Baltimore, Maryland
Greater Dayton Cancer Center Kettering, Ohio
Greater Regional Medical Center Creston, Iowa	Site Public Contact - (cancerresearch@mercydesmoines.org)
Guthrie Medical Group PC-Robert Packer Hospital Sayre, Pennsylvania
HSHS Sacred Heart Hospital Eau Claire, Wisconsin
HSHS Saint Elizabeth's Hospital O'Fallon, Illinois	Site Public Contact - (morganthaler.jodi@mhsil.com)
Hackensack University Medical Center Hackensack, New Jersey
Harold Alfond Center for Cancer Care Augusta, Maine
Hartford HealthCare - Avon Avon, Connecticut
Hartford HealthCare - Manchester Manchester, Connecticut
Hartford HealthCare - Saint Vincent's Medical Center Bridgeport, Connecticut
Hartford Hospital Hartford, Connecticut
Hawaii Cancer Care - Westridge ‘Aiea, Hawaii	Site Public Contact - (info@hawaiicancercare.com)
Hawaii Cancer Care Inc - Waterfront Plaza Honolulu, Hawaii	Site Public Contact - (i.webster@hawaiicancercare.com)
Hawaii Diagnostic Radiology Services LLC Honolulu, Hawaii	Site Public Contact - (mmiyoshi@hawaiidrs.com)
HaysMed Hays, Kansas
Health Central Ocoee, Florida	Site Public Contact - (Roster@nrgoncology.org)
Heartland Regional Medical Center Saint Joseph, Missouri	Site Public Contact - (Trisha.England2@mymlc.com)
Helen F Graham Cancer Center Newark, Delaware	Site Public Contact - (lbarone@christianacare.org)
Hematology Oncology Consultants PC-Royal Oak Royal Oak, Michigan
Hematology Oncology Consultants PC-Troy Troy, Michigan
Hematology Oncology Consultants-Clarkston Clarkston, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Hennepin County Medical Center Minneapolis, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Henry Ford Cancer Institute-Downriver Brownstown, Michigan	Site Public Contact - (CTOResearch@hfhs.org)
Henry Ford Health Providence Novi Hospital Novi, Michigan	Site Public Contact - (kfife3@hfhs.org)
Henry Ford Health Providence Southfield Hospital Southfield, Michigan	Site Public Contact - (kfife3@hfhs.org)
Henry Ford Health Saint John Hospital Detroit, Michigan	Site Public Contact - (Kkeenan1@hfhs.org)
Henry Ford Health Warren Hospital Warren, Michigan	Site Public Contact - (kforman1@hfhs.org)
Henry Ford Hospital Detroit, Michigan	Site Public Contact - (CTOResearch@hfhs.org)
Henry Ford Macomb Hospital-Clinton Township Clinton Township, Michigan	Site Public Contact - (CTOResearch@hfhs.org)
Henry Ford Madison Heights Hospital - Breast Warren, Michigan	Site Public Contact - (kforman1@hfhs.org)
Henry Ford Medical Center-Columbus Novi, Michigan	Site Public Contact - (CTOResearch@hfhs.org)
Henry Ford River District Hospital East China Township, Michigan	Site Public Contact - (kforman1@hfhs.org)
Henry Ford Saint John Hospital - Academic Grosse Pointe Woods, Michigan	Site Public Contact - (kforman1@hfhs.org)
Henry Ford Saint John Hospital - Breast Grosse Pointe Woods, Michigan	Site Public Contact - (karen.forman@ascension.org)
Henry Ford Saint John Hospital - Macomb Medical Macomb, Michigan	Site Public Contact - (kforman1@hfhs.org)
Henry Ford Saint John Hospital - Van Elslander Grosse Pointe Woods, Michigan	Site Public Contact - (kforman1@hfhs.org)
Henry Ford Warren Hospital - Breast Macomb Macomb, Michigan	Site Public Contact - (kforman1@hfhs.org)
Henry Ford Warren Hospital - GLCMS Warren, Michigan	Site Public Contact - (kforman1@hfhs.org)
Henry Ford West Bloomfield Hospital West Bloomfield, Michigan	Site Public Contact - (CTOResearch@hfhs.org)
Hi-Line Sletten Cancer Center Havre, Montana	Site Public Contact - (Roster@nrgoncology.org)
Hillcrest Hospital Cancer Center Mayfield Heights, Ohio	Site Public Contact - (TaussigResearch@ccf.org)
Holy Cross Hospital Fort Lauderdale, Florida	Site Public Contact - (eileen.georgi@holy-cross.com)
Holy Name Hospital Teaneck, New Jersey
Hope Cancer Care of Nevada Las Vegas, Nevada	Site Public Contact - (research@sncrf.org)
Hope Cancer Care of Nevada-Pahrump Pahrump, Nevada	Site Public Contact - (research@sncrf.org)
Hope Cancer Center Pontiac, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Hospital de Clinicas Dr Manuel Quintela Montevideo,	Site Public Contact - (comunicaciones@msp.gub.uy)
Huntington Memorial Hospital Pasadena, California
Huntsman Cancer Institute/University of Utah Salt Lake City, Utah	Site Public Contact - (cancerinfo@hci.utah.edu)
Hurley Medical Center Flint, Michigan	Site Public Contact - (wstrong@ghci.org)
Huron Gastroenterology PC Ypsilanti, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
IU Health North Hospital Carmel, Indiana	Site Public Contact - (iutrials@iu.edu)
IU Health West Hospital Avon, Indiana	Site Public Contact - (iutrials@iu.edu)
Idaho Urologic Institute-Meridian Meridian, Idaho	Site Public Contact - (stephanie.couch@stjoeshealth.org)
Illinois CancerCare - Washington Washington, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Bloomington Bloomington, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Canton Canton, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Carthage Carthage, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Dixon Dixon, Illinois
Illinois CancerCare-Eureka Eureka, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Galesburg Galesburg, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Kewanee Clinic Kewanee, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Macomb Macomb, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Ottawa Clinic Ottawa, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Pekin Pekin, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Peoria Peoria, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Peru Peru, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Princeton Princeton, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
Indiana University/Melvin and Bren Simon Cancer Center Indianapolis, Indiana	Site Public Contact - (iutrials@iu.edu)
Indu and Raj Soin Medical Center Beavercreek, Ohio
Ingalls Memorial Hospital Harvey, Illinois	Site Public Contact - (clinicaltrials@ingalls.org)
Instituto Nacional De Cancerologia Bogota, Cundinamarca
Instituto Nacional De Cancerologia de Mexico Mexico City, Tlalpan
Instituto Nacional de Enfermedades Neoplasicas Lima,
Intercoastal Medical Group - Cattleridge II Sarasota, Florida
Intermountain Health Lutheran Hospital Wheat Ridge, Colorado
Intermountain Health West End Clinic Billings, Montana
Jefferson Cherry Hill Hospital Cherry Hill, New Jersey	Site Public Contact - (ONCTrialNow@jefferson.edu)
Jefferson Hospital Jefferson Hills, Pennsylvania	Site Public Contact - (ddefazio@wpahs.org)
Jefferson Torresdale Hospital Philadelphia, Pennsylvania	Site Public Contact - (ONCTrialNow@jefferson.edu)
Jersey City Medical Center Jersey City, New Jersey	Site Public Contact - (Roster@nrgoncology.org)
Jewish General Hospital Montreal, Quebec
John H Stroger Jr Hospital of Cook County Chicago, Illinois
Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland	Site Public Contact - (jhcccro@jhmi.edu)
Jupiter Medical Center Jupiter, Florida	Site Public Contact - (clinicaltrials@jupitermed.com)
Kadlec Clinic Hematology and Oncology Kennewick, Washington	Site Public Contact - (research@kadlecmed.org)
Kaiser Permanente - Kensington Medical Center Kensington, Maryland	Site Public Contact - (Charmaine.A.Mckie@kp.org)
Kaiser Permanente - Largo Medical Center Largo, Maryland	Site Public Contact - (Charmaine.A.Mckie@kp.org)
Kaiser Permanente - Panorama City Panorama City, California	Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente Cancer Treatment Center South San Francisco, California	Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente Downtown Commons Sacramento, California	Site Public Contact - (kpoct@kp.org)
Kaiser Permanente Dublin Dublin, California
Kaiser Permanente Fresno Orchard Plaza Fresno, California
Kaiser Permanente Los Angeles Medical Center Los Angeles, California	Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente Lutherville - Timonium Medical Center Lutherville, Maryland	Site Public Contact - (Charmaine.A.Mckie@kp.org)
Kaiser Permanente Medical Center - Santa Clara Santa Clara, California	Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente Medical Center-Vacaville Vacaville, California	Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente Moanalua Medical Center Honolulu, Hawaii	Site Public Contact - (shelley.a.clark@kp.org)
Kaiser Permanente Northwest Portland, Oregon	Site Public Contact - (information@kpchr.org)
Kaiser Permanente Oakland-Broadway Oakland, California	Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente San Leandro San Leandro, California	Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente South Bay Harbor City, California	Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente Tysons Corner Medical Center McLean, Virginia	Site Public Contact - (Charmaine.A.Mckie@kp.org)
Kaiser Permanente West Los Angeles Los Angeles, California	Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente- Marshall Medical Offices Redwood City, California
Kaiser Permanente-Anaheim Anaheim, California	Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente-Baldwin Park Baldwin Park, California	Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente-Bellflower Bellflower, California	Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente-Burke Medical Center Burke, Virginia	Site Public Contact - (Charmaine.A.Mckie@kp.org)
Kaiser Permanente-Capitol Hill Medical Center Washington D.C., District of Columbia	Site Public Contact - (Charmaine.A.Mckie@kp.org)
Kaiser Permanente-Caton Hill Medical Center Woodbridge, Virginia	Site Public Contact - (Charmaine.A.Mckie@kp.org)
Kaiser Permanente-Deer Valley Medical Center Antioch, California	Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Fontana Fontana, California	Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente-Fremont Fremont, California	Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Fresno Fresno, California	Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Gaithersburg Medical Center Gaithersburg, Maryland	Site Public Contact - (Charmaine.A.Mckie@kp.org)
Kaiser Permanente-Irvine Irvine, California	Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente-Modesto Modesto, California	Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Oakland Oakland, California	Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Ontario Ontario, California	Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente-Rancho Cordova Cancer Center Rancho Cordova, California	Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Richmond Richmond, California	Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Riverside Riverside, California	Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente-Roseville Roseville, California	Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-San Diego Mission San Diego, California	Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente-San Diego Zion San Diego, California	Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente-San Francisco San Francisco, California	Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-San Marcos San Marcos, California	Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente-Santa Rosa Santa Rosa, California	Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Santa Teresa-San Jose San Jose, California	Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-South Sacramento Sacramento, California	Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-South San Francisco South San Francisco, California	Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Stockton Stockton, California	Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Vallejo Vallejo, California	Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Walnut Creek Walnut Creek, California	Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Woodland Hills Woodland Hills, California	Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente-Woodlawn Medical Center Baltimore, Maryland	Site Public Contact - (Charmaine.A.Mckie@kp.org)
Kaiser San Rafael-Gallinas San Rafael, California	Site Public Contact - (Kpoct@kp.org)
Kaiser Sunnyside Medical Center Clackamas, Oregon	Site Public Contact - (information@kpchr.org)
Kapiolani Medical Center for Women and Children Honolulu, Hawaii
Karmanos Cancer Institute at McLaren Greater Lansing Lansing, Michigan	Site Public Contact - (ctoadmin@karmanos.org)
Katmai Oncology Group Anchorage, Alaska	Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org)
Keck Medical Center of USC Pasadena Pasadena, California
Keck Medicine of USC Buena Park Buena Park, California
Keck Medicine of USC Koreatown Los Angeles, California
Kent Hospital Warwick, Rhode Island
Kettering Medical Center Kettering, Ohio
King's Daughter's Medical Center Ashland, Kentucky
Kingman Regional Medical Center Kingman, Arizona	Site Public Contact - (research@sncrf.org)
Kootenai Clinic Cancer Services - Post Falls Post Falls, Idaho	Site Public Contact - (mccinfo@mtcancer.org)
Kootenai Clinic Cancer Services - Sandpoint Sandpoint, Idaho	Site Public Contact - (mccinfo@mtcancer.org)
Kootenai Health - Coeur d'Alene Coeur d'Alene, Idaho	Site Public Contact - (mccinfo@mtcancer.org)
Kuakini Medical Center Honolulu, Hawaii
Lahey Hospital and Medical Center Burlington, Massachusetts	Site Public Contact - (lhmc-cancer-clinical-trials@lahey.org)
Lahey Medical Center-Peabody Peabody, Massachusetts	Site Public Contact - (lhmc-cancer-clinical-trials@lahey.org)
Lake Regional Hospital Osage Beach, Missouri	Site Public Contact - (clinicaltrials@lakeregional.com)
Lakeridge Health Oshawa Oshawa, Ontario
Lakeview Hospital Stillwater, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Langlade Hospital and Cancer Center Antigo, Wisconsin	Site Public Contact - (Juli.Alford@aspirus.org)
Lankenau Medical Center Wynnewood, Pennsylvania	Site Public Contact - (turzoe@mlhs.org)
Las Vegas Prostate Cancer Center Las Vegas, Nevada	Site Public Contact - (research@sncrf.org)
Las Vegas Urology - Cathedral Rock Las Vegas, Nevada	Site Public Contact - (research@sncrf.org)
Las Vegas Urology - Green Valley Henderson, Nevada	Site Public Contact - (research@sncrf.org)
Las Vegas Urology - Pebble Henderson, Nevada	Site Public Contact - (research@sncrf.org)
Las Vegas Urology - Pecos Las Vegas, Nevada	Site Public Contact - (research@sncrf.org)
Las Vegas Urology - Smoke Ranch Las Vegas, Nevada	Site Public Contact - (research@smcrf.org)
Las Vegas Urology - Sunset Las Vegas, Nevada	Site Public Contact - (research@sncrf.org)
Laura and Isaac Perlmutter Cancer Center at NYU Langone New York, New York	Site Public Contact - (CancerTrials@nyulangone.org)
Lawrence Memorial Hospital Lawrence, Kansas	Site Public Contact - (Stephanie.Norris@LMH.ORG)
Lehigh Valley Hospital - Muhlenberg Bethlehem, Pennsylvania	Site Public Contact - (Morgan_M.Horton@lvhn.org)
Lehigh Valley Hospital-Cedar Crest Allentown, Pennsylvania	Site Public Contact - (Morgan_M.Horton@lvhn.org)
Lehigh Valley Hospital-Hazleton Hazleton, Pennsylvania	Site Public Contact - (Morgan_M.Horton@lvhn.org)
Lenox Hill Hospital New York, New York
Levine Cancer Institute - Huntersville Huntersville, North Carolina
Levine Cancer Institute - Rutherford Forest City, North Carolina
Levine Cancer Institute - Union West Matthews, North Carolina
Levine Cancer Institute-Ballantyne Charlotte, North Carolina
Levine Cancer Institute-Gaston Gastonia, North Carolina
Levine Cancer Institute-Rock Hill Rock Hill, South Carolina
Levine Cancer Institute-SouthPark Charlotte, North Carolina
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler Savannah, Georgia	Site Public Contact - (underberga@sjchs.org)
Logan Health Medical Center Kalispell, Montana	Site Public Contact - (mccinfo@mtcancer.org)
Loma Linda University Medical Center Loma Linda, California
London Regional Cancer Program London, Ontario
Longmont United Hospital Longmont, Colorado	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Los Angeles General Medical Center Los Angeles, California	Site Public Contact - (uscnorrisinfo@med.usc.edu)
Louisiana Hematology Oncology Associates LLC Baton Rouge, Louisiana	Site Public Contact - (clinicalresearch@marybird.com)
Louisiana State University Health Science Center New Orleans, Louisiana	Site Public Contact - (emede1@lsuhsc.edu)
Lowell General Hospital Lowell, Massachusetts	Site Public Contact - (ghincks@lowellgeneral.org)
Loyola Center for Health at Burr Ridge Burr Ridge, Illinois
Loyola Medicine Homer Glen Homer Glen, Illinois
Loyola University Medical Center Maywood, Illinois
Luminis Health Anne Arundel Medical Center Annapolis, Maryland
Lutheran Hospital - Cancer Centers of Colorado Golden, Colorado	Site Public Contact - (peaksresearch@imail.org)
Lyndon Baines Johnson General Hospital Houston, Texas
M D Anderson Cancer Center Houston, Texas	Site Public Contact - (askmdanderson@mdanderson.org)
MD Anderson Cancer Center at Cooper-Voorhees Voorhees Township, New Jersey
MD Anderson League City League City, Texas	Site Public Contact - (askmdanderson@mdanderson.org)
MD Anderson West Houston Houston, Texas	Site Public Contact - (askmdanderson@mdanderson.org)
MD Anderson in Sugar Land Sugar Land, Texas	Site Public Contact - (askmdanderson@mdanderson.org)
MD Anderson in The Woodlands Conroe, Texas	Site Public Contact - (askmdanderson@mdanderson.org)
MU Health - University Hospital/Ellis Fischel Cancer Center Columbia, Missouri
MU Health Care Goldschmidt Cancer Center Jefferson City, Missouri
Macomb Hematology Oncology PC Warren, Michigan
MaineHealth Cancer Care Center of York County Sanford, Maine
MaineHealth Cancer Care and IV Therapy - Sanford Sanford, Maine	Site Public Contact - (clinicalresearch@mainehealth.org)
MaineHealth Cancer Care and IV Therapy - South Portland South Portland, Maine	Site Public Contact - (clinicalresearch@mainehealth.org)
MaineHealth Maine Medical Center - Biddeford Biddeford, Maine
MaineHealth Waldo Hospital Belfast, Maine	Site Public Contact - (clinicalresearch@mainehealth.org)
Manhattan Eye Ear and Throat Hospital New York, New York
Marjorie Weinberg Cancer Center at Loyola-Gottlieb Melrose Park, Illinois
Marshall Cancer Center Cameron Park, California	Site Public Contact - (cancerservices@marshallmedical.org)
Marshfield Clinic - Wisconsin Rapids Center Wisconsin Rapids, Wisconsin	Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Clinic-Chippewa Center Chippewa Falls, Wisconsin	Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Clinic-Wausau Center Wausau, Wisconsin	Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center - Ladysmith Ladysmith, Wisconsin	Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center - Minocqua Minocqua, Wisconsin	Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center - Neillsville Neillsville, Wisconsin	Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center - Weston Weston, Wisconsin	Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-EC Cancer Center Eau Claire, Wisconsin	Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-Marshfield Marshfield, Wisconsin	Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-Rice Lake Rice Lake, Wisconsin	Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-River Region at Stevens Point Stevens Point, Wisconsin	Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Mary Bird Perkins Cancer Center - Covington Covington, Louisiana	Site Public Contact - (clinicalresearch@marybird.com)
Mary Greeley Medical Center Ames, Iowa
Matthews Radiation Oncology Center Matthews, North Carolina	Site Public Contact - (kashah@novanthealth.org)
Mayo Clinic Health System-Franciscan Healthcare La Crosse, Wisconsin
Mayo Clinic Health Systems-Mankato Mankato, Minnesota
Mayo Clinic Hospital in Arizona Phoenix, Arizona
Mayo Clinic in Florida Jacksonville, Florida
Mayo Clinic in Rochester Rochester, Minnesota
McFarland Clinic - Ames Ames, Iowa	Site Public Contact - (ksoder@mcfarlandclinic.com)
McFarland Clinic - Boone Boone, Iowa
McFarland Clinic - Jefferson Jefferson, Iowa
McFarland Clinic - Marshalltown Marshalltown, Iowa
McFarland Clinic - Trinity Cancer Center Fort Dodge, Iowa
McLaren Cancer Institute-Bay City Bay City, Michigan	Site Public Contact - (ctoadmin@karmanos.org)
McLaren Cancer Institute-Clarkston Clarkston, Michigan	Site Public Contact - (ctoadmin@karmanos.org)
McLaren Cancer Institute-Flint Flint, Michigan	Site Public Contact - (ctoadmin@karmanos.org)
McLaren Cancer Institute-Lapeer Region Lapeer, Michigan	Site Public Contact - (ctoadmin@karmanos.org)
McLaren Cancer Institute-Macomb Mount Clemens, Michigan	Site Public Contact - (ctoadmin@karmanos.org)
McLaren Cancer Institute-Northern Michigan Petoskey, Michigan	Site Public Contact - (ctoadmin@karmanos.org)
McLaren-Port Huron Port Huron, Michigan	Site Public Contact - (ctoadmin@karmanos.org)
MedStar Franklin Square Medical Center/Weinberg Cancer Institute Baltimore, Maryland
MedStar Georgetown University Hospital Washington D.C., District of Columbia
MedStar Good Samaritan Hospital Baltimore, Maryland	Site Public Contact - (Barbara.rector@medstar.net)
MedStar Health Bel Air Medical Campus Bel Air, Maryland	Site Public Contact - (David.j.perry2@medstar.net)
MedStar Montgomery Medical Center Olney, Maryland
Medical College of Wisconsin Milwaukee, Wisconsin
Medical Oncology Hematology Consultants PA Newark, Delaware	Site Public Contact - (lbarone@christianacare.org)
Medical University of South Carolina Charleston, South Carolina	Site Public Contact - (hcc-clinical-trials@musc.edu)
Medstar Washington Hospital Center Washington D.C., District of Columbia
Memorial Hospital East Shiloh, Illinois	Site Public Contact - (dschwab@wustl.edu)
Memorial Hospital North Colorado Springs, Colorado
Memorial Hospital of Carbondale Carbondale, Illinois	Site Public Contact - (clinical.research@sih.net)
Memorial Medical Center Modesto, California	Site Public Contact - (clinicalresearch@sutterhealth.org)
Memorial Medical Center-Las Cruces Las Cruces, New Mexico	Site Public Contact - (Deborah.Brown@LPNT.net)
Mercy Cancer Center Merced, California	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Mercy Cancer Center - Cape Girardeau Cape Girardeau, Missouri
Mercy Cancer Center - Carmichael Carmichael, California	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Mercy Cancer Center - Elk Grove Elk Grove, California	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Mercy Cancer Center - Rocklin Rocklin, California	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Mercy Cancer Center - Sacramento Sacramento, California	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Mercy Cancer Center-West Lakes Clive, Iowa	Site Public Contact - (cancerresearch@mercydesmoines.org)
Mercy Clinic-Rolla-Cancer and Hematology Rolla, Missouri
Mercy Hospital Coon Rapids, Minnesota
Mercy Hospital Coon Rapids, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Mercy Hospital Fort Smith Fort Smith, Arkansas
Mercy Hospital Joplin Joplin, Missouri	Site Public Contact - (esmeralda.carrillo@mercy.net)
Mercy Hospital Oklahoma City Oklahoma City, Oklahoma
Mercy Hospital Pittsburg Pittsburg, Kansas
Mercy Hospital Saint Louis St Louis, Missouri
Mercy Hospital South St Louis, Missouri	Site Public Contact - (Danielle.Werle@mercy.net)
Mercy Hospital Springfield Springfield, Missouri
Mercy Hospital Washington Washington, Missouri
Mercy Infusion Center - Chippewa St Louis, Missouri
Mercy Medical Center Springfield, Massachusetts	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Mercy Medical Center Springfield, Massachusetts	Site Public Contact - (acline@mdmercy.com)
Mercy Medical Center - Des Moines Des Moines, Iowa	Site Public Contact - (cancerresearch@mercydesmoines.org)
Mercy Medical Center-West Lakes West Des Moines, Iowa	Site Public Contact - (cancerresearch@mercydesmoines.org)
Mercy Oncology and Hematology - Clayton-Clarkson Ballwin, Missouri
Mercy San Juan Medical Center Carmichael, California	Site Public Contact - (OncologyResearch@DignityHealth.org)
Mercyhealth Hospital and Cancer Center - Janesville Janesville, Wisconsin	Site Public Contact - (oncologyclinicaltrials@mhemail.org)
Methodist Medical Center of Illinois Peoria, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
Miami Cancer Institute Miami, Florida
Miami Cancer Institute at Plantation Plantation, Florida
Miami Valley Cancer Care and Infusion Greenville, Ohio
Miami Valley Hospital Dayton, Ohio	Site Public Contact - (clinical.trials@daytonncorp.org)
Miami Valley Hospital North Dayton, Ohio	Site Public Contact - (clinical.trials@daytonncorp.org)
Miami Valley Hospital South Centerville, Ohio	Site Public Contact - (clinical.trials@daytonncorp.org)
Michigan Healthcare Professionals Pontiac Pontiac, Michigan	Site Public Contact - (Emily.Crofts@trinity-health.org)
Michigan Institute of Urology-Town Center Troy, Michigan
Mid Coast Hospital Brunswick, Maine	Site Public Contact - (Roster@nrgoncology.org)
Midlands Community Hospital Papillion, Nebraska
Midstate Medical Center Meriden, Connecticut
Miller-Dwan Hospital Duluth, Minnesota	Site Public Contact - (CancerTrials@EssentiaHealth.org)
Mills Health Center San Mateo, California	Site Public Contact - (clinicalresearch@sutterhealth.org)
Mills-Peninsula Medical Center Burlingame, California	Site Public Contact - (clinicalresearch@sutterhealth.org)
Minnesota Oncology - Burnsville Burnsville, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Minnesota Oncology Hematology PA-Maplewood Maplewood, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Minnesota Oncology Hematology PA-Woodbury Woodbury, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Mission Hope Medical Oncology - Arroyo Grande Arroyo Grande, California	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Mission Hope Medical Oncology - Santa Maria Santa Maria, California	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Missouri Baptist Medical Center St Louis, Missouri
Missouri Baptist Sullivan Hospital Sullivan, Missouri
Monmouth Medical Center Long Branch, New Jersey	Site Public Contact - (mary.danish@rwjbh.org)
Monmouth Medical Center Southern Campus Lakewood, New Jersey	Site Public Contact - (mary.danish@rwjbh.org)
Monticello Cancer Center Monticello, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Morristown Medical Center Morristown, New Jersey
Morton Plant Hospital Clearwater, Florida
Mount Sinai Comprehensive Cancer Center at Aventura Aventura, Florida	Site Public Contact - (yenrique@msmc.com)
Mount Sinai Hospital Medical Center Chicago, Illinois	Site Public Contact - (suhi@sinai.org)
Mount Sinai Medical Center Miami Beach, Florida	Site Public Contact - (yenrique@msmc.com)
Munson Medical Center Traverse City, Michigan	Site Public Contact - (crcwm-regulatory@crcwm.org)
MyMichigan Medical Center Alpena Alpena, Michigan	Site Public Contact - (CVResearch@mymichigan.org)
MyMichigan Medical Center Gladwin Gladwin, Michigan	Site Public Contact - (CVResearch@mymichigan.org)
MyMichigan Medical Center Gratiot Alma, Michigan	Site Public Contact - (CVResearch@mymichigan.org)
MyMichigan Medical Center Midland Midland, Michigan	Site Public Contact - (CVResearch@mymichigan.org)
MyMichigan Medical Center Mount Pleasant Mount Pleasant, Michigan	Site Public Contact - (CVResearch@mymichigan.org)
MyMichigan Medical Center Saginaw Saginaw, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
MyMichigan Medical Center Tawas Tawas City, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro Jonesboro, Arkansas	Site Public Contact - (Emily.Carvell@bmhcc.org)
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center New York, New York	Site Public Contact - (cancerclinicaltrials@cumc.columbia.edu)
NYP/Hudson Valley Hospital Cortlandt Manor, New York
NYP/Weill Cornell Medical Center New York, New York
NYU Langone Hospital - Brooklyn Brooklyn, New York	Site Public Contact - (david.wallach@nyulangone.org)
NYU Langone Hospital - Long Island Mineola, New York	Site Public Contact - (cancertrials@nyulangone.org)
National Jewish Health-Main Campus Denver, Colorado
National Jewish Health-Northern Hematology Oncology Thornton, Colorado
National Jewish Health-Western Hematology Oncology Golden, Colorado	Site Public Contact - (glicht@co-cancerresearch.org)
Nebraska Medicine-Bellevue Bellevue, Nebraska	Site Public Contact - (unmcrsa@unmc.edu)
Nebraska Medicine-Village Pointe Omaha, Nebraska
Neurosurgeons of New Jersey-Ridgewood Ridgewood, New Jersey
New England Cancer Specialists Westbrook, Maine
New England Cancer Specialists - Kennebunk Kennebunk, Maine	Site Public Contact - (research@newecs.org)
New England Cancer Specialists - Topsham Topsham, Maine	Site Public Contact - (research@newecs.org)
New Hampshire Oncology Hematology PA-Concord Concord, New Hampshire
New Ulm Medical Center New Ulm, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
New York-Presbyterian Westchester Hospital Bronxville, New York	Site Public Contact - (cancerclinicaltrials@cumc.columbia.edu)
New York-Presbyterian/Brooklyn Methodist Hospital Brooklyn, New York	Site Public Contact - (Adg9003@nyp.org)
Newark Beth Israel Medical Center Newark, New Jersey	Site Public Contact - (Christine.Kosmides@rwjbh.org)
Newland Medical Associates-Clarkston Clarkston, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Newland Medical Associates-Pontiac Pontiac, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
North Coast Cancer Care Sandusky, Ohio	Site Public Contact - (TaussigResearch@ccf.org)
North Memorial Medical Health Center Robbinsdale, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
North Shore Medical Center Skokie, Illinois	Site Public Contact - (Roster@nrgoncology.org)
North Star Lodge Cancer Center at Yakima Valley Memorial Hospital Yakima, Washington	Site Public Contact - (Memorial-ClinicalTrials@yvmh.org)
NorthShore University HealthSystem-Evanston Hospital Evanston, Illinois
NorthShore University HealthSystem-Glenbrook Hospital Glenview, Illinois
NorthShore University HealthSystem-Highland Park Hospital Highland Park, Illinois
Northern Westchester Hospital Mount Kisco, New York	Site Public Contact - (AMellor@northwell.edu)
Northside Hospital Atlanta, Georgia	Site Public Contact - (ClinicalTrials@northside.com)
Northside Hospital - Duluth Duluth, Georgia	Site Public Contact - (Clinical.trials@northside.com)
Northside Hospital - Gwinnett Lawrenceville, Georgia	Site Public Contact - (Clinical.trials@northside.com)
Northwell Health Cancer Institute at Huntington Greenlawn, New York
Northwell Health Imbert Cancer Center Bay Shore, New York
Northwell Health/Center for Advanced Medicine Lake Success, New York
Northwest Hospital Center Randallstown, Maryland	Site Public Contact - (cancerinstitute@lifebridgehealth.org)
Northwest Wisconsin Cancer Center Ashland, Wisconsin	Site Public Contact - (CancerTrials@EssentiaHealth.org)
Northwestern Medicine Cancer Center Delnor Geneva, Illinois	Site Public Contact - (Donald.Smith3@nm.org)
Northwestern Medicine Cancer Center Kishwaukee DeKalb, Illinois	Site Public Contact - (Donald.Smith3@nm.org)
Northwestern Medicine Cancer Center Warrenville Warrenville, Illinois	Site Public Contact - (Donald.Smith3@nm.org)
Northwestern Medicine Glenview Outpatient Center Glenview, Illinois
Northwestern Medicine Grayslake Outpatient Center Grayslake, Illinois
Northwestern Medicine Lake Forest Hospital Lake Forest, Illinois	Site Public Contact - (cancertrials@northwestern.edu)
Northwestern Medicine Oak Brook Oak Brook, Illinois	Site Public Contact - (nctnprogram_rhlccc@northwestern.edu)
Northwestern Medicine Orland Park Orland Park, Illinois	Site Public Contact - (nctnprogram_rhlccc@northwestern.edu)
Northwestern University Chicago, Illinois	Site Public Contact - (cancer@northwestern.edu)
Norwalk Hospital Norwalk, Connecticut	Site Public Contact - (jennifer.long@norwalkhealth.org)
Novant Health Breast Surgery - Greensboro Greensboro, North Carolina	Site Public Contact - (pjordan@novanthealth.org)
Novant Health Cancer Institute - Huntersville Huntersville, North Carolina	Site Public Contact - (kashah@novanthealth.org)
Novant Health Cancer Institute - Kernersville Kernersville, North Carolina	Site Public Contact - (asmarrs@novanthealth.org)
Novant Health Cancer Institute - Matthews Matthews, North Carolina	Site Public Contact - (kashah@novanthealth.org)
Novant Health Cancer Institute - Mooresville Mooresville, North Carolina	Site Public Contact - (kashah@novanthealth.org)
Novant Health Cancer Institute - Mount Airy Mount Airy, North Carolina	Site Public Contact - (asmarrs@novanthealth.org)
Novant Health Cancer Institute - Rowan Salisbury, North Carolina	Site Public Contact - (kashah@novanthealth.org)
Novant Health Cancer Institute - Statesville Statesville, North Carolina	Site Public Contact - (pjordan@novanthealth.org)
Novant Health Cancer Institute - Thomasville Thomasville, North Carolina	Site Public Contact - (pjordan@novanthealth.org)
Novant Health Cancer Institute - Wilkesboro North Wilkesboro, North Carolina	Site Public Contact - (pjordan@novanthealth.org)
Novant Health Colon and Rectal Clinic Clemmons, North Carolina	Site Public Contact - (pjordan@novanthealth.org)
Novant Health Forsyth Medical Center Winston-Salem, North Carolina	Site Public Contact - (pjordan@novanthealth.org)
Novant Health Presbyterian Medical Center Charlotte, North Carolina	Site Public Contact - (kashah@novanthealth.org)
Novant Health Presbyterian Medical Center Huntersville Huntersville, North Carolina	Site Public Contact - (kashah@novanthealth.org)
OSF Saint Anthony's Health Center Alton, Illinois
OSF Saint Francis Hospital and Medical Group Escanaba, Michigan	Site Public Contact - (WI_research_admin@hshs.org)
OSF Saint Francis Medical Center Peoria, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
OSF Saint Francis Radiation Oncology at Pekin Pekin, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
OSF Saint Francis Radiation Oncology at Peoria Cancer Center Peoria, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
OSF Saint Joseph Medical Center Bloomington, Illinois	Site Public Contact - (andersonj@illinoiscancercare.com)
Oakland Colon Rectal Associates Royal Oak, Michigan
Oakland Medical Group Royal Oak, Michigan
Oakville Trafalgar Memorial Hospital Oakville, Ontario
Ochsner Hematology Oncology North Shore - Covington (West Region) Covington, Louisiana
Ochsner Medical Center Jefferson New Orleans, Louisiana	Site Public Contact - (Elisemarie.curry@ochsner.org)
Odette Cancer Centre- Sunnybrook Health Sciences Centre Toronto, Ontario
Ohio State University Comprehensive Cancer Center Columbus, Ohio	Site Public Contact - (Jamesline@osumc.edu)
OhioHealth Mansfield Hospital Mansfield, Ohio	Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
OhioHealth Marion General Hospital Marion, Ohio	Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
OhioHealth O'Bleness Hospital Athens, Ohio	Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
OhioHealth Pickerington Methodist Hospital Pickerington, Ohio	Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
OhioHealth Westerville Medical Campus/Westerville Cancer Center Westerville, Ohio	Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Oncology Associates at Mercy Medical Center Cedar Rapids, Iowa
Oncology Hematology Associates of Saginaw Valley PC Saginaw, Michigan
Oncology Hematology Care Inc-Kenwood Cincinnati, Ohio
Oncology Las Vegas - Henderson Henderson, Nevada	Site Public Contact - (research@sncrf.org)
Oncology Las Vegas - Tenaya Las Vegas, Nevada	Site Public Contact - (research@sncrf.org)
OptumCare Cancer Care at Charleston Las Vegas, Nevada	Site Public Contact - (research@sncrf.org)
OptumCare Cancer Care at Fort Apache Las Vegas, Nevada	Site Public Contact - (research@sncrf.org)
OptumCare Cancer Care at MountainView Las Vegas, Nevada	Site Public Contact - (research@sncrf.org)
OptumCare Cancer Care at Seven Hills Henderson, Nevada	Site Public Contact - (research@sncrf.org)
Orion Cancer Care Findlay, Ohio
Orlando Health Cancer Institute Orlando, Florida	Site Public Contact - (CancerClinicalTrials@orlandohealth.com)
Orlando Health Cancer Institute - Lake Mary Lake Mary, Florida	Site Public Contact - (r-adultoncnewops@orlandohealth.com)
Overlook Hospital Summit, New Jersey
PCR Oncology Arroyo Grande, California	Site Public Contact - (research@sncrf.org)
PROncology San Juan,	Site Public Contact - (info@PRoncology.com)
Pacific Central Coast Health Center-San Luis Obispo San Luis Obispo, California	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Pali Momi Medical Center ‘Aiea, Hawaii
Palo Alto Medical Foundation Health Care Palo Alto, California	Site Public Contact - (clinicalresearch@sutterhealth.org)
Palo Alto Medical Foundation-Camino Division Mountain View, California	Site Public Contact - (clinicalresearch@sutterhealth.org)
Palo Alto Medical Foundation-Fremont Fremont, California	Site Public Contact - (clinicalresearch@sutterhealth.org)
Palo Alto Medical Foundation-Gynecologic Oncology Mountain View, California	Site Public Contact - (clinicalresearch@sutterhealth.org)
Palo Alto Medical Foundation-Santa Cruz Santa Cruz, California	Site Public Contact - (clinicalresearch@sutterhealth.org)
Palo Alto Medical Foundation-Sunnyvale Sunnyvale, California	Site Public Contact - (clinicalresearch@sutterhealth.org)
Paoli Memorial Hospital Paoli, Pennsylvania	Site Public Contact - (turzoe@mlhs.org)
Park Nicollet Clinic - Saint Louis Park Saint Louis Park, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Parkland Health Center - Farmington Farmington, Missouri
Parkview Regional Medical Center Fort Wayne, Indiana
PeaceHealth Saint John Medical Center Longview, Washington	Site Public Contact - (kmakin-bond@peacehealth.org)
PeaceHealth Saint Joseph Medical Center Bellingham, Washington
PeaceHealth Southwest Medical Center Vancouver, Washington
PeaceHealth United General Medical Center Sedro-Woolley, Washington	Site Public Contact - (rcrompton@peacehealth.org)
Penn State Milton S Hershey Medical Center Hershey, Pennsylvania	Site Public Contact - (CTO@hmc.psu.edu)
Penobscot Bay Medical Center Rockport, Maine	Site Public Contact - (clinicalresearch@mainehealth.org)
Penrose-Saint Francis Healthcare Colorado Springs, Colorado	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Phelps Health Delbert Day Cancer Institute Rolla, Missouri	Site Public Contact - (research@phelpshealth.org)
Phelps Memorial Hospital Center Sleepy Hollow, New York
Phoebe Putney Memorial Hospital Albany, Georgia	Site Public Contact - (ga_cares@augusta.edu)
Piedmont Fayette Hospital Fayetteville, Georgia
Piedmont Henry Hospital Stockbridge, Georgia
Piedmont Hospital Atlanta, Georgia
Piedmont Newnan Hospital Newnan, Georgia
Pluta Cancer Center Rochester, New York	Site Public Contact - (Roster@nrgoncology.org)
Pocono Medical Center East Stroudsburg, Pennsylvania	Site Public Contact - (Morgan_M.Horton@lvhn.org)
Premier Blood and Cancer Center Dayton, Ohio
Premier Hematology Oncology Care Sterling Heights, Michigan
Presbyterian Kaseman Hospital Albuquerque, New Mexico	Site Public Contact - (WBurman@phs.org)
Presbyterian Rust Medical Center/Jorgensen Cancer Center Rio Rancho, New Mexico	Site Public Contact - (WBurman@phs.org)
Princeton Community Hospital Princeton, West Virginia
ProMedica Flower Hospital Sylvania, Ohio	Site Public Contact - (PCIOncResearch@promedica.org)
ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital Toledo, Ohio	Site Public Contact - (PCIOncResearch@promedica.org)
Providence Alaska Medical Center Anchorage, Alaska	Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org)
Providence Cancer Institute Clackamas Clinic Clackamas, Oregon
Providence Hood River Memorial Hospital Hood River, Oregon	Site Public Contact - (canrsrchstudies@provdience.org)
Providence Medical Foundation - Santa Rosa Santa Rosa, California
Providence Newberg Medical Center Newberg, Oregon	Site Public Contact - (CanRsrchStudies@providence.org)
Providence Portland Medical Center Portland, Oregon	Site Public Contact - (CanRsrchStudies@providence.org)
Providence Queen of The Valley Napa, California
Providence Regional Cancer Partnership Everett, Washington	Site Public Contact - (marilyn.birchman@providence.org)
Providence Regional Cancer System-Aberdeen Aberdeen, Washington	Site Public Contact - (deidre.dillon@providence.org)
Providence Regional Cancer System-Centralia Centralia, Washington	Site Public Contact - (deidre.dillon@providence.org)
Providence Regional Cancer System-Lacey Lacey, Washington	Site Public Contact - (deidre.dillon@providence.org)
Providence Regional Cancer System-Shelton Shelton, Washington
Providence Regional Cancer System-Yelm Yelm, Washington
Providence Saint Joseph Medical Center/Disney Family Cancer Center Burbank, California	Site Public Contact - (Najee.Boucher@providence.org)
Providence Saint Mary Regional Cancer Center Walla Walla, Washington	Site Public Contact - (Cheryl.Dodd@providence.org)
Providence Saint Vincent Medical Center Portland, Oregon	Site Public Contact - (CanRsrchStudies@providence.org)
Providence Santa Rosa Memorial Hospital Santa Rosa, California
Providence Willamette Falls Medical Center Oregon City, Oregon	Site Public Contact - (CanRsrchStudies@providence.org)
Puerto Rico Hematology Oncology Group Bayamón,
Queen's Cancer Cenrer - POB I Honolulu, Hawaii
Queen's Cancer Center - Kuakini Honolulu, Hawaii
Queen's Cancer Center - Pearlridge ‘Aiea, Hawaii
Queen's Medical Center Honolulu, Hawaii
Radiation Oncology Associates Reno, Nevada	Site Public Contact - (research@sncrf.org)
Radiation Oncology Centers of Nevada Central Las Vegas, Nevada	Site Public Contact - (research@sncrf.org)
Radiation Oncology Centers of Nevada Southeast Las Vegas, Nevada	Site Public Contact - (research@sncrf.org)
Rapid City Regional Hospital Rapid City, South Dakota
Reading Hospital West Reading, Pennsylvania
Reading Hospital McGlinn Cancer Institute at Phoenixville Phoenixville, Pennsylvania
Redeemer Health Meadowbrook, Pennsylvania
Regional Cancer Center-Lee Memorial Health System Fort Myers, Florida
Regions Hospital Saint Paul, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Reid Health Richmond, Indiana
Renown Regional Medical Center Reno, Nevada	Site Public Contact - (research@sncrf.org)
Rex Hematology Oncology Associates-Cary Cary, North Carolina	Site Public Contact - (CancCtrOncologyClinicalResearch@unchealth.unc.edu)
Rex Hematology Oncology Associates-Garner Garner, North Carolina	Site Public Contact - (CancCtrOncologyClinicalResearch@unchealth.unc.edu)
Rice Memorial Hospital Willmar, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Riddle Memorial Hospital Media, Pennsylvania	Site Public Contact - (turzoe@mlhs.org)
Ridgeview Medical Center Waconia, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Ridley-Tree Cancer Center Santa Barbara, California	Site Public Contact - (clinicalresearch@sutterhealth.org)
Riverside Methodist Hospital Columbus, Ohio	Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Riverwood Healthcare Center Aitkin, Minnesota	Site Public Contact - (CancerTrials@EssentiaHealth.org)
Robert Wood Johnson University Hospital Somerset Somerville, New Jersey	Site Public Contact - (Siby.Varughese@rwjbh.org)
Rocky Mountain Cancer Centers-Penrose Colorado Springs, Colorado	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Rohnert Park Cancer Center Rohnert Park, California	Site Public Contact - (Kpoct@kp.org)
Roswell Park Cancer Institute Buffalo, New York	Site Public Contact - (askroswell@roswellpark.org)
Rowan Regional Medical Center Salisbury, North Carolina	Site Public Contact - (nnechiporchik@novanthealth.org)
Royal Victoria Regional Health Centre Barrie, Ontario
Rush MD Anderson Cancer Center Chicago, Illinois	Site Public Contact - (Cancer_Studies@rush.edu)
Rush MD Anderson Cancer Center at Rush Lisle Lisle, Illinois	Site Public Contact - (Cancer_Studies@rush.edu)
Rush MD Anderson Cancer Center at Rush Oak Park Oak Park, Illinois	Site Public Contact - (Cancer_Studies@rush.edu)
Rush-Copley Healthcare Center Yorkville, Illinois	Site Public Contact - (Cancer.Research@rushcopley.com)
Rush-Copley Medical Center Aurora, Illinois	Site Public Contact - (RCMC_Cancer_Research@rush.edu)
Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey
SIH Cancer Institute Carterville, Illinois	Site Public Contact - (clinical.research@sih.net)
SMC Center for Hematology Oncology Union Union, South Carolina	Site Public Contact - (kmertz-rivera@gibbscc.org)
SSM Health Good Samaritan Mount Vernon, Illinois	Site Public Contact - (gayla.hall@ssmhealth.com)
Saint Alphonsus Cancer Care Center-Baker City Baker City, Oregon	Site Public Contact - (mccinfo@mtcancer.org)
Saint Alphonsus Cancer Care Center-Boise Boise, Idaho	Site Public Contact - (stephanie.couch@stjoeshealth.org)
Saint Alphonsus Cancer Care Center-Caldwell Caldwell, Idaho	Site Public Contact - (stephanie.couch@stjoeshealth.org)
Saint Alphonsus Cancer Care Center-Nampa Nampa, Idaho	Site Public Contact - (mccinfo@mtcancer.org)
Saint Alphonsus Cancer Care Center-Ontario Ontario, Oregon	Site Public Contact - (mccinfo@mtcancer.org)
Saint Anthony Hospital Lakewood, Colorado	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Anthony North Hospital Westminster, Colorado	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Anthony's Hospital Cancer Care Center St. Petersburg, Florida	Site Public Contact - (Research.CTO@baycare.org)
Saint Barnabas Medical Center Livingston, New Jersey	Site Public Contact - (joanne.loeb@rwjbh.org)
Saint Charles Health System Bend, Oregon	Site Public Contact - (nosall@stcharleshealthcare.org)
Saint Charles Health System-Redmond Redmond, Oregon
Saint Elizabeth Boardman Hospital Boardman, Ohio
Saint Elizabeth Regional Medical Center Lincoln, Nebraska
Saint Elizabeth Youngstown Hospital Youngstown, Ohio
Saint Francis Cancer Center Greenville, South Carolina	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Francis Medical Center Cape Girardeau, Missouri	Site Public Contact - (sfmc@sfmc.net)
Saint Francis Regional Medical Center Shakopee, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Saint James Community Hospital and Cancer Treatment Center Butte, Montana
Saint John's Hospital - Healtheast Maplewood, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
Saint Joseph Hospital Lexington, Kentucky	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Joseph Hospital - Cancer Centers of Colorado Denver, Colorado
Saint Joseph Hospital East Lexington, Kentucky	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Joseph London London, Kentucky	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Joseph Mount Sterling Mount Sterling, Kentucky	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Joseph Radiation Oncology Resource Center Lexington, Kentucky	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Joseph Warren Hospital Warren, Ohio
Saint Joseph's Medical Center Stockton, California
Saint Joseph's/Candler - Bluffton Campus Bluffton, South Carolina	Site Public Contact - (underberga@sjchs.org)
Saint Luke's Cancer Center - Allentown Allentown, Pennsylvania
Saint Luke's Cancer Institute - Boise Boise, Idaho	Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Fruitland Fruitland, Idaho	Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Meridian Meridian, Idaho	Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Nampa Nampa, Idaho	Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Twin Falls Twin Falls, Idaho	Site Public Contact - (eslinget@slhs.org)
Saint Luke's Hospital - Monroe Campus Stroudsburg, Pennsylvania	Site Public Contact - (Roster@nrgoncology.org)
Saint Luke's Hospital - Upper Bucks Campus Quakertown, Pennsylvania
Saint Luke's Hospital-Anderson Campus Easton, Pennsylvania	Site Public Contact - (Roster@nrgoncology.org)
Saint Luke's University Hospital-Bethlehem Campus Bethlehem, Pennsylvania
Saint Mary Corwin Medical Center Pueblo, Colorado	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Mary's Hospital Centralia, Illinois	Site Public Contact - (Roster@nrgoncology.org)
Saint Mary's Hospital and Regional Medical Center Grand Junction, Colorado	Site Public Contact - (ccrp@co-cancerresearch.org)
Saint Mary's Oncology/Hematology Associates of Marlette Marlette, Michigan
Saint Mary's Oncology/Hematology Associates of West Branch West Branch, Michigan
Saint Mary's Regional Medical Center Reno, Nevada	Site Public Contact - (research@sncrf.org)
Saint Michael Cancer Center Silverdale, Washington	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Patrick Hospital - Community Hospital Missoula, Montana	Site Public Contact - (amy.hanneman@providence.org)
Saint Vincent Frontier Cancer Center Billings, Montana
Saint Vincent Hospital Erie, Pennsylvania
Saint Vincent Hospital Cancer Center Green Bay Green Bay, Wisconsin	Site Public Contact - (WI_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Oconto Falls Oconto Falls, Wisconsin	Site Public Contact - (WI_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Saint Mary's Green Bay, Wisconsin	Site Public Contact - (wi_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Sheboygan Sheboygan, Wisconsin	Site Public Contact - (wi_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Sturgeon Bay Sturgeon Bay, Wisconsin	Site Public Contact - (wi_research_admin@hshs.org)
Sainte Genevieve County Memorial Hospital Sainte Genevieve, Missouri
Salina Regional Health Center Salina, Kansas	Site Public Contact - (mleepers@srhc.com)
Salinas Valley Memorial Salinas, California	Site Public Contact - (tnielsen2@svmh.com)
San Juan City Hospital San Juan,
San Juan Community Oncology Group San Juan,
Sanford Bismarck Medical Center Bismarck, North Dakota	Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford Broadway Medical Center Fargo, North Dakota	Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford Cancer Center Oncology Clinic Sioux Falls, South Dakota	Site Public Contact - (OncologyClinicTrialsSF@sanfordhealth.org)
Sanford Cancer Center Worthington Worthington, Minnesota
Sanford Joe Lueken Cancer Center Bemidji, Minnesota	Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford Medical Center Fargo Fargo, North Dakota
Sanford Roger Maris Cancer Center Fargo, North Dakota	Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford South University Medical Center Fargo, North Dakota
Sanford Thief River Falls Medical Center Thief River Falls, Minnesota
Sanford USD Medical Center - Sioux Falls Sioux Falls, South Dakota	Site Public Contact - (OncologyClinicalTrialsSF@SanfordHealth.org)
Santa Cruz Radiation Oncology Medical Group Santa Cruz, California	Site Public Contact - (clinicalresearch@sutterhealth.org)
Sarasota Memorial Health Care Center at University Parkway Sarasota, Florida
Sarasota Memorial Hospital Sarasota, Florida
Sarasota Memorial Hospital-Venice N. Venice, Florida
Sechler Family Cancer Center Lebanon, Pennsylvania	Site Public Contact - (doxenberg@wellspan.org)
Shaw Cancer Center Edwards, Colorado
Sheboygan Physicians Group Sheboygan, Wisconsin	Site Public Contact - (wi_research_admin@hshs.org)
Sibley Memorial Hospital Washington D.C., District of Columbia	Site Public Contact - (jquiver1@jhmi.edu)
Sidney Kimmel Cancer Center Washington Township Sewell, New Jersey	Site Public Contact - (ONCTrialNow@jefferson.edu)
Sidney and Lois Eskenazi Hospital Indianapolis, Indiana	Site Public Contact - (iutrials@iu.edu)
Sinai Hospital of Baltimore Baltimore, Maryland
Siteman Cancer Center at Christian Hospital St Louis, Missouri	Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center at Saint Peters Hospital City of Saint Peters, Missouri	Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center at West County Hospital Creve Coeur, Missouri	Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center-South County St Louis, Missouri	Site Public Contact - (info@siteman.wustl.edu)
Skagit Regional Health Cancer Care Center Mount Vernon, Washington	Site Public Contact - (rcccclinicalresearch@skagitvalleyhospital.org)
Smilow Cancer Hospital Care Center - Guilford Guilford, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center - Waterford Waterford, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center - Westerly Westerly, Rhode Island	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center at Glastonbury Glastonbury, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center at Greenwich Greenwich, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center at Long Ridge Stamford, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center at Saint Francis Hartford, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center-Fairfield Fairfield, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center-Trumbull Trumbull, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital-Derby Care Center Derby, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital-Torrington Care Center Torrington, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital-Waterbury Care Center Waterbury, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Solinsky Center for Cancer Care Manchester, New Hampshire
South Carolina Cancer Specialists PC Hilton Head Island, South Carolina	Site Public Contact - (underberga@sjchs.org)
South Georgia Medical Center/Pearlman Cancer Center Valdosta, Georgia	Site Public Contact - (maryann.heddon@sgmc.org)
South Jordan Health Center South Jordan, Utah	Site Public Contact - (cancerinfo@hci.utah.edu)
South Pointe Hospital Warrensville Heights, Ohio	Site Public Contact - (TaussigResearch@ccf.org)
South Sacramento Cancer Center Sacramento, California	Site Public Contact - (Kpoct@kp.org)
Southern Illinois University School of Medicine Springfield, Illinois
Southpointe-Sanford Medical Center Fargo Fargo, North Dakota
Spartanburg Medical Center Spartanburg, South Carolina	Site Public Contact - (kmertz-rivera@gibbscc.org)
Springfield Clinic Springfield, Illinois
Springfield Memorial Hospital Springfield, Illinois	Site Public Contact - (pallante.beth@mhsil.com)
Stamford Hospital/Bennett Cancer Center Stamford, Connecticut
Stanford Cancer Center South Bay San Jose, California	Site Public Contact - (ccto-office@stanford.edu)
Stanford Cancer Institute Palo Alto Palo Alto, California	Site Public Contact - (ccto-office@stanford.edu)
Staten Island University Hospital Staten Island, New York
Stony Brook University Medical Center Stony Brook, New York
Straub Clinic and Hospital Honolulu, Hawaii
Straub Medical Center - Kahului Clinic Kahului, Hawaii	Site Public Contact - (lori.kam@hawaiipacifichealth.org)
Straub Pearlridge Clinic ‘Aiea, Hawaii
Summa Health Medina Medical Center Medina, Ohio	Site Public Contact - (cancerresearch@summahealth.org)
Summa Health System - Akron Campus Akron, Ohio	Site Public Contact - (cancerresearch@summahealth.org)
Summa Health System - Barberton Campus Barberton, Ohio	Site Public Contact - (cancerresearch@summahealth.org)
Summerlin Hospital Medical Center Las Vegas, Nevada	Site Public Contact - (research@sncrf.org)
Sunrise Hospital and Medical Center Las Vegas, Nevada	Site Public Contact - (research@sncrf.org)
Sutter Auburn Faith Hospital Auburn, California	Site Public Contact - (clinicalresearch@sutterhealth.org)
Sutter Cancer Centers Radiation Oncology Services-Auburn Auburn, California	Site Public Contact - (clinicalresearch@sutterhealth.org)
Sutter Cancer Centers Radiation Oncology Services-Cameron Park Cameron Park, California	Site Public Contact - (clinicalresearch@sutterhealth.org)
Sutter Cancer Centers Radiation Oncology Services-Roseville Roseville, California	Site Public Contact - (clinicalresearch@sutterhealth.org)
Sutter Cancer Research Consortium Novato, California	Site Public Contact - (clinicalresearch@sutterhealth.org)
Sutter Davis Hospital Davis, California	Site Public Contact - (NCIclinicaltrials@sutterhealth.org)
Sutter Medical Center Sacramento Sacramento, California	Site Public Contact - (clinicalresearch@sutterhealth.org)
Sutter Pacific Medical Foundation Santa Rosa, California	Site Public Contact - (clinicalresearch@sutterhealth.org)
Sutter Roseville Medical Center Roseville, California	Site Public Contact - (clinicalresearch@sutterhealth.org)
Sutter Solano Medical Center/Cancer Center Vallejo, California	Site Public Contact - (clinicalresearch@sutterhealth.org)
Swedish Cancer Institute-Edmonds Edmonds, Washington	Site Public Contact - (PCRC-NCORP@Swedish.org)
Swedish Cancer Institute-Issaquah Issaquah, Washington	Site Public Contact - (PCRC-NCORP@Swedish.org)
Swedish Covenant Hospital Chicago, Illinois
Swedish Medical Center-Ballard Campus Seattle, Washington	Site Public Contact - (PCRC-NCORP@Swedish.org)
Swedish Medical Center-Cherry Hill Seattle, Washington	Site Public Contact - (PCRC-NCORP@Swedish.org)
Swedish Medical Center-First Hill Seattle, Washington	Site Public Contact - (PCRC-NCORP@Swedish.org)
Tamarack Health Hayward Medical Center Hayward, Wisconsin
Texas Tech University Health Sciences Center-Lubbock Lubbock, Texas
The Cancer Center of Hawaii-Liliha Honolulu, Hawaii
The Cancer Center of Hawaii-Pali Momi ‘Aiea, Hawaii
The Cancer Institute at Saint Francis Hospital East Hills, New York	Site Public Contact - (Stephanie.Solito@chsli.org)
The Cancer Institute of New Jersey Hamilton Hamilton, New Jersey
The Christ Hospital Cincinnati, Ohio
The Don and Sybil Harrington Cancer Center Amarillo, Texas	Site Public Contact - (Gina.Cravey@bsahs.org)
The Hospital of Central Connecticut New Britain, Connecticut
The Iowa Clinic PC West Des Moines, Iowa
The James Graham Brown Cancer Center at University of Louisville Louisville, Kentucky
The New York Hospital Medical Center of Queens Flushing, New York	Site Public Contact - (Roster@nrgoncology.org)
The Permanente Medical Group-Roseville Radiation Oncology Roseville, California	Site Public Contact - (Kpoct@kp.org)
The Queen's Medical Center - West Oahu ‘Ewa Beach, Hawaii	Site Public Contact - (rohta@queens.org)
The University of Kansas Cancer Center - Olathe Olathe, Kansas	Site Public Contact - (OlatheCCResearch@kumc.edu)
The Valley Hospital - Luckow Pavilion Paramus, New Jersey	Site Public Contact - (clinicaltrialsresearch@valleyhealth.com)
The West Clinic - Wolf River Germantown, Tennessee	Site Public Contact - (afletcher@westclinic.com)
ThedaCare Cancer Care - Berlin Berlin, Wisconsin	Site Public Contact - (ResearchDept@thedacare.org)
ThedaCare Cancer Care - Shawano Shawano, Wisconsin	Site Public Contact - (ResearchDept@thedacare.org)
ThedaCare Cancer Care - Waupaca Waupaca, Wisconsin	Site Public Contact - (ResearchDept@thedacare.org)
ThedaCare Regional Cancer Center Appleton, Wisconsin	Site Public Contact - (ResearchDept@thedacare.org)
ThedaCare Regional Medical Center - Neenah Neenah, Wisconsin	Site Public Contact - (ResearchDept@thedacare.org)
Thomas Jefferson University Hospital Philadelphia, Pennsylvania	Site Public Contact - (ONCTrialNow@jefferson.edu)
Torrance Memorial Physician Network - Cancer Care Torrance, California	Site Public Contact - (courtney.steeneken@tmphysicians.com)
Tower Cancer Research Foundation Beverly Hills, California	Site Public Contact - (towercancerresearch@toweroncology.com)
TriHealth Cancer Institute-Anderson Cincinnati, Ohio	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
TriHealth Cancer Institute-Westside Cincinnati, Ohio	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Trinity Health Grand Rapids Hospital Grand Rapids, Michigan	Site Public Contact - (crcwm-regulatory@crcwm.org)
Trinity Health IHA Medical Group Hematology Oncology - Brighton Brighton, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology - Canton Canton, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital Chelsea, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus Ypsilanti, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Medical Center - Brighton Brighton, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Medical Center - Canton Canton, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Muskegon Hospital Muskegon, Michigan	Site Public Contact - (crcwm-regulatory@crcwm.org)
Trinity Health Saint Joseph Mercy Hospital Ann Arbor Ann Arbor, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Saint Joseph Mercy Oakland Hospital Pontiac, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Saint Mary Mercy Livonia Hospital Livonia, Michigan	Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Medical Center Moline, Illinois
Tripler Army Medical Center Honolulu, Hawaii
Tufts Medical Center Boston, Massachusetts	Site Public Contact - (ContactUsCancerCenter@TuftsMedicalCenter.org)
Tufts Medical Center Cancer Center Stoneham Stoneham, Massachusetts	Site Public Contact - (NCCCR@Tuftsmedicalcenter.org)
UC Comprehensive Cancer Center at Silver Cross New Lenox, Illinois	Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu)
UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California	Site Public Contact - (ucstudy@uci.edu)
UCHealth - Cherry Creek Denver, Colorado	Site Public Contact - (Roster@nrgoncology.org)
UCHealth Highlands Ranch Hospital Highlands Ranch, Colorado
UCHealth Lone Tree Health Center Lone Tree, Colorado	Site Public Contact - (Roster@nrgoncology.org)
UCHealth Memorial Hospital Central Colorado Springs, Colorado
UCHealth University of Colorado Hospital Aurora, Colorado
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California	Site Public Contact - (ucstudy@uci.edu)
UCLA / Jonsson Comprehensive Cancer Center Los Angeles, California
UChicago Medicine Northwest Indiana Crown Point, Indiana	Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu)
UI Health Care Mission Cancer and Blood - Ankeny Clinic Ankeny, Iowa
UI Health Care Mission Cancer and Blood - Des Moines Clinic Des Moines, Iowa
UI Health Care Mission Cancer and Blood - Laurel Clinic Des Moines, Iowa
UI Health Care Mission Cancer and Blood - Waukee Clinic Waukee, Iowa
UI Health Care Mission Cancer and Blood - West Des Moines Clinic Clive, Iowa
UI Healthcare Mission Cancer and Blood - Fort Dodge Fort Dodge, Iowa	Site Public Contact - (trials@missioncancer.com)
UM Baltimore Washington Medical Center/Tate Cancer Center Glen Burnie, Maryland
UM Sylvester Comprehensive Cancer Center at Aventura Aventura, Florida
UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables, Florida
UM Sylvester Comprehensive Cancer Center at Deerfield Beach Deerfield Beach, Florida
UM Sylvester Comprehensive Cancer Center at Doral Doral, Florida	Site Public Contact - (kginnity@med.miami.edu)
UM Sylvester Comprehensive Cancer Center at Kendall Miami, Florida
UM Sylvester Comprehensive Cancer Center at Plantation Plantation, Florida
UM Upper Chesapeake Hematology and Oncology - Aberdeen Aberdeen, Maryland
UM Upper Chesapeake Medical Center Bel Air, Maryland
UMC Cancer Center / UMC Health System Lubbock, Texas
UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina	Site Public Contact - (cancerclinicaltrials@med.unc.edu)
UNC REX Cancer Center of Wakefield Raleigh, North Carolina	Site Public Contact - (CancCtrOncologyClinicalResearch@unchealth.unc.edu)
UNC Rex Healthcare Raleigh, North Carolina	Site Public Contact - (CancCtrOncologyClinicalResearch@unchealth.unc.edu)
UP Health System Hematology Oncology Marquette Marquette, Michigan	Site Public Contact - (Dianna.Larson@mghs.org)
UP Health System Marquette Marquette, Michigan	Site Public Contact - (Dianna.Larson@mghs.org)
UPMC Cancer Center at UPMC Horizon Farrell, Pennsylvania	Site Public Contact - (Roster@nrgoncology.org)
UPMC Cancer Centers - Arnold Palmer Pavilion Greensburg, Pennsylvania
UPMC Hillman Cancer Center - Monroeville Monroeville, Pennsylvania	Site Public Contact - (haneydl@upmc.edu)
UPMC Hillman Cancer Center - New Castle New Castle, Pennsylvania	Site Public Contact - (haneydl@upmc.edu)
UPMC Hillman Cancer Center - Passavant - Cranberry Cranberry Township, Pennsylvania	Site Public Contact - (haneydl@upmc.edu)
UPMC Hillman Cancer Center Erie Erie, Pennsylvania	Site Public Contact - (haneydl@upmc.edu)
UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion Mechanicsburg, Pennsylvania	Site Public Contact - (haneydl@upmc.edu)
UPMC Pinnacle Cancer Center/Community Osteopathic Campus Harrisburg, Pennsylvania	Site Public Contact - (klitchfield@PINNACLEHEALTH.org)
UPMC-Magee Womens Hospital Pittsburgh, Pennsylvania
UPMC-Saint Clair Hospital Cancer Center Pittsburgh, Pennsylvania
UPMC-Shadyside Hospital Pittsburgh, Pennsylvania
USC / Norris Comprehensive Cancer Center Los Angeles, California
USC Norris Oncology/Hematology-Newport Beach Newport Beach, California
UTMB Cancer Center at Victory Lakes League City, Texas
UTMB Health Angleton Danbury Campus Angleton, Texas
UW Health Carbone Cancer Center Rockford Rockford, Illinois	Site Public Contact - (lkline@uwhealth.org)
United Hospital Saint Paul, Minnesota	Site Public Contact - (mmcorc@healthpartners.com)
United Hospital Center Bridgeport, West Virginia
Unity Hospital Fridley, Minnesota
University Cancer Center Las Vegas, Nevada	Site Public Contact - (research@sncrf.org)
University Cancer and Blood Center LLC Athens, Georgia	Site Public Contact - (research@universitycancer.com)
University Health Truman Medical Center Kansas City, Missouri
University Medical Center New Orleans New Orleans, Louisiana	Site Public Contact - (emede1@lsuhsc.edu)
University Medical Center of Southern Nevada Las Vegas, Nevada	Site Public Contact - (research@sncrf.org)
University of Alabama at Birmingham Cancer Center Birmingham, Alabama
University of Arkansas for Medical Sciences Little Rock, Arkansas
University of California Davis Comprehensive Cancer Center Sacramento, California
University of Chicago Comprehensive Cancer Center Chicago, Illinois	Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu)
University of Chicago Medicine-Orland Park Orland Park, Illinois	Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu)
University of Florida Health Science Center - Gainesville Gainesville, Florida
University of Hawaii Cancer Center Honolulu, Hawaii
University of Iowa Healthcare Cancer Services Quad Cities Bettendorf, Iowa	Site Public Contact - (katherine-daprile@uiowa.edu)
University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa
University of Kansas Cancer Center Kansas City, Kansas	Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Cancer Center - Briarcliff Kansas City, Missouri
University of Kansas Cancer Center - Lee's Summit Lee's Summit, Missouri	Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Cancer Center - North Kansas City, Missouri	Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Cancer Center at North Kansas City Hospital North Kansas City, Missouri	Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Cancer Center-Overland Park Overland Park, Kansas	Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Health System Saint Francis Campus Topeka, Kansas
University of Kansas Hospital-Indian Creek Campus Overland Park, Kansas	Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Hospital-Westwood Cancer Center Westwood, Kansas	Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kentucky/Markey Cancer Center Lexington, Kentucky
University of Maryland/Greenebaum Cancer Center Baltimore, Maryland
University of Miami Miller School of Medicine-Sylvester Cancer Center Miami, Florida
University of Michigan - Brighton Center for Specialty Care Brighton, Michigan
University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan	Site Public Contact - (slusserb@med.umich.edu)
University of Michigan Health - Sparrow Lansing Lansing, Michigan	Site Public Contact - (harsha.trivedi@umhsparrow.org)
University of Michigan Health - West Wyoming, Michigan	Site Public Contact - (crcwm-regulatory@crcwm.org)
University of Nebraska Medical Center Omaha, Nebraska	Site Public Contact - (unmcrsa@unmc.edu)
University of New Mexico Cancer Center Albuquerque, New Mexico	Site Public Contact - (HSC-ClinicalTrialInfo@salud.unm.edu)
University of North Carolina-Hillsborough Campus Hillsborough, North Carolina	Site Public Contact - (cancerclinicaltrials@med.unc.edu)
University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma	Site Public Contact - (ou-clinical-trials@ouhsc.edu)
University of Pennsylvania/Abramson Cancer Center Philadelphia, Pennsylvania	Site Public Contact - (PMCancerResearch@pennmedicine.upenn.edu)
University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania
University of Rochester Rochester, New York
University of Tennessee - Knoxville Knoxville, Tennessee
University of Texas Health Science Center at San Antonio San Antonio, Texas	Site Public Contact - (phoresearchoffice@uthscsa.edu)
University of Texas Medical Branch Galveston, Texas	Site Public Contact - (clinical.research@utmb.edu)
University of Utah Sugarhouse Health Center Salt Lake City, Utah	Site Public Contact - (cancerinfo@hci.utah.edu)
University of Vermont Medical Center Burlington, Vermont	Site Public Contact - (rpo@uvm.edu)
University of Vermont and State Agricultural College Burlington, Vermont	Site Public Contact - (rpo@uvm.edu)
University of Virginia Cancer Center Charlottesville, Virginia	Site Public Contact - (uvacancertrials@hscmail.mcc.virginia.edu)
University of Washington Medical Center - Montlake Seattle, Washington
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center Madison, Wisconsin	Site Public Contact - (clinicaltrials@cancer.wisc.edu)
University of Wisconsin Carbone Cancer Center - Johnson Creek Johnson Creek, Wisconsin	Site Public Contact - (clinicaltrials@cancer.wisc.edu)
University of Wisconsin Carbone Cancer Center - University Hospital Madison, Wisconsin	Site Public Contact - (clinicaltrials@cancer.wisc.edu)
UofL Health Medical Center Northeast Louisville, Kentucky	Site Public Contact - (ctoinfo@louisville.edu)
Upper Valley Medical Center Troy, Ohio	Site Public Contact - (clinical.trials@daytonncorp.org)
Urology Specialists of Nevada - Central Las Vegas, Nevada	Site Public Contact - (research@sncrf.org)
Urology Specialists of Nevada - Green Valley Henderson, Nevada	Site Public Contact - (research@sncrf.org)
Urology Specialists of Nevada - Northwest Las Vegas, Nevada	Site Public Contact - (research@sncrf.org)
Urology Specialists of Nevada - Southwest Las Vegas, Nevada	Site Public Contact - (research@sncrf.org)
VCU Community Memorial Health Center South Hill, Virginia	Site Public Contact - (nemer.elmouallem@vcuhealth.org)
VCU Massey Cancer Center at Stony Point Richmond, Virginia	Site Public Contact - (ctoclinops@vcu.edu)
VCU Massey Comprehensive Cancer Center Richmond, Virginia	Site Public Contact - (CTOclinops@vcu.edu)
Valley Health System Ridgewood Campus Ridgewood, New Jersey	Site Public Contact - (clinicaltrialsresearch@valleyhealth.com)
Valley Health System-Hematology/Oncology Westwood, New Jersey
Valley Medical Center Renton, Washington	Site Public Contact - (research@valleymed.org)
Valley Medical Group - Wayne Multispecialty Practice Wayne, New Jersey
Valley Radiation Oncology Peru, Illinois
Vince Lombardi Cancer Clinic - Oshkosh Oshkosh, Wisconsin	Site Public Contact - (ncorp@aurora.org)
Vince Lombardi Cancer Clinic-Sheboygan Sheboygan, Wisconsin	Site Public Contact - (ncorp@aurora.org)
Vince Lombardi Cancer Clinic-Two Rivers Two Rivers, Wisconsin	Site Public Contact - (ncorp@aurora.org)
Virginia Mason Medical Center Seattle, Washington	Site Public Contact - (cancerresearch@virginiamason.org)
Virtua Samson Cancer Center Moorestown, New Jersey	Site Public Contact - (nctn@pennmedicine.upenn.edu)
Virtua Voorhees Voorhees Township, New Jersey	Site Public Contact - (nctn@pennmedicine.upenn.edu)
WVUH-Berkely Medical Center Martinsburg, West Virginia
Wake Forest University Health Sciences Winston-Salem, North Carolina
Wake Forest University at Clemmons Clemmons, North Carolina
Walter Knox Memorial Hospital Emmett, Idaho
Washington University School of Medicine St Louis, Missouri	Site Public Contact - (info@siteman.wustl.edu)
Waterloo Regional Health Network Kitchener, Ontario	Site Public Contact - (research@wrhn.ca)
Waverly Hematology Oncology Cary, North Carolina	Site Public Contact - (TCHILDRESS@wakemed.org)
Wayne Hospital Greenville, Ohio
Wayne State University/Karmanos Cancer Institute Detroit, Michigan	Site Public Contact - (ctoadmin@karmanos.org)
Weisberg Cancer Treatment Center Farmington Hills, Michigan	Site Public Contact - (ctoadmin@karmanos.org)
Welch Cancer Center Sheridan, Wyoming
WellSpan Health-York Cancer Center York, Pennsylvania
WellSpan Health-York Hospital York, Pennsylvania
WellSpan Medical Oncology and Hematology Hanover, Pennsylvania
West Michigan Cancer Center Kalamazoo, Michigan	Site Public Contact - (crcwm-regulatory@crcwm.org)
West Penn Hospital Pittsburgh, Pennsylvania
West Suburban Medical Center River Forest, Illinois
West Virginia University Healthcare Morgantown, West Virginia	Site Public Contact - (cancertrialsinfo@hsc.wvu.edu)
Western Illinois Cancer Treatment Center Galesburg, Illinois
Wexford Health and Wellness Pavilion Wexford, Pennsylvania	Site Public Contact - (Dawnmarie.DeFazio@ahn.org)
Wheeling Hospital/Schiffler Cancer Center Wheeling, West Virginia
Wilcox Memorial Hospital and Kauai Medical Clinic Lihue, Hawaii
William E Kahlert Regional Cancer Center/Sinai Hospital Westminster, Maryland
Wilmot Cancer Institute at Webster Webster, New York
Winter Haven Hospital Winter Haven, Florida	Site Public Contact - (Research.CTO@baycare.org)
Women and Infants Hospital Providence, Rhode Island
Woodland Memorial Hospital Woodland, California	Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Yale University New Haven, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Yale-New Haven Hospital North Haven Medical Center North Haven, Connecticut	Site Public Contact - (canceranswers@yale.edu)
Yolanda G Barco Oncology Institute Meadville, Pennsylvania	Site Public Contact - (Roster@nrgoncology.org)

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies (CaDAnCe-101)

Contact(s):

BeOne Medicines - clinicaltrials@beonemed.com

Principal Investigator:

System ID: NCT05006716

Show full eligibility criteria

Inclusion Criteria :
• Confirmed diagnosis (per World Health Organization (WHO) guidelines, unless otherwise noted) of one of the following: Marginal Zone Lymphoma (MZL), R/R follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), R/R diffuse large B-cell lymphoma (DLBCL), or Richter's transformation to DLBCL.
• Participants who have previously received a covalently-binding Bruton´s tyrosine kinase (BTK) inhibitor (BTKi) in any line of therapy must have received treatment with the BTK inhibitor for ≥ 8 weeks (unless reason for discontinuation is intolerance).
• For dose-finding and dose-expansion, participants who had previously received a covalently-binding BTK inhibitor as monotherapy or in combination with other anticancer agents are eligible for the study if they meet any of the following criteria: discontinued the previous BTK inhibitor due to disease progression, experienced disease progression after completing treatment with a BTK inhibitor or discontinued the BTK inhibitor due to toxicity or intolerance.
• Measurable disease by radiographic assessment or serum IgM level (WM only)
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2
• Participants enrolling in the dose finding phase of the study may be previously treated with a BTKi or may be naïve to BTKi therapy depending on the diagnosis and country of enrollment; participants with MCL enrolling in the expansion cohorts (Phase 2) must have been treated with a BTKi in a prior line of therapy; CLL/SLL participants, in addition to being treated with a BTKi in a prior line of therapy, must also have received a Bcl-2 inhibitor in a prior line of therapy as well (Phase 2).

Exclusion Criteria:

• Prior malignancy (other than the disease under study) within the past 2 years, except in situ malignancies that have been curatively resected, localized breast cancer treated with curative intent with no evidence of breast active disease for more than 3 years and receiving adjuvant hormonal therapy, localized Gleason score ≤ 6 prostate cancer undergoing observation or treatment with androgen depravation, or any other cancer treated with curative intent, not on adjuvant treatment, and in the opinion of the investigator is unlikely to recur.
• Requires ongoing systemic treatment for any other malignancy
• Requires ongoing systemic (defined as ≥ 10 mg/day of prednisone or equivalent) corticosteroid treatment.
• Current or history of central nervous system involvement including the brain, spinal cord, leptomeninges, and cerebrospinal fluid (as documented by imaging, cytology, or biopsy) by B-cell malignancy, regardless of whether participants had received treatment for central nervous system disease
• Known active plasma cell neoplasm, prolymphocytic leukemia, T-cell lymphoma, Burkitt lymphoma, acquired immunodeficiency syndrome (AIDS)-related B-cell lymphoma, Castleman disease, post-transplant lymphoproliferative disorders, hairy cell leukemia, germinal center B-cell (GCB), DLBCL, EBV+ DLBCL NOS, primary DLBCL of the central nervous system (CNS), primary cutaneous DLBCL - leg type, DLBCL associated with chronic inflammation, primary mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, ALK+ large B-cell lymphoma, primary effusion lymphoma, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, high-grade B-cell lymphoma - NOS, B-cell lymphoma unclassifiable with features intermediate between DLBCL and classical Hodgkin lymphoma, or history of or currently suspected transformation of an indolent lymphoma to an aggressive histology (except for participants with Richter Transformation to DLBCL are eligible for Part 1a, 1c, or Phase 2 and participants with history of follicular lymphoma transforming to non-GCB DLBCL who are eligible for Part 1a, 1c, or Phase 2). Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Interventions: DRUG: BGB-16673

Conditions: B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma, Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma

I'm interested

Share via email

Show 108 locations

Study Locations

Hide all locations

Location	Contacts
Aichi Cancer Center Hospital Clinical Oncology Nagoya, Aichi-ken
American Oncology Partners of Maryland Pa Bethesda, Maryland
Arensia Exploratory Medicine Llc Tbilisi,
Arthur Je Child Comprehensive Cancer Centre Calgary, Alberta
Asan Medical Center Seoul,
Augusta University Augusta, Georgia
Austin Health Heidelberg, Victoria
British Columbia Cancer Agency the Vancouver Centre Vancouver, British Columbia
CHU Henri Mondor Créteil,
Calvary Mater Newcastle Waratah,
Cancer Institute Hospital of Jfcr Kotoku, Tokyo
Centre Henri Becquerel Rouen,
Centre Leon Berard Lyon,
Centre de Lutte Contre Le Cancer Institut Bergonie Bordeaux,
Centro Gaucho Integrado de Oncologia Hospital Mae de Deus Porto Alegre,
Centroricerche Cliniche Di Verona Srl Verona,
Chiba Cancer Center Chiba, Chiba
Chu Montpellier Hopital Saint Eloi Montpellier,
Chu de Quebec Universite Laval, Hopital de Lenfant Jesus, Centre Integre de Cancerologie (Cic) Québec,
Churchill Hospital Oxford University Hospital Nhs Trust Headington,
Columbia University Medical Center New York, New York
Comprehensive Cancer Centers of Nevada Las Vegas, Nevada
Concord Repatriation General Hospital Concord, New South Wales
Cross Cancer Institute Edmonton, Alberta
Dana Farber Cancer Institute Boston, Massachusetts
Derriford Hospital Plymouth,
Dokuz Eylul University Balçova,
Edinburgh Cancer Centre Edinburgh,
Erciyes University Kayseri,
Fondazione Policlinico Universitario Agostino Gemelli Roma,
Fred Hutchinson Cancer Research Center Seattle, Washington
Freeman Hospital High Heaton,
Honor Health Research Institute Scottsdale, Arizona
Hopital Claude Huriez Chu Lille Lille,
Hopital Estaing Clermontferrand,
Hopital de la Pitie Salpetriere Paris,
Hospital Alemão Oswaldo Cruz São Paulo, São Paulo
Hospital Clinico Universitario de Valencia Valencia,
Hospital Erasto Gaertner Curitiba, Paraná
Hospital General Universitario Gregorio Marañon Madrid,
Hospital Nove de Julho Dasa São Paulo,
Hospital Santa Rita de Cassia Afecc Vitória,
Hospital Sirio Libanes Brasilia Brasília,
Hospital Universitario Fundacion Jimenez Diaz Madrid,
Hospital Universitario La Paz Madrid,
Hospital Universitario Puerta de Hierro Majadahonda Majadahonda,
Hospital Universitario Vall Dhebron Barcelona,
Inje University Busan Paik Hospital BusanjinGu, Busan Gwang'yeogsi
Institut Paoli Calmettes Marseille,
Instituto Dor de Pesquisa E Ensino Sao Paulo São Paulo,
Istituto Europeo Di Oncologia Milan,
Karmanos Cancer Institute Detroit, Michigan
Karolinska Universitetssjukhuset Solna Stockholm,
Klinikum Grosshadern Ludwig Maximilians Universitat Munchen München,
Klinikum Johannes Gutenberg Universitaet Mainz Mainz,
Linear Clinical Research Nedlands, Western Australia
MD Anderson Cancer Center Houston, Texas
Mary Bird Perkins Cancer Center Baton Rouge, Louisiana
Mayo Clinic Jacksonville Jacksonville, Florida
Mayo Clinic Phoenix Phoenix, Arizona
Mayo Clinic Rochester Rochester, Minnesota
Md Anderson Cancer Center Madrid Spain Madrid,
Memorial Sloan Kettering Cancer Center MSKCC New York, New York
Midwestern Regional Medical Center Zion, Illinois
Mount Sinai Comprehensive Cancer Center Miami Beach, Florida
Niguarda Cancer Center Division of Hematology Milan,
Norton Cancer Institute Pavilion Louisville, Kentucky
Nottingham University Hospitals NHS Trust Nottingham,
Ondokuz Mayis University Samsun,
Ospedale San Raffaele Milan,
Perth Blood Institute West Perth, Western Australia
Peter MacCallum Cancer Centre Melbourne, Victoria
Policlinico Sorsola Malpighi, Aou Di Bologna Bologna,
Princess Alexandra Hospital Queensland, Queensland
Princess Margaret Cancer Centre Toronto, Ontario
Pusan National University Hospital Seogu, Busan Gwang'yeogsi
Real E Benemerita Associacao Portuguesa de Sao Paulo São Paulo,
Roswell Park Comprehensive Cancer Center Buffalo, New York
Sahlgrenska University Hospital Hematology Gothenburg,
Sakarya Training and Research Hospital Adapazarı,
Samsung Medical Center Seoul,
Seoul National University Hospital Seoul,
Severance Hospital Yonsei University Health System SeodaemunGu, Seoul Teugbyeolsi
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein São Paulo,
Southeastern Regional Medical Center Lumberton, North Carolina
St Jamess University Hospital Leeds,
St Vincents Hospital Melbourne Fitzroy, Victoria
Stanford Medicine Palo Alto, California
Tampa General Hospital Cancer Institute Tampa, Florida
Tennesse Oncology Chattanooga Downtown Chattanooga, Tennessee
Tennessee Oncology, Pllc Nashville Nashville, Tennessee
The Alfred Hospital Melbourne, Victoria
The Catholic University of Korea, Seoul St Marys Hospital SeochoGu, Seoul Teugbyeolsi
The Institute of Oncology, Arensia Exploratory Medicine Chisinau,
UCLA Santa Monica Cancer Care Santa Monica, California
Uchealth North Fort Collins, Colorado
Uniklinik Koeln (Aoer) Cologne,
Universitaetsklinikum Schleswig Holstein Campus Luebeck Lübeck,
Universitaetsklinikum Ulm Ulm,
Universitares Krebszentrum Leipzig Leipzig,
Universitatsklinikum Carl Gustav Carus An Der Technischen Universitat Dresden Dresden,
University of Alabama at Birmingham Hospital Birmingham, Alabama
University of Arizona Cancer Center Tucson, Arizona
University of California San Diego (Ucsd) Moores Cancer Center La Jolla, California
University of Iowa Hospitals and Clinics Iowa City, Iowa
Virginia Commonwealth University Massey Cancer Center Richmond, Virginia
Weill Cornell Medical College Newyork Presbyterian Hospital New York, New York
Yokohama Municipal Citizens Hospital Yokohama,

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics (COSMIC)

Contact(s):

Karen Craver - NCORP@wfusm.edu

Principal Investigator:

System ID: NCT06418204

Show full eligibility criteria

Inclusion Criteria:

* Adults aged 18 years or older with one of the following newly diagnosed cancers: breast cancer, colorectal cancer, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer (e.g. adenocarcinoma, squamous cell carcinoma, large cell carcinoma, adenosquamous cell carcinoma, and not otherwise specified). * Planned treatment with systemic chemotherapy (single or multi-agent, includes targeted therapy) and/or immune checkpoint inhibitor therapy (targeting PD-1, PD-L1 or CTLA-4). If unable to engage participant before treatment starts, enrollment is allowed up to the start of Cycle 2 treatment. * Participants must be able to comprehend English or Spanish (for survey completion). * Participants must have a working email address and be must be willing to complete surveys online. This can be completed at home, in the clinic or other location. * Completion of the confidential Self-Reported Screening Survey and receipt of a screening result - eligible for enrollment. * Participant must reside in the United States, officially determined per patient report on Self-reported Screening Survey * In the treating provider's opinion, the participant should have a life expectancy of \>=6 months. Participants in hospice are not eligible. Optional Sub-study (available at select sites only): * Must be willing to participate in both the main study and the sub-study at the Wake Forest University Comprehensive Cancer Center (WF CCC) and Virginia Commonwealth University (VCU). * Must be receiving treatment at the WF CCC and VCU. * Must be diagnosed with non-small cell lung cancer. * Must be planning to receive paclitaxel as part of their chemotherapy in conjunction with Immune Checkpoint Inhibitor (ICIs) PD-1, PD-L1 or CTLA-4.

Exclusion Criteria:

* Currently enrolled in an interventional supportive treatment trial to manage cancer symptoms. * Participants with known pregnancy. * Participant received systemic therapy treatment for prior cancer(s) including chemotherapy, immunotherapy, targeted therapy, and hormonal therapy. * Participants enrolled in hospice. Optional Substudy (available at select sites only): * Participants with chronic or ongoing steroid or immunomodulatory agents (i.e., prednisone, dexamethasone, etanercept, infliximab, etc.). The use of glucocorticoids as pre-medications for chemotherapy treatment is allowed. * Participants with a history of HIV, hepatitis B or hepatitis C.

Interventions: OTHER: Non-interventional Study

Conditions: Breast Carcinoma, Colorectal Carcinoma, Lung Non-Small Cell Carcinoma, Melanoma, Non-Hodgkin Lymphoma

I'm interested

Share via email

Show 447 locations

Study Locations

Hide all locations

Location	Contacts
AMG Crystal Lake - Oncology Crystal Lake, Illinois	- (advocateresearch@advocate.com)
AMG Libertyville - Oncology Libertyville, Illinois	- (advocateresearch@advocatehealth.com)
Abbott-Northwestern Hospital Minneapolis, Minnesota	- (mmcorc@healthpartners.com)
Adams Cancer Center Gettysburg, Pennsylvania
Advocate Christ Medical Center Oak Lawn, Illinois
Advocate Good Samaritan Hospital Downers Grove, Illinois	- (Barbara.barhamand@advocatehealth.com)
Advocate Good Shepherd Hospital Barrington, Illinois
Advocate High Tech Medical Park Palos Heights, Illinois	- (ncorp@aah.org)
Advocate Illinois Masonic Medical Center Chicago, Illinois
Advocate Lutheran General Hospital Park Ridge, Illinois
Advocate Outpatient Center - Aurora Aurora, Illinois	- (ncorp@aah.org)
Advocate Outpatient Center - Oak Lawn Oak Lawn, Illinois	- (ncorp@aah.org)
Advocate Sherman Hospital Elgin, Illinois
Advocate South Suburban Hospital Hazel Crest, Illinois
AnMed Health Cancer Center Anderson, South Carolina	- (rhonda.ballew@anmedhealth.org)
Armes Family Cancer Center Findlay, Ohio	- (clinical.trials@daytonncorp.org)
Ascension All Saints Hospital Racine, Wisconsin	- (AWRI.Inquiry@Ascension.org)
Ascension Calumet Hospital Chilton, Wisconsin	- (AWRI.inquiry@ascension.org)
Ascension Columbia Saint Mary's Hospital - Milwaukee Milwaukee, Wisconsin	- (AWRI.Inquiry@Ascension.org)
Ascension Columbia Saint Mary's Hospital Ozaukee Mequon, Wisconsin	- (AWRI.Inquiry@Ascension.org)
Ascension Medical Group Southeast Wisconsin - Mayfair Road Wauwatosa, Wisconsin	- (AWRI.Inquiry@Ascension.org)
Ascension Mercy Hospital Oshkosh, Wisconsin	- (AWRI.inquiry@ascension.org)
Ascension Saint Elizabeth Hospital Appleton, Wisconsin	- (AWRI.inquiry@ascension.org)
Ascension Saint Francis - Reiman Cancer Center Franklin, Wisconsin	- (AWRI.Inquiry@Ascension.org)
Ascension Southeast Wisconsin Hospital - Elmbrook Campus Brookfield, Wisconsin	- (AWRI.Inquiry@Ascension.org)
Aspirus Cancer Care - James Beck Cancer Center Rhinelander, Wisconsin	- (Beth.Knetter@aspirus.org)
Aspirus Cancer Care - Stevens Point Stevens Point, Wisconsin	- (Beth.Knetter@aspirus.org)
Aspirus Cancer Care - Wisconsin Rapids Wisconsin Rapids, Wisconsin
Aspirus Langlade Hospital Antigo, Wisconsin	- (Juli.Alford@aspirus.org)
Aspirus Medford Hospital Medford, Wisconsin	- (Beth.Knetter@aspirus.org)
Aspirus Regional Cancer Center Wausau, Wisconsin
Atrium Health Cabarrus/LCI-Concord Concord, North Carolina
Atrium Health Cleveland/LCI-Cleveland Shelby, North Carolina
Atrium Health Navicent Macon, Georgia	- (andrew.weatherall@atriumhealth.org)
Atrium Health Pineville/LCI-Pineville Charlotte, North Carolina
Atrium Health Stanly/LCI-Albemarle Albemarle, North Carolina
Atrium Health Union/LCI-Union Monroe, North Carolina
Atrium Health University City/LCI-University Charlotte, North Carolina
Augusta Health Center for Cancer and Blood Disorders Fishersville, Virginia
Aurora Bay Area Medical Group-Marinette Marinette, Wisconsin	- (ncorp@aurora.org)
Aurora BayCare Medical Center Green Bay, Wisconsin	- (ncorp@aurora.org)
Aurora Cancer Care-Grafton Grafton, Wisconsin	- (ncorp@aurora.org)
Aurora Cancer Care-Kenosha South Kenosha, Wisconsin	- (ncorp@aurora.org)
Aurora Cancer Care-Milwaukee Milwaukee, Wisconsin	- (ncorp@aurora.org)
Aurora Cancer Care-Milwaukee West Wauwatosa, Wisconsin	- (ncorp@aurora.org)
Aurora Cancer Care-Racine Racine, Wisconsin	- (ncorp@aurora.org)
Aurora Cancer Care-Southern Lakes VLCC Burlington, Wisconsin	- (ncorp@aurora.org)
Aurora Health Care Germantown Health Center Germantown, Wisconsin	- (ncorp@aurora.org)
Aurora Medical Center in Summit Summit, Wisconsin	- (ncorp@aurora.org)
Aurora Saint Luke's Medical Center Milwaukee, Wisconsin	- (ncorp@aurora.org)
Aurora Saint Luke's South Shore Cudahy, Wisconsin	- (ncorp@aurora.org)
Aurora Sinai Medical Center Milwaukee, Wisconsin	- (ncorp@aurora.org)
Aurora West Allis Medical Center West Allis, Wisconsin	- (ncorp@aurora.org)
BJC Outpatient Center at Sunset Hills Sunset Hills, Missouri
Baptist Cancer Center-Grenada Grenada, Mississippi	- (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Collierville Collierville, Tennessee	- (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Desoto Southhaven, Mississippi	- (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Golden Triangle Columbus, Mississippi	- (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Memphis Memphis, Tennessee	- (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Oxford Oxford, Mississippi	- (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Union County New Albany, Mississippi	- (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital for Women Memphis, Tennessee	- (BCCclintrials@bmhcc.org)
Beaufort Memorial Hospital Beaufort, South Carolina	- (kwade@bmhsc.org)
Beebe Health Campus Rehoboth Beach, Delaware	- (research@beebehealthcare.org)
Beebe South Coastal Health Campus Millville, Delaware	- (research@beebehealthcare.org)
Benefis Sletten Cancer Institute Great Falls, Montana	- (mccinfo@mtcancer.org)
Billings Clinic Cancer Center Billings, Montana	- (research@billingsclinic.org)
Blanchard Valley Hospital Findlay, Ohio	- (clinical.trials@daytonncorp.org)
Bozeman Health Deaconess Hospital Bozeman, Montana	- (mccinfo@mtcancer.org)
Broadlawns Medical Center Des Moines, Iowa
Bronson Battle Creek Battle Creek, Michigan	- (crcwm-regulatory@crcwm.org)
CHI Health Good Samaritan Kearney, Nebraska	- (ResearchInstituteInquiries@CommonSpirit.org)
Cancer Care Center of O'Fallon O'Fallon, Illinois	- (morganthaler.jodi@mhsil.com)
Cancer Care Specialists of Illinois - Decatur Decatur, Illinois	- (morganthaler.jodi@mhsil.com)
Cancer Center at Saint Joseph's Phoenix, Arizona	- (ResearchInstituteInquiries@CommonSpirit.org)
Cancer Hematology Centers - Flint Flint, Michigan	- (wstrong@ghci.org)
Cancer and Hematology Centers of Western Michigan - Norton Shores Norton Shores, Michigan
Carilion Roanoke Memorial Hospital Roanoke, Virginia
Carle Cancer Center Urbana, Illinois	- (Research@carle.com)
Carle Cancer Institute Normal Normal, Illinois	- (Research@Carle.com)
Carle Physician Group-Effingham Effingham, Illinois	- (Research@carle.com)
Carle Physician Group-Mattoon/Charleston Mattoon, Illinois	- (Research@carle.com)
Carle at The Riverfront Danville, Illinois	- (Research@Carle.com)
CaroMont Health - Lincoln Cancer Center Lincolnton, North Carolina
CaroMont Regional Medical Center Gastonia, North Carolina	- (tammy.cozad@caromonthealth.org)
Carolinas Medical Center/Levine Cancer Institute Charlotte, North Carolina
Centra Alan B Pearson Regional Cancer Center Lynchburg, Virginia	- (Kevin.Patel@centrahealth.com)
CentraState Medical Center Freehold, New Jersey
Centralia Oncology Clinic Centralia, Illinois	- (morganthaler.jodi@mhsil.com)
Chilton Medical Center Pompton, New Jersey
Christiana Care - Union Hospital Elkton, Maryland	- (frank.crum@christianacare.org)
Coborn Cancer Center at Saint Cloud Hospital Saint Cloud, Minnesota	- (coborncancercenter@centracare.com)
Colorado Blood Cancer Institute Denver, Colorado	- (info@westernstatesncorp.org)
Community Hospital of Anaconda Anaconda, Montana	- (mccinfo@mtcancer.org)
Community Medical Center Missoula, Montana	- (mccinfo@mtcancer.org)
Community Medical Center Missoula, Montana	- (HemonCCTrials@geisinger.edu)
Condell Memorial Hospital Libertyville, Illinois	- (advocateresearch@advocatehealth.com)
Contra Costa Regional Medical Center Martinez, California
Contra Costa Regional Medical Center Martinez, California
Corewell Health Grand Rapids Hospitals - Butterworth Hospital Grand Rapids, Michigan	- (crcwm-regulatory@crcwm.org)
Corewell Health Reed City Hospital Reed City, Michigan	- (crcwm-regulatory@crcwm.org)
Cotton O'Neil Cancer Center / Stormont Vail Health Topeka, Kansas
Cox Health South Hospital Springfield, Missouri
CoxHealth South Hospital Springfield, Missouri
Crossroads Cancer Center Effingham, Illinois	- (morganthaler.jodi@mhsil.com)
Dayton Physician LLC - Englewood Dayton, Ohio	- (clinical.trials@daytonncorp.org)
Dayton Physicians LLC-Atrium Franklin, Ohio	- (clinical.trials@daytonncorp.org)
Decatur Memorial Hospital Decatur, Illinois	- (morganthaler.jodi@mhsil.com)
Duluth Clinic Ashland Ashland, Wisconsin	- (CancerTrials@EssentiaHealth.org)
Edwards Comprehensive Cancer Center Huntington, West Virginia	- (Christina.Cole@chhi.org)
Englewood Hospital and Medical Center Englewood, New Jersey
Ephrata Cancer Center Ephrata, Pennsylvania
Essentia Health - Deer River Clinic Deer River, Minnesota	- (CancerTrials@EssentiaHealth.org)
Essentia Health - Fosston Fosston, Minnesota	- (CancerTrials@EssentiaHealth.org)
Essentia Health - Park Rapids Park Rapids, Minnesota	- (CancerTrials@EssentiaHealth.org)
Essentia Health Cancer Center Duluth, Minnesota	- (CancerTrials@EssentiaHealth.org)
Essentia Health Cancer Center-South University Clinic Fargo, North Dakota	- (CancerTrials@EssentiaHealth.org)
Essentia Health Hibbing Clinic Hibbing, Minnesota
Essentia Health Saint Joseph's Medical Center Brainerd, Minnesota	- (CancerTrials@EssentiaHealth.org)
Essentia Health Saint Mary's - Detroit Lakes Clinic Detroit Lakes, Minnesota	- (CancerTrials@EssentiaHealth.org)
Essentia Health Sandstone Sandstone, Minnesota	- (CancerTrials@EssentiaHealth.org)
Essentia Health Virginia Clinic Virginia, Minnesota	- (CancerTrials@EssentiaHealth.org)
Fairbanks Memorial Hospital Fairbanks, Alaska	- (Veronica.Stevenson@foundationhealth.org)
Fairview Northland Medical Center Princeton, Minnesota	- (mmcorc@healthpartners.com)
Fairview Southdale Hospital Edina, Minnesota	- (mmcorc@healthpartners.com)
Flaget Memorial Hospital Bardstown, Kentucky	- (ResearchInstituteInquiries@CommonSpirit.org)
Geisinger Cancer Center Dickson City Dickson City, Pennsylvania	- (hemoncctrials@geisinger.edu)
Geisinger Cancer Services-Pottsville Pottsville, Pennsylvania	- (HemonCCTrials@geisinger.edu)
Geisinger Medical Center Danville, Pennsylvania	- (HemonCCTrials@geisinger.edu)
Geisinger Medical Center-Cancer Center Hazleton Hazleton, Pennsylvania	- (HemonCCTrials@geisinger.edu)
Geisinger Medical Oncology-Lewisburg Lewisburg, Pennsylvania	- (HemonCCTrials@geisinger.edu)
Geisinger Wyoming Valley/Henry Cancer Center Wilkes-Barre, Pennsylvania	- (HemonCCTrials@geisinger.edu)
Genesee Hematology Oncology PC Flint, Michigan	- (wstrong@ghci.org)
Gibbs Cancer Center-Gaffney Gaffney, South Carolina	- (kmertz-rivera@gibbscc.org)
Gibbs Cancer Center-Pelham Greer, South Carolina	- (kmertz-rivera@gibbscc.org)
Glens Falls Hospital Glens Falls, New York	Misty J DeCaro - (lacrosmj@glensfallshosp.org)
Greater Dayton Cancer Center Kettering, Ohio	- (clinical.trials@daytonncorp.org)
Gundersen Lutheran Medical Center La Crosse, Wisconsin	- (cancerctr@gundersenhealth.org)
HSHS Saint Elizabeth's Hospital O'Fallon, Illinois	- (morganthaler.jodi@mhsil.com)
Hackettstown Medical Center Hackettstown, New Jersey
Harold Alfond Center for Cancer Care Augusta, Maine
Hawaii Cancer Care - Westridge ‘Aiea, Hawaii	- (info@hawaiicancercare.com)
Hawaii Cancer Care Inc - Waterfront Plaza Honolulu, Hawaii	- (i.webster@hawaiicancercare.com)
HaysMed Hays, Kansas
Hayworth Cancer Center High Point, North Carolina
Heartland Regional Medical Center Saint Joseph, Missouri	- (Trisha.England2@mymlc.com)
Helen F Graham Cancer Center Newark, Delaware	- (lbarone@christianacare.org)
Hematology Oncology Associates of Fredericksburg Inc Fredericksburg, Virginia	- (cvaughn@hoafredericksburg.com)
Hennepin County Medical Center Minneapolis, Minnesota	- (mmcorc@healthpartners.com)
Hi-Line Sletten Cancer Center Havre, Montana	- (mccinfo@mtcancer.org)
Holy Name Hospital Teaneck, New Jersey
Illinois CancerCare - Washington Washington, Illinois	- (andersonj@illinoiscancercare.com)
Illinois CancerCare-Bloomington Bloomington, Illinois	- (andersonj@illinoiscancercare.com)
Illinois CancerCare-Canton Canton, Illinois	- (andersonj@illinoiscancercare.com)
Illinois CancerCare-Carthage Carthage, Illinois	- (andersonj@illinoiscancercare.com)
Illinois CancerCare-Dixon Dixon, Illinois
Illinois CancerCare-Eureka Eureka, Illinois	- (andersonj@illinoiscancercare.com)
Illinois CancerCare-Galesburg Galesburg, Illinois	- (andersonj@illinoiscancercare.com)
Illinois CancerCare-Kewanee Clinic Kewanee, Illinois	- (andersonj@illinoiscancercare.com)
Illinois CancerCare-Macomb Macomb, Illinois	- (andersonj@illinoiscancercare.com)
Illinois CancerCare-Ottawa Clinic Ottawa, Illinois	- (andersonj@illinoiscancercare.com)
Illinois CancerCare-Pekin Pekin, Illinois	- (andersonj@illinoiscancercare.com)
Illinois CancerCare-Peoria Peoria, Illinois	- (andersonj@illinoiscancercare.com)
Illinois CancerCare-Peru Peru, Illinois	- (andersonj@illinoiscancercare.com)
Illinois CancerCare-Princeton Princeton, Illinois	- (andersonj@illinoiscancercare.com)
Indu and Raj Soin Medical Center Beavercreek, Ohio	- (clinical.trials@daytonncorp.org)
Iowa Methodist Medical Center Des Moines, Iowa
Jefferson Healthcare Port Townsend, Washington
Kadlec Clinic Hematology and Oncology Kennewick, Washington	- (research@kadlecmed.org)
Kaiser Permanente Bellevue Medical Center Bellevue, Washington	- (KPWAoncologytrials@kp.org)
Kaiser Permanente Downtown Commons Sacramento, California	- (kpoct@kp.org)
Kaiser Permanente Dublin Dublin, California
Kaiser Permanente Fresno Orchard Plaza Fresno, California
Kaiser Permanente Medical Center - Santa Clara Santa Clara, California	- (Kpoct@kp.org)
Kaiser Permanente Medical Center-Vacaville Vacaville, California	- (Kpoct@kp.org)
Kaiser Permanente Moanalua Medical Center Honolulu, Hawaii	- (shelley.a.clark@kp.org)
Kaiser Permanente Northwest Portland, Oregon	- (information@kpchr.org)
Kaiser Permanente San Leandro San Leandro, California	- (Kpoct@kp.org)
Kaiser Permanente Washington Seattle, Washington	- (KPWAoncologytrials@kp.org)
Kaiser Permanente- Marshall Medical Offices Redwood City, California
Kaiser Permanente-Deer Valley Medical Center Antioch, California	- (Kpoct@kp.org)
Kaiser Permanente-Franklin Denver, Colorado	- (kristi.m.bronkan@kp.org)
Kaiser Permanente-Fremont Fremont, California	- (Kpoct@kp.org)
Kaiser Permanente-Fresno Fresno, California	- (Kpoct@kp.org)
Kaiser Permanente-Lone Tree Lone Tree, Colorado	- (kristi.m.bronkan@kp.org)
Kaiser Permanente-Modesto Modesto, California	- (Kpoct@kp.org)
Kaiser Permanente-Oakland Oakland, California	- (Kpoct@kp.org)
Kaiser Permanente-Richmond Richmond, California	- (Kpoct@kp.org)
Kaiser Permanente-Rock Creek Lafayette, Colorado	- (kristi.m.bronkan@kp.org)
Kaiser Permanente-Roseville Roseville, California	- (Kpoct@kp.org)
Kaiser Permanente-San Francisco San Francisco, California	- (Kpoct@kp.org)
Kaiser Permanente-Santa Rosa Santa Rosa, California	- (Kpoct@kp.org)
Kaiser Permanente-Santa Teresa-San Jose San Jose, California	- (Kpoct@kp.org)
Kaiser Permanente-South Sacramento Sacramento, California	- (Kpoct@kp.org)
Kaiser Permanente-South San Francisco South San Francisco, California	- (Kpoct@kp.org)
Kaiser Permanente-Stockton Stockton, California	- (Kpoct@kp.org)
Kaiser Permanente-Vallejo Vallejo, California	- (Kpoct@kp.org)
Kaiser Permanente-Walnut Creek Walnut Creek, California	- (Kpoct@kp.org)
Kaiser San Rafael-Gallinas San Rafael, California	- (Kpoct@kp.org)
Kapiolani Medical Center for Women and Children Honolulu, Hawaii
Kettering Medical Center Kettering, Ohio	- (clinical.trials@daytonncorp.org)
Kettering Medical Center Kettering, Ohio	- (clinical.trials@daytonncorp.org)
Kingman Regional Medical Center Kingman, Arizona	- (research@sncrf.org)
Kootenai Clinic Cancer Services - Post Falls Post Falls, Idaho	- (mccinfo@mtcancer.org)
Kootenai Clinic Cancer Services - Sandpoint Sandpoint, Idaho	- (mccinfo@mtcancer.org)
Kootenai Health - Coeur d'Alene Coeur d'Alene, Idaho	- (mccinfo@mtcancer.org)
Lake Regional Hospital Osage Beach, Missouri	- (clinicaltrials@lakeregional.com)
Lakeview Hospital Stillwater, Minnesota	- (mmcorc@healthpartners.com)
Lawrence Memorial Hospital Lawrence, Kansas	- (Stephanie.Norris@LMH.ORG)
Lehigh Valley Hospital - Muhlenberg Bethlehem, Pennsylvania	- (Morgan_M.Horton@lvhn.org)
Lehigh Valley Hospital-Cedar Crest Allentown, Pennsylvania	- (Morgan_M.Horton@lvhn.org)
Lehigh Valley Hospital-Hazleton Hazleton, Pennsylvania	- (Morgan_M.Horton@lvhn.org)
Levine Cancer Institute - Huntersville Huntersville, North Carolina
Levine Cancer Institute - Rutherford Forest City, North Carolina
Levine Cancer Institute - Union West Matthews, North Carolina
Levine Cancer Institute-Ballantyne Charlotte, North Carolina
Levine Cancer Institute-Gaston Gastonia, North Carolina
Levine Cancer Institute-Rock Hill Rock Hill, South Carolina
Levine Cancer Institute-SouthPark Charlotte, North Carolina
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler Savannah, Georgia	- (underberga@sjchs.org)
Liberty County Cancer Care Hinesville, Georgia	- (Oncologyresearch@sjchs.org)
Licking Memorial Hospital Newark, Ohio	- (Jeffh@columbusccop.org)
Logan Health Medical Center Kalispell, Montana	- (mccinfo@mtcancer.org)
Lovelace Medical Center-Saint Joseph Square Albuquerque, New Mexico	- (ZPollock@salud.unm.edu)
Lovelace Women's Hospital Albuquerque, New Mexico	- (AYost@nmcca.org)
MaineHealth Cancer Care Center of York County Sanford, Maine
MaineHealth Cancer Care and IV Therapy - Brunswick Brunswick, Maine	- (clinicalresearch@mainehealth.org)
MaineHealth Cancer Care and IV Therapy - Sanford Sanford, Maine	- (clinicalresearch@mainehealth.org)
MaineHealth Cancer Care and IV Therapy - South Portland South Portland, Maine	- (clinicalresearch@mainehealth.org)
MaineHealth Maine Medical Center - Biddeford Biddeford, Maine	- (clinicalresearch@mainehealth.org)
MaineHealth Maine Medical Center- Scarborough Scarborough, Maine	- (clinicalresearch@mainehealth.org)
MaineHealth Penobscot Bay Hospital Rockport, Maine	- (clinicalresearch@mainehealth.org)
MaineHealth Waldo Hospital Belfast, Maine	- (clinicalresearch@mainehealth.org)
Marshfield Clinic - Wisconsin Rapids Center Wisconsin Rapids, Wisconsin	- (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Clinic-Chippewa Center Chippewa Falls, Wisconsin	- (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Clinic-Wausau Center Wausau, Wisconsin	- (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center - Ladysmith Ladysmith, Wisconsin	- (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center - Minocqua Minocqua, Wisconsin	- (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center - Neillsville Neillsville, Wisconsin	- (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center - Weston Weston, Wisconsin	- (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center Dickinson Iron Mountain, Michigan	- (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-EC Cancer Center Eau Claire, Wisconsin	- (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-Marshfield Marshfield, Wisconsin	- (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-Rice Lake Rice Lake, Wisconsin	- (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-River Region at Stevens Point Stevens Point, Wisconsin	- (oncology.clinical.trials@marshfieldresearch.org)
Mayo Clinic Jacksonville, Florida
Mayo Clinic Health System in Albert Lea Albert Lea, Minnesota
Mayo Clinic Health System-Eau Claire Clinic Eau Claire, Wisconsin
Mayo Clinic Health System-Franciscan Healthcare La Crosse, Wisconsin
Mayo Clinic Health Systems-Mankato Mankato, Minnesota
Medical Oncology Hematology Consultants PA Newark, Delaware	- (lbarone@christianacare.org)
Medical University of South Carolina Charleston, South Carolina	- (hcc-clinical-trials@musc.edu)
Memorial Hospital Chattanooga, Tennessee	- (Jeffh@columbusccop.org)
Memorial Medical Center-Las Cruces Las Cruces, New Mexico	- (Deborah.Brown@LPNT.net)
Mercy Cancer Center - Carmichael Carmichael, California	- (ResearchInstituteInquiries@CommonSpirit.org)
Mercy Cancer Center - Elk Grove Elk Grove, California	- (ResearchInstituteInquiries@CommonSpirit.org)
Mercy Cancer Center - Rocklin Rocklin, California	- (ResearchInstituteInquiries@CommonSpirit.org)
Mercy Cancer Center - Sacramento Sacramento, California	- (ResearchInstituteInquiries@CommonSpirit.org)
Mercy Cancer Center-West Lakes Clive, Iowa	- (cancerresearch@mercydesmoines.org)
Mercy Health - Paducah Cancer Center Paducah, Kentucky	- (BJWarner@mercy.com)
Mercy Hospital Coon Rapids, Minnesota	- (mmcorc@healthpartners.com)
Mercy Hospital Fort Smith Fort Smith, Arkansas
Mercy Hospital Joplin Joplin, Missouri	- (esmeralda.carrillo@mercy.net)
Mercy Hospital Oklahoma City Oklahoma City, Oklahoma
Mercy Hospital Saint Louis St Louis, Missouri
Mercy Hospital South St Louis, Missouri	- (Danielle.Werle@mercy.net)
Mercy Hospital Springfield Springfield, Missouri
Mercy Medical Center - Des Moines Des Moines, Iowa	- (cancerresearch@mercydesmoines.org)
Mercy Oncology and Hematology - Clayton-Clarkson Ballwin, Missouri
Mercy San Juan Medical Center Carmichael, California	- (OncologyResearch@DignityHealth.org)
Mid Coast Hospital Brunswick, Maine	- (elizabeth.mutina@mainehealth.org)
Minnesota Oncology - Burnsville Burnsville, Minnesota	- (mmcorc@healthpartners.com)
Minnesota Oncology Hematology PA-Maplewood Maplewood, Minnesota	- (mmcorc@healthpartners.com)
Minnesota Oncology Hematology PA-Woodbury Woodbury, Minnesota	- (mmcorc@healthpartners.com)
Mission Hope Medical Oncology - Arroyo Grande Arroyo Grande, California	- (ResearchInstituteInquiries@CommonSpirit.org)
Mission Hope Medical Oncology - Santa Maria Santa Maria, California	- (ResearchInstituteInquiries@CommonSpirit.org)
Missouri Baptist Medical Center St Louis, Missouri
Missouri Baptist Sullivan Hospital Sullivan, Missouri
Missouri Baptist Sullivan Hospital Sullivan, Missouri
Montana Cancer Consortium NCORP Billings, Montana	- (mccinfo@mtcancer.org)
Montefiore Medical Center - Moses Campus The Bronx, New York	- (eskwak@montefiore.org)
Montefiore Medical Center-Einstein Campus The Bronx, New York	- (eskwak@montefiore.org)
Monticello Cancer Center Monticello, Minnesota	- (mmcorc@healthpartners.com)
Monument Health Rapid City Hospital Rapid City, South Dakota	- (research@monument.health)
Morristown Medical Center Morristown, New Jersey
Morton Plant Hospital Clearwater, Florida
Munson Medical Center Traverse City, Michigan	- (crcwm-regulatory@crcwm.org)
MyMichigan Medical Center Alpena Alpena, Michigan	- (CVResearch@mymichigan.org)
MyMichigan Medical Center Gladwin Gladwin, Michigan	- (CVResearch@mymichigan.org)
MyMichigan Medical Center Gratiot Alma, Michigan	- (CVResearch@mymichigan.org)
MyMichigan Medical Center Midland Midland, Michigan	- (CVResearch@mymichigan.org)
MyMichigan Medical Center Mount Pleasant Mount Pleasant, Michigan	- (CVResearch@mymichigan.org)
MyMichigan Medical Center Saginaw Saginaw, Michigan	- (MCRCwebsitecontactform@stjoeshealth.org)
MyMichigan Medical Center Tawas Tawas City, Michigan	- (MCRCwebsitecontactform@stjoeshealth.org)
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro Jonesboro, Arkansas
New Ulm Medical Center New Ulm, Minnesota	- (mmcorc@healthpartners.com)
Newton Medical Center Newton, New Jersey
North Memorial Medical Health Center Robbinsdale, Minnesota	- (mmcorc@healthpartners.com)
Northside Hospital Atlanta, Georgia	- (ClinicalTrials@northside.com)
Northside Hospital - Duluth Duluth, Georgia	- (Clinical.trials@northside.com)
Northside Hospital - Gwinnett Lawrenceville, Georgia	- (Clinical.trials@northside.com)
OSF Saint Anthony Medical Center Rockford, Illinois
OSF Saint Anthony's Health Center Alton, Illinois
OSF Saint Francis Hospital and Medical Group Escanaba, Michigan	- (ewd_research_admin@hshs.org)
Oncology Associates at Mercy Medical Center Cedar Rapids, Iowa
OptumCare Cancer Care at Charleston Las Vegas, Nevada	- (research@sncrf.org)
OptumCare Cancer Care at Seven Hills Henderson, Nevada	- (research@sncrf.org)
Overlook Medical Center Summit, New Jersey
PCR Oncology Arroyo Grande, California	- (research@sncrf.org)
Pacific Central Coast Health Center-San Luis Obispo San Luis Obispo, California	- (ResearchInstituteInquiries@CommonSpirit.org)
Pali Momi Medical Center ‘Aiea, Hawaii
Park Nicollet Clinic - Saint Louis Park Saint Louis Park, Minnesota	- (mmcorc@healthpartners.com)
Parkland Health Center - Farmington Farmington, Missouri
Penrose-Saint Francis Healthcare Colorado Springs, Colorado	- (ResearchInstituteInquiries@CommonSpirit.org)
Physicians' Clinic of Iowa PC Cedar Rapids, Iowa
Pocono Medical Center East Stroudsburg, Pennsylvania	- (Morgan_M.Horton@lvhn.org)
Presbyterian Kaseman Hospital Albuquerque, New Mexico	- (WBurman@phs.org)
Presbyterian Rust Medical Center/Jorgensen Cancer Center Rio Rancho, New Mexico
Prisma Health Cancer Institute - Butternut Greenville, South Carolina
Prisma Health Cancer Institute - Easley Easley, South Carolina	- (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Eastside Greenville, South Carolina
Prisma Health Cancer Institute - Faris Greenville, South Carolina
Prisma Health Cancer Institute - Greer Greer, South Carolina
Prisma Health Cancer Institute - Seneca Seneca, South Carolina
Prisma Health Cancer Institute - Spartanburg Boiling Springs, South Carolina
Providence Medical Foundation - Santa Rosa Santa Rosa, California
Providence Saint Mary Regional Cancer Center Walla Walla, Washington	- (Cheryl.Dodd@providence.org)
Queen's Cancer Center - Kuakini Honolulu, Hawaii
Queen's Cancer Center - POB I Honolulu, Hawaii
Queen's Medical Center Honolulu, Hawaii
Queens Hospital Center Jamaica, New York	Linda Bulone - (buloneL@nychhc.org)
Regional Cancer Care - Jesup Jesup, Georgia	- (Oncologyresearch@sjchs.org)
Regions Hospital Saint Paul, Minnesota	- (mmcorc@healthpartners.com)
Reid Health Richmond, Indiana	- (clinical.trials@daytonncorp.org)
Rice Memorial Hospital Willmar, Minnesota	- (mmcorc@healthpartners.com)
Ridgeview Medical Center Waconia, Minnesota	- (mmcorc@healthpartners.com)
Rocky Mountain Cancer Centers - Centennial Centennial, Colorado	- (info@westernstatesncorp.org)
Rocky Mountain Cancer Centers-Aurora Aurora, Colorado	- (info@westernstatesncorp.org)
Rocky Mountain Cancer Centers-Boulder Boulder, Colorado	- (info@westernstatesncorp.org)
Rocky Mountain Cancer Centers-Littleton Littleton, Colorado	- (info@westernstatesncorp.org)
Rocky Mountain Cancer Centers-Midtown Denver, Colorado	- (info@westernstatesncorp.org)
Rocky Mountain Cancer Centers-Rose Denver, Colorado	- (info@westernstatesncorp.org)
Rocky Mountain Cancer Centers-Sky Ridge Lone Tree, Colorado	- (info@westernstatesncorp.org)
Rocky Mountain Cancer Centers-Thornton Thornton, Colorado	- (info@westernstatesncorp.org)
Rush-Copley Healthcare Center Yorkville, Illinois	- (Cancer.Research@rushcopley.com)
Rush-Copley Medical Center Aurora, Illinois	- (Cancer.Research@rushcopley.com)
SMC Center for Hematology Oncology Union Union, South Carolina	- (kmertz-rivera@gibbscc.org)
SSM Health Good Samaritan Mount Vernon, Illinois	- (gayla.hall@ssmhealth.com)
Saint Agnes Medical Center Fresno, California	- (medresearch@samc.com)
Saint Alphonsus Cancer Care Center-Baker City Baker City, Oregon	- (mccinfo@mtcancer.org)
Saint Alphonsus Cancer Care Center-Boise Boise, Idaho	- (stephanie.couch@stjoeshealth.org)
Saint Alphonsus Cancer Care Center-Caldwell Caldwell, Idaho	- (stephanie.couch@stjoeshealth.org)
Saint Alphonsus Cancer Care Center-Nampa Nampa, Idaho	- (mccinfo@mtcancer.org)
Saint Alphonsus Cancer Care Center-Ontario Ontario, Oregon	- (mccinfo@mtcancer.org)
Saint Anthony North Hospital Westminster, Colorado	- (ResearchInstituteInquiries@CommonSpirit.org)
Saint Anthony's Hospital Cancer Care Center St. Petersburg, Florida	- (Research.CTO@baycare.org)
Saint Elizabeth Youngstown Hospital Youngstown, Ohio	- (clinical.trials@daytonncorp.org)
Saint Francis Cancer Center Greenville, South Carolina	- (ResearchInstituteInquiries@CommonSpirit.org)
Saint Francis Cancer Center Greenville, South Carolina	- (melissa_beckman@bshsi.org)
Saint Francis Hospital Federal Way, Washington	- (melissa_beckman@bshsi.org)
Saint Francis Regional Medical Center Shakopee, Minnesota	- (mmcorc@healthpartners.com)
Saint John's Hospital - Healtheast Maplewood, Minnesota	- (mmcorc@healthpartners.com)
Saint Joseph Hospital East Lexington, Kentucky	- (ResearchInstituteInquiries@CommonSpirit.org)
Saint Joseph London London, Kentucky	- (ResearchInstituteInquiries@CommonSpirit.org)
Saint Joseph Mount Sterling Mount Sterling, Kentucky	- (ResearchInstituteInquiries@CommonSpirit.org)
Saint Joseph's Hospital/Children's Hospital-Tampa Tampa, Florida	- (jennifer.manns@baycare.org)
Saint Joseph's Medical Center Stockton, California
Saint Joseph's/Candler - Bluffton Campus Bluffton, South Carolina	- (underberga@sjchs.org)
Saint Louis Cancer and Breast Institute-Ballwin Ballwin, Missouri
Saint Luke's Hospital of Duluth Duluth, Minnesota	- (kdean@slhduluth.com)
Saint Vincent Hospital Cancer Center Green Bay Green Bay, Wisconsin	- (ewd_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Oconto Falls Oconto Falls, Wisconsin	- (ewd_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Saint Mary's Green Bay, Wisconsin	- (ewd_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Sheboygan Sheboygan, Wisconsin	- (ewd_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Sturgeon Bay Sturgeon Bay, Wisconsin	- (ewd_research_admin@hshs.org)
Sainte Genevieve County Memorial Hospital Sainte Genevieve, Missouri
Salina Regional Health Center Salina, Kansas	- (mleepers@srhc.com)
Sechler Family Cancer Center Lebanon, Pennsylvania	- (doxenberg@wellspan.org)
Sheboygan Physicians Group Sheboygan, Wisconsin	- (ewd_research_admin@hshs.org)
Shenandoah Oncology PC Winchester, Virginia	- (William.Houck@usoncology.com)
Sinai Hospital of Baltimore Baltimore, Maryland	- (pridgely@lifebridgehealth.org)
South Carolina Cancer Specialists PC Hilton Head Island, South Carolina	- (underberga@sjchs.org)
South Florida Baptist Hospital Plant City, Florida	- (Claudia.Quinones@baycare.org)
Southern Illinois University School of Medicine Springfield, Illinois
Spartanburg Medical Center Spartanburg, South Carolina	- (kmertz-rivera@gibbscc.org)
Springfield Clinic Springfield, Illinois
Springfield Memorial Hospital Springfield, Illinois	- (pallante.beth@mhsil.com)
Straub Benioff Medical Center Honolulu, Hawaii
Straub Pearlridge Clinic ‘Aiea, Hawaii
Strecker Cancer Center-Belpre Belpre, Ohio	- (Jeffh@columbusccop.org)
Swedish Cancer Institute-Edmonds Edmonds, Washington	- (PCRC-NCORP@Swedish.org)
Swedish Cancer Institute-Issaquah Issaquah, Washington	- (PCRC-NCORP@Swedish.org)
Swedish Medical Center-First Hill Seattle, Washington	- (PCRC-NCORP@Swedish.org)
The Queen's Medical Center - West Oahu ‘Ewa Beach, Hawaii	- (rohta@queens.org)
The Radiation Oncology Center-Hilton Head/Bluffton Hilton Head Island, South Carolina	- (underberga@sjchs.org)
The University of Kansas Cancer Center - Olathe Olathe, Kansas	- (OlatheCCResearch@kumc.edu)
ThedaCare Cancer Care - Berlin Berlin, Wisconsin	- (ResearchDept@thedacare.org)
ThedaCare Cancer Care - New London New London, Wisconsin	- (ResearchDept@thedacare.org)
ThedaCare Cancer Care - Oshkosh Oshkosh, Wisconsin	- (ResearchDept@thedacare.org)
ThedaCare Cancer Care - Shawano Shawano, Wisconsin	- (ResearchDept@thedacare.org)
ThedaCare Cancer Care - Waupaca Waupaca, Wisconsin	- (ResearchDept@thedacare.org)
ThedaCare Regional Cancer Center Appleton, Wisconsin	- (ResearchDept@thedacare.org)
ThedaCare Regional Medical Center - Neenah Neenah, Wisconsin	- (ResearchDept@thedacare.org)
Tidelands Georgetown Memorial Hospital Georgetown, South Carolina	- (broe@tidelandshealth.org)
Trinity Health Grand Rapids Hospital Grand Rapids, Michigan	- (crcwm-regulatory@crcwm.org)
Trinity Health Muskegon Hospital Muskegon, Michigan	- (crcwm-regulatory@crcwm.org)
Trinity Health Saint Joseph Mercy Hospital Ann Arbor Ann Arbor, Michigan	- (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Saint Joseph Mercy Oakland Hospital Pontiac, Michigan	- (MCRCwebsitecontactform@stjoeshealth.org)
UI Health Care Mission Cancer and Blood - Ankeny Clinic Ankeny, Iowa
UI Health Care Mission Cancer and Blood - Des Moines Clinic Des Moines, Iowa
UI Health Care Mission Cancer and Blood - Laurel Clinic Des Moines, Iowa
UI Health Care Mission Cancer and Blood - Waukee Clinic Waukee, Iowa
UI Health Care Mission Cancer and Blood - West Des Moines Clinic Clive, Iowa
UM Baltimore Washington Medical Center/Tate Cancer Center Glen Burnie, Maryland
UM Saint Joseph Medical Center Towson, Maryland	- (Jeanmarie.downing@umm.edu)
United Hospital Saint Paul, Minnesota	- (mmcorc@healthpartners.com)
University Health Truman Medical Center Kansas City, Missouri
University of Iowa Healthcare Cancer Services Quad Cities Bettendorf, Iowa	- (katherine-daprile@uiowa.edu)
University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa
University of Kansas Cancer Center - Lee's Summit Lee's Summit, Missouri	- (KUCC_Navigation@kumc.edu)
University of Kansas Cancer Center - North Kansas City, Missouri	- (KUCC_Navigation@kumc.edu)
University of Kansas Cancer Center-Overland Park Overland Park, Kansas	- (KUCC_Navigation@kumc.edu)
University of Kansas Health System Saint Francis Campus Topeka, Kansas
University of Kansas Hospital-Indian Creek Campus Overland Park, Kansas	- (KUCC_Navigation@kumc.edu)
University of Kansas Hospital-Westwood Cancer Center Westwood, Kansas	- (KUCC_Navigation@kumc.edu)
University of Maryland/Greenebaum Cancer Center Baltimore, Maryland
University of Michigan Health - West Wyoming, Michigan	- (crcwm-regulatory@crcwm.org)
University of New Mexico Cancer Center Albuquerque, New Mexico	- (HSC-ClinicalTrialInfo@salud.unm.edu)
University of Wisconsin Carbone Cancer Center - University Hospital Madison, Wisconsin	- (clinicaltrials@cancer.wisc.edu)
VCU Community Memorial Health Center South Hill, Virginia	- (nemer.elmouallem@vcuhealth.org)
VCU Massey Cancer Center at Stony Point Richmond, Virginia	- (ctoclinops@vcu.edu)
Vince Lombardi Cancer Clinic - Oshkosh Oshkosh, Wisconsin	- (ncorp@aurora.org)
Vince Lombardi Cancer Clinic-Sheboygan Sheboygan, Wisconsin	- (ncorp@aurora.org)
Vince Lombardi Cancer Clinic-Two Rivers Two Rivers, Wisconsin	- (ncorp@aurora.org)
Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia	- (CTOclinops@vcu.edu)
Wake Forest NCORP Research Base Winston-Salem, North Carolina	Glenn Lesser, MD - (ncorp@wakehealth.edu) Beth Reboussin, PhD - (ncorp@wakehealth.edu)
Wake Forest University Health Sciences Winston-Salem, North Carolina
Wake Forest University at Clemmons Clemmons, North Carolina
WellSpan Medical Oncology and Hematology Hanover, Pennsylvania
Wellspan Health - York Cancer Center York, Pennsylvania
West Michigan Cancer Center Kalamazoo, Michigan	- (crcwm-regulatory@crcwm.org)
Westfields Hospital/Cancer Center of Western Wisconsin New Richmond, Wisconsin	- (mmcorc@healthpartners.com)
Wilcox Memorial Hospital and Kauai Medical Clinic Lihue, Hawaii
William E Kahlert Regional Cancer Center/Sinai Hospital Westminster, Maryland
Winter Haven Hospital Winter Haven, Florida	- (Research.CTO@baycare.org)
Woodland Cancer Care Center Michigan City, Indiana	- (sally.arnett@franciscanalliance.org)
Woodland Memorial Hospital Woodland, California	- (ResearchInstituteInquiries@CommonSpirit.org)

Search Results

Study Locations

Study Locations

Study Locations

Study Locations

Study Locations

Study Locations

Study Locations

Study Locations

Study Locations

Study Locations

Study Locations

Study Locations

Study Locations

Study Locations

Study Locations

Study Locations

Study Locations

Study Locations

Study Locations

Study Locations

Study Locations

Study Locations

Study Locations

Study Locations

Study Locations

Study Locations

Study Locations

Study Locations

Study Locations

Study Locations

Email this study information to me

Contact the study team